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Despite its widespread use, little research has been undertaken on the use of progestogen-
only injectable contraceptives by South African women. This thesis is comprised of two
sections. Section I provides the first comprehensive description of injectable
contraceptive use among rural South African women. It includes an analysis of the
contraceptive method mix, prevalence of injectable contraceptive use, discontinuation
patterns and reported side effects. A comparison of depot medroxyprogesterone acetate
(DMPA) versus norethisterone oenanthate (NET-EN) focuses on utilization patterns and
costs. The second section gives an account of the pharmacokinetics ofDMPA including
the first ever population analysis.
A cross-sectional, community-based household survey was undertaken in the Hlabisa
sub-district ofKwaZulu-Natal, South Africa. Interviews were held during 1998 and 1999,
with 848 randomly selected women (aged 15-49years) and with 14 focus groups. There
was a heavy reliance on injectable contraceptives which were used by 74% of women
practising contraception. By contrast, the condom was the current method of only 4%.
The injectable method was the most commonly used method among teenagers. However,
in most cases, contraceptive use appeared to commence only after the first pregnancy.
Slightly more NET-EN (54%) than DMPA (46%) was used, with younger women more
likely to use NET-EN than DMPA (p=O.OOOl). No significant differences in self-reported
side effects were found between current users of the two injectables. Health workers
played an important role in women's decisions to use the injectable, and in product
selection, with NET-EN being recommended for younger women on the basis of concerns
about method reversibility. While some women used injectables for long periods of time ,
xm
discontinuation rates at two years were high, most commonly due to menstrual
disturbances. Many side effects were reported by users ofboth DMPA and NET-EN, with
amenorrhoea the most common, experienced by 63% of current injectable users. Heavy
bleeding was most commonly reported by previous users (38%). Vaginal wetness was
also common, mentioned by 18% and 29% of current and previous users respectively.
Utilisation patterns of the two injectable products (DMPA and NET-EN) were analysed
by means of a Pareto analysis of injectables issued from four South African provincial
pharmaceutical depots over three financial years (1997/8, 1998/9and 1999/2000).
Injectables accounted for a substantial share oftotal state expenditure on drugs. While
more DMPA than NET-EN was issued, NET-EN distribution from two depots increased
over the period of analysis, even though DMPA was the cheaper option.
The pharmacokinetic analysis was undertaken amongst DMPA users routinely attending
family planning services in three Durban clinics in 1996. Medroxyprogesterone acetate
levels at the end of the dosing interval were analysed for 94 women. In addition a
population pharmacokinetic analysis of291 serum levels from 111 DMPA users was
undertaken. This involved the use ofNon Linear Mixed Effect Modelling (NONMEM) to
fit the data and determine the pharmacokinetic parameters, apparent clearance (CLIP) and
apparent volume of distribution (VIP), and to estimate the influence of covariates on CLIP
and VIP (where P is the bioavailability). The final model estimates for CLIP and VIP
were 1080 (95% confidence interval: 994, 1166) litreslday and 86200 litres (95%
confidence interval: 68246, 104154) respectively. No significant relationships were found
between the covariates tested and CLIP and VIP. Concerns raised in the literature about
xiv
the influence of weight or ethnicity on the pharmacokinetics of DMPA were shown to be
unfounded.
In the context of South Africa 's HIV epidemic, the heavy reliance on injectable
contraceptives, which offer no protection against HIV, should be addressed by expanding
the contraceptive method mix to include barrier methods such as the female condom.
Health providers are influential in contraceptive decision-making and should be
encouraged and supported to redress the dependence on the injectable method alone,
taking into account the need of many for dual protection against HIV and unwanted
pregnancy. Provider counselling should also focus on adherence to dosing regimens,
improving continuation rates , and should provide appropriate advice for women
complaining about vaginal wetness with injectable use. Promotion of one injectable
product over another to younger women is not appropriate. Since DMPA is the cheaper
product, provider training about the rational use of injectable contraceptives should
include cost considerations.
xv
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Where is the Condom? Contraceptive Practice in
a Rural District of South Africa
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ABSTRACT
Interviews were conducted with 848 African women aged 15-49 years in a rural area of South Africa to determine the
extent to which condoms are used, reasons for contraceptive method choice and unmet contraceptive need. Injectable
contraceptives were being used by 22.1% of respondents, who considered them to be convenient, safe, effective, and/or a
method that could be used secretly. The decision to use this method was often made on the recommendation of a health
worker Eleven women said they were using the male condom, seven of whom were using it because it provides protection
against pregnancy and sexually transmitted infections. Many (70.3%) women were not using any form of contraception.
Counselling about contraceptive options should take into account the need for dual protection, and strategies for
increasing condom use should be promoted. (AfrfReprrxlHadth2002; 6(2): 71-78)
RESUME
Ou est le preservatif? Iusage du contraceptif clans un district rural de I' Afrique du Sud. Nous avons eu des
entretiens avec 848 femmes africaines igees de 15-49 ans dans une region rurale de I'Afrique du Sud pour determiner
l'ampleur de l'usage des preservatifs, la raison pour le choix de la methode contraceptive et le besoin de contraceptif qui
n'a pas ete satisfait 22,1% des repondantes utilisaient des contraceptifs injectables qu'elles consideraient comme etant
convenables, saufs, efficaces et/ou comme une methode qu'on pouvait utiliser en cachette. C'etait sur la recommendation
d'une assistante sociale que la decision d'employer cette methode a ete souvent prise. Onze femmes ont declare qu'elles
utilisaient le preservatif pour hommes; 7 d'entre elles l'utilisaient parce qu'il sect de protection contre la grossesse et les
infections sexuellement transmissibles. Beaucoup de femmes (70,3%) n'utilisaient point de contraception. It faut que les
conseils sur les options contraceptives tiennent compte de la necessite pour la double protection; il faut egalement
promouvoir les strategies pour l'augmentation de l'usage du preservatif (RevAfrSanteReprrxl2002; 6[2]:71-78)
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Introduction
Use of barrier methods of contraception in South Africa is reponed to be very low. The 1998 South Africa Demographic
and Health Survey (SADHS)' found current male condom use to be 1.9% amongst all women interviewed in the age range
15 to 49 years, and 2.3% amongst women sexually active in the four weeks prior to being interviewed. Male condom use
was reported to be onlyO.6% amongst all non-urban women interviewed.' The SADHS report did not include information
about female condom use. A national introductory strategy of the female condom to some South African public sector
health facilities commenced in 1998.2 However, the female condom is not yet available at all facilities. On the other hand,
the progestagen only injectable hormonal contraceptives are widely used by South African women.I,3·g
According to the SADHS,I injectable contraceptives were currently used by 27.3% of all women aged 15·49 years and by
30.1% of women sexually active in the four weeks prior to being interviewed. The injectable contraceptive is particularly
popular amongst younger users and women living in rural areas.' While studies undertaken in South Africa have examined
contraceptive prevalence, contraceptive method mix, and reasons for method switching or discontinuation.tt? an
extensive literature search revealed no published studies that describe reasons for method choice amongst South African
users. With the exception of one qualitative study amongst 40 adolescents in the Northern Province of South Africa,"!
published studies that explore reasons for non-use of contraception amongst potential South African users were not
found. In this one study, the main barriers to contraceptive use among adolescents were the experience or fear of side
effects and harassment by clinic nurses, who regard them to be too young to be sexually active.11
With one in four women attending antenatal clinics found to be infected with HIV in 2000,12one would expect to see
a move away from injectables as the main method of contraception to the use of condoms, which provides dual
protection against sexually transmitted infections (STIs) including HIV and unwanted pregnancy. HIV prevalence as high
as 37.4% was reported among 20-24 year-old pregnant women in a study undertaken in rural Kwa'Zulu-Natal." Teenage
pregnancy rates are also high, with 35.1% of teenage girls reponed to have been pregnant by age 19,1 and the need for
effective contraceptive methods remains. However, the low use of barrier contraceptive methods is disquieting and the
development of an understanding of what guides decisions about contraceptive use is urgently required. Against this back-
ground, this paper describes contraceptive use patterns and the extent to which condoms are used in a rural area of
KwaZulu-Natal in South Africa. Reasons for contraceptive method choice and unmet contraceptive needs are analysed.
Based on this analysis, and taking into account the need for dual protection against unwanted pregnancy and HIV
infection , appropriate contraceptive options are proposed and strategies for increasing condom use identified.
Methods
Setting and Sample
Contraceptive patterns of use were determined by means of a community-based cross-sectional survey undertaken in a
rural sub-district comprising 13 wards (isigrxlt) in northern KwaZulu-Natal, South Africa. Commencing from a randomly
selected starting point, every second household in each isigrxii was chosen until 40% of the estimated 2088 households in
each isigodi had been visited. Verbal and written explanations of the study were given to each woman selected, and 848
women aged 15-49 years were interviewed. Prior to commencing the survey, workshops and meetings were held to
introduce the study to local traditional leaders, community health workers and health service providers. Approval to
conduct the study was granted by the Ethics Committee of the University of Durban- Westville.
Data Collection and Analysis
Data were collected by means of an extensive structured interview, which included questions on demographic
characteristics, reasons for selection of contraceptive methods , problems and side effects experienced with current and
previous contraceptive methods , and reasons for not using contraception. Since the focus of the study was on
contraceptive use and method choice, questions about HIV/ AIDS were not included. The study did not explicitly explore
concurrent use of more than one method (dualmethod use) or consistencyof condom use.
Interviews. were conducted in Zulu between September and December 1998. They were conducted during the day from
Monday to Fnday, but where a selected woman was not at home a repeat visit was made in the evening or on Saturday. Data
were coded, d0u.ble entered and analysed usingEpi-IrjOVersion 6.43 (Centre for Disease Control, Atlanta) and the StaIistinlAml;sis
Sytan(SAS)Vemon 6.12.
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Results
Description ofthe Study Population
In total, 848 African women, whose home language was Zulu, were interviewed. Selected demographic characteristics of
respondents are shown in Table 1. Their mean age was 26.3 years (SD 7.7) and almost two thirds had an education level of
Grade 8 or above. Only 8.6% were employed (fonnallyor informally) and 23.9% were students or scholars. Most of the women
(61.6%) were in a stable relationship, but few were married (17.1%). Whilst nearly all respondents (97.2%) were resident in the
area, many of their partners (67.6%) were not, and 74.1% of these migrant partners did not return home for a month or longer.
In a few cases (n = 14) partners returned only once a year, usually for the Christmas holidays. Many respondents (58.8%) were
first pregnant in their teens and 41.3% of those under 20 years at the time of the survey were or had been pregnant at least once.
Current Contraceptive Practice
Less than one third (29.7%) of allwomen (N = 848) reported use of a contraceptive method at the time of the survey.
Only 1.3% of respondents reported the male condom as their current method and none was using the female condom. As
expected, the most commonly used methods were the long-acting progestagen only injectable contraceptives, depot
medroxyprogesterone acetate and norethisterone oenanthate, used by 22.1% of all the women. Current use of natural family
planning methods such as the calendar or rhythm method or the basal bodytemperature method was not reported.
Of those using a method (n = 252), 94.4% were using a modem method (injectable or oral hormonal contraceptive, male
condom, intrauterine contraceptive device, tubal ligation), 3.2% a traditional method and 2.4% other methods not registered with
the Medicines Control Council for contraceptive use (Table 2). In contrast to the widespread use of the injectable method
(74.2% of women practising contraception), the condom was used by only 4.4% of current users. In the age range 15-24 years,
73.0% of those using a method (n = 111) were using the injectable, whilst only four women (3.6%) were using the condom
(Table 3). Amongst students and scholars, 18.4% were using the injectable and only 1.0% used the condom (Table 4).
Reasons for Method Choice
In response to an open-ended question about reasons for choosing the injectable method, the most common reason given by
35.0% of respondents was that it was convenient. The method was considered to be convenient since it only has to be used
every two or three months, or because one does not have to remember to take it everyday as with the oral contraceptive. Nearly
one quarter of the injectable users (23.0%) chose this method because it is effective, often making statements such as its always
in my blood" or "it stays in the blood a long time". The third most common reason given for using the injectable is that it was
recommended by the clinic health personnel (19.7%). Some respondents (4.9%) simply stated that the method "suited them",
and others expressed a dislike for oral contraceptives because of side effects experienced (4.4%). A few respondents chose the
method because it could be used without their partner's knowledge (2.7%).
a24.8% iftk848uann intenieooirE?jXJrt1dthutky'll£resexually imaile(n = 136}, J7If!i!/W1l(n =39)orir{ertile(sdfifpzrtn:Jj,~ or
badah:Js~(n = 36}.
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Similar responses were given when injectable users were prompted to respond to each of a list of 10 possible reasons for
choosing the injectable method. Almost all (96.3%) the 187 injectable users indicated that they chose this method for
convenience, as they only had to return to the clinic evety two or three months. Others said it was effective (47.6%), it was
recommended at the clinic (37.4%), few problems or side effects were experienced (27.3%), it caused amenorrhoea (23.0%), it
was recommended by friends or relatives (21.5%), and it was a method that could be hidden from partners (20.9%). Although
not reported in response to the open-ended question, 52.9% agreed that they chose the injectable method because they felt that
it was a safe way to prevent pregnancy.
A quarter (25.8%) women were using a method other than the injectable, and the most common reason for method choice given
by43.3% in response to an open-ended question was related to injectable side effects. Although almost half of the women giving
this response had used the injectable method before, only 55.6% of these previous injectable users gave this as their reason for
current method choice. A few were using a method on the recommendation of their partner (n = 4), relatives or friends (n = 1),
or the health provider (n= 2). Six of the women giving this response were using the oral contraceptive and one was using the
withdrawal method. Of note is that seven women were using the condom and three were using thighsex, because these methods
were considered to provide protection against both pregnancy and sexually transmined diseases. The remaining condom users
indicated that they did not like the side effects of oral contraceptives or that their partner was often away and a regular
method was not needed.
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Ta1ie2 Current Contraceptive Practice (n = 252)






















































20 (18.0) 4(3.6) 6(5.4)
16 (14.0) 16(5.3) 5(404)
2 (704) 1(3.7) 5(18.5)
Injectablen(%)(years)
15-24 111 (44.0) 81(73.0)
25-34 114 (45.2) 87(76.3)
35-49 '~ 27 (10.7) 19(70.3)
>lQiyCH'1ImUYI our 44)lIDSw:tS I6Uga mtbcd(the iri«:talill
Age group Current users
Table 4 Contraceptive Practice of Scholars and Students (n =201)
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Reasons for not Using a Method.. .
Of the 848 women interviewed 703% were not usmg a contraceptive method. Reasons for not usmg a method are broadly
grouped as follows :,
1. Most women (66.8%) indicated that they did not need to practise contraception. These women reported that they had
never been sexuallyactive (11.1%), were not sexuallyactive (11.8%), had sex infrequently (11.1%), were pregnant
(6.6%), were wanting to conceive or waiting until after the birth of their first baby (11.0%), were breastf:eding (9.1%),
were menopausal, had had a hysterectomy, or their husbands were infertile (6.1%). Women who had sexinfrequently
and those who were' breastfeeding (202%) believed that they did not need to practise contraception, yet they were at
risk of an unplanned pregnancy. Also potentially at risk of an unplanned pregnancy were those who reported that they
were menopausal or had infertile husbands, as they may not have had these conditions clinicallyconfirmed.
2. Disapproval of contraception was given as a reason for non-use by 13.3%. Disapproval was based on partners' views,
personal views or the views of others, or on religious or cultural grounds.
3. Reasons related to the method itself such as side effects, health concerns and inconvenience were given by 14.6% of the
respondents, with over three quarters of reasons in this category related to side effects. Close to 90% of these women had
used a contraceptive method previously, most commonly the injectable method, suggesting that many had given reasons
based on experience.
4. Reasons related to the provision of contraceptive services were given by only 2.4% and included lack of knowledge about
contraceptives, long distances from the health facility, and that the respondent was too shy to go to the clinic.
5. Other reasons were given by 7.3% of the women. For instance, some respondents were awaiting parental permission
to use contraception while others said that they didn't have a reason.
In all, less than two thirds (612%) of those not using a method were not sexually active, were pregnant or wanting to get
pregnant, or had had a hysterectomy. This suggests an unmet need for more appropriate contraceptive methods or services than
those availableamongst nearly 40%of women not practising contraception.
Discussion
The pattern of low condom use and high injectable contraceptive use reported in this study is consistent with findings from the
SADHS. Given the high prevalence of HlV in rural areas of KwaZulu-Natal, the low use of condoms for contraception requires
attention. Only 11 women reported the male condom as their current method and none was using the female condom. The prac-
tice of thigh sex, which may offer some degree of protection against HlV and pregnancy, is also low with only three women
reporting that they use this method. Since teenage pregnancy rate is also high, the need for effective but appropriate contracep-
tive methods is clearlyevident.
Understanding why women choose a particular contraceptive method and recognising that many women do not need or
wish to use a contraceptive method and why, are essential to the provision of effective advice about Hl'V preventive measures.
Findings from this study assist in the development of pragmatic guidelines for counselling women about appropriate
contraceptive options.
Understanding Method Choice
Health workers play an important role in women's decisions to use injectable contraceptives. In this study, many injectable users
indicated that they chose the method because it was recommended at the clinic. Only two women using other contraceptive
methods gave this as a reason for method choice. This suggests that there are missed opportunities for counselling potential
condom uses about barrier method use to minimise the dual risk of pregnancy and Hl'V infection. Other reasons of note for
choice of the injectable were that it was a convenient and effective method that could be used secretly. The low use of condoms
may:be explained by their failure to meet these .criteria ~o the extent ~t the injectable does. The need by some for secrecy
particularly precludes the use of the condom, which reqUIres the cooperation of the partner. Where contraceptive efficacy is the
criterion for method choice, women at risk of HfV infection should be counselled to use condoms in addition to their hormonal
method.
. An important observation from this study is that at least 10 respondents had embraced the concept of dual protection -the
slIm~taneous pr~ventio~ of pregnancy and S11s -indicating that they were using the male condom or thigh sex because it
provided prote~tion ag~lIlSt pregnancy and S11s. This finding is encouraging as it may indicate that educational messages aimed
at dual protection. ~galIlSt unwanted pregnancy and HfV/S11s are reaching even remote rural areas of the country, or that
women are recogrusmg the need for dual protection.
'More than one reason was given by some respondents
XXll
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Understanding why Women are not Currently Practising Contraception .
Over two thirds of the women interviewed were not using a contraceptive method. Many had never been sexually active or were
sexually inactive at the time, and these women were not at risk of unwanted pre~nanc!or infection. However, nearly 40%. of
non- users were estimated to be at risk of an unplanned pregnancy and even more, mcluding those who were pregnant or wantmg
to conceive, were at risk of contracting HlV
Many of the women had migrant partners who were absent for long periods of time and a reason put forward for not
practising contraception was infrequent sexual intercourse. These women's contraceptive needs an: intermittent ~nd of~en
unpredictable. Provided that the partner is willing the condom (male or female) would be an appropnate contraceptive option
for them, particularly as a dual protection method, since several studies have shown that migrants are at greater risk of being in-
fected with HlV and other S'Ils.l"
The much promoted message "use condoms to prevent HlV" is clearly inappropriate and unhelpful for women trying to
conceive. These women, who are at risk of being infected, should be counselled about risk reduction strategies such as having
unprotected sexual intercourse onlyat the fertile period of the cycle.
The "use a condom" message, which generally refers to male condoms, is also inappropriate for women whose partners
refuse to use male condoms. For these women who want to prevent pregnancy the injectable remains a rational choice. The
female condom was not widely available in South Africa at the time of this survey; however, the national female condom
introductory strategy launched just prior to the survey is being expanded to more public sector health facilities.t! This will make
this female controlled method more widely available. However, it should be noted that two female condom acceptability studies
undertaken in South Africa have reported a mixed reaction to the acceptability of the female condom.2,16 Behavioural
interventions designed to develop negotiation and decision-making skills for women and to promote gender equality and respect
by men for women's reproductive rights are urgently needed. The promotion of mutual monogamy and other low risk sexual
behaviours is also important Where women attempt to negotiate condom use and fail, awareness of emergency contraception to
prevent pregnancy is important.
Women who do not need contraceptive protection; for example, those who are pregnant, should be encouraged to use
protective measures against HlV infection should they be at risk Breastfeeding women may derive a level of protection against
pregnancy, but this is not an effective contraceptive method and it does not provide protection against HlVIS11s. If the mother
is HlV positive breastfeeding also carries the increased risk of transmission of HlV to the child. Individualised counselling on
the appropriateness of breastfeeding is thus extremely important.
Since this study did not explicitly explore whether condoms were used concurrently with other methods
ofcontraception, it is possible that the number ofwomen practicing dual protection could have been
higher.
Recommendations
Dual protection against unwanted pregnancy and HlV1S11s is an appropriate strategy for many women in the context of South
Africa's HlV epidemic, and should be integrated into counselling about contraceptive options. Strategies to increase use of male
and female condoms should be promoted. First, for women wishing to delay or prevent pregnancy, counselling and decision-
making about appropriate contraceptive methods should take into account the dual risk of pregnancy and infection with
HIVISTIs. Second, appropriate counselling about reducing the risk of HlVISTIs for women wanting to conceive or
those not wishing or needing to practise contraception is also required. Third, health workers clearly play an important role
in decision-making about contraception and may be happier to promote condom use over the injectable method if they are
reassured about efficacy. Promoting the use of emergency contraceptive pills as a back-up for condom use may result in
increased likelihood of condom promotion. Fourth, more attention should be paid to promoting female condom, which
provid~s dual protection and is.under the control o~ women. Micr:obicides, which protect against HIVISTIs and pregnancy
are bemg developed and may m the future be an important option for women. The search for microbicides that are not
spermicidal is also underway. These research efforts should be vigorously supported. Finally, effective sexuality education
programmes are urgently required especially for young women who are particularly vulnerable to unplanned pregnancies and
HIV/STIs .
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Background: InSouth Africa,where health care resources are limited, it is important to ensure
that drugs provision and use is rational. The Esse"ntial Drug Ust includes depot
medroxyprogesterone acetate (DMPA) and norethisterone oenanthate (NET-EN) as injectable
progestagen-only contraceptives (IPes), and both products are extensively used.
Objectives and Methods: Utilisation patterns of the injectable contraceptive products DMPA
and NET-EN are compared in the context of current knowledge of the safety and efficacy ofthese
agents. Utilisation patterns were analysed by means of a Pareto (ABC) analysis of IPCs issued from
4 South African provincial phannaceutical depots over 3 financial years. A case study from rural
KwaZulu-Natal, South Africa, is used to examine utilisation patterns and self-reported side effects
experienced by 187 women using IPCs.
Results: IPCs accounted for a substantial share of total state expenditure on drugs. While more
DMPA than NET-EN was issued, NET-EN distribution from 2 depots increased over the 3-year
period . Since DMPAwas cheaper, if all NET-ENclients in the 1999/2000 financial year (annualised)
had used DMPA, the 4 depots could have saved 4.95 million South African Rands on product
acquisition costs alone. The KZN case study showed slightly more NET-EN (54%) than DMPA
(46%) use; no significantdifferences in self-reported side effects; and that younger women were
more likelyto use NET-EN than DMPA(p =0.0001).
Conclusions: Providing IPCson the basis of age is not appropriate or cost effective. Rational use
of these products should include consideration of the cost of prescribing one over another.
Introduction
Mfordabilityof drugs by developing countries is current-
lya topic of heated debate. In South Africa, where finan-
cial resources for health care are limited , and where
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health care costs are expected to soar as the HIVepidem-
ic escalates, it becomes increasingly important to ensure
that all drugs are rationally provided and used. The in-
jectable progestagen-only contraceptives (lPCs) depot
medroxyprogesterone acetate (DMPA) and norethister-
one oenanthate (NET-EN) are by far the most widelyuti-
lised contraceptives in South Africa, especially amongst
younger users and women living in rural areas [1]. Both
drugs are on the South African Essential Drug List [2]
and are available free of charge at public sector primary
health care facilities. Although not extensively docu-
mented, it is claimed that there has been a shift away
from the predominant use ofDMPA,which is given every
12 weeks, to NET-EN, given every 8 weeks, especially
amongst younger, nulliparous women [3, 4]. Combined
injectable contraceptives (CICs), which contain a combi-
nation of oestrogen and progestagen, are not registered
for use in South Africa.
The World Health Organisation's general criteria - safe-
ty, affordability, necessity and efficacy - for inclusion on
the Model List of Essential Drugs (EDL) [s] provide a
useful basis upon which to make decisions about drug se-
lection and rational use. Taking into account published
findings on efficacy, reversibility, side effects and safety,
this paper analyses IPC supply patterns and costs from
four pharmaceutical depots, and describes a case study
of IPC utilisation patterns and side effects in a rural sub-
district of KwaZulu-Natal, South Africa. Based on these
analyses, appropriate recommendations for the rational
use of IPCs are made.
What the literature tells us
Published clinical trials and reviews on efficacy, side ef-
fects, reversibility and safetyof DMPAand NET-EN were
sought by means of computerized and hand searches.
Copies of relevant publications and citations from these
publications were obtained and reviewed. Relevant in-
ternational and South African policy documents were
also reviewed. This extensive search revealed that:
DMPAis better researched than NET-EN, few studies di-
rectly compare DMPA and NET-EN, few clinical trials
have been undertaken in Southern Africa, few clinical
studies have been undertaken amongst young users, and
most published studies, upon which review after review
are based, were undertaken in the 1970Sand early 1980s.
Methodological differences in subject recruitment, ex-
clusion criteria, frequency and nature of procedures for
follow-up, types of observations made, method of re-
cording, methods of analysis and large intersite variabil-
ity in some studies, make it difficult to evaluate the
published data. Trusselet al. provide a useful account of
difficulties in analysing and comparing contraceptive ef-
ficacy trials [6]. Nevertheless, to the extent that this is
possible, a comparative synopsis of the efficacy, side ef-
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fects, delay in return to fertility and safety of DMPAand
NET-EN is provided in this section. It is not the purpose
of this paper to provide a detailed review, but merely to
highlight relevant findings. The authors can be contacted
for a more extensive bibliography.
Both IPCs are demonstrably highly effective. There are
minor differences in published efficacy rates of both
drugs depending on the study, timing of the first injec-
tion, the population, body weight, dosage regimen and
provider training. An illustration of the high efficacy of
these two products is provided by a World Health Organ-
isation (WHO) comparative trial [7]. According to this
study the efficacy of DMPA given every 90 days and
NET-EN given every 60 days are comparable, with a cu-
mulative z-year pregnancy rate of 0-4 per 100 woman-
years. In an evaluation of slarge controlled multicentre
studies, Kaunitz [8] reported that there were only 24
pregnancies among 7 849 women using DMPA for 122
496 patient-months. Trussel et al. [6] provide "summary
estimates of contraceptive failure" and give the lowest
expected, and typical percentage, of accidental pregnan-
cies in the United States, during the first year of use, as
0.3 for DMPAand 0.4 for NET-EN (unspecified dose in-
terval).
There is little direct comparative data on the reversibility
of DMPAand NET-EN. While return to fertility is report-
ed by some reviewers to be more rapid with NET-EN [9,
10], more recently, Bigrigg et al. [11] in examining early
data, suggest that there is no delay in return to fertility
with DMPAuse, if one considers the methodological bias
of earlystudies, which did not take in to account the date
of the last DMPA injection. They state further that "if
there is a delay it is not statistically significant and is less
than 30 days". Kaunitz gives the shortest reported time
before fertility is returned with DMPA, as 4 months after
the last injection i.e, 4 weeks after the due date of the
next injection [8] and, according to Hatcher et aI. return
to fertility is delayed by DMPAfor about 4 months longer
on average, compared with the combined oral contracep-
tive method, intrauterine contraceptive device, and con-
doms [12].
The poor side effect profile of progestagen-only injeeta-
bles is extensively documented. The most frequently re-
ported side effects, and those most likely to result in
discontinuation, are menstrual disturbances such as
amenorrhoea, irregular bleeding and heavy bleeding [3,
13]. Menstrual irregularities are reported to occur more
often with DMPA than with NET-EN use. For instance,
the WHO clinical trial undertaken in 1983 compared
menstrual disturbances resulting from DMPA given at
9o-day intervals, with NET-EN given every 60 days and
with NET-EN given every 60 days for 6 months and then
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every 84 days [7]. Significantlyless amenorrhoea was re-
ported by NET-EN users (on both dosage regimens),
than by DMPAusers. Amenorrhoea was also found to re-
sult in significantly higher discontinuation rates with
DMPA users than with NET-EN. During the first six
months of use, both dosage regimens of NET-EN were
reported to result in more defined cyclic patterns and
fewer prolonged bleeding and spotting episodes than
DMPA, but similar discontinuation rates were found
with the two products. However, in a study undertaken
in Egypt, despite the more frequent occurrence of men-
strual irregularities with DMPA,better one-year contin-
uation rates were found with DMPAthan with NET-EN
[14].Weight gain is also a commonly reported side effect
and in comparing DMPA and NET-EN, the findings on
weight gain appear to be similar. A multinational WHO
comparative clinical trial found no statistical difference
in weight gain between NET-EN and DMPA (both ad-
ministered at 12 week intervals) after a year of use - the
weight gain with NET-EN was reported as 1.5 kg and
with DMPA was 2.0 kg [15]. Headache was the most
common non-menstrual side effect reported in this com-
parative trial and was more frequently reported by
DMPAusers than NET-EN users, however, it is impor-
tant to note that in this study, NET-EN was administered
every 12 weeks.
IPCs are considered to be relatively safe contraceptive
methods [16, 17]and recent studies indicate that there is
little reason to be concerned about either DMPAor NET-
EN causing an increased risk ofbreast cancer [18]. How-
ever, the possible effect of DMPAon bone density, partic-
ularly in adolescents and long-term users is cause for
concern [19]. Little is published on the possible effect of
NET-EN on bone density. Findings from prospective
studies in progress are awaited.
The World Health Organization's Medical Eligibility
Criteria for Contraceptive Use classifies DMPA and
NET-EN together, and makes no differentiation between
the two in regard to their side effects or eontraindiea-
tions [20]. The only restriction this document makes
about age, for IPC use, is that "For women under 16years
of age, there are theoretical concerns regarding hypo-
oestrogenic effects...." P.54. The WHO states further that
there is no need to restrict use of progestagen-only con-
traceptive methods for nulliparous women. The Primary
Health Care Essential Drugs List for South Africa pro-
vides no guidelines with respect to the circumstances un-
der which DMPA rather than NET-EN should be
prescribed (or vice versa) [2].
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Methods
Supply patterns and costs
Consumption figures of IPCstock issued from provincial
pharmaceutical depots were requested from the Deputy
Director, Procurement ofthe South African National De-
partment of Health. Data for DMPAand NET-EN were
made available for the KwaZulu-Natal (KZN), Guateng
and Free State Provincial Pharmaceutical depots and for
the Port Elizabeth depot, which serves the western part
of the Eastern Cape Province. These four provinces (of
nine South African provinces) represent over 50% of the
total South African population. Gauteng has a mostly ur-
ban population and KZNand Eastern Cape are more ru-
ral. The following data were analysed for financial years
1997/8,1998/9, and for 1/04/99 to 7/12/99 ofthe 1999/
2000 financial year:
• Position number on Pareto (ABC) analyses for DMPA
and NET-EN. An ABC analysis is a method which ranks
drugs according to their annual usage (unit cost times
annual consumption). Class A items are the 10 to 20 %
which account for 75 to 80% of the funds spent. Class B
items have an intermediate contribution to total expend-
iture, whereas Class C items (the majority of items) ac-
count for a small percentage of funds spent. ABC
analyses are used to identify priority cost drivers for in-
tervention [21].
• Number of units of each item issued in the same time
period per depot.
• Total cost of each item per time period per depot (at
constant 1999 prices).
• Current and previous tender prices for DMPA and
NET-EN. Note exchange rate: 1 British Pound = 11
South Mrican Rands.
Case study: use patterns and side effects
Prevalence of IPC use was determined by means of a
community-based cross-sectional survey undertaken in
a rural sub-district in northern KZN,South Africa. Com-
mencing from a randomly selected starting point, every
second household was chosen until 40% ofhouseholds in
the sub-district had been visited. In this way, 849 house-
holds of an estimated 2088 were selected and, one wom-
an from each household, in the age range 15 to 49, was
randomly selected for interview. Verbal and written ex-
planations of the studywere provided to each woman se-
lected (in Zulu and/or English) and consent to
participate in the studywas requested. In all, 848 women
were interviewed and no-one refused to participate. Pri-
or to commencing the survey, workshops and meetings
were held to introduce the study to local traditional lead-
ers, community health workers, and health service pro-
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viders. Ethical clearance for the study was provided by
the Ethics Committee of the University of Durban-West-
ville.
Each woman selected was asked if she was currently us-
ing an IPC and those who were, were asked whether they
were using DMPA or NET-EN. Data were collected by
means of an extensive structured interview, including
questions on demographic characteristics, reasons for
http://www.biomedcentral.com/1472-6963/1/4
method selection, and problems and side effects experi-
enced. Interviews were conducted in Zulu, between Sep-
tember and December 1998. They were conducted
during the day from Mondays to Fridays, but where a se-
lected woman was not home, a revisit was made in the
evening or on a Saturday. Data were coded, double en-
tered and analysed using Epi-Info Version 6.43 and the
SAS Version 6.12.
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*Exchange rate: I British Pound ~ I I SouthAfrican Rands(SAR) # Tender not awarded




DMPA 3 4 4
NET-EN 2 3 2
KWAZULU-NATAL
DMPA 4 6 4
NET-EN 19 19 19
FREE SATE
DMPA 2 3 5
NET·EN 5 5 6
PORT ELIZABETH
DMPA 3 6 3
NET·EN 4 4 4
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Figure I
Ratio of NET-EN:DMPA issued from the four pharmaceutical














Supply patterns and costs
Cost of injectable contraceptive products
DMPA products issued at primary health care outlets in
the three financial years analysed were obtained from
the original patent holder (Pharmacia-Upjohn) and a ge-
neric manufacturer (Aspen Pharmacare). NET-EN was
available only from the innovator (Schering) . Table 1
shows that the acquisition cost of a vial of both DMPA
and NET-EN products increased every year, and that the
cost of both DMPA products rose particularly steeply. In
the 1999/2000 financial year, the generic product, was
almost the same price as the innovator product. Their
costs were exactly the same in the 1999/2000 fiscal year.
Since DMPA is given less frequently than NET-EN, cost
per couple years ofprotection (CYP) provides a more ac-
curate cost comparison of DMPA and NET-EN. Based on
the 1999/2000 state tender prices for the DMPA and
NET-EN innovator products, the cost per couple year
was SAR28.68 for NET-EN (6 vials per year) and
SAR19.12 for DMPA (4 vials per year). If the calculation
were based on the DMPA generic product price, use of
DMPA would be even cheaper (SAR17.16). It should be
noted that the cost of syringes, needles and swabs, per-
sonnel costs and client transport and time were not in-
cluded in the calculations. These costs can be
considerable and are obviously higher for NET-EN be-
cause it is administered more frequently.
Analysis ofannual expenditure on DMPA andNET-E.N
In all 4 depots, both IPCs consumed an important share
of total drug expenditure (table 2). A Pareto analysis
shows that both DMPA and NET-EN appeared in the top
10 in each year (based on actual volumes multiplied by
constant 1999 prices), with the exception of NET-EN in
KZNwhere itwas19thin 1997/8,1998/9 and 1999/2000.
More was spent on NET-EN than DMPA in Gauteng in
all 3 years, but less in the other 3 depots. Only in 1998/9
in the Port Elizabeth area was more spent on NET-EN
than DMPA. Total annualised expenditure on both prod-
ucts in the 4 depots in 1999/2000 was projected to be
SAR28.77 million.
Ratio of NET-EN:DMPA issued
The ratios of NET-EN:DMPA issued from the 4 depots
were calculated based on CYPrather than on number of
vials issued. As shown in Figure 1, DMPA was increasing-
ly used in Port Elizabeth where the ratio of NET-EN:DM-
PA decreased from 0.64 in 1997/8 to 0.57 in 1999/2000.
In Free State the market share was more or less stable
(0 .42,0.44, 0 .40). A similar picture emerged in KZN
(0 .22,0.23,0.25), with some increase in NET-EN use.
However, in Gauteng, while DMPA was still used most,
NET-EN use was clearly increasing (0 .67, 0.73, 0.81).
Counting the cost ofinjectable contraceptive product droice
If all NET-EN clients in the 1999/2000 financial year
(annualised) had been given DMPAinstead, the 4 depots
together might have saved SAR4.95 million . Conversely,
ifNET-EN had been issued to all DMPAclients, then the
estimated additional cost in the same year for the 4 de-
pots would have been SAR9.35 million. Savings and ad-
ditional costs would be increased if other costs (surgical
supplies, personnel costs, client transport etc.) were in-
cluded. The savings are calculated on the annualised to-
tal CYPfor innovator versions of both DMPA and NET-
EN. If the price of the cheaper generic preparation of
DMPA had been used in the calculation, the savings
would have been greater.
To illustrate the potential savings or additional costs fur-
ther, in KZl'f, a 9.0% saving on the expected 1999/2000
annual IPC drug bill might have been effected if only
DMPA had been supplied. On the other hand, if only
NET-EN had been available, the additional load would
have been 36.5%. In Gauteng, the savings or additional
costs could have been 18.3% and 22.6% respectively.
Case study: use patterns and side effects
Injectable contraceptive prevalence andcost
All respondents (848) were African, Zulu-speaking
women in the age range 15-49 years . Of these, 187
(22.1%) were using an injectable contraceptive method,
either the innovator product of DMPA or NET-EN. For-
ty-six per cent (86) of the IPC users were using DMPA
and 54% (101) were using NET-EN. The mean age of
DMPA users was 29.6 years (median 29, range 18-49)
and that of NET-EN users was 23.2 (median 23; range
17-37)· Younger women were thus more likely to use
NET-EN than DMPA (p = 0.0001). The age distribution
of DMPA and NET-EN users is shown in Figure 2. The
mean length of use was 2.2 years (range 0.1 to 11).
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Figure 2
Age distribution of DMPA and NET-EN users
The ratio of NET-EN:DMPA users in this rural sub-dis-
trict was 1.2 to 1. Based on 1999/2000 product costs, by
supplying only DMPA, a saving of 21.3% on the annual
drug bill for IPCs could have been achieved by the local
health facility. On the other hand, if only NET-EN had
been supplied, the annual IPC cost would have increased
by 18.1%.These figures are based on product costs alone.
Reasons for product choice
Current users were asked, by means of an open-ended
question, why they preferred the injectable product they
were using, and the following findings are of note:
- Many DMPA users (42 .4%) indicated that they pre-
ferred this product because it was"stronger". On the oth-
er hand, NET-EN was favoured by 36.0% of those using
it as it was regarded as "weaker" or "lighter".
- Concern about delayed return to fertility with DMPA
was expressed by 5.0% of NET-EN users and 14.0% indi-
cated that they chose NET-EN because it did not delay
return to fertility.
- The idea that the NET-EN is for younger women or
teenagers and DMPA for older women was expressed by
14.6% of the IPC users. This preference is clearly reflect-
ed in the age distribution of DMPA& NET-EN users de-
picted in Figure 2.
- Recommendation by health worker was given as one of
the most common reasons for product choice (21.1%).
- Relatively few women (6.5%) mentioned that concern
about side effects influenced choice of either product.
Sideeffects with injectable contraceptives
IPC users were asked to indicate what side effects, if any,
they were experiencing with DMPA or NET-EN by re-
sponding to a list of 22 possible side effects. Consistent
with the international literature, many women reported
hltp:llwww.biomedcentral.com/1472-6963/1/4
menstrual irregularities such as amenorrhoea, spotting,
heavy periods or irregular periods (table 3). Other side
effects commonly reported were vaginal wetness and
weight gain. The side effect profile for DMPAor NET-EN
users was similar with no significant differences found
between users of the two products in terms of their expe-
rience of side effects.
Discussion
In highlighting key issues in financing family planning
services in Sub-Saharan Africa, Janowitz et aI. make the
following statement "Given limited resources, the uni-
versal provision of methods based on demand and with-
out regard to cost will restrict the number of individuals
whose need for family planning services can be met" p.
64 [22]. The balancing of needs and resources becomes
even more challenging when attempting to meet repro-
ductive health needs more broadly. For instance, in de-
veloping countries like South Africa many drugs, such as
antiretrovirals for the management ofHIV, are not avail-
able through the public sector. Careful analysis of cur-
rent expenditure on drugs is thus required so that
resources are allocated to meet changing therapeutic
needs.
Findings presented in this paper show that IPCs account
for a substantial share of the total state expenditure on
drugs in South Africa. Of the two IPCs available on the
EDL, DMPA is a cheaper option than NET-EN, even if
only considering acquisition costs . Analysis of supply
patterns from the 4 pharmaceutical depots shows that if
all NET-EN clients had been given DMPA,between 9.0%
and 18.3% of the expected annual drug bill for IPCs could
have been saved per depot. Rational use of drugs cannot
however be based on cost alone and clinical criteria, such
as efficacy, safety, and acceptability of side effects, must
also be considered. The context within which contracep-
tion is provided should also be taken into account. An ex-
tensive review of the literature on IPCs shows little
difference between NET-EN and DMPAin terms of effi-
cacy, safety, reversibility and side effect profile. Howev-
er, a systematic comparative review has not been
published and little clinical data on African women are
available. NET-EN appears to have a slightly better side
effect profile and a slightly shorter delay in return to fer-
tility. DMPA is marginally more effective and is more
convenient as users onlyhave to return to the clinic every
12 weeks rather than after 8 weeks, as is the case for
NET-EN users. As noted earlier, no differentiation in re-
gard to side effects or contraindications of the two prod-
ucts is made by the WHO in terms of its medical
eligibility criteria for contraceptive use [20].
Findings from the KZN case study show that slightly
more NET-EN was used than DMPA. No significant dif-
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ferences were found in self-reported experience of side
effects. What does emerge clearly is that NET-EN is
viewed as the product of choice for young women and
DMPA for older women. This is reflected in reasons giv-
en for product preference by clients, and in the age dis-
tribution of DMPA and NET-EN users. Further, health
workers appear to play an important role in decision-
making about which IPC product is provided. That dif-
ferent products are considered to be more appropriate
for different age groups may be linked to the perception
that DMPAis "stronger" while NET-EN is "weaker", and
may well be related to concerns about delay in return to
fertility after IPC use, particularly with DMPA. This is
consistent with results from a study undertaken in the
Northern Province of South Africa where providers were
found to recommend NET-EN for younger women based
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on their perception that DMPA use may result in perma-
nent infertility, whilst NET-EN was considered ".... less
strong and 'usually reversible' " p. 13 [4]·
Age as a criterion for prescribing one or other IPC prod-
uct is not supported by the literature, and some policy
documents and publications specifically debunk the na-
tion that IPCs should be restricted according to age. For
instance, Lande recommends that:
"Providers may need to reassure clients and the public
that injectables do not cause infertility but to note that
women should expect a wait of some months after stop-
ping injectables to become pregnant. Service policies
based on a fear of infertility - in particular, age and parity
restrictions - can be dropped P.7 [23].
Table J: Side effects most frequently reported by DMPAand NET-EN users
Side Effect DMPA(%) NET-EN (%) PValueo
(n =84) (n =95)
Menstrual irregularities
Amenorrhoea# 67.5 58.9 0.240
Spotting 9.5 12.6 0.510
Heavy periods 8.3 7.4 0.792
Irregularperiods 3.6 10.5 0.074
Longer periods 2.4 4.2 0.497
Dysmenorrhoea 1.2 1.1 0.930
Vaginal wetness 22.6 14.7 0.175
Weightgain 14.3 8.4 0.214
Loss of libido 10.7 8.4 0.601
DizZiness 10.7 6.3 0.289
Headache 10.7 4.2 0.094
Nausea 9.5 3.2 0.077
Vaginal discharge 8.3 3.2 0.132
Vaginal discharge with odour 7.1 3.2 0.223
: clnhc~udes thirty breastfeeding women. Although amenorrhoea was reported asa sideeffectof IPCuse. it could have been lactational amenorrhoea
i-square(I degree of freedom,significance tested at the 5% level)
xxxi
BMC HealthServicesResearch (2001) 1:4
The second draft of the South African Department of
Health's Draft National Framework & Guidelines for
Contraceptive Services explicitly states that:
"Youngclients should not beprevented from using either
DMPAorNET-ENbecause of their age." p.64 [24].
If one were to embrace the WHO promoted Essential
Drugs concept [5] the decision about which IPC to supply
should be made on cost since DMPAand NET-EN have
comparable efficacy and safety profiles. Based on the
cost analysis presented in this paper, DMPA should be
the product selected. However, reducing contraceptive
options flies in the face of progressive reproductive
health policies which promote expansion of contracep-
tive choice. For instance, the WHO "is giving priority to
improving access to high-quality care in family planning
through a variety of strategies" p.z, and lists one of these
strategies as "promoting the widest availability of differ-
ent contraceptive methods so that people may select
what is most appropriate to their needs and circumstanc-
es" p.z [20]. The Programme of Action adopted at the In-
ternational Conference on Population and Development
held in Cairo in 1994 recommended that family planning
programmes should "Recognize that appropriate meth-
ods for couples and individuals vary according to their
age, parity, family-size preference and other factors, and
ensure that women and men have information and ac-
cess to the widest possible range of safe and effective
family-planning methods in order to enable them to ex-
ercise free and informed choice" P.39/132 [25]. The Pop-
ulation Council's new approach to contraceptive
introduction in developing countries involves an assess -
ment of the context of contraceptive use in that country,
on the basis of which "recommendations for upgrading
contraceptive services - which could include introducing
new methods, improving the utilisation of existing ones,
and/or removing one or more from the method mix". p.i
[26].
The injectable contraceptive method is an important op-
tion in South Africa, since many women choose this
method because its use does not require partner knowl-
edge or consent [27]. The review of the literature shows
that menstrual irregularities are reported to occur more
often with DMPAthan with NET-EN use. In cases where
side effects such as amenorrhoea are particularly prob-
lematic with DMPA, NET-EN may be a good alternative.
Byproviding NET-EN explicitly as a second-line option,
the range of contraceptive products would be restricted,
but not reduced.
Conclusions and Recommendations
Providing IPCs on the basis of age is not appropriate or
cost effective.Training of health workers and counselling
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of clients to correct this misconception is clearly re-
quired. Where clients require immediate return to fertil-
ity upon discontinuing contraception, neither IPC
preparation is ideal. Since DMPA is a cheaper option
than NET-EN, health worker training about the rational
use of injectable contraceptives should include consider-
ation of the cost implications of prescribing one product
over another. DMPAshould be consideredas the first op-
tion, but where DMPA is not well tolerated, NET-EN
should be available as a second option. It is also recom-
mended that a comparative systematic review of DMPA
and NET-EN be undertaken. Based on the outcome of
this review, consideration may be given to conducting a
comparative clinical trial of NET-EN and DMPA when
used by African women.
Consideration should be given to encouraging the regis-
tration of the combined injectable contraceptive in South
Africa, which has a better side effect profile than the IPCs
[28]. This would be an expensive option thus combined
injectable contraceptives should only be provided where
side effects with the IPCs are intolerable. Abetter contra-
ceptive option, especially for young people, might how-
ever be the male or female condom with back up of
emergencycontraceptive pills to provide dual protection
against unwanted pregnancy and HIVand other sexually
transmitted infections.
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Women who use injectable contraceptives struggle
with the many side effectsassociated with their use. Yet,
despite these side effects, long acting progestogen
injectable contraceptives are by far the most popular
method ofcontraception in South Africa, and have been
for many years (Smit & Venter, 1993; Chimere-Dan,
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Abstract
This paper reports on the common experience of vaginal wetness amongst South African users of progestogen-only
injectable contraceptives. The observations emerged in the course of a community-based cross-sectional household
survey undertaken in a rural district of KwaZulu-Natal in South Africa. The purpose of the survey was to elicit self-
reporting on side effects of injectable contraceptive methods. Eight hundred and forty-eight women aged 15-49 were
interviewed and 22.1% reported current use of an injectable contraceptive method, either depot medroxyprogesterone
acetate (Depo-Provera'P) or norethisterone oenanthate (Nur-Isterate'f), Other modem methods used were oral
hormonal contraceptives (4.5%), male condoms (1.3%), the intrauterine device (0.1%), and tuballigation (0.1%).
Vaginal wetness was reported by 18.4% of users and was one of the most common side effects, second only to
amenorrhoea (62.5%). It was also what 17.5% of the women liked least about using this method. According to almost
half the respondents, men regard women who use the injectable contraceptive as "wet", "cold" and/or "tasteless".
These survey findings were supported by participants of 14 focus group interviews held in the sub-district, Since some
South African men may prefer dry sex the perception that the injectable contraceptive increases vaginal wetness may be
problematic for women who use it. Whilst vaginal wetness can only be classified as a subjective side effect at this stage,
further investigations are needed as many South African women opt to use this method. © 2002 Elsevier Science Ltd.
All rights reserved.
Keywords: Progestogen injectable contraceptives; Side effects; Vaginal wetness; South Africa
1996; Beksinska, Rees, Nkonyane, & McIntyre, 1998).
Depot medroxyprogesterone acetate was first introduced
in South Africa in the late 1960s (Kaufman, 1997), and
in the early 1990saccounted for between 66% and 80%
of contraceptive use (Reproductive Health Task Force,
1994). In rural areas of South Africa injectables have
become almost exclusivelythe method of choice of both
user and provider. The two injectable contraceptives
available in South Africa are progestogen-only prepara-
tions, depot medroxyprogesterone acetate (Depo-Pro-
vera~~ and Petogen ~\,) and norethisterone oenanthate
(Nur-Isterate'f), The combined injectable contraceptive,
containing a combination of oestrogen and progestogen




In order to test for significant differences in the
prevalence of side effects between users of depot
medroxyprogesterone acetate and norethisterone oe-
nanthate, it was determined that at least 40% of the
estimated 2088 households should be visited. The sub-
district comprises 13 local areas, known as isigodi.
Commencing from a randomly selected starting point,
every second household in each isigodi was chosen until
40% of households in each isigodi had been visited.
Among women in the age range 15-49 years, one
woman was randomly selected to be interviewed from
each household visited. Verbal and written explanations
were given (in Zulu and/or English) and no one refused
to participate. In all, 848 women were interviewed.
Community groups active in the study area were
identified by key informants living in the area. Focus
groups interviews (thematic guided discussions) were
held with 14 groups identified in this way, to draw out
contextual information and to provide insight, depth
and perspective to the quantitative cross-sectional data.
It is important to note that both women and men were
focus group participants. Six groups were comprised of
women only, two of men only, and six of women and
The study was undertaken in a rural sub-district in the
province of KwaZulu-Natal, South Africa. The popula-
tion in this sub-district is estimated at about 20000.
Contraceptive methods are provided by the only health
facility in the area, a district hospital which houses a
family planning clinic. Prior to commencing the survey,
workshops and meetings were held to introduce the
study to local leaders, community health workers, and
health service providers. Ethical clearance for the study
was provided by the Ethics Committee of the University
of Durban-WestviUe.
Research site
Both quantitative and qualitative data were collected
by means of a cross-sectional, community-based house-
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tyre, 1999;.Brown & Brown, 20(0), the perception that
the injectable contraceptive increases vaginal wetness
may be problematic for South African women who
choose to use it. This paper documents reports of, and
perceptions about "vaginal wetness" with the injectable
contraceptive method.
is not yet available in South Africa and all reference to
injectable contraceptives in this paper is confined to
progestogen-only products.
Side effects reported by South African women are, on
the whole, consistent with those reported elsewhere in
the world (Fraser & Weisberg, 1981; Paul, Skegg, &
Williams, 1997), with amenorrhoea and other menstrual
disturbances the most common (Beksinska et aI., 1998).
In addition, however, women refer frequently to the side
effect described or translated from the vernacular as
"vaginal wetness", and no reports of this side effect can
be found in the published medical literature. However,
four published references have been found which report
vaginal discharge as a side effect. One quotes vaginal
discharge as a rare symptom of depot medroxyproges-
terone acetate (Tyler, 1970). Another reports vaginal
discharge as a temporary, short-lived complaint, asso-
ciated with the use of depot medroxyprogesterone
acetate (zartman, 1967), while the third refers to it as
a major side effect (Schwallie, 1976). El-Mahgoub and
Karim (1972) report vaginal discharge as a minor side
effect of norethisterone oenanthate. Vaginal discharge
was also reported as a side effect among injectable
contraceptive users at a family planning clinic in
KwaZulu-Natal, South Africa (Smit, Goga, & Khan,
1989a; Smit, Mahabeer, & Naranbhai, 1989b). The
product brochure of Petogen'P, the locally manufac-
tured depot medroxyprogesterone acetate (DMPA)
product, lists vaginal discharge under "other side
effects" (Intramed, 1993). No such side effect is listed
in the product brochures of Nur-Isterate'f and Depo-
ProveraP (Schering (Pty.) Ltd., 1992; Pharmacia and
Upjohn (Pty.) Ltd. , 1993). It is not clear whether the
early reports of vaginal discharge, and the vaginal
wetness reported in the present study, are analogous.
Whether either of these effects is in reality a consequence
of injectable contraceptive use is also unclear, and if so
the mechanisms by which they occur are not under-
stood.
This paper reports on a study undertaken in a rural
community of KwaZulu-Natal. The purpose of the
study was to establish the prevalence of long acting
injectable hormonal contraceptive use, to elicit self-
reporting of associated side effects from injectable users,
and to obtain the views of users, non-users and
community groups about side effects and problems
experienced with injectable contraceptive use. It was in
respect to the reported side effects that interesting
insights surfaced with regard to notions of "wetness"
and perceptions of the link between injectable hormonal
contraceptives and vaginal wetness. Since studies have
shown that men and women in many parts of Central
and Southern Africa have a preference for dry sex
(Brown, Ayowa, & Brown, 1993a; Brown, Brown, &
Ayowa, 1993b; Civic & Wilson, 1996; Morar & Abdool
Karim, 1998; Beksinska, Rees, Kleinschmidt, & McIn-
1512
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men. The composition of the groups is provided in
Table 1.
Data collection
An extensive structured interview schedule was
administered during home visits. The interview schedule
was designed in consultation with health providers,
other researchersand interviewers. A thorough reviewof
instruments used in studies with similar methodologies,
including the 1998 South African Demographic and
Health Survey instrument (Department of Health of
South Africa, 1999) was also undertaken. Included in
the interview schedule were questions on household
demographic characteristics; respondents' contraceptive
history; user experiencessuch as reasons for selection of
the injectable contraceptive, and problems and side
effects experienced with this method; knowledge, per-
ceptions and opinions about injectable contraceptives;
relevant medical history; and plans about future contra-
ceptive use.
After much consultation, the approach of partial
translation of key phrases was adopted to ensure that
nuances of meanings were not lost in the translation
process. An extensive participative workshop was held
to identify key phrases for translation. Senior research-
ers, the fieldwork manager and fieldworkers were
involved in this process. Key phrases identified for
translation were printed on the interview schedule in
English and Zulu. For instance, the English and Zulu
translation of all side effects listed, including increased
vaginal wetness and vaginal discharge, appeared one
below the other in all cases. The instrument was
subjected to face validation (Katzenellenbogen, Joubert ,
& AbdoolKarim, 1997) by a group of Pharmacology
Table 1
Composition of focus groups
master's students, and a skilled English/Zulu translator,
and was piloted in a neighbouring sub-district.
Since almost all the respondents were expected to be
Zulu speakers, interviewers whose first language was
Zulu, but who were also fluent in English, were
employed. They were all women, recruited from the
study site, and were integrally involved in the develop-
ment and translation of the interview schedule. Inter-
viewers were intensively trained to standardize verbal
translation of the complete instrument during interview-
ing. All the interviews were conducted in Zulu and the
quality of interviewingwas assessedon a daily basis. The
interviews took place between September and December
1998 and were largely conducted during the day from
Monday to Friday, but where a selectedwoman was not
home, a revisit was made in the evening or on Saturday.
A semi-structured aide memoire was designed for the
focus group interviews. Six themes, identified from
responses to the individual household interviews, were
included for discussion. The experience of vaginal
wetness was included in the schedule as the fourth
theme. The other five themes were: general views and
opinions on contraception; general views about inject-
able contraceptive use; side effects associated with
injectable contraceptives; the use of the injectable
contraceptive in the context of high HIV prevalence;
and the views of community leaders and elders on the
use of contraceptives. The focus groups were held from
February to April 1999 and were facilitated by a
moderator and a recorder. The interviewers from the
survey were trained to facilitate the group discussions
and the fieldwork manager, a man, was the moderator
for the groups which included men. Discussions
were conducted in Zulu, tape recorded, transcribed
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Grade 11 and 12 secondary school boys
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Number of women aged 15-49 (reproductive age)
Total


























1514 J. Smit et al. / Social Science & Medicine 55 (2002) 1511-1522
information was collected from each participant of each
focus group at the end of the group discussion.
Analyses
Household interview schedules were coded and
double entered using Epi-Info Version 6.43 (Centres
for Disease Control and Prevention, Atlanta). The
Statistical Analysis System (SAS) Version 6.12 (SAS
Institute, Cary Ne) was used for statistical analyses.
Statistical methods employed were univariate statistics.
Differences in quantitative variables were assessed using
Student's r-test. Tests of significance for categorical
variables were based on the Chi-squared test or Fisher's
exact test as appropriate. All p-values were based on a
two-sided test. A p-value of less than or equal to 0.05
was considered to be statistically significant.
Focus group interviews were coded and analysed




All respondents (n = 848) who participated in the
community-based survey were African, Zulu-speaking
women. One hundred and eighty-seven women (22.1%)
were using the injectable contraceptive method at the
time of the survey, and it is this sub-sample which forms
the main focus of this paper. The majority of the
injectable users (75.3%) had an education level of Grade
8 (8 years of schooling) or above and 61.0% were
unemployed. Their mean age was 26.1 years (median 25;
range 17-49). On average , they had 1.9 living children
and the maximum number of living children was seven.
The mean age at first pregnancy was reported to be 19.2
years. The youngest age at first pregnancy was 12 and
the oldest was 30, with 7.2% first pregnant when they
were under 16 years and 60.2% when they were under
20. The average age at first contraceptive use was 22. I
years with an age range of 16-42 years.
Table 2 shows that injectable contraceptive users had
attained a higher education level than non-injectable
users (p = 0.001), more were in a stable relationship
(p<O.OOI) and were unemployed (p = 0.025), and they
were more likely, on average, to have fewer children
(p = 0.005). In other respects , the demographic char-
acteristics of injectable contraceptive users were similar
to those not using this method.
The total number of women participating in the focus
group discussions was 63 and there .were 37 male
participants (Table 1). The age range of the women
was 17-60 years and that of the men was 18-75 years.
The age range and gender of the participants of each
focus group are provided in Table 1.
Contraceptive use
Less than a third (29.7%) of all respondents (n = 848)
interviewed at household level reported use of a contra-
ceptive method at the time of the survey. Of these, 187
(22.1%) were using an injectable method, either Depo-
Provera 'f (DMPA) or Nur-Isterate'f (NET-EN), mak-
ing the progestogen injectables by far the most popular
contraceptive method. Other modem methods used
were: oral hormonal contraceptives (4.5%); male con-
doms (1.3%); the intrauterine device (0.1%); and tubal
ligation (0.1%). Traditional methods such as withdrawal
and thigh sex were reportedly used by 0.9%, and
medications not registered for contraceptive use (e.g.
quinine) were being used for contraceptive purposes by
0.7% of respondents. Twelve (24.0%) of the women
participating in the focus group discussions, who were of
reproductive age (15-49), were using the injectable
method.
Injectable contraceptive use
Forty-six per cent (86) of the women on injectables
were using Depo-Provera'f and 54% (101) were using
Nur-Isterate'P, The mean length of use was 2.2 years
(range 0.1-11), with 41.2% (71) using injectable contra-
ceptives for 1 year or less, 23.5% (44) using them for
more than a year, but less than 2 years, and 10.2% (19)
using them for 5 years or more.
Almost all injectable users (96.3%) chose the method
for convenience, as they only had to return to the clinic
every two months for NET-EN or every three months
for DMPA. Respondents could provide more than one
reason, and other reasons given were that: it was
perceived to be safe (52.9%); it was effective (47.6%);
it was recommended at the clinic (37.4%); few problems
or side effects were experienced (27.3%); it caused
amenorrhoea (23.0%); it was recommended by friends
or relatives (21.5%); and it was a method that could be
hidden from her partner (20.9%). Whilst many side
effects were reported, as described in the next section,
the majority of the injectable users (86.0%) were
satisfied with the method, 6.5% were dissatisfied and
7.5% were unsure how they felt. Those who expressed
dissatisfaction, only 12 women, indicated that their
dissatisfaction was related to menstrual problems
(61.5%) and/or to what they referred to as vaginal
wetness (38.5%). A description of vaginal wetness is
given in the next section. Almost all (98.4%) indicated
that they would continue to use this method.
Participants of the focus group discussions corrobo-
rated the above survey findings, being of the opinion
that the injectable contraceptive was the most popular
xxxvii
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Table 2
Selected demographic characteristics of respondents according to injectable contraceptive user status (injectable users: n = 187; non-
users n = 661)
Characteristic Women using injectable
contraceptives
Women not using injectable p-value
contraceptives
Age (years)
0.636Mean (SO) 26.1 (5.9) 26.4 (8.1)
Range 17-49 15-48
Education level grade 8 or above (%) 75.3 62.3 0.001
Unemployed (%) 61.0 52.8 0.025
Average household income of SARI000 per month or less (%) 91.6 92.3 0.775
Marital status
Married" 13.4 18.2 0.125
Stable relationship 77.5 57.0 <0.001
Mean number of living children 1.9 2.4 0.005
Maximum number of living children 7 10
Age at first pregnancy (years)
Mean (SO) 19.2 (2.9) 19.2 (3.2) 0.777
Range 12-30 12-40
Age at first contraceptive use (years)
Mean (SO) 22.1 (4.9) 21.6 (4.9) 0.081
Range 16-42 14-41
"By civil, religious, traditional or customary ceremony.
method in the area. The main reasons given for its
popularity were:
• it is convenient, especiallyin that one does not forget
to take it, as was thought to be the case with oral
contraceptives,
• it is effective,
• it can be hidden from one's partner and others.
It was felt that whilst women experience many
problems with the injectable method, they will continue
to use it. The followingstatements illustrate these views:
It is [used] because one forgets to take the pill. And
with the injection, you forget nothing, because you
might already have many children or maybe you have
a small baby, and you do not want to get another
one, so using injection is good although it has got
problems. It stays a long time in the blood. It is also
effective (female primary school teacher).
... there are lot of side effectsassociated with the use
of the injection, but it still comes number one. [This
is] because you will find that some of their husbands
or partners do not like their women to use methods
of contraception, and the injection will only be
known by her-whereas there is no hiding place for
the pill, the husbands find them within no time
(nurse).
They do not want to fall pregnant, they tolerate all
kinds of side effects for only one thing which is
prevention of pregnancy (high school girl from group
of girls and boys).
Side effects
Injectable users interviewed in the household survey
were asked to indicate what sideeffects, if any, they were
experiencing with the injectable contraceptive method.
They were first asked to respond to an open-ended
question about their experienceof side effects, and were
subsequently prompted to respond to a list of 22
possible side effects. This list was compiled after a
comprehensive review of the published and unpublished
literature and after consultation with family planning
health care providers. Both English and Zulu versions of
each side effect appeared on the interview schedule. In
responding to this list, the majority of women (88.4%)
reported that they experienced at least one side effect
and 7% reported 5 or more side effects. The side effects
most commonly reported were amenorrhoea (62.5%),
vaginal wetness (18.4%), weight gain (11.2%) and
spotting (11.2%) (Table 3). The side effect profile for
DMPA and NET-EN users was similar (Table 3). No
significant differences were found between DMPA users
and NET-EN users in terms of their experience of side
effects. Findings from the unprompted version of the
question on side effects were consistent with the
prompted responses, but frequencies of reporting were
lower. All those who spontaneously reported vaginal
wetness as a side effect, also reported vaginal wetness
when prompted. Again, amenorrhoea and vaginal
xxxviii
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Table 3
Side effects reported by DMPA and NET·EN users
Side effecta DMPA (%) (n = 84) NET-EN (%) (11 =95) Total % (11 - 179)
Amenorrhoea'' 67.5 58.9 62.5
Vaginal wetness 22.6 14.7 18.4
Weight gain 14.3 8.4 11.2
Spotting" 9.5 12.6 11.2
Loss of libido 10.7 8.4 9.5
Dizziness 10.7 6.3 8.4
Heavy periods 8.3 7.4 7.8
Irregular periods 3.6 10.5 7.3
Headache 10.7 4.2 7.3
Nausea 9.5 3.2 6.1
Vaginal discharge 8.3 3.2 5.6
Vaginal dischargewith odour 7.1 3.2 5.0
Longer periods 2.4 4.2 3.4
aSide effects reported by five or less respondents are not listed. These side effectswere:hair falls out, depression, painful periods,
breast tenderness, sweating, bloating of abdomen, bloating of breasts, delayed return to fertility, vaginal dryness.
b Amenorrhoea is the absenceof menstrual periods (Hatcher, Rinehart, Blackburn, Geller,& Shelton, 1997). The number of women
reporting amenorrhoea as a side effectof the injectablecontraceptive includes thirty breast feedingwomen. The amenorrhoea could
have been lactational amenorrhoea.
CSpotting refers to light vaginal bleedingthat occurs at a time other than during a menstrual period (Hatcher et al., 1997).
moistness were the most frequently experienced side
effects, reported by 45.3% and 8.4%, respectively.
In response to an unprompted question in the
household survey, none of the women using contra-
ceptive methods other than the injectable reported any
of the side effects most frequently experienced by
injectable users. However, in the focus groups discus-
sions, reference was made to vaginal wetness being a
problem with use of oral hormonal contraceptives only
once in each of three groups. In each of these cases, the
participants linking vaginal wetness to oral contra-
ceptives were men.
Vaginal wetness was the second most common side
effect reported by survey respondents (see Table 3), and
was reported separately from vaginal discharge. Vaginal
wetness, vaginal discharge, and vaginal discharge with
unpleasant odour were listed 15th, 16th and 17th,
respectively, on the list of side effects provided. Whilst
the nature of the difference in the experience of vaginal
wetness and vaginal discharge was not explicitly
explored in the survey, different Zulu phrases were used
in referring to vaginal wetness and vaginal discharge.
The distinction was identified in the development and
translation of the interview schedule prior to commen-
cing the survey and has been corroborated with Zulu/
English translators subsequently (Gwamanda, Z., Ku-
beka, M., Ngcarnu, R., 1998; Dlamini, W., Msweli, D.,
2000, personal communication). The approximate Eng-
lish translations of Zulu concepts or commonly used
phrases (in brackets) were:
• Increased vaginal moisture or wetness (Ukubamanzt)
• Vaginal discharge (Ukuphuma koketshezi ebulilini
bowesimame)
• Vaginal discharge with unpleasant odour/smell
(Ukuphuma koketshezi olunephunga elibl).
Vaginal wetnesswas lesslikely to be reported as a side
effect by those who stated that they had used the
injectable contraceptive for a longer period of time
(p =0.005), with the mean length of use of 1.21years for
those who reported vaginal wetness and a mean length
of use for those who did not report it of 2.33 years. Less
frequently reported sideeffects, givenonly in response to
the prompted question about side effects, were vaginal
discharge (5.6%) and malodorous vaginal discharge
(5.0%).
Amenorrhoea (24.6%), heavy periods (18.6%) wet-
ness (17.5%) and weight gain (13.7%) were the most
frequent responses given when the respondents were
asked what they liked least about using the injectable
contraceptive. Similar dislikeswereexpressed by DMPA
and NET-EN users (Table 4). However, 24.0% of the
respondents indicated that there was nothing they
disliked about using this method. All the respondents
who least liked amenorrhoea, 59.4% of those who least
liked wetness, 30.3% of those who least liked heavy
periods and 28.0% of those who least liked weight gain,
indicated that they were experiencing these side effects.
This may indicate that the amenorrhoea and wetnessare
less tolerable side effectsthan heavy bleeding and weight
gain. On the other hand, it is worth noting that many
women worry about the potential for experiencing
wetness, heavy bleeding and weight gain when using
xxxix
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Relevant Zulu phrases transcribed from focus group interviews with English translation
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Loss of sexual appetite
the injectable, even if they were not experiencing these
side effects.
During focus group interviews, the most commonly
mentioned side effects of injectable contraceptives were:
vaginal wetness (14 groups), delayed return to fertility
(13 groups), heavy bleeding (12 groups), weight gain (12
groups) and amenorrhoea (10 groups). The side effects
regarded as the worst were vaginal wetness (9 groups),
heavy bleeding (7 groups) and amenorrhoea (1 group).
The problem of vaginal wetness with injectable
contraceptive use was raised repeatedly in every focus
group interview, and was raised spontaneously in the
first instance. It came up repeatedly in the discussions
with the group of high school teachers (women and
men), with the group of high school girls, with the
traditional healers (women and men), with the garden-
ing group (women), and with the members of the school
g?verning board (women and men). As noted pre-
viously, the worry about the potential for experiencing
vaginal wetness exists even among those not using this
method. Some comments about the experience of
vaginal wetness follow,2 with the English translations
of relevant Zulu phrases used by focus group partici-
pants provided in Table 5:
I heard that if you use injectables you become wet
and experience lots of problems but we have no
2.All quotes have been translated from Zulu. Responses,
which are the outcome of probing, are identified as such .
alternative...... (high school girl in the girls only
group).
People using the injection used to complain about
vaginal wetness. They say their partners do not enjoy
sex with them and state that it all becomes a big dam.
This vaginal wetness is associated with coldness and
you eventually loose sex appetite (woman from
sewing group).
Depo makes you wet. You feel that you are wet and
become ashamed or sorry when sleeping with your
husband (community health worker).
They say a lot of things like the injection makes one
to be always wet and sometimes that their male
partners complain that women who are using
injection do not taste good...... (nurse). The group
of nurses all agreed that women report experiencing
vaginal wetness with injectable contraceptive use.
.. .... truly speaking our children are finished by this
injection, they are big in sizes, they are wet. There is
another problem from the male side, I once overhead
them talking saying that it is much better to have sex
with an old lady because she is not wet, teenagers are
just swimming pools (woman traditional healer) .
...... injection makes them gain weight, not that they
are fat, the body is just full of water, and when
having sex with such a person she is just a pool of
xl
Sixty-one women (32.6%) surveyed reported that
their partners did not know that they were using this
contraceptive method and 4 (2.1 %) did not know if their
partners knew. However, 121 women (65.1%, n = 186)
believed that men are not well disposed towards women
using the injectable method of contraception , and, in
explaining why they felt this way, the problem of vaginal
wetness really came to the fore. Table 6 shows that
reasons related to vaginal moistness, causing "coldness"
and making women "tasteless" amount to nearly half
(46.3%) of the reasons given.
Focus group participants, men and women, made
frequent reference to the problems of "wetness" "cold-
ness" and "tastelessness" with injectable contraceptive
use. Coldness was used in the context of the female
partner being perceived to be sexually unresponsive or
losing her sexual appetite, and tastelessnessas the female
partner being sexually unappetizing or undesirable.
Examples of comments made are:
They [men] also say we become cold, wet and the
vagina opens, as it opens you are tasteless (high
school girl in the girls only group).
... as soon as the woman gets injection, she becomes
wet, it makes the body to be full of water. It is a water
with some kind of odour (female primary school
teacher in response to what kind of water is it?).
...sometimes this wetnesscomes out as an unpleasant
discharge making you not confident of yourself in
public (woman from sewing group).
Wetness, bleeding, becoming fat, tasteless, coldness
which is caused by moistness in the vagina (high
school boy in the boys only group in response to the
question What don't you like about injectables?).
Partnersand injectable contraceptive use
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Wetness is worse [the worst side effect with the
injectable] because these girls always wear pads to
stop water from oozing down (high school girl from
group of girls and boys).
Yes we do feel that we are wet and we do not only
feel it when doing sex even if you are just sitting you
can feel it and it comes as a discharge with unpleasant
smell, and ... . .. this wetness is not a thing that is
psychological to men it does happen to us (2 female
high school teachers in response to the question Does
the female feel that she is wet or it is something said
by men?)
You can feel it [the wetness from injectable use]even
when you are alone but it is worse when you are
making love (woman from parent group).
They [women] say they become wet when on
injection, it causes wetness, and this water just oozes,
other women sometimes always wear a pad to block
it from going down the legs (female member of the
school governing board). This same respondent,
when prompted, stated that it was supposed to have
an unpleasant odour.
There is great difference [between wetness of sexual
arousal and wetness of injectable], you know how far
she will be wet when you have touched her (male
primary school teacher).
.., . .. they become wet, this is continous slow flowing
of water, that makes them to be always wet (female
traditional healer).
You feel wet always when you have sex with your
partner. Sometimes you feel that wetness even if you
are alone and not having sex (woman from gardening
group).
water, you do not feel anything (male church
minister).
Several participants (mainly women) in the focus
group discussions described vaginal wetness associated
with injectable use. Some of their comments, in addition
to those made above, were:
The nature of vaginal wetness
1518
Table 6
Reasons, given by 121 injectable users, for why men do not favour this contraceptive method
Reason Respondents (%) (n = 121)
Reasons related to vaginal wetness/coldness/tastelessness
Men want more children
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'" ... a lot of men know that once she is wet she is
using the pill or injection, so these days secret is out.
Men can sense that the woman is using contraceptive
method (traditional healers).
They also say you become tasteless and cold (woman
high school teacher, in response to the question What
do men think about women using the injection?).
Users say that the injection makes the girl or the
woman to become tasteless, they are cold because of
the moistness of the vagina, they are so wet, they are
bleeding for a long time, and that they are always wet
(high school girl from group of girls and boys).
To tell you the honest truth my son, there are women
out there who are luke warm and there are women
out there who are ice cold and full of water, the
reason for that is one they are using injection. So I
have got muti that I can give them as a drying agent
to this water (male traditional healer).
They say we are wet (one woman), they say we
become tasteless (another woman) they say we are
cold (a third woman) (parent group in response to
the question What do men think about women using
the injection?).
Much concern was expressed that women who use the
injectable contraceptive are, or are perceived to be,
promiscuous-because they are freed from the worry of
pregnancy and/or they are "wet".
Men commented as follows:
... ...if the women begin at an early age to use these
things [injection], when she has sexual intercourse
with her man, she becomes wet. Sometimes, you can
even think that she has been with the other man
(male primary school teacher).
This wetness is the main problem and since it is
associated with lack of desire for sex, then when the
women prove not to worry much about sex then the
man adds these two things up, which is wetness and
no desire for sex and come up with an answer which
is that the woman has been with another man. Then
the fight breaks out (male primary school teacher) .
The injection causes women to be wet and you as a
man do not enjoy sex with such a woman to the
extent that if it is your girlfriend and not a wife, you
can be sure that she is from another man, she has
been with someone else (male member of the school
governing board).
Women made the following comments:
They say we are always wet, and also that we are
having many boyfriends and misbehave (woman
from gardening group, in response to the question
What do men think about women using the injec-
tion?).
To me wetness is the worst because the partner fights
thinking that you have been sleeping with other men
(woman high school teacher).
They do not tell them [their husbands that they are
using the injection], but it happens sometimes that
the secret gets out, when the partner will be asking as
to why are you so wet, and it will only be then that
the woman will tell him that it is because she is using
the injection that is why she is wet and not that she
has been with someone, sexually (female nurse).
..... .it [the injection] gets them into trouble, once she
is wet the man would say she is having an affair
(female member of the school governing board).
Discussion
Among injectable contraceptive users, vaginal wet-
ness, often linked to "coldness" and "tastelessness", was
a recurrent theme and was the second most commonly
reported side effect for DMPA and NET-EN. Vaginal
wetness was more frequently reported by DMPA users
(22.6%) than by NET-EN users (14.7%), but, as
previously noted, this difference was not statistically
significant. Wetness was significantly less likely to be
reported as a side effect by those who stated that they
had used the injectable contraceptive for a longer period
of time.
Early studies and the Petogeaf product brochure
describe vaginal discharge as a side effect, whereas
respondents in the survey differentiate between vaginal
wetness and vaginal discharge, both of which are
reported as side effects. Respondents in the survey were
not asked to describe vaginal wetness, however,
reproductive health workers suggest that it is of a
watery consistency (N. Ntuli, 1999, personal commu-
nication) and discussions in the focus groups also
describe it as a watery substance which occurs in
excessive quantities. Female participants in a study
described by Brown et al. (l993a) distinguish between
three types of vaginal secretions-(i) secretions which
occur in small amounts at certain stages of the menstrual
cycle and during sexual arousal; (H) excessive secretions
described as "too much water", resulting in a "wet
vagina"; and (iii) unusual discharges resulting from
infections. The second type of secretion described by
Brown et al. is consistent with the KZN focus group
respondents' description of the vaginal moistness they
associate with injectable contraceptive use. A study is
being developed to discover more information about the
nature and possible etiology of vaginal wetness, how it
may differ from the vaginal discharge reported by
xlii
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respondents, and whether it is a consequence of a
vaginal infection or a relatively transient problem that
resolves for most women on continued use.
Since vaginal wetness also comes up as the third most
frequently mentioned reason for what the survey
respondents liked least about using the injectable
contraceptive, and was identified as the worst side effect .
in the majority of focus group discussions, it can be
assumed that vaginal wetness is a side effect that is not
well accepted in the study area, and may result in
method discontinuation. Many comments made in focus
group interviews convey the negative way in which
vaginal wetness is regarded and the negative impact it
may have on the enjoyment of sexual intercourse and on
relationships. It is noteworthy that some survey
respondents who did not report it as a side effect
(40.6%) were clearly concerned about the possibility of
experiencing it, as they listed this as a reason for least
liking the injection.
Previous studies have shown that men and women in
many parts of Central and Southern Africa have a
preference for "dry sex", 3,4 (Brown et al., 1993a, b, 2000;
Civic & Wilson, 1996; Morar & Abdool Karim, 1998;
Beksinska et al., 1999). For instance, in a study
undertaken in Zaire (now the Democratic Republic of
Congo), Brown et al. (1993b) found that "Both men and
women expressed a definite preference for dryness and
tightness, saying that when a woman's vagina is moist or
large, neither she nor her partner experience full sexual
pleasure" p. 97. Further, Beksinska et al. (1999) found
that 60% of men and 46% of women surveyed in
Orange Farm, South Africa expressed a preference for
dry sex. One of the main reasons for practising dry sex
given by both men and women respondents was that it
shows that the woman is not promiscuous. Another
reason given, but only by women, was "for partner
satisfaction" (Beksinska et al., 1999). Where dry sex
practices are preferred women resort to potentially
harmful measures to dry, tighten and warm their vaginas
(Baleta, 1998; Beksinska et al., 1999).
Increased vaginal wetness associated with the most
popular contraceptive method used in South Africa, is
consequently a problem which must be regarded
seriously. According to respondents in our study, some
men regard women who use the injectable contraceptive
as "wet", "cold" and "tasteless". Almost half the
injectable contraceptive users surveyed, who believed
that men do not favour the injectable contraceptive,
3The practice of dry sex is defined as the drying, tightening,
and sometimes warming of the vagina for sexual intercourse
(Brown et al., 1993a; Dallabetta et al., 1995; Beksinska et al.,
1999).
40nly some of these studies were conducted exclusively
amongst commercial sex workers and the practice of dry sex is
not restricted to commercial sex workers.
used one or more of these words to describe why men do
not like the method. Women also stated that the reason
men dislike the injectable was because women who use it
misbehave. Injectable users are clearly concerned about
the response of their male partners to vaginal wetness
thought to be produced by injectable use. Likewise, in
focus group discussions, women using the injectable
method were frequently described as wet, cold and/or
tasteless and were sometimes perceived as being
unfaithful or promiscuous. This notion can only serve
to deepen the disempowerment experienced by many
South African rural women.
A limitation of this study is that it draws upon the
experiences and views of African women and men from
a deep rural area of KwaZulu-Natal. It is, therefore, not
possible to directly extrapolate the findings to residents
of urban areas or even of rural areas in other provinces
in South Africa. Nevertheless, findings from this study
indicate that increased vaginal wetness is regarded as a
problem experienced by injectable contraceptive users,
and it needs to be addressed.
At this stage we do not have an explanation for this
problem which is widely reported by women in our
study as well as by family planning service providers. It
is possible that, even if women from western countries
have experienced vaginal wetness with injectable use, it
may not have been reported or documented, since in
these countries, increased vaginal moistness may not be
regarded as a problem. One would in fact expect the
anti-oestrogenic properties of progestogen to result in
vaginal dryness, which is a documented, though rarely
reported side effect (Guillebaud, 1993; Nelson , 1996).
One possible explanation for the reported wetness is that
the women who report this problem have sexually
transmitted infections (STI's). However, the nature of
the wetness does not, for the most part, appear to fit the
description of an infection. It is important though to
note that the prevalence of sexually transmitted infec-
tions in South Africa is very high (Baleta, 1998; Abdool
Karim & Abdool Karim, 1999). Abdool Karim et al.
(1999) reported that on any given day, approximately
one in every four of the women between the age of 15
and 49 years from a rural area of Kwazulu-Natal was
infected with at least one STI. The prevalence of STI's
amongst injectable contraceptive users should, there-
fore , be investigated. Another possible explanation is
that vaginal wetness, attributed to progestogen inject-
able contraceptive use, is a perception that has grown
and spread over time, possibly fueled by men's concerns
about loss of control of their partner's fidelity and
fertility if she uses the injectable contraceptive. This too
warrants further investigation.
In summary, this study has found that vaginal wetness
is a commonly reported side effect of the widely used
progestogen-only injectable contraceptive. This side
effect appears to be particularly disturbing in terms of
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the way in which men view women who use it. Yet,
despite this undesirable effect, women continue to use
the injectable method, mainly because they find it a
convenient and effective method which can be hidden
from their partners. Whilst vaginal wetness can only be
classifiedas a subjective side effect at this stage, further
investigations are needed. It is also an issue that must be
addressed by health workers responsible for counselling
women who use this method of contraceptive.
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Abstract
In the absence of published data on serum medroxyprogesterone acetate (MPA) levels in
South African users, this study examines such levels in new and repeat users of depot
medroxyprogesterone acetate at the end of the dosing interval. The study was undertaken
at three family planning clinics in Durban, South Africa. Serum MPA levels were
measured in 94 Black African, Indian and White women returning between 11 and 14
weeks after their last injection. The median (range) serum MPA level was 0.88«0.04-
1.77) ng/mL and wide interindividual variability was observed. Levels in all but one
woman were higher than 0.1 ng/mL, the level at which ovulation is reported to resume.
MPA levels were not found to vary according to weight, BMI or ethnicity. Although
there was a slight tendency towards higher MPA levels with longer duration of use
(FO.13) , the wide interindividual variability precluded the possibility of determining
whether this was a real trend. A prospective study, using standardized assay techniques
and following individual women, is required to further clarify this issue.
Introduction
Early published studies have determined serum or plasma concentrations of
medroxyprogesterone acetate (MPA) after intramuscular injection of 150 mg of depot
medroxyprogesterone acetate (DMPA) [1-9]. These studies used a variety of different
assay techniques and, in all but three [2,4,9], MPA levels were reported after only one
dose. In addition, the sample sizes were small and none of the populations studied were
African. Following injection of DMPA, blood concentrations of MPA are reported to
peak within 3 weeks [3,6,9], after which they remain somewhat constant in the range of
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1.0-1.5 ng/mL for the 2 to 3 months post injection [3]. Levels then decrease gradually to
0.2 ng/mL by the sixth month and eventually to undetectable levels of less than 0.02
ng/mL by up to nine months [3,10].
DMPA has been shown to be effective as a contraceptive for at least 90 days [3,5-7,9,10]
and ovulation is reported to resume when MPA blood concentrations decline to less than
0.1 ng/mL [3,10]. Three studies have reported specifically on serum or plasma MPA
levels at the end of the dosing interval after injection of 150 mg DMPA intramuscularly
in women who had at least one previous DMPA injection. In the first study of two
women, the MPA levels 12 weeks after injection were reported to be approximately 0.5
ng/mL in a woman who had had one previous injection, and 1.0 ng/mL in a woman who
had received her 20th injection [9]. The second study of 11 women, who had received
between 6 and 18 injections, found a mean (SD) MPA level of 0.6 (±0.1) ng/ml, 84 days
after the last injection [2]. In the third study, amongst Thai women who had received only
one injection (n=10) 90 days earlier, plasma MPA levels ranged between <0.10 ng/mL
and 1.28 ng/mL, with a mean of 0.61 ng/mL. In those who had received 8 consecutive
doses (n=l1) the range was 0.12 ng/mL to 2.56 ng/mL, with a mean of 0.90 ng/ml., The
difference between the group receiving multiple injections and the group receiving only
one injection was not statistically significant [4].
The injectable progestagen-only contraceptives DMPA and norethisterone oenanthate
(NET-EN) are the most widely used contraceptives in South Africa, especially amongst
Black African women, and account for almost half of all contraceptive use (48%) [11-
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13]. Injectables which contain a combination of oestrogen and progestagen are not
registered for use in South Africa. Whilst use of NET-EN is increasing, especially
amongst younger women [12], DMPA is still the most commonly used injectable [13].
Despite its extensive use there are no published data on serum MPA levels in South
African users. This paper examines serum MPA levels amongst new and repeat South
African DMPA users at the end of the dosing interval.
Materials and Methods
The study was approved by the ethics committees of the Nelson R Mandela School of
Medicine of the University of Natal, and the University of Durban-Westville, Durban
South Africa. Permission to conduct the study was obtained from the Durban local health
authority.
Trough serum MPA levels were measured in 97 DMPA users attending three Durban
family planning clinics between October 1996 and January 1997. The DMPA product
supplied at these clinics was Depo-Provera'" (Pharmacia & Upjohn (Pty.) Ltd.,
Johannesburg, Gauteng Province). Ninety-four of the women returned between 11 and 14
weeks of receiving their last dose. The remaining three returned more than 14 weeks after
their last injection and were classified as "defaulters" in keeping with clinic policy. The
dosage regimen for DMPA at the clinics is 150 mg every 12 weeks.
Blood samples were obtained immediately before administration of the next dose of
DMPA. After being allowed to clot, they were centrifuged and the serum obtained was
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stored at -70°C. The MPA assay was performed by Immunometrics Ltd., London, United
Kingdom, using materials and methods developed for the World Health Organization
(WHO) Special Programme of Research in Human Reproduction [14]. These
standardized materials have been extensively used for over 15 years in international
clinical trials sponsored by the WHO, pharmaceutical companies and non-governmental
organizations. The assay methodology is a first generation radioimmunoassay (RIA)
involving an ether extraction step (standards and samples); incubation with antibody and
a tritium labelled MPA; a charcoal separation of free and antibody bound analyte. All
samples are measured in duplicate. Standards were prepared by weighing pure material
prepared for WHO. The concentration of stock solutions were checked using DV
absorption before the standards were further diluted in human serum. The potency of
these serum standards was further cross checked by RIA against reference standards
previously prepared for WHO and external quality control samples. In four separate
recovery sample vials per assay, after adding tritiated MPA to plasma and an ether
extraction step, an aliquot was taken for recovery measurement and results were corrected
for losses. Four replicates of each of three quality control (QC) samples (target
concentrations 0.12, 0.29, 0.77 ng/mL) were included in each assay batch. QCs were in
two groups, one set of duplicates at the front of the assay, the remaining duplicates at the
end. Assay runs were accepted if the mean values of all three QC pools were within the
acceptance limits (±15% of the target value) or if five out of the six QC results were
within limits.
The antibody was tested for cross-reaction with MPA (100%), 17«-hydroxy-6«-
methylprogesterone (0.02%), 6-dehydromedroxyprogesterone acetate (9.5%), 6j3-
hydroxy-medroxyprogesterone acetate (64.6%), 20«-dihydroprogesterone (none
detected), 20j3-dihydroprogesterone (none detected) and 17«-hydroxyprogesterone (none
detected). Results were statistically indistinguishable (using a paired t-test) when samples
from 35 patients were assayed with and without chromatography [LH-20 column, using
toluene:methanoI85:15] (means: 1.48 ng/mL and 1.49 ng/mL respectively; ranges: 0.17-
5.02 ng/mL and 0.15-4.87 ng/mL respectively).
The lower limit of detection was 0.04 ng/mL. This was estimated by using an
immunoassay data processing program which calculated precision profiles in the range of
0.02 ng/mL to 3.13 ng/mL. No drift was observed in any assays performed for this study.
The percentage coefficient of variation (CV) observed in the 11 assay runs carried out for
this study were 8.8%, 6.9% and 6.5% for QCs with mean values 0.12, 0.30, and 0.76
ng/mL respectively. Any sample whose duplicates showed poor replication (more than
three times the expected SD at that dose) was re-analysed. Results below the bottom
standard were reported as <0.04 ng/mL. Samples found to contain doses higher than the
top point of the standard curve were diluted (1:2, 1:4 and 1:8 times) in zero standard
serum and re-analysed. Samples from subjects who had not received MPA exhibited
unmeasurable levels ofMPA in most cases; in about 20% of plasma samples, low «0.08
ng/mL) apparent MPA levels (plasma blanks) were found.
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Body weight, height and blood pressure were recorded and body mass index (BM!) was
calculated. Participants were interviewed to obtain relevant demographic and medical
details. Data were analysed using Microsoft®Excel 2002.
Results
Demographic data and serum MPA levels of the 94 women returning between 11 and 14
weeks after their last dose are presented in Table 1. On recruitment into the study, 12%
of these had had one dose ofDMPA, 7% two doses, 5% three doses and the remainder
had been using DMPA for a year or more. Sixty-four were Black Africans, 24 were of
Indian descent, and six were White. The MPA level of one woman was below the
minimum level of detection (0.04 ng/mL). Where this value was included in determining
a mean value, the level was set at half the limit of quantitation (0.02 ng/mL).
Serum MPA levels in relation to the time after the last injection are presented in Figure 1.
Levels of those who returned up to a week early, or up to two weeks late, were similar to
those returning exactly 84 days after their previous dose. The large interindividual
variability is well illustrated by the wide range of levels, particularly in the large group
who returned at 84 days. MPA levels in these 55 women ranged between <0.04 ng/mL
and 1.53 ng/mL (median: 0.90 ng/mL; mean [SD]: 0.86[0.31] ng/mL). The MPA levels
of the three defaulters who returned 109, 112 and 168 days after their last dose were 0.77
ng/mL, 0.74 ng/mL and 0.29 ng/mL respectively.
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Figure 1 also shows that the trough MPA levels of Africans and Caucasians were similar.
In the group returning at 84 days, the median (range) MPA levels were 0.90 (0.10-1.40)
ng/mL and 0.90 «0.04-1.53) ng/mL for Africans (n=41) and Caucasians (n=14)
respectively. Although widely varied within each ethnic group, BMIs were similar
between groups with a median (range) BMI of 25.8 (17.4-39.4) for African women
(n==51) and 23.6 (15.4-33.8) for Caucasians (n=29). The MPA levels of subjects with a
BMI less than 25 were similar to those of subjects with a BMI of 25 or more (Table 2).
There was a slight trend (pearson's Product Moment=O.13) towards higher MPA levels at
the end of the dosing interval with longer duration of use (Figure 2). However, wide
interindividual variability was evident irrespective of length of use.
Discussion
Wide interindividual variability in serum MPA levels has been noted before [5,15,16].
Our findings, based on a much larger sample size than those of previous studies, also
clearly show the wide interindividual variability in MPA levels in DMPA users on return
for their next dose. MPA levels were found to be in a similar range to levels reported in
previous studies [2,4,9].
Most studies have found MPA levels at the end of the three month dosing period to be
above the level at which ovulation is reported to resume (0.1 ng/mL) [1-4,6]. In our
study, with the exception of one undetectable level «0.04 ng/mL), all MPA levels
between 11 and 14 weeks after the dose were above this level, although the level for one
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woman was found to be 0.104 ng/mL. Even the MPA levels of three defaulters, two who
returned 4 weeks late and one 12 weeks late, were still above 0.1 nglmL. In four of five
women studied, Fotherby et al. reported undetectable levels by day 55,64,87 and 87 post
injection respectively (minimum detectable level >0.1 ng/mL) [5] and, in a study by
Koetsawang et al., two of 21 women had levels of less than 0.1 nglmL at the end of the
dosing period [4]. It should be noted, however, that the assay used in these two earlier
studies was less sensitive (0.1 nglmL) than that of our study where the lower limit of
quantitation was 0.04 nglmL. In addition, assays used in early studies varied. More
recently, recognizing the difficulty in interpreting results from different studies, the
World Health Organisation's Task Force on the Long Acting Systemic Agents for
Fertility Regulation has produced standardized protocols and matched reagents for
radioimmunoassay of synthetic progestagens [14]. These procedures were used in our
study assays and should be used in future studies to improve standardization and
between-center comparability of assay results.
The possible influence of weight, BMI and ethnicity on MPA levels has been studied by
other investigators [6,7,16,17,18]. One study comparing the rate of uptake and
metabolism of DMPA in obese and thin women showed no difference in MPA serum
levels between the two groups [17]. However, Garza-Flores et al. reported a tendency for
DMPA to be absorbed more rapidly in thin than in obese women [18]. Bassol et al.
reported a longer delay in resumption of ovulation in Mexican than in Thai women,
which they considered to be in keeping with the longer disappearance of MPA from the
serum of the Mexican women [7]. In another study undertaken amongst Indian and
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Swedish women [6], luteal activity was found to return later in the Swedish women, but
no difference was found between the two populations in time taken for plasma MPA to
become undetectable. In our study of Black African, Indian and White South Africans,
MPA levels at the end of the dosing interval were not found to vary according to weight,
BMI or ethnicity. Overall, few studies have investigated the population differences in
DMPA users and the methodologies of some of the published studies is unclear, once
again suggesting a need for more rigorous investigation.
The possibility of MPA levels increasing with successive injections has also been
investigated, although not by many. For instance, the study undertaken in Thailand by
Koetsawang et al. reported a higher mean plasma level at the end of the dosing period for
those receiving multiple injections than that of those receiving a single dose [4], although
the difference was not significant. Fraser and Weisberg [15] in reviewing these findings,
suggested that no significant difference was found because of the wide interindividual
variation within each group and recommended further investigation. In an early review of
Depo-Provera" studies, Schwallie presented data (Depo-Provera Protocol 9A) which
showed no accumulation of MPA when comparing median serum levels after the first and
fifth injection period [19]. Our South African study showed a slight tendency towards
increased MPA levels at the end of the dosing interval with longer duration of use.
However, the wide interindividual variability precluded the possibility of determining
whether or not this was a real trend. In addition, our study, like that of Koetsawang et al.
was cross-sectional. A prospective study, which follows DMPA use in the same women
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Table 1. Demographic data and MPA levels
Age Weight BMI MPAlevel
(years) (kg) (ng/mL)
n=94 n=94 n=80* n=94
Mean 28 62 25.4 0.88
Median 27 61 24.3 0.88
Range 17-42 38-106 15.4-39.4 <0.04-1.77
'The heights of 14 women were not recorded
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Table 2. MPA levels of women of different BMIs
MPA level (nz/ml.)
n Mean Median Range
BM! < 25 43 0.85 0.85 <0.04-1.58
BM! ~ 25 37 0.88 0.88 0.31-1.45
Desirable BMI range is 19-24 [17]
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BACKGROUND AND NEED FOR THE STUDY
Access to safe and effective contraception is an essential prerequisite to the promotion of
reproductive health (United Nations Population and Development, 1994; United Nations
1995; World Health Organization, 1996a; 1996b; 2000; 2002). In South Africa, the long
acting injectable progestogen-only contraceptives are by far the dominant method used
(Roberts and Ripp, 1984; Smit and Venter 1993; Reproductive Health Task Force et al,
1994; Chimere-Dan, 1996; Progress in Human Reproduction, 1996; Westaway et al,
1996a; Westaway et al, 1996b; Bailie et a11997; Beksinska et al, 1998; Beksinska et al,
2001a; Smit et al, 2001; Department ofHealth et al, 2002). In a study undertaken in 1994,
injectables were reported to account for between 60% and 95% of contraceptive methods
used (Reproductive Health Task Force et al, 1994). More recently, the 1998 South Africa
Demographic and Health Survey (SADHS) reported that 57% of all the women (aged 15-49
years) interviewed had used the injectable method at some time. Ofthe women who were
sexually active in the four weeks prior to being interviewed and using a modern
contraceptive method, 49% reported that they had been using an injectable progestogen-
only contraceptive (IPC) (Department ofHealth et ai, 2002).
Injectables are more extensively used in rural areas of South Africa (Reproductive Health
Task Force et al, 1994; Department ofHealth et al, 2002), and are used for longer periods
of time than anywhere else in the world (Bailie et al, 1997). The injectable contraceptive is
also widely used by young South African women (Lucas , 1992; Chimere-Dan, 1993;
Department ofHealth et al, 2002). Furthermore, in South Africa, the injectable is used far
more extensively by African 1 and coloured women than by Asian, or white women
(Chimere-Dan, 1993; Bailie et al, 1997; Kaufman, 1997; Molefe and Mthembu, 1997;
Ramsaran et al, 1997; Department ofHealth et al, 2002). The Reproductive Health Task
Force et al (1994) reported that 70 to 80% ofblack family planning clients were using
injectable contraceptives compared with 10% of white clients. A study (Morrison, 1995,
p.9) undertaken in Durban, South Africa, pointed to the extensive use of injectable
contraceptives by young women and stated further that there is "extreme racial and
economic stratification of users of the injection".
Unlike many countries in the world, where only one IPC product is available, in South
Africa both progestogen-only injectable contraceptives, depot medroxyprogesterone
acetate (Depo-Provera'" and Petogen") and norethisterone oenanthate (Nur-Isterate'"), are
available. The combined injectable contraceptive, containing both oestrogen and
progestogen, is not yet available. Both depot medroxyprogesterone acetate (DMPA)
and norethisterone oenanthate (NET-EN) are extensively used in the public sector in
South Africa , both are on the South African Essential Drug List (National Department of
Health, 1998) and both are available free of charge at public sector primary health care
facilities. However, few studies have been undertaken which directly compare DMPA
and NET-EN in terms ofutilization patterns, side effects , reversibility, and
discontinuation. Affordability of drugs by developing countries is currently a topic of
heated debate, especially with regard to access to HN (human immunodeficiency virus)
1 Racial Classification. The Health Systems Trust approach to race classification is used in this thesis,
namely African , Asian (or Indian), coloured and white. "The categories reflect the system of racial
classification under apartheid. The use of these classifications is necessary in order to indicate the
challenges and progress made in achieving goals of equity . The terms African, Asian, coloured and white
are used except when referring to Africans, Asians and coloureds collectively, in which case the term Black
is used." (Health Systems Trust, 1997, p. 16)
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related drugs. In South Africa financial resources for health care are limited. At the same
time, health care costs are soaring as the HIV epidemic bites and anti-retroviral treatment
through the public sector becomes inevitable. It thus becomes increasingly important to
ensure that all drugs are rationally provided and used. Taking into account published
findings on efficacy, reversibility, side effects and safety, a cost analysis of the provision
of IPCs is essential if appropriate policies for the rational use of IPCs are to be developed.
Yet no analyses of this nature have been published.
The efficacy of the progestogen-only injectable contraceptives is extremely high (Garza-
Flores et al, 1992; Garza-Flores et al, 1994; Kaunitz, 1994; Kaunitz and Rosenfield, 1994;
Lande, 1995; Diaz, 2001; Kaunitz, 2002). An illustration of the high efficacies of these two
products is provided by a World Health Organization (1983) comparative trial. According
to this study, the efficacy of DMPA given every 90 days and NET-EN given every 60
days are comparable, with a cumulative 2-year pregnancy rate of 0.4 per 100 woman-years.
Trussell et al (1990) provide "summary estimates of contraceptive failure" and give the
lowest expected, and typical percentage, of accidental pregnancies in the United States,
during the first year ofuse, as 0.3 for DMPA and 0.4 for NET-EN (unspecified dose
interval). Progestogen-only injectables are also considered to be relatively safe with regard
to the risk ofserious adverse events (Fraser, 1986a; Garza-Flores et al, 1992; Kaunitz,
1994; Kaunitz and Rosenfield, 1994; Lande, 1995; Cayley, 1998; Diaz, 2001), although
there are concerns about the reduction ofbone density in long-term users ofDMPA
(Cayley, 1998; Bigrigg et al, 1999; Diaz, 2001). The relatively poor side effect profile of
IPCs is extensively documented in the international literature (World Health Organization,
1978; Fraser and Weisberg, 1981, Fraser 1982; World Health Organization, 1983; Fraser,
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1986b; Lande, 1995; Polaneczky et al, 1996; Paul et al, 1997; Bigrigg et al, 1999; Kaunitz,
2000) . However, there is little published literature about the experience of side effects with
injectab1es in South Africa, although side effects are frequently mentioned by users and are
well-known amongst health workers (Smit et al, 1989a; Smit et al, 1989b; Smit and Venter,
1993; Beksinska et al, 2001b). As in other parts of the world, side effects are considered to
be a major reason for discontinuing the method amongst South African users (Beksinska et
al, 1998).
Whilst pharmacokinetic studies of IPCs have been undertaken internationally,
pharmacokinetic studies ofthese drugs , when used by South African women, are entirely
lacking. It is widely recognised that a high priority should be placed on understanding the
pharmacokinetic variability ofdrugs (Whiting et al, 1986) and the assessment of
pharmacokinetic parameters of contraceptives is considered to be critically important in
assessing efficacy and side-effects (Sang, 1994) . Given their extensive use, the lack of
pharmacokinetic data for IPCs in South African women is a serious omission, as
international studies suggest that regional and population differences, and intraindividual
and interindividual variation exist in the pharmacokinetics of steroidal contraceptives
(Fotherby et al, 1980b; Sang, 1994; Garza-F1ores et aI1994).
Importantly, a pharmacokinetic study undertaken amongst Thai and Mexican women found
that medroxyprogesterone acetate disappeared more rapidly from the blood and that return
ofovulation was more rapid in the Thai than in the Mexican women participating in the
study (Garza-Flores et al, 1994). These authors postulated that the pharmacokinetic
differences between the Thai and Mexican women could be explained by ethnic differences
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in fat distribution and the behaviour of fat cells in steroid storage. The implications of this
study for South African women are important, as it is possible, given the morphology of
African women, that DMPA may remain in the body for longer periods of time than
expected. Garza-Flores et al (1992) recommended that each country or region collect its
own pharmacological data for fertility regulation agents, pointing to the need for
pharmacokinetic studies to be undertaken amongst African users of the injectable. Further,
an extensive literature search reveals that no population' pharmacokinetic studies of
injectable hormonal contraceptives have been published and Sang (1994) highlights the
need to undertake population pharmacokinetic studies in order to assess regional or
population differences. He questions the clinical significance of comparisons made between
regions or populations where a population approach has not been adopted and stresses the
importance ofcollecting data in the population actually using the contraceptives. A
population approach can be successfully used to estimate population pharmacokinetic data
from sparse clinical data (Whiting and Kelman, 1985).
Despite its proven efficacy and its widespread use, the injectable contraceptive has been an
extremely controversial method. The pharmaco-politics surrounding this form of
contraception has long been under debate in South Africa and elsewhere. An important
theme in this debate has been the coercive imposition oflong-acting injectable
contraceptives (Weisberg, 1992; Chimere-Dan, 1993; Moskovitch and
Jennings, 1996; Kaufman, 1997), particularly amongst black women, in the apartheid era
(Gready, 1996). Whilst in post-apartheid South Africa the context of the debate has
2 Population Pharmacokinetics: Defined as ".. the estimation of population-typical (e.g. mean) 'and
population-variability (e.g. standard deviation) values for each phannacokinetic parameter" (Sang 1994 p.
233). ' ,
5
changed, the concerns remain similar. Moreover the issues of women's rights in
reproductive health, and more specifically freedom of contraceptive choice, informed
consent, quality ofcare and safety of contraceptive method have come
more sharply into focus: "The basis for action in family planning, as stated in the
Programme ofAction of the United Nations International Conference on Population and
Development, must be to enable couples and individuals to decide freely and responsibly
the number and spacing of their children, to have information and means to do so, to ensure
informed choices and to make available a full range of safe and effective methods" (World
Health Organization, 1996a, p.1). South Africa's National Health Policy, based on the
primary health care approach to the delivery ofhealth care, emphasises reproductive health
and contraceptive choice as a priority. An important component of the South African
National Drug Policy is its emphasis on the promotion ofthe rational use of drugs
(Department ofHealth, 1996). The White Paper on Health states that" Women and men
will be provided with services which will enable them to achieve optimal reproductive and
sexual health" (Department ofHealth, 1997, p.98). These progressive policy developments
have important implications for the use and provision of the widely used injectable
hormonal contraceptive method in South Africa.
Considering the wide-spread use of IPCs in South Africa, the controversy about its use
and the need to promote informed and rational use of this method of contraception,
research which examines the extent of use, the demographic characteristics of users,
reasons for choice, side effect profile and the relative advantages and disadvantages of
brands is essential. Research of this nature becomes particularly important in a setting like
6
South Africa where HIV prevalence, fertility rates and teenage pregnancy rates are high
as illustrated below.
There has been a dramatic increase in HIV infection in South Africa, with sero-
prevalence among antenatal clients of public sector health clinics increasing from less
than I% in 1990 to almost 25% in 2001. KwaZulu-Natal is particularly hard-hit with a
prevalence of34% amongst women attending antenatal clinics (Department ofHealth,
2002). Of great concern are the HIV rates in young pregnant women amongst whom the
prevalence was found to be 15% in 2001 (Department ofHealth, 2002). Pregnant women
in their late twenties were found to have the highest infection rate (31%) with a rate of
28% found for those aged 20 to 24 years (Department of Health , 2002). A recent national
population-based survey of South African men, women and children, irrespective of
whether or not they were sexually active, estimates the HIV prevalence to be 11%, with
15% in the 15-49 year age group found to be HIV positive. Prevalence amongst women in
the age group 25-29 years was the highest at 32% (Shisana and Leickness, 2002). HIV
infection is reported to be more prevalent among women than men, women are infected at
a younger age than men, (Health Systems Trust, 2000; Shisana and Leickness, 2002) and
Africans are disproportionately infected compared to other race groups (Shisana and
Leickness, 2002.
Although contraceptive prevalence is relatively high in South Africa (Department ofHealth
et al (2002), so is teenage pregnancy, especially amongst rural South African women
(Makiwane, 1998). The 1998 SADHS reports that by the age of 19 years, 35% ofteenagers
would be pregnant (Department ofHealth et ai, 2002). Further, many teenage mothers are
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unmarried (Makiwane, 1998; Garenne et aI2000). The rate of unplanned pregnancies is
also high, as indicated by a recent survey ofwomen attending primary health care
facilities in South Africa in 199912000, where 65% of those ever pregnant indicated that
they had been pregnant (at least once) when they were not ready to have a baby. Fourteen
of the 89 health facilities surveyed in this study were those which served the Hlabisa
district, including the Hlabisa Hospital, and the rate ofunplanned pregnancies reported by
clients attending these clinics was higher than in the other areas (78%) surveyed (Smit et
al, 2001). The SADHS also found high rates of unplanned or mistimed pregnancies
(Department of Health et al, 2002).
Given the high HN prevalence, especially amongst young women, the low use ofbarrier
contraceptive methods is disquieting. The 1998 SADHS (Department ofHealth et aI, 2002)
reported current condom use to be 2% amongst women sexually active in the 4 weeks prior
to being interviewed. Condom use amongst sexually active women aged 15-24 years was
4%. By contrast, this survey found that the most widely used contraceptive method was the
injection, which was currently used by 27% of all women aged 15-49 and by 30% of
women sexually active in the 4 weeks prior to being interviewed. It is particularly popular
amongst younger users, being used by 51% of 15-19 year old women who were sexually
active in the 4 weeks prior to interview. Unlike the barrier methods, injectables do not offer
protection against HIV and sexually transmitted infections (STls). Moreover, there are
questions about whether injectable hormonal contraceptives may increase the risk of
contracting HIV and other STIs (Daly et aI, 1994; Marx et al, 1996; Mostad et al, 1997;
Stephenson, 1998). Whether a relationship exists between progestogens and HN
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transmission warrants further investigation (Family Health International, 1996) as the
evidence currently available is conflicting (Ntozi and Kirunga, 1998; Stephenson, 1998).
The more recent Nelson MandelalHuman Sciences Research Council survey conducted in
2002 found higher levels ofcondom use amongst men and women in the 15-24 year age
range (57% and 46% respectively at last sexual intercourse) (Shisana and Leickness,
2002). This survey did not collect data on hormonal contraceptive use. While condom use
may be increasing amongst younger South Africans, it is likely that some young people use
two methods for dual protection: condoms for HIV/STI prevention, and the injectable for
the most effective method ofpregnancy prevention. For instance, Morroni et al (2003)
found that dual method use was more common amongst primary health facility clients than
condoms used alone. An integrated strategy which addresses contraceptive needs and the
simultaneous need to prevent HIV and STIs is advocated (Ntozi and Kirunga, 1998,
Mantell et al, 2003; Morroni et al, 2003) . In order to do this, a sound understanding of
injectable use in South Africa is urgently required.
Little research focusing exclusively on injectable hormonal contraceptives has been
undertaken in South Africa. Few studies have drawn comparisons between the two
injectable products available (Depo-Provera'" and Nur-Isterate"). Even fewer studies
examine a number ofinterlinked aspects on utilization and pharmacokinetics of injectable
contraceptives. Moreover, research which has been undertaken has been largely clinic-
based, amongst current users of the injectable contraceptive. The clinic-based orientation of
the scant research that has been undertaken has meant that the voices of those who have
discontinued injectable use, and those who have never opted to use it, have seldom been
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heard. In-depth studies of this nature have also not been undertaken in rural areas where the
injectable method is extensively used, and where HIV rates are at their highest.
FOCUS OF THE THESIS
This thesis investigates and analyses factors which impact on utilisation oflong acting
injectable hormonal contraceptives in South Africa. Findings from this comprehensive
research programme will feed into and inform, on a scientific basis, contemporary policy
formulation about appropriate provision and use of injectable contraceptives. This is
particularly necessary in the context of soaring HIV prevalence, which is driving a move
towards the promotion of barrier methods of contraception and dual method use
(Department ofHealth, 2001). As detailed below, the thesis provides primary data
collected at household and health facility level in a deep rural area of KwaZulu-Natal,
South Africa, and at family planning clinics in the Durban Metropolitan area. It also
comprehensively and critically reviews, analyses and synthesizes data from secondary
sources in order to understand, interpret and validate primary data. Guidelines for
injectable contraceptive use within a progressive reproductive health policy are developed
and priority research needs are identified.
a) The primary research comprises one of the largest community-based surveys ever
undertaken in a deep rural area of South Africa . The geographical focus of this study
is the Hlabisa District of KwaZulu-Natal, and the study is designed to provide primary
data about:
the prevalence oflong acting progestogen-only injectable contraceptive use
injectable contraceptive product mix (Depo-Provera'" and Nur-Isterate'")
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contraceptive method mix
characteristics of the injectable contraceptive user
reasons for choosing to use injectable hormonal contraceptives
side effects experienced by current and previous users of injectable hormonal
contraceptives
discontinuation rates and reasons for discontinuation of the injectable method
perceptions ofusers and nonusers, and community groups about side effects and
reversibility of injectable contraceptives.
b) Findings from a population pharmacokinetic study ofDMPA undertaken at family
planning clinics in Durban, South Africa are reported.
c) This thesis also examines data drawn from secondary sources as follows:
primary data obtained from the community-based survey are compared with the
contraceptive use patterns reported in the 1998 South Africa Demographic and
Health Survey
a comprehensive review of the literature on injectable contraceptive use in South
Africa, Africa, and other parts of the world, including a review of randomised
clinical trials, pharmacokinetic and pharmacodynamic studies and other clinical
studies of the injectable contraceptive is undertaken.
d) A cost analysis ofDMPA versus NET-EN use in South Africa is undertaken.
e) Guidelines for the rational provision, choice of contraceptive method and use of
injectable contraceptives are developed and priority areas for further research are
identified.
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AIM AND RESEARCH QUESTIONS
The aim of this thesis is to develop a picture oflong acting progestogen-only injectable
contraceptive use among South African women, with a view to informing contemporary
policy formulation for appropriate contraceptive service provision.
This is not a thesis which seeks to test one or two hypotheses. It is more inductive in
orientation and involves:
• The scoping of injectable contraceptive use in rural South Africa and the identification
ofpossible statistical associations and their statistical analysis.
• A comparative analysis ofDMPA versus NET-EN focusing particularly on utilization
patterns, side effects, discontinuation patterns and costs.
• A pharmacokinetic analysis ofdepot medroxyprogesterone.
To do this, the following research questions are posed:
1. What is the prevalence of injectable contraceptive use amongst rural women in
KwaZulu-Natal, South Africa?
2. What are the demographic characteristics of the injectable contraceptive user?
3. What other contraceptive methods are used by women in rural KwaZulu-Natal?
4. What side effects are experienced by users of the two progestogen-only injectable
contraceptive products?
5. What are the discontinuation patterns of injectable contraceptive use?
6. What are the costs of providing one injectable contraceptive brand compared to the
other?




8. What are appropriate recommendations for rational use of injectable contraceptives?
9. What aspects of injectable contraceptive use should be investigated further?
FORMAT OF THE THESIS
The issues addressed in this thesis are numerous, complex and often interrelated. To
facilitate reading and application of the findings and recommendations to practice, the
thesis is divided into two main sections as follows:
A detailed description and analysis of injectable contraceptive use
including: a detailed literature review; the methodology used in the
community-based survey undertaken in the Hlabisa district ofKwaZulu-
Natal; survey data and analysis; a discussion section.
The Pharmacokinetics of depot medroxyprogesterone acetate including: a
detailed review of the literature; the methods used in collecting and
analyzing the data obtained from family planning clinics in the Durban
Metropolitan area; a description of the data and application of the
population approach to determine pharmacokinetic parameters of depot
medroxyprogesterone acetate; a discussion section.
These two sections are preceded by an overall introduction chapter and copies of the four
publications emanating from the thesis findings. In the concluding chapter of the thesis
recommendations for rational provision of injectable contraceptives and priority areas for
further research are presented.
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CONTRIBUTION TO THE FIELD
A main contribution of this study to the field is to provide the first comprehensive
description and analysis of injectable contraceptive use in a deep rural area in South
Africa. It serves to address the paucity of rigorous community-based research on
injectable hormonal contraceptives and to establish user experiences amongst rural
women. The clinic-based orientation of the few existing South African studies on injectable
contraceptives has meant that little is known about reasons for discontinuation of the
injectable, or about why some women do not access contraceptive services. This study
addresses this knowledge gap and in this respect makes a unique and original
contribution.
The inferences drawn from this study are wide in scope and have important policy
implications with respect to the provision of injectable contraceptives, not only in rural
KwaZulu-Natal, but also in the rest of South Africa and elsewhere in Africa. The
guidelines for provision and rational use of injectable contraceptives developed in this
thesis are considered a major contribution to the effective formulation of reproductive
health policy. Whilst others (Lucas, 1992; Chimere-Dan, 1993; Chimere-Dan 1996;
Kaufinan 1997) have provided analyses of "reproductive control", family planning and
contraceptive use in South Africa more broadly, this is the first comprehensive study
which focuses specifically on the injectable contraceptive.
The study has, based on empirical findings , identified a number of unique outcomes and
correlations which suggest an agenda for further research. Identifying these associations
is considered a major contribution. Particularly important in this regard are side effects ,
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not documented in the literature, reported by South African injectable users. The
relationship between age of user and injectable contraceptive product used is also
highlighted.
An in-depth review of studies reporting on utilization patterns, efficacy, reversibility, side
effects and discontinuation patterns experienced by users ofboth progestogen-only
contraceptive methods since the method was first introduced in South Africa in the late
1960s is provided. An attempt is made to interpret the meaning of this information in
relation to the experience of South African women. Little analysis of this kind has been
undertaken amongst African women. Further, many of the studies were undertaken in the
late 1970's and early 1980's. Current practice tends therefore to be based on studies
undertaken over two decades ago. A critical examination of the design of these studies is
long overdue and is another important contribution of this thesis. Data drawn from
secondary sources are utilized and synthesized into a set of reviews which have value in
their own right. More specifically, contributions in this regard include a review of
contraceptive use patterns reported in the 1998 South Africa Demographic and Health
Survey and a review of studies which examine injectable method reversibility, side
effects and discontinuation patterns of injectable users.
Another unique contribution is the first ever population pharmacokinetic study of DMPA
which includes an exhaustive review of relevant pharmacokinetic literature.
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SECTION 1
INJECTABLE CONTRACEPTIVE USE IN
RURAL SOUTH AFRICA
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CHAPTER 1.1 LITERATURE REVIEW AND OBJECTIVES
In this chapter a detailed review of studies relevant to the use of long acting progestogen-
only hormonal contraceptive injectables in South Africa is undertaken. Published surveys,
clinical trials, and reviews, focusing particularly on utilisation patterns, efficacy,
reversibility, side effects and discontinuation patterns ofmedroxyprogesterone acetate
(DMPA) and norethisterone oenanthate (NET-EN), were sought by means of
computerized and hand searches. Copies of relevant publications and citations from these
publications were obtained and reviewed. International and South African policy
documents were also reviewed. As there appears to be a shift away from the predominant
use ofDMPA, to NET-EN, in South Africa, (Wood, Maepa and Jewkes, 1997RM473;
Beksinska, 1998; Beksinska et al, 2001a) studies which specifically compared DMPA
and NET-EN were particularly sought. A review of the phannacokinetic literature is not
included here as a detailed review of the pharmacokinetics of DMPA is provided in
Section 2, Chapter 2.1.
This extensive literature search reveals that few clinical trials have been undertaken in
Southern Africa, few studies have been undertaken-amongst younger users, DMPA is
better researched than NET-EN and most published studies, upon which review after
review are based, were undertaken in the 1970s and early 1980s. Few systematic reviews
of studies have been undertaken and studies directly comparing DMPA and NET-EN
preparations are rare. Methodological limitations and differences in study population,
sample size, subject recruitment, exclusion criteria, frequency and nature ofprocedures
for follow-up, types of observations made, doses and dosing regimens of injectable
progestogen-only contraceptives (IPC), provider counselling, definitions of side effects,
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methods of recording, reliability of self-reported data, methods of analysis, criteria for
determining efficacy or discontinuation rates , and large inter-site variability in some
studies, make it difficult to evaluate and compare the published data. Trussell et al (1990)
provide a useful account of difficulties in analysing and comparing contraceptive efficacy
trials. A critical review of the literature on injectable progestogen contraceptives
published since the late 1950s, including a comparison ofDMPA and NET-EN, is
provided in this chapter.
1.1.1 INJECTABLE CONTRACEPTIVE UTILISATION PATTERNS
The first injectable progestin was developed in 1953 and NET-EN was the first injectable
contraceptive, developed in 1957 (Lande, 1995). MPA was first synthesized in the late
1950s (Babcock et ai, 1958) and the first clinical trials ofDMPA were conducted in 1963
(Weisberg, 1992). Johns Hopkins' Population Program's Population Report (Lande, 1995)
provides a comprehensive international review of injectable contraceptive use up to the
mid-1990s (Lande, 1995). According to this report, DMPA was available in more countries
in the world than NET-EN. In general , injectable contraceptives were not a commonly used
method except in South Africa, Indonesia, Thailand and New Zealand (Lande, 1995). The
report, published in 1995, estimates that 12 million couples in developing countries used
injectable contraceptives, and Bigrigg et al (1999) reported that Depo Provera®has been
used by more than 30 million women in the world since its introduction in 1963.
Although it has been widely available in the developing world since its introduction,
DMPA was only approved for contraceptive use in the United States of America (USA)
in 1992 (Weisberg, 1992). Since the USA Food and Drug Administration's (FDA)
approval of DMP A for contraceptive use, and the granting of a general license for DMPA
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in the United Kingdom (UK) in 1995 (Cayley 1998), use ofDMPA has increased in
countries in the developed world (Moore et al, 1995; Bigrigg et al,1999; Margulies and
Miller, 2001). For instance, Bigrigg et al (1999) report that the number of women in the
UK using Depo-Provera" increased from 40000 in 1993 to 270000 in 1996. There also
appears to be increasing popularity of injectable contraceptives among adolescents
(American Health Consultants , 1994; Davis, 1996; Chotnopparatpattara and
Taneepanichskul, 2000; Margulies and Miller, 2001).
The Population Report (Lande, 1995) indicated that the ratio ofDMPA to NET-EN
shipments by the United Nation's Population Fund was 3:1, and stated further that donor
agencies reported increasing orders for both progestogen-only injectable products in the
1990s. Use of injectable contraceptives by married women of reproductive age, based on
survey findings from 1984 to 1994, as published in the Population Report (Lande, 1995)
were found to vary widely from country to country. For instance, the percentage of
contraceptive users using injectables in India (1992-1993) was reported to be 0%, and in
Burundi (1987) to be 100%. Figures for South Africa (1987-1989) were reported to be
41%, the third highest usage rate of the 55 countries listed. The report does not
differentiate between DMPA and NET-EN use and figures providing this level of detail
do not appear to be readily available in a comprehensive form.
A more recent account ofworldwide contraceptive use amongst women married or in
informal unions reports that injectable contraceptives were used by 4% ofwomen in less
developed countries and by 4% ofwomen in Sub-Saharan Africa (Population Reference
Bureau, 2002). This data sheet claimed to provide the most recent statistics on
contraceptive use globally, reporting on 138 countries in the developed and developing
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world. It should be noted that data on injectable use were not available for all countries
included in the data sheet. The data are based on reproductive health surveys from 1990
onward, and injectable use amongst all women married or in informal unions in South
Africa was reported to be higher (23%) than in any other country. The next highest rate of
use was in Indonesia (21%), followed by Malawi and Thailand (16% each) and Peru (15%).
Use in the UK, New Zealand and the USA was reported to be quite low (2%, 2% and 1%
respectively).
According to Bongaarts and Johansson (2002) the contraceptive method mix is highly
variable across regions and countries, with sterilization more prevalent in Asia and Latin
America, and oral contraceptive (QC) and traditional method use more common in Africa.
They comment that in some countries a single method accounts for more than halfof all
use. The predominance ofone method is ascribed to the emphasis placed on that method by
providers, with little method choice offered to users (Bongaarts and Johansson, 2002).
As reported in the introductory chapter of this thesis, the widespread use of the injectable
method among Black South African women was the focus ofmuch criticism in the 1970s
and 1980s. Nevertheless, post-apartheid, with a progressive national contraceptive policy in
place (Department ofHealth, 2001), the method is still the most widely used contraceptive-
- being used, according to the South Africa Demographic and Health Survey (SADHS), by
27% ofall women aged 15-49 and by 30% of sexually active womerr' (Department of
Health et aI, 2002). As Bongaarts and Johansson (2002) found for certain countries in the
3 The SADHS defines "sexually active" as those who were sexually active in the four weeks preceding the
interview (Department of Health et ai, 2002).
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developing world, South African contraceptive use reflects a heavy reliance on one method,
the injectable method, used by 54% of current contraceptive users in 1998 (Department of
Health et al, 2002).
Although the contraceptive prevalence found in the SADHS was higher in urban than non-
urban areas, injectable use was higher in non-urban areas (33% versus 28% amongst
sexually active women). Ofthe non-urban women using a modern method of contraception,
62% were using the injectable (Department ofHealth et al, 2002). Contraceptive prevalence
in KwaZulu-Natal (KZN) was lower (58%) than the overall contraceptive prevalence
(62%), and injectable contraceptives were used by 26% ofsexually active women --lower
than all but one other province (23% in Gauteng) (Department ofHealth et al, 2002). Just
under half (46%) ofKZN women practicing contraception were using the injectable
method. The SADHS does not provide statistics for urban and non-urban areas within
provinces. The injectable method was particularly popular amongst younger South African
users, used by 51% of 15-19 year old sexually active women (Department ofHealth et al,
2002). This means that 80% ofthese young women who were using a modern method of
contraception, were using the injectable.
The SADHS does not break:down injectable use according to whether DMP A or NET-EN
was being used. Findings from other studies show that NET-EN is particularly popular
amongst younger, nulliparous South African women (Wood et al, 1997; Beksinska et al,
1998; Beksinska et al, 2001a). However no studies have specifically explored the reasons
for this pattern ofuse. Comparative data of this kind is not readily available in other
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countries of the world, perhaps because of the availability ofonly one injectable product in
most countries.
After the injectable contraceptive, the next most commonly used methods were the oral
contraceptive and female sterilization, used by 13.2% and 12% of sexually active women
respectively (SADHS). The intrauterine device (IDD) , male condom and male
sterilization were each used by 2% of sexually active women (Department ofHealth et al,
2002). The SADHS also reports that condom use at last sexual act was 8%.
The injectable contraceptives currently available in South Africa are the progestogen-only
preparations, depot medroxyprogesterone acetate (DMPA), registered as Depo-Provera'"
and the generic equivalent, Petogen", and norethisterone oenanthate (NET-EN) registered
as Nur-Isterate®. DMPA was first used in South Africa in the late 1960s (Karstadt, 1970;
Ferguson, 1974), and NET-EN became available in 1978 (Sapire, 1979). The product
formulation, brand name, manufacturer and dosing schedule of each of these products is
provided in Table 1.1.1. The same progestogen-only formulations are widely available
across the world . According to Lande in a report published in 1995, DMPA was
registered in over 100 countries and NET-EN in over 60 countries worldwide. Combined
injectable contraceptives (CICs), which contain a combination of oestrogen and
progestogen, are not yet registered for use in South Africa, but are widely available in
other parts ofthe world, especially China and Latin America (Lande, 1995).
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Table 1.1.1 Formulation, brand name, and dosing schedule of injectable
contraceptives available in South Africa
Formulation Brand Name Manufacturer Dosing Schedule
Progestogen-only: DMPA Depo-Provera Pharmacia & (a) Every 3 months
150mg depot medroxyprogesterone Upjohn (b) Every 12 weeks
acetate
Progestogen-only: DMPA Petogen Intramed (a) Every 3 months
150mg depot medroxyprogesterone (b) Every 12 weeks
acetate
Progestogen-only: NET-EN Nur-Isterate Schering (a) Every 8 weeks for
200mg norethisterone oenanthate 24 weeks, then every
12 weeks thereafter
(b) Every 8 weeks
(a) According to the approved package insert (Pharmacia and Upjohn, 1993; Intramed, 1993; Schenng, 1992)
(b) According to the South African Medicines Formulary (Gibbon, 2000)
Note: according to Lande (1995), the 2-month schedule for NET- EN is recommended by the World Health
Organization
1.1.2 MECHANISM OF ACTION AND EFFICACY OF INJECTABLE
PROGESTOGEN CONTRACEPTIVES
1.1.2.1 Mechanism of Action
The main mode of action of DMPA is the inhibition of ovulation by suppression of the
release ofpituitary gonadotrophins, resulting in the abolition of the mid-cycle surge of
lutenizing hormone (LH) and follicle stimulating hormone (FSH) (Mishell et al, 1968;
Mishell et al, 1972; Kirton and Cornette, 1974; Schwallie, 1974; Jeppsson and Johansson,
1976; Garza-Flores et al, 1992; Mishell , 1996; Clark et al, 2001). Other mechanisms of
action include alteration of cervical mucus secretion; thinning of the endometrium thus
secreting insufficient glycogen to support the entry of a blastocyte into the endometrial
cavity (MishellI968; Mishell , 1996); alteration of the normal contractile pattern ofthe
reproductive tract (Kirton and Cornette, 1974) and inhibition of capacitation of
spermatozoa and reduced sperm motility (Theron and Grobler, 1998). DMPA does not
have oestrogenic, anti-oestrogenic or androgenic effects (Theron and Grobler, 1998). A
more detailed account of the pharmacology and pharmacokinetics ofDMPA is provided
in Section 2.
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The contraceptive mechanism ofNET-EN is more complex than that ofDMPA (Fraser
and Weisberg, 1981; Theron and Grobler, 1998), inhibiting fertility through a mixed
mechanism (Benagiano and Primiero, 1983a). Initially, the effect is the same as DMPA:-
inhibition of ovulation, thickening of cervical mucus, prevention of implantation and
possibly alteration of tubal function (El-Mahgoub et al, 1972; Fraser and Weisberg, 1981;
Benagiano and Primiero, 1983a; Theron and Grobler, 1998). After 60 days, ovulation is
not always inhibited and the main action is reported to be on the cervix (Fraser and
Weisberg, 1981; Benagiano and Primiero, 1983a; Theron and Grobler, 1998).
Little is known about the molecular mechanisms of action ofDMPA and NET-EN, but
work in progress by a team of researchers in the Department of Biochemistry at the
University of Stellenbosch, led by Or Janet Hapgood, suggests that the two substances
have different molecular modes of action (J Hapgood, pers. comm., January 2001).
1.1.2.2 Efficacy
The progestogen-only injectable contraceptives are demonstrably extremely effective
(Mishell et al, 1968; Tyler, 1970; Garza-Flores et al, 1992; Kaunitz, 1992; Garza-Flores
et al, 1994; Kaunitz, 1994; Kaunitz and Rosenfield, 1994; Lande, 1995; Bigrigg, 1999).
Many clinical trials have investigated the efficacy of these preparations, but most were
conducted some time ago, in the 1970s and early 1980s. Efficacy findings are discussed
below and a summary of relevant studies is presented in Table 1.1.2.
DMPA Studies
One of the first efficacy studies undertaken on DMPA (150mg given every 3 months)
found no pregnancies, even amongst women who reported from one to four weeks late for
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their next injection (Mishell et al, 1968). This study was conducted amongst 100
Caucasian women and lasted for one year. Another early collaborative study of 3857
women receiving 150mg of DMPA every three months was conducted between 1965 and
1971. It set the two year cumulative pregnancy rate for DMPA, calculated by the life
table technique, at 0.53 per 100 women after two years (Schwallie and Azenzo, 1973).
The DMPA efficacy findings (pregnancy rate=Oo4 at 15 months) in Chinnatamby's (1971)
study were comparable with the efficacy reported in the World Health Organization
(WHO) (1983) trial (Table 1.1.2). A recent study, which retrospectively examined
contraceptive failures amongst DMPA users, reported to the Insurance Division of the
Planned Parenthood Federation ofAmerica Inc. from 1994 to 1998, found a crude rate of
pregnancy of 0042 per 1000 women using DMPA in each year (Borgatta et al, 2002).
Overall, in the studies summarized in Table 1.1.2, the failure rates for DMPA were
similar.
NET-EN Studies
Banerjee et al (1984) conducted a large clinical trial (N=2388) on NET-EN, used by
Indian women from 16 Human Reproductive Research Centres located in different parts
ofIndia, with two dosing schedules (two monthly, and two monthly for six months then
three monthly). They reported failure rates at six months of 1.2 per 100 users for the two
monthly group, and 0.7 per 100 users from the second dosage regimen" These authors
suggested that the unexpectedly high method failure rates in the first six months of use,
compared with findings from previous studies, could be due to the lower average body
weight of Indian women compared to women from western countries. However, failure
rates reported in a field study in six family planning clinics in Bangladesh (Rahman et al,
4 Note: during the first six months the dosage schedule was the same for the two groups .
29
1985) were lower than the Indian study (Banerjee et al, 1984). In this study, Rahman et al
(1985) found a cumulative pregnancy rate at 18 months of 0.4 for NET-EN given every 8
weeks for six months and then every 12 weeks. In a study of Mexican women taking
NET-EN on a two monthly dosage regimen, the efficacy at 18 months was reported to be
0.3 (Meade et al, 1984). The NET-EN efficacy findings from the studies summarized in
this chapter are less consistent, even within dosage regimens, than the DMPA efficacy
findings.
Comparative Studies
One ofthe earliest multi-national clinical trials compared the efficacy ofDMPA (150mg)
and NET-EN (200mg), with both preparations given every twelve weeks (World Health
Organization, 1977). This study was to have lasted for two years, but was terminated after
about one year as the NET-EN pregnancy rate exceeded the allowed maximum. The
cumulative pregnancy rate at one year was found to be 0.7 for DMPA and 3.6 for Net-
EN. It should be noted that 75% of all conceptions with NET-EN were estimated to have
occurred during the first injection period, that 54% of all pregnancies occurred in only
two of the ten centres (Bangkok and Chandigarh), and that efficacy was found to decrease
with decreased body weight, as the mean admission body weight ofNET-EN users who
became pregnant was significantly lower (World Health Organization, 1977). EI-
Mahgoub and Karim (1972), in a study of Egyptian women (1968-1971), found no
pregnancies with NET-EN given every 84 days, even though, in some instances, delays
between injections of95 days were reported. Zanartu and Navarro (1968) in a study in
Chile , and Chinnatamby (1971) in a study in Ceylon (now Sri Lanka), reported a
pregnancy rate of2.3 per 100 woman-years for NET-EN given every twelve weeks ,
which is lower than the pregnancy rate recorded in the World Health Organization (1977)
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trial. A later WHO multi-national clinical trial (World Health Organization, 1983) of
1587 women given DMPA every 90 days, 789 women given NET-EN every 60 days , and
796 women given NET-EN every 60 days for 6 months and then every 84 days, found the
cumulative life-table accidental pregnancy rates after two years to be 0.4, 0.4 and 1.4 per
100 women respectively.
Reviews
Several reviews ofstudies on progestogen-only injectable efficacy have been published and
the pregnancy rates are reported as follows:
• DMPA 150mg given every 12 weeks/3 months: 0 to 1.2 pregnancies per 100 women
(Fraser and Weisberg, 1981; Fraser, 1982; Fraser and HoIck, 1983); 0.5 per 100
woman-years in the largest trials (Fraser and Weisberg, 1981; Fraser, 1982); not
exceeding 0.5 per 100 woman-years at one year Benagiano and Primiero, 1983a); life
table failure rate: less than 1.0 per 100 woman-years (Hickey and Fraser, 1995); first-
year failure rate in the United States of 0.3% (Lande, 1995); in-use failure rate of 0.0 to
0.7 per 100 woman-years (Kaunitz, 1992; Bigrigg et al, 1999; Kaunitz, 2000); in taking
the mean of all available studies at the time, a ' typical' failure rate of 0.3% (Trussell
and Kost, 1987).
• In an evaluation of five large controlled multi-centre studies, Kaunitz (1992) reported
that there were only 24 pregnancies among 7849 women using Depo-Provera for
122496 patient-months.
• Weight and concurrent medication does not affect DMPA efficacy, presumably because
ofhigh circulating levels ofMPA (Kaunitz, 2000) .
• Contraceptive failure ofDMPA with perfect or typical use is <0.3% per year which is
comparable with the failure rate ofsurgical sterilization (Kaunitz,2002)
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• NET-EN given every 8 weeks or 60 days: less than one pregnancy per 100 woman-
years at 18 months (World Health Organization 1982); 0.6 per 100 woman-years
(Benagiano and Primiero, 1983b).
• NET-EN given 10 weeks after the first injection, and then every 12 weeks; or given
every 60 days or 8 weeks for six months and then every 12 weeks: 0.7 per 100
woman-years (Benagiano and Primiero, 1983b); less than I per 100 woman-years at 12
months and 1.6 at 18 months (World Health Organization 1982).
• NET-EN given every 12 weeks/90 days : 3.6 per 100 woman-years (World Health
Organization, 1982); 1.5 to 5.2 per 100 woman-years (Benagiano and Primiero,
1983b)
• NET-EN (unspecified regimen): 1.0 to 1.5 per 100 woman-years (Fraser, 1982); 0.5 to
1.5 (Bigrigg et al, 1999).
• Trussell et al (1990) provide "summary estimates ofcontraceptive failure" and give the
lowest expected, and typical percentage, of accidental pregnancies in the United States,
during the first year ofuse, as 0.3 for DMPA and 0.4 for NET-EN (unspecified dose
interval).
Bigrigg et at (1999, p.?l) state that Depo Provera is " . .. the most effective reversible
contraceptive available", with a user failure rate approaching the method failure rate. The
efficacy ofDMPA and NET-EN given every 8 weeks is comparable, however, since
women on the NET-EN regimen have to return to the clinic every eight weeks (versus




Whilst there are minor differences in published efficacy rates, depending on the study,
timing of the first injection, the population, body weight, dosage regimen and provider
training, the efficacy rate ofboth the IPCs is very high. The efficacy of 150mg DMPA
given every 90 days and 200mg NET-EN given every 60 days are comparable. Because
women using NET-EN have to return for their next dose earlier than DMPA users, the in-




Table 1.1.2 Summary of findings on efficacy from relevant studies
Study Notes Measure DMPA NET-EN 200mg"
150mg* Regimen 1 Regimen 2 I Regimen 3
Pregnancy rate per 100 woman-years
1. Zanartu & Navarro, 1968 N/A N/A N=130
(NET-EN only, fertile ~, Chile, N=130)
Pregnancy rate 2.3
(average observation per
patient for 17.6 months)
2. Chinnatamby, 1971 N=5l5 N/A N/A N=520
(Comparative study, Ceylon - now Sri
Lanka, N=1035) Most NET-EN users who became Pregnancy rate at 15 months 0.4 2.3
pregnant, did so in the 1st course of
therapy
3. EI-Mahgoub & Karim, 1972 N/A N/A N/A N=171
("birth control clinic", NET-EN only,
Egypt (1968-1971), proven fertility , non- In some instances, delays between Pregnancy rate 0.0
breastfeeding, no hormonal contraceptive injections of95 days occurred
history, N=17l)
4. SchwaIIie & Azenzo, 1973T N=3857 N/A N/A N/A
(Multi-centre, collaborative study, 1965-
1971,54 investigators, DMPA only, Pregnancy rate:
healthy women, 54.7% were white, at 12 months 0.31
demonstrated fertility, N=3857) at 24 months 0.53
* Given every 12 weeks or every 90 days




Study Notes Measure DMPA NET-EN 200mgll
(WHO=World Health Organization) 150mg* Regimen 1 Regimen 2 Regimen 3
Pregnancy rate per 100 woman-years
5. WHO, 1977 t Study was to have lasted for 2 yrs, but N=846 N/A N/A N=832
(Randomised 10-centre comparative was terminated after ± 1 yr as NET-EN
trial, healthy non-breastfeeding ~ of pregnancy rate exceeded the allowed Cumulative 12-month 0.7 ± 004 3.6± 0.7
demonstrated fertility, N=1678) maximum gross pregnancy rate per
100 woman-years
Participating Centres: Alexandria, No pregnancies in Ibadan & Utrecht statistically significant
Bahia-Salvador, Bangkok, Bombay,
Chandigarh, Ibadan, Ljubljana, 54% ofpregnancies for NET-EN
Manila, Utrecht, Lima observed in Bangkok & Chandigarh
75% of all conceptions with NET-EN
estimated to have occurred during
first injection period
Mean admission body wt. of NET-EN
users who became pregnant
significantly lower
6. WHO, 1983 t N-1587 N-789 N-796 N/A
(2 year multi-national comparative
0.6± 0.3randomized trial, 13 centres, healthy Cumulative 12-month 0.1±0.1 OA±O.2
non-breastfeeding ~ N=31 72) pregnancy rate per 100
woman-years
Participating Centres: Alexandria, not statistic. significant
Bangkok, Ibadan, Karachi, Lusaka,
004 ± 0.3 004 ± 0.2 lA ± 0.6Manila, Mexico City, Salvador, Cumulative 2-year
Santiago , Ljubljana, Luxembourg, pregnancy rate/lOO
Milan, Utrecht woman-years
not statistic. significant
* Given every 12 weeks or every 90 days
# Regimen 1: Given every 60 days; Regimen 2: Given every 60 days or 8 weeks for six months and then every 12 weeks; Regimen 3: Given every 12 weeks




Study Notes Measure DMPA NET-EN 200mg"
150mg* Regimen 1 Regimen 2 Regimen 3
Pregnancy rate per 100 woman-years
7. Banerjee et 011984 Speculated that the unexpectedly N/A N=1181 N=1207 N/A
(comparative clinical trial oftwo dosage high failure rates may be a result of
regimens ofNET-EN, Indian ~, 16 lower body weights of Indian Method failure rates: 1.2 0.7
Human Reproductive Research Centres, women at 6 months
N=2388) not statistic. significant
Life-table reconstructed & day
1 set where dosage schedule
was changed (Le. after the 4th
injection) (statistic. Significant
difJfound
at 12 months 0.0 1.1
at 18 months 0.2 2.1
at 24 months 0.2 6.0
8. Rahman et at, 1985
(field study in 6 clinics, NET-EN only,
Bangladesh, N=913)
Cumulative pregnancy rate at 18months 0.4
* Given every 12 weeks or every 90 days
# Regimen 1: Given every 60 days; Regimen 2: Given every 60 days or 8 weeks for six months and then every 12 weeks ; Regimen 3: Given every 12 weeks .
1.1.3 RETURN TO FERTILITY
DMPA Studies
Delay in return to fertility has been more extensively documented for DMPA than for
NET-EN. A very early study (n=752), conducted from 1965 to 1968 (44months), only
one pregnancy occurred (Seyrnour et al, 1970). Tyler (1970), in studying the time to
returned ovulation in 30 women who had used DMPA, reported that a third of these
women ovulated within six months of the last injection and almost all ovulated within a
year. McDaniel and Pardethaisong (1973) studied the return to fertility of 135 Thai
women who discontinued DMPA to become pregnant, and reported a life-table return to
fertility rate of 82% after 14 months. Discontinuation was taken at 15 weeks after the last
injection. Even if women lost to follow-up were included in the analysis, the return to
fertility rate would have been 71.3% (McDaniel and Pardethaisong, 1973). These authors
concluded that "the monthly probabilities of conception among IUD users were equal to,
or lower than, those ofDMPA users within 4 months of discontinuation" p.511. In a later
study of 796 Thai women, Pardethaisong et al (1980) reported a median delay before
conception after discontinuing DMPA of 5.5 months plus the duration of effect of the last
injection, and 4.5 months after discontinuing the IUD. The proportions who did not
conceive within one year and two years of discontinuation of these two methods were
similar. Prolonged use ofDMPA did not appear to increase the delay, and return to
fertility among never pregnant and ever pregnant ex-users was similar (Pardethaisong et
aI1980).
Schwallie and Azenzo (1973) found the mean time to return to normal cyclic menses in
245 women using DMPA was 5.8 months with a range of 1-28 months. A range of3 to
31.5 months and an average of 12 months from last injection to conception are reported
37
for 285 women who became pregnant after discontinuing the method. However the
authors warn that the number ofmonths to conception may be biased upward as it was not
known ifthe subjects, on discontinuing the method, actually tried to conceive
immediately. Schwallie and Azenzo (1973) also found no difference in time to return to
fertility between short and long term users ofDMPA. Pardethaisong et al (1980), in
referring to Schwallie and Azenzo's (1973) findings and McDaniel and Pardethaisong's
(1973) findings, noted that these earlier studies used different study designs, had smaller
sample sizes with women ofdiffering ages and that observations were made for shorter
time periods. Nevertheless, the findings from these three studies were fairly consistent. In
an updated analysis of the data from the 796 Thai women (Pardethaisong et al, 1980),
Pardethaisong (1984) concluded that the return of fertility with DMPA is only about a
month longer (after the date of the last scheduled injection) than after removal ofthe IUD.
NET-EN Studies
In 81 Egyptian women who had received at least ten doses ofNET-EN injections at a
dosing interval of84 days, El-Mahgoub and Karim (1972) found that a normal menstrual
pattern had been established within 2-4 months. Only seven women in the follow-up
study wished to conceive, and four of these became pregnant within 5 to 14 months.
Fotherby et al (1984) found that 14 of40 women who stopped using NET-EN were
pregnant within 12 weeks of discontinuing the method and 21 women within 6 months
and suggested that NET-EN does not impair fertility. The Indian Council of Medical
Research (ICMR) (Banerjee et al, 1986) reported a median time for conception of7.8
months for 69 NET-EN users who had discontinued use because they planned to get
pregnant. The dosage regimen ofNET-EN used by the women participating in this study
is not mentioned. The ICMR also found that the return to fertility was slower in 51
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subjects who had discontinued NET-EN because of amenorrhoea. Only 51% of these
women conceived within 12 months, compared with 73% of those who discontinued
injectable use as they were planning a pregnancy. A difference in the median time for
conception of4 months longer in NET-EN users who had discontinued the method,
compared with former copper IUD users, was reported. The authors of this study
concluded that NET-EN does not adversely affect the return of fertility (Banerjee et al,
1986).
Comparative Studies
Few studies have been undertaken which directly compare DMPA and NET-EN in terms
ofreturn to fertility. However, in a comparative pilot study carried out by the WHO to
determine the pharmacokinetic and pharmacodynamic properties ofDMPA and NET-EN
it was found that ovarian function returns more quickly after discontinuation ofNE'P-EN
than after DMPA discontinuation (Fotherby et al, 1980b). Garza-Flores et al (1985) in a
comparative study of24 women who discontinued DMPA and NET-EN, found that the
mean time to return to ovulation occurred significantly earlier with NET-EN than with
DMPA - 2.6 months and 5.5 months respectively " ... overall data was interpreted as
demonstrating a clear-cut difference between the two long-acting progestogens in terms
of ovulation suppression" p.31. These authors also conclude that neither DMPA nor NET-
EN permanently or irreversibly affect ovarian function (Garza-Flores et al, 1985).
Reviews
Several reviews of the reversibility ofprogestogen-only injectables have been undertaken.
Fraser (l986a, p. 40) stated that "the conception rate curve following DMPA use parallels
the normal conception rate curve but is shifted 3-5 months to the right". The reviews
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show no evidence that the injectables cause permanent infertility (Fraser, 1982; Fraser
and Weisberg, 1982; Fraser and Hoick, 1983; World Health Organization, 1982; Kaunitz,
1992; Kaunitz, 1994; Fraser, 1986a; Lande, 1995). Nor is it felt that any of the injectables
should not be given to adolescent and nulliparous women (Fraser, 1982; Fraser and
Hoick, 1983; Kaunitz, 1992; Lande, 1995) and no difference in time to return to fertility
has been found when comparing long-term and short-term users (Fraser, 1982; Fraser and
HoIck, 1983; Kaunitz, 1992; Lande, 1995).
In a more recent review, Bigrigg et at (1999), in examining early data, suggest that there
is no delay in return to fertility with DMPA use if one considers the methodological bias
of early studies, which did not take in to account the date of the last DMPA injection.
They state further that "if there is a delay it is not statistically significant and is less than
30 days. According to Hatcher et at(1997) return to fertility is delayed by DMPA for about
4 months longer on average compared with the combined OC method, IUD, and condoms.
It is reported that the pregnancy rates for users ofDMPA, the IUD and OCs are the same
two years after discontinuation of the method (Lande, 1995).
A South African textbook (Theron and Grobler, 1991; revised edition, 1998),
recommended in the early 1990s by the National Department of Health for training of
pharmacists and pharmacy students, gives the average time to pregnancy following
administration of the last injection ofDMPA as 9 months and ofNET-EN as 7-8 months
The average time to pregnancy reported by these authors for no method is 5 months. The
South African Medicines Formulary (Gibbon, 2000, p.215) gives a delay of 'usually 9
months' for DMPA and 'generally' 6 months for NET-EN and the draft National
Contraception Service Delivery Guidelines (Department ofHealth, 2001) records an
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average delay of 6-9 months without referring to a particular product. According to the
World Health Organization medical eligibility criteria for contraceptive use, the median
delay in return to fertility is ten months from the date of the last injection for DMPA and
six months for NET-EN (World Health Organization, 2000).
The approved package insert for the NET-EN product (Nur-Isteratef'j registered for use
in South Africa states that "Following discontinuation, normal ability to conceive usually
returns 7-8 months after the last injection" (Schering, 1992). The Depo-Proveraf'package
insert states that "Restoration ofnormal menstrual cycling may take from 5 to 28 months
after the last injection..." (Pharmacia and Upjohn, 1993). There is no reference to
reversibility or return to fertility in the Petogen® package insert (Intramed, 1993).
Conclusion
The delay in return to fertility with progestogen-only injectables appears to be only a few
months longer than with oral contraceptives, IUDs and condoms, regardless oflength of
use. The methodological bias of early studies which did not take into account the date of
the last DMPA injection should be noted. Further, earlier studies also tended to have
smaller sample sizes with women of differing ages, and in some cases observations were
made for short time periods. The search of the literature on return to fertility revealed no
publication of primary data after 1986. The existing evidence thus seems to be based
entirely on these early studies . Published studies also used different study designs . While
there is little direct comparative data on the delay in return to fertility between DMPA
and NET-EN users , it seems that NET-EN is likely to result in a slightly shorter delay, but
there appears to be little long term difference.
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1.1.4 SIDE EFFECTS
The poor side effect profile ofprogestogen-only injectables is extensively documented in
the intemationalliterature. It is clear that IPCs result in numerous side effects , with many
women experiencing a number of side effects concurrently. For instance, in the study of
3857 women undertaken by Schwallie and Assenzo (1973), side effects were reported by
36% of the DMPA users, giving an average of five side effects per woman. Many clinical
studies investigate one or other ofthese products and some directly compare the side
effects associated with their use. The injectable contraceptive has also been extensively
reviewed. It is beyond the scope of this thesis to review data on every possible side effect.
Rather, this sub-section focuses on side effects most frequently reported or most likely to
result in discontinuation, particularly in regard to South African women. Studies which
compare the side effects experienced with DMPA and NET-EN were ofparticular
interest. To avoid repetition, a selection of only the most pertinent studies and reviews are
described below. A summary of studies which compare common side effects experienced
by DMPA and NET-EN users is also provided in Table 1.1.3. It is ofnote that little is
documented about side effects experienced by South African injectable users and no
publications could be found which provide a detailed description of the experience of side
effects amongst South African users.
1.1.4.1 Menstrual Disturbances
The most frequently reported side effects experienced, and those most likely to result in
discontinuation, are menstrual disturbances (Zanartu and Navarro, 1968; Seymour et aI,
1970; Tyler, 1970; Chinnatamby, 1971; El-Mahgoub and Karim, 1972; Schwallie and
Assenzo, 1973; World Health Organization, 1977; World Health Organization, 1978;
Sapire, 1979; Fraser and Weisberg, 1981, Fraser 1982; Benagiano and Primiero, 1983b;
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Fraser, 1983; Howard et al, 1985; Belsey et al, 1986; Fraser, 1986b; Salem et al, 1988;
Kaunitz, 1992; Olive and Schlaff, 1992; Datey et al,1995; Be1sey and World Health
Organization Task Force, 1988; Hadisaputra and Affandi, 1990; Keller, 1995; Lande 1995;
Polaneczky et al, 1996; Paul et ai, 1997; Beksinska et al, 1998; Bigrigg et al, 1999;
Chotnopparatpattara and Taneepanichskul, 2000; Danli et al, 2000; Kaunitz, 2000;
Beksinska et ai, 2001a).
Findings from earlier studies have been criticized, with clinical evaluations referred to by
Olive and Schlaff (1992) as "crude and inadequate" because, for instance, of the lack of
uniformity in definitions. From the mid-eighties methodological advances led to a more
standardized approach and more sophisticated analytical procedures (Olive and Schlaff,
1992). In contrast to the prolific amount ofpublished information worldwide, and despite
the widespread use of the injectable contraceptive in South Africa, little data on side effects
experienced by South African injectable users are published. One very early South African
study was undertaken which compared two dosage regimens ofDMPA (150mg every three
months and 450 mg every 6 months) (Rall et ai, 1977). This was a large study (n=19875)
undertaken from 1970 to 1975 and few side effects were reported. However, the authors
point out that a large number ofparticipants were lost to follow-up and it was not known
what proportion of these dropped out for personal reasons.
Bleeding disturbances frequently reported are amenorrhoea, irregular bleeding, spotting
between periods, unpredictable bleeding patterns, heavy bleeding, prolonged menses
(Kaunitz, 1992; Kaunitz, 2000; International Planned Parenthood Federation, 2002). Some
side effects (e.g. amenorrhoea) predominate in the early months of use, but with increased
duration ofuse, amenorrhoea becomes very common (Kaunitz, 1992; Kaunitz, 2002). The
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effects of the IPCs on the menstrual cycle result in what has been referred to as
"menstrual chaos" (Fraser, 1986b; Datey et al, 1995). Tyler (1970, p.3), in referring to
bleeding problems associated with DMPA, states that "These occurrences are so
numerous as to be considered an inherent part of the method."
DMPA Studies
Data from menstrual diary records of 314 women using DMP A were analysed by Belsey
and the World Health Organization Task Force (1988) and showed that DMPA users had
unpredictable menstrual patterns. What is predictable however is that the proportion of
woman experiencing excessive bleeding decreases over time (Schwallie and Azenzo ,
1973). In the study by Belsey and the World Health Organization Task Force, (1988) , the
rate of amenorrhoea rose from 8% in the first injection interval to 45% in the fourth. By
contrast, prolonged bleeding decreased from 29% in the first injectable interval to 10% in
the fourth. Further, a marked inter-regional variation in bleeding patterns was noted. For
instance, by the fourth dosing interval amenorrhoea was reported by 25% of respondents
from Europe compared with 72% of those from North Africa (Belsey et al, 1988). In a
study among 108 Thai adolescents (under 19 years) amenorrhoea increased from 7% in
the first injection cycle to 58% by the fourth. In the same time-frame, irregular bleeding
decreased from 94% to 42% ChotnopparatIJattara and Taneepanichskul, 2000) . The main
side effects reported in a multi-centre clinical trial ofDMPA use among 1994 Chinese
women who were followed up for a total of20294 months were spotting, bleeding,
prolonged bleeding and amenorrhoea (Danli et al, 2000). Sixty Thai women between 36
and 45 years were followed for a year and most commonly reported irregular bleeding with
DMPA use (Taneepanichskul, 2000).
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NET-EN Studies
In a trial conducted from 1968 to 1971 amongst 171 NET-EN users in Egypt, El-Mahgoub
and Karim (1972) found that a high proportion (46-71%) ofwomen using NET-EN had
disturbed menstrual cycles. Menstrual irregularities (prolonged bleeding, spotting or
amenorrhoea) were the most commonly reported side effects reported in a London-based
clinical trial of NET-EN undertaken among 707 women, from 1974 to 1981 (total women
months=9024) (Howard et al, 1985). In an analysis of clinical trials carried out by the
Indian Council of Medical Research from 1981 to 1987, Datey et al, (1995) determined
that NET-EN use (2 monthly and 3 monthly dosage regimen) resulted in disturbances in
bleeding pattern in the majority ofusers (80% during the first year of use). The proportion
ofwomen experiencing bleeding disturbances did not improve with prolonged use. Very
heavy or prolonged bleeding was uncommon with infrequent bleeding more commonly
observed (Datey et al, 1995).
Comparative Studies
Menstrual irregularities are reported to occur more often with DMPA than with NET-EN
use (World Health Organization, 1978; Fotherby et al, 1980b; Howard et al, 1985; Salem
etaI1988). A World Health Organization (1978) multi-national comparative clinical
evaluation ofthe two injectables found that 71% ofDMPA users and 47% ofNET-EN
users did not experience even one normal cycle over four injection intervals. It is important
to note that in these studies both NET-EN and DMPA injections were administered every
twelve weeks. During the first six months of use, NET-EN was reported to result in more
defined cyclic patterns and fewer prolonged bleeding and spotting episodes than DMPA
(World Health Organization, 1983). These results were obtained for both NET-EN dosage
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regimens in the WHO multi-national comparative study in which NET-EN was given
every 60 days to one group ofwomen and every 60 days for 6 months and then every 84
days to another group of women. On the other hand, Swenson et al (1980) reported that
NET-EN, given 10 weeks after the first injection and then every twelve weeks, resulted in
more irregular bleeding than DMPA (given every 12 weeks). They found that less than
15% ofboth DMPA and NET-EN users reported having regular cycles by the fourth
injection.
The Multi-national WHO comparative clinical trial (World Health Organization, 1978)
found that amenorrhoea occurred significantly more often with DMPA than with NET-EN,
with 35% ofDMPA users and 9% ofNET-EN users experiencing total amenorrhoea at the
end ofone year. They found further that the number of women who experienced total
amenorrhoea increased significantly over time for both drugs, and that the difference in the
proportion of women experiencing amenorrhoea with use of the two drugs increased over
time (World Health Organization, 1978). It is important to note that NET-EN was
administered every 12 weeks in this study. This same trial also found that heavier women,
who used DMPA, were more likely to experience total amenorrhoea than lighter women,
with amenorrhoea occurring in 17% ofwomen under 47kg, in 19% ofwomen 48 to 61kg
and in 25% of women over 62kg (World Health Organization, 1978). The relationship
between weight and amenorrhoea was not found among women using NET-EN on a 12
week dosing schedule. That efficacy was found to decrease with body weight ofNET-EN
users (World Health Organization, 1977) has already been mentioned in sub-section 1.1.2.2
above. A later clinical trial undertaken by the World Health Organization (1983) comparing
DMPA given at 90-day intervals with NET-EN given every 60 days to one group of
women and with NET-EN given every 60 days for 6 months and then every 84 days to
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another group of women, reported significantly less amenorrhoea with both groups of
NET-EN users than with the DMPA users. Findings from a study undertaken by Swenson
et al (1980) in Bangladesh, concurred with the finding of greater experience of
amenorrhoea amongst DMPA users than NET-EN users.
The World Health Organization (1978) reported that DMP A caused significantly more
spotting than NET-EN (given every 12 weeks). The later World Health Organization
(1983) findings are consistent and significantly longer episodes ofbleeding and spotting
were found to occur with DMPA than with either ofthe NET-EN regimens used. The
experience of spotting is reported to diminish over time (World Health Organization, 1978),
especially for DMPA and the NET-EN 60 day regimen (World Health Organization, 1983).
Chinnatamby (1971) reported that leucorrhoea is experienced more by NET-EN users than
DMP A users, bearing in mind though that the number reporting this side effect at all was
small.
Reviews
Comprehensive reviews highlight the extensive menstrual disturbance that occurs with
injectable use (Rosenfie1d, 1974; Gray, 1979; Fraser and Weisberg, 1981; Benagiano and
Primiero, 1983b; Lande 1995; Bigrigg et al, 1999). Kaunitz (2002) encapsulates the
evidence well, noting that injectables alter menstrual bleeding patterns, particularly during
the first three to six months ofuse when spotting and prolonged bleeding are common.
Spotting and prolonged bleeding diminish over time, but the incidence ofamenorrhoea
increases. Bya year after discontinuation of DMPA, regular menstrual cycles are said to be
resumed in three quarters ofusers (Kaunitz, 2002) . Heavy bleeding is not a common side
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effect ofIPCs, with reported incidences of 1-2% (Fraser, 1983). Menstrual irregularities
are reported to occur more often with DMPA than with NET-EN use (Fraser, 1982; Fraser,
1986b).
Amenorrhoea has been found to be more frequent in obese women than in underweight
women (Fraser and Weisberg, 1981; Benagiano and Primerio, 1983b). Lande (1995)
suggests that bleeding patterns with IPC use may differ with ethnicity. For instance he
reports that Southeast Asian women using DMPA reported more days of spotting and
bleeding than those in the Caribbean, Europe, South East Asia, or North America, and
amenorrhoea was reported more often by North African women than by European
women.
Conclusion
Bleeding disturbances with IPC use are the norm. Amenorrhoea is the most prevalent
menstrual irregularity, especially with DMPA, and incidence increases with duration ofuse
(Table 1.1.3). The weight of evidence suggests that menstrual irregularities are reported to
occur more often with DMPA than with NET-EN use. Some studies raise the possibility
that factors such as body weight and ethnicity may influence the frequency ofbleeding
disturbances.
1.1.4.2 Weight Gain
Weight gain is also a commonly reported side effect amongst progestogen-only injectable
users (Schwallie and Assenzo, 1973; Guillebaud, 1993; Lande 1995; Paul et al, 1997;
Bigrigg et al, 1999). Many studies have examined the association between weight gain
and IPC use. For instance, Westhoff (1996) systematically reviewed five cross-sectional
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studies comparing weights in women receiving DMP A with non-hormonal contraceptives
users. Whilst all studies showed higher weights amongst the DMP A users, Westhoff
suggests that the findings are not conclusive as the studies did not consider the differences
in weight of study participants when contraception was started, and that several
confounders - age, parity, smoking - were not taken into account by the investigators.
Westhoff (1996) also reviewed a number oflongitudinal studies and opined that , since
these studies did not include a control group, the observed changes in weight could not be
attributed to DMPA use. Indeed the author of one of the studies she reviewed, who found
a small mean weight gain of3kg with 5-8 injections (n=76), reported that this finding had
"little statistical validity" (Fraser and Dennerstein, 1994, p.555). Westhoff (1996, p.404)
concluded that "Weight gain is not inevitable during DMPA use, although some of the
other data suggest that DMPA or MPA use may be associated with increased appetite".
Taneepanichskul et al (1998) , in a study designed to limit some confounders through
subject selection and matching techniques, found no difference in the mean weight of 50
DMPA users at 120 months of use and 50 women using an IUD over the same period .
These authors , like Westhoff, suggested that the conflicting findings of studies reporting on
weight changes with DMPA use results from differing study designs and the lack of control
for confounding factors such as age, parity, smoking, income, nutrition, lifestyle and
duration of contraceptive use. However, more recently, Espey et al (2002) studied weight
gain in Navajo DMPA users (n=172) and non-users (n=134). After controlling for age,
parity and initial weight, they found that DMPA use is associated (p<0.001) with weight
gain in this population and that weight gain increased with duration ofuse. These authors
also point to possible metabolic differences between racial and ethnic groups as this study
demonstrated greater weight gain with injectable use than that reported in studies of non-
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Navajo DMPA users . Bahamondes et al (2001) also concluded that weight increases in
DMP A users were significantly higher compared with IUD users. This finding was based
on a five year retrospective record review of 103 DMPA users and an equal number of IUD
users .
As already highlighted above, there is concern that weight gain increases with increased
duration ofuse of IPCs. Schwallie and Azenzo (1973) found that weight, in DMPA users,
increased over time, and Westhoff (1996) reported the weight gain in this study as 10kg
over five years. Bigrigg et al 's (1999) review ofDMPA suggests that studies have shown
(unreferenced) that there is an increase in weight gain over time with DMPA, reporting that
the mean weight increase after a year was 2kg, but after 5.5 years of use it was 9kg.
Benagiano and Primiero (1983b, pA8) make similar inferences about weight gain and NET-
EN use, saying that there is " .. .a direct correlation between total dose over time and gain in
body weight".
In comparing DMPA and NET-EN, the findings on weight gain appear to be similar (Table
1.1.3), although comparative studies are few and far between. The Multi-national WHO
comparative clinical trial (World Health Organization, 1978) found no statistical difference
in weight gain between NET-EN and DMPA, after a year ofuse. The weight gain with
NET-EN was reported as 1.5kg and with DMPA was 2.0kg. Chinnatamby (1971) reported
that changes in weight changes are more frequent amongst DMPA than NET-EN users, but
found that weight change was not given as a reason for discontinuing the method. Salem et




Few studies on the association between weight gain and IPC use have dealt adequately with
confounders including age, weight at the beginning of the study, nutritional habits, ethnicity
and level ofphysical activity. Findings on weight gain and IPC use are inconclusive,
although findings from more recent studies seem to indicate that there may be an
association. There appears to be little evidence of differences in weight gain between users
ofDMPA and NET-EN.
1.1.4.3 Vaginal Discharge
A side effect of IPCs occasionally reported in early published studies is vaginal discharge.
It is described here, as anecdotal reports suggest that it is a problem amongst South Africa
injectable users. Four early publications reported vaginal discharge as a side effect. It has
been described as a rare symptom ofDMPA (Tyler, 1970), as a temporary, short-lived
complaint, associated with the use of DMPA (Zartman, 1967), and as a major side effect
ofDMPA (Schwallie, 1976). El-Mahgoub and Karim (1972) reported vaginal discharge
as a minor side effect ofNET-EN. Only recently, in South Africa, has this side effect
been reported again -- by injectable users at a family planning clinic in Soweto, South
Africa. In this study, 20% reported vaginal discharge as a side effect experienced with IPC
use (Beksinska et al, 2001b) . There was no difference between DMPA users and NET-En
users in the reporting of this side effect. Described as a watery discharge, it was more often
experienced in the first few months ofuse and was given as a reason for discontinuation by
4% ofthose discontinuing the method. It was also reported to be disliked by men
(Beksinska et al, 2001b). The product brochure of Petogen'", the South African generic
depot medroxyprogesterone acetate (DMPA) product, lists vaginal discharge under "other
side effects" (Intramed, 1993). No such side effect is listed in the product brochures ofNur-
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Isterate®and Depo-Provera" (Schering, 1992; Pharmacia and Upjohn, 1993). Finally,
Nelson (1996) provides a list ofDMPA side effects from a committee meeting ofthe
United States Food and Drug Administration. Vaginal discharge was one ofthe side effects
listed.
Conclusion
Although reference to vaginal discharge as a side effect of IPCs is sparse, it has been
documented, particularly in early studies. While no association between IPCs and vaginal
discharge has been published (Wright, 2003), it can be classified as a subjective side effect.
1.1.4.4 Other Side Effects
Headache was the most common non-menstrual side effect reported in the World Health
Organization (1978) study and was said to be more frequently reported by DMPA users
than NET-EN users (reported by 11% and 7% respectively). Similar results were reported
by Salem et al (1988), who also found that the incidence of headache increased with
prolonged use for both products. In the study published by Chinnatamby (1971)
"headaches and giddiness" were more frequently reported by NET-EN (12%) than by
DMPA users (10%). Numerous other side effects are less commonly reported such as
mood changes (e.g. depression), weight loss, abdominal bloating and discomfort,
nervousness, fatigue, backache, loss of libido, nausea, diarrhoea, chills, acne, breast




Table 1.1.3 Summary of findings on side effects from comparative studies
Study Measure Notes DMPA NET-EN 200mg#
(WHO=World Health Organization) 150mg* Regimen 1 Regimen 2 Regimen 3
1. WHO,1978 N=846 N/A N/A N=832
(Randomised 10-Centre No normal cycles Significant difference, incidence i 70.6% 47%
comparative trial, healthy non- Over 4 injection intervals with time
breastfeeding women of
demonstrated fertility, N=1678) Total amenorrhoea Significantly more frequent with 35% 8.6%
after one year DMPA; ~ on DMPA with higher
Participating Centres: body wts. significantly i amen.
Alexandria, Bahia-Salvador,
Bangkok, Bombay, Chandigarh, Spotting Significant difference
Ibadan, Ljubljana, Manila,
Utrecht, Lima Frequency/duration of Minor differences
bleeding episodes
Headache Most important non-menstrual side 10.7% 6.9%
effect (statistically significant)
Average weight gain after one year Slight i in both groups (not statistic. 2.0kg 1.5kg
significant)
2. Swenson et a/1980 More ~ received DMPA as supplies 133 N/A 106 N/A
(randomized, single blind control ofNET-EN ran out.
study, one clinic, all ~ had at
least one child, Bangladesh, No regular cycles Less than 15% from both groups 40f26 40f28
N=239) at 3rd follow-up visit (4th injection)
Amenorrhoea
at 3rd follow-up visit (4th injection) Significantly higher for DMPA 140f26 100f28
at 4th follow-up visit (5th injection) Significantly higher for DMPA 12 of 14 70f14
Irregular bleeding
Siznificantlv higher for NET-ENat 4th follow-up visit (5th iniection 20f14 60f14
* Given every 12 weeks or every 90 days
# Regimen 1: Given every 56/60 days; Regimen 2: Given 10 weeks after the first injection, and then every 12 weeks (study 2 above) or given every 60 days for six months




Study Measure Notes DMPA NET-EN 200mg"
(WHO=World HealthOrganization) 150mg* Regimen 1 Regimen 2 Regimen 3
3. WHO, 1983T N=1587 N=789 N=796 N/A
(2 year multi-national
comparative randomized trial, 13 Amenorrhoea > 90days Significant difference between 54.1% 27.4% 30.9%
centres, healthy non- at 6-12 months DMPA & both NET-EN regimens
breastfeeding ~ N=3172)
at 18-24 months Significant difference between the 61.9% 33.5% 28.7%
Participating Centres: two NET-EN regimens
Alexandria, Bangkok, Ibadan,
Karachi, Lusaka, Manila, Mexico Bleeding &/or spotting Both NET-EN regimens 10.5% 4.1% 4.4%
City, Salvador, Santiago, at 0-6 months significantly different from DMPA
LjubIjana, Luxembourg, Milan,
Utrecht at 7-12 months No statistical difference 4.6% 2.4% 3.3%
at 19-24 months NET-EN Regimen 2 statistically 1.9% 0.9% 3.5%
different from DMPA
4. Salem et al, 1988 N=200 N=200 N/A N/A
(randomized comparative field
trial, Egypt, N=400) Amenorrhoea incidence Most common complaint 55.1% 42.5%
at 12 months
Incidence of irregular bleeding 9.4% 16.9%
at 12 months
Incidence of heavy bleeding 0.0% 2.1%
at 12 months
Weh!ht gain Not statistic. significant 73.8% 72.3%
* Given every 12 weeks or every 90 days
# Regimen 1: Given every 56/60 days; Regimen 2: Given 10 weeks after the first injection, and then every 12 weeks (study 2 above) or given every 60 days forsix months
and then every 12 weeks; Regimen 3: Given every 12 weeks
t Additional information about the study design obtained from Kaunitz (1992).
1.1.5 DISCONTINUATION PATTERNS
The literature abounds with findings from studies on discontinuation patterns and reasons
for discontinuation of the IPCs. However, only one South African study could be found
which provides any detail on discontinuation patterns amongst South African injectable
users (Beksinska et al, 2001a). As described earlier in this chapter, bleeding disturbances
are the most commonly reported reasons for discontinuation. Some studies directly
compare discontinuation rates ofDMPA and NET-EN and these are described in this sub-
section. Where pertinent, studies on discontinuation of one or other injectable product are
also described. Findings from relevant studies are summarized in Table 1.1.4 below.
1.1.5.1 Overall Discontinuation ofDMPA and NET-EN
As can be seen in Table 1.1.4, no statistical difference was found for the 12-month gross
cumulative discontinuation rate for the two products for bleeding irregularities in the
World Health Organization 1983 clinical trial , with continuation rates slightly better for
NET-EN than for DMPA. Salem et al (1988) show better continuation rates at one year
with DMPA than with NET-EN. In a study ofNET-EN use, given every 8 weeks for the
first 6 months and every 12 weeks thereafter, in 6 clinics in Bangladesh, amongst 913
women (Rahman et al, 1985), the overall cumulative discontinuation rate at 12 months
was 37.3 per 100 women, less than that found for the same NET-EN dosage regimen in
the World Health Organization (1983) trial which documented a discontinuation rate of
50.3 per 100 women.
Discontinuation rates of 41% at one year, reported by Schwallie and Azenzo (1973) for
DMPA were similar to the NET-EN discontinuation rates reported by Rahman et al
(1985), lower than the discontinuation rate of50.4 per 100 women reported in the World
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Health Organization (1983) trial, and higher than those (31.2 per 100 women) reported by
Salem et at (1988). In a comparative trial ofNET-EN and DMPA conducted in Ceylon
(now Sri Lanka), Chinnatamby, (1971) found a much higher continuation rate, with only
15% discontinuation at end of 15 months. Although both DMPA and NET-EN were
studied, discontinuation rates were not broken down according to the product used .
The continuation rate for injectables was reported to be much higher than for other
methods used in Ceylon at the time (Chinnatamby, 1971). Similarly, El-Mahgoub and
Karim (1972) report a lower crude drop-out rate for Egyptian women using NET-EN, than
for women from the same health facility who were using oral contraceptives or IUDs.
Fraser's (1982) review of published trials reports that 50-80% ofwomen would continue to
use DMPA after a year, which was better than the continuation rate for users oforal
contraceptives and comparable to that ofIUD users. Westfall et at (1996) report low
continuation rates (23% at one year) amongst injectable users (n=5178) compared with
rates cited for other contraceptives such as the oral contraceptives, IUD and implant.
However in a study undertaken in New Zealand amongst 2469 OC users, 2072 IUD users
and 1721 DMPA users, discontinuation rates at two years were similar across methods used
(42%,44%,48%, respectively) (Colli et al, 1999). In one of few studies undertaken among
African women, Sekadde-Kigondu et al (1996) found discontinuation rates highest among
OC users (80%), lowest among IUD users (20%) and 39% for DMPA users.
In a prospective study of South African IPC users (n=189; 52 using DMPA; 137 using
NET-EN) at an urban Soweto family planning clinic, discontinuation rates of28% and
41% were found after one and two years respectively (Beksinska et at2001a). These rates
do not include women who were lost to follow-up (35% after two years). The authors
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report no difference in continuation rates between DMPA and NET-EN (21% versus
20%) users after two years.
Potter (1999) writes that "DMPA's apparently high discontinuation rates are artificially
inflated" compared to condoms and OCs because of the application of different criteria in
determining continuation among methods. She suggested that DMPA is required to meet a
higher standard than other methods in regard to discontinuation, with women returning late
for their next injectable often classified as discontinuers. Potter advocated the development
ofa more systematic definition ofdiscontinuation for application to all contraceptive
methods, taking into account rates ofprotection, adherence and discontinuation.
1.1.5.2 Side Effects Leading to Discontinuation ofDMPA and NET-EN
As described earlier in this chapter, bleeding disturbances are the most commonly
reported side effect for discontinuation ofIPCs. Although there is little published data for
South Africa users, bleeding disturbances, mainly amenorrhoea, are the most common as
reported in a study on IPC use undertaken in a family planning clinic in Soweto
(Beksinska et al, 2001a). In one study, undertaken in New Zealand, weight gain was
given as the most common side effect leading to discontinuation, followed by heavy
bleeding (Colli et al, 1999).
Bleeding Disturbances
Some studies report that DMPA users were more likely to discontinue use of the method
due to amenorrhoea than NET-EN users. For instance, a statistically significant difference
was found between DMPA and NET-EN given every 12 weeks , for the 12-month gross
cumulative discontinuation rate for amenorrhoea (1.8 per 100 woman-years for NET-EN
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and 11.5 for DMPA) (World Health Organization, 1977). The later World Health
Organization (1983) clinical trial verified these results, finding the discontinuation rates
for amenorrhoea at 12 months and at 24 months to be significantly greater with DMPA
than with NET-EN given on a 60 day regimen and for NET-EN given for 60 days for six
months and then every 84 days. By contrast, Salem et al (1988) found that , even though
amenorrhoea was more commonly experienced by DMPA users than by NET-EN (given
every 8 weeks) users , the rate of discontinuation for amenorrhoea amongst NET-EN users
was higher than amongst the DMPA users. The findings on discontinuation due to
amenorrhoea for NET-EN users from Banerjee et al 's (1984) comparative study of
different dosages ofNET-EN (Table 1.1.4 below) were similar to the findings for NET-
EN discontinuation reported in the World Health Organization (1983) study.
Salem et al (1988) found that the second most common reason for method
discontinuation was "bleeding irregularities" with rates for DMPA found to be lower than
for NET-EN (8.1 and 12.5 per 100 women respectively). The discontinuation rate for
DMPA (Salem et al, 1988) was less than the rates found in the World Health
Organization comparative trials (1977 ; 1983). Rhaman et al (1985) reported that the most
common reasons for discontinuing NET-EN were bleeding disturbances with heavy
and/or prolonged bleeding being the single most frequent reason with a discontinuation
rate of6.3 per 100 women. The discontinuation rate at 12 months for amenorrhoea was
found to be somewhat less at 5.1 per 100 women (Rhaman et al, 1985), and this is also
less than the findings from the World Health Organization (1983) study which found the
discontinuation rate for amenorrhoea at 12 months, amongst NET-EN users on the same
dosage regimen, to be 8.4 per 100 women (Table 1.1.4 below).
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Benagiano and Primerio's (1983b) analysis of the 1978 World Health Organization study
suggests that increased bleeding and amenorrhoea are more likely to lead to
discontinuation of injectables than spotting, decreased flow and irregularity ofmenstrual
cycles. These authors submit therefore that bleeding patterns produced by NET-EN may
be more acceptable than those resulting from DMPA use. On the other hand, Datey, et al
(1995), in an analysis of clinical trials carried out by the Indian Council of Medical
Research from 1981 to 1987, found that women experiencing frequent or prolonged
bleeding were more likely to discontinue contraceptive use than those having delayed
bleeding episodes or oligomenorrhoea.
Other Side Effects Leading to Discontinuation
Other reasons for discontinuation commonly reported in the World Health Organization
(1983) trial were abdominal distention and weight gain, once again more frequently given
as reasons for discontinuation by DMPA users, but not statistically different. Salem et al
(1988) reported that weight gain, which occurred in both DMPA and NET-EN users was
welcomed by the Egyptian women who participated in the study, particularly those living
in rural areas. Other side effects given as reasons for discontinuation amongst South
Africa users in the study by Beksinska et al (2001a) were: weight change (increase and
decrease), headache, vaginal discharge, skin problems, breast tenderness and dizziness.
1.1.5.3 Other Factors Influencing Discontinuation ofDMPA and NET-EN
DoseofDMPA
In a WHO multi-centre Phase III comparative clinical trial ofDMPA 100mg given every
three months versus 150mg given every three months found that users of the higher dose
(150mg) ofDMPA were significantly more likely to discontinue use of the method than
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those using the lower dose (100mg) preparation (World Health Organization, 1986). Of
note is the comparison drawn by the authors ofthe publication of this study (World Health
Organization, 1986) who observe that the discontinuation rate for amenorrhoea of7.2%
found with the 100mg group is similar to the rate for NET-EN users (6.8%) previously
reported in a comparative trial ofDMPA and NET-EN (World Health Organization, 1983).
Provider Influence and Attitudes towards Bleeding Irregularities
Meade et al (1984) conducted a phase IV prospective clinical study ofNET-EN, given
every two months, in rural Mexico in the late 1970s. They reported higher discontinuation
rates with NET-EN (57.0 per 100 women) than reported in the WHO Phase III Clinical
Trial (World Health Organization, 1983,49.7 per 100 women), but point out that the
Mexico study findings are similar to those reported for the Mexico City centre participating
in the WHO study (53.1 per 100 women). These authors found further differences with the
World Health Organization (1983) trial, in that discontinuation rates due to amenorrhoea
were higher and those due to bleeding problems to be lower than the World Health
Organization (1983) study. They suggested that these differences could be attributed to
different attitudes toward bleeding irregularities; different counselling by health workers on
provision of the method; or different drug effects amongst users ofdifferent ethnicity
(Meade et al, 1984). They point to the marked inter-centre variation found in discontinuation
rates which characterize phase III studies of Il'Cs. Paul et al (1997) also draw attention to
the marked inter-centre variability in study continuation rates and suggest that cultural
differences may be an important influence on continuation patterns. Rahman et al (1985)
also commented on the inter-clinic variation in discontinuation patterns ofNET-EN in their
Bangladesh study and attribute this variability to differences in staff attitudes and
counselling approaches.
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More recently, a prospective study of 430 DMPA users was undertaken to determine
factors influencing continuation rates (Hubacher et al, 2000). The continuation rate at one
year was 51%. Consistent with the findings above, providers were found to have an
important influence on continuation rates, with women counselled to return to the clinic if
they experienced side effects 2.7 times more likely to continue with the method. Those told
that amenorrhoea might occur with injectable use were more than 2.5 times more likely to
continue. Other factors found to be influential were number of children, attitudes towards
menstruation, lactating on admission and spousal input on method choice.
Study Population
Paul et al (1997) report on a national population-based retrospective study of 1864 women
in New Zealand. They submit that most studies undertaken on DMPA use have been among
clinic attenders or women recruited into clinical trials , including the studies conducted by
the WHO, and are therefore less likely to be representative ofDMPA users. In comparing
DMPA continuation rates from their study with other studies, rates were found to be "as
short or shorter". For instance, continuation rates at one year for first-time users was only
49% in the population-based New Zealand study, compared to 69% in the clinic-based
Egypt study (Salem et al 1988).
1.1.5.4 Temporary Discontinuation
A handful of studies have followed injectable users after method discontinuation and have
found that some discontinuers return to the method after having a "break" (Howard et al,
1985;Beksinska et al, 1998; Beksinska et al, 2001 a). Potter et al (1997), reporting on a
retrospective population based study of IPC users (n=51 0), found that about 20% of
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discontinuations could be attributed to default , because return for a repeat injection
occurred more than 16 weeks after the last dose. It was suggested that these women be
regarded as "poorly compliant continuers" rather than discontinuers (Potter et al, 1997,
p.310). This poor compliance behaviour was also reported to occur amongst IPC users in
a Kenyan study (Sekadde-Kigondu et al, 1996). A reason given for taking a break was to
allow menstruation to recommence before returning for the next injection (Beksinska et
al, 2001a; Department of Health et al, 2002). Beksinska et al (2001a) reported further that
some injectable users believed that they would not conceive as long as they were
amenorrhoeic. Periods of temporary discontinuation, referred to as nonuse segments
(Beksinska et al, 2001a), can lead to unintended pregnancy. Counselling about side
effects and the need to adhere to the dosing regimen is advocated.
Conclusion
In general , discontinuation rates for IPCs were high. Study findings are conflicting and
confusing and need to be interpreted cautiously. Discrepancies in overall discontinuation
rates are found to be the rule rather than the exception. Cultural, religious and personal
attitudes and provider influence are important determinants of individual response to
menstrual disturbances (Fraser and Weisberg, 1981; Meade et al, 1984; Salem et al, 1988;
Datey et al, 1995), and generalization of findings from discontinuation studies may not be
appropriate. Poorly defined criteria for discontinuation and differences in study design
and population also make comparison of discontinuation rates problematic. However,
discontinuation based on experience of side effects , will not, with the possible exception





Table 1.1.4 Summary of findings on discontinuation patterns from relevant studies
Study Notes Measure DMPA NET-EN 200mg"
(WHO=World Health Organization) 150mg* Regimen 1 Regimen 2 Regimen 3
1. Chinnatamby, 1971 N=515 N/A N/A N=520
(comparative study, Ceylon - now
Sri Lanka, N=1035) Discontinuation rates were not Discontinuation rate at 15 months ± 15% ± 15%
broken down according to
whether DMPA or NET-EN
was used
2. Schwallie & Azenzo, 1973T N=3857
(Multi-centre , collaborative study, Continuation rates:
1965-1971, 54 investigators, at 12 months 59.4/100 Q
DMPA only, healthy women, 55% at 24 months 41.5/100 Q
white, demonstrated fertility, at 36 months 30.2/l00Q
N=3857) at 48 months 24.1/100 2
3. WHO, 1977T Chandigarh had an atypically N=846 N/A N/A N=832
(Randomised 10-centre high discontinuation rate for Cumulative discontin. Rates at one
comparative trial, healthy, non- menstrual abnormalities with year:
breastfeeding women of both products which had a Amenorrhoea 1I.5/100 Q 1.8/l00 Q
demonstrated fertility, N= 1678) pronounced effect on the difference significant
analysis of the pooled data Bleeding problems 9.3/100 Q 10.3/l00Q
Participating Centres: difference not significant
16.9/l00QAlexandria, Bahia-Salvador, All medical reasons 23.4/100Q
Bangkok, Bombay, Chandigarh, difference significant
Ibadan, Ljubljana, Manila, Non-medical reasons 7.7/100Q 9.5/l00Q
Utrecht, Lima difference not significant
* Given every 12 weeks or every 90 days
# Regimen 1: Given every 56/60 days; Regimen 2: Given every 60 days or 8 weeks for six months and then every 12 weeks; Regimen 3: Given every 12 weeks
t Additional information about the study design obtained from Kaunitz (1992).
0'1.,.
Table 1.1.4 Continued
Study Notes Measure DMPA NET-EN 200mg"
(WHO=World Health Organization) 150mg* Regimen 1 Regimen 2 Regimen 3
4. WHO, 1983T Considerable variation found N=1587 N=789 N-796 N/A
(2 year multi-national comparative between centres Total discontinuation rates:
randomized trial, 13 centres , at 1 year (no significant difference) 51.4/100~ 49.7/100~ 50.3/100~
healthy non-breastfeeding ~ at 2 years (no significant difference) 73.5/l00 ~ 70.7/100 ~ 72.4/100~
N=3172)
Discontinuation rates due to:
Participating Centres: Amenorrhoea
Alexandria, Bangkok, Ibadan, at one year (significant difference) 11.9/100~ 6.8/100~ 8.4/100~
Karachi, Lusaka, Manila, Mexico at two years (significant difference) 24.2/100~ 14.7/100 ~ 14.6/l00 ~
City, Salvador, Santiago, Bleeding problems
Ljubljana , Luxembourg, Milan, at 1 year (no significant difference) 15.0/100~ 13.6/100~ 13 .7/100~
Utrecht at 2 years (no significant difference) 18.8/100~ 18.4/100~ 21.8/100 ~
Weight at 2 years
(no significant difference between DMPA 2.1/100~ 1.6/100~ O.8/100~
& NET-EN Regimen 1)
* Given every 12 weeks or every 90 days
# Regimen 1: Given every 56/60 days; Regimen 2: Given every 60 days or 8 weeks for six months and then every 12 weeks; Regimen 3: Given every 12 weeks




Study Notes Measure DMPA NET-EN 200mg"
150mg* Regimen I Regimen 2 Regimen 3
5. Banerjee et al1984 N=1181 N=1207
(comparative clinical trial of two No statistical differences Total discontinuation rates:
dosage regimens ofNET-EN, at 6 months 21.8/IOO ~ 22.0/IOO~
Indian ~ , 16 Human Reproductive at 12 months 41.5/100~ 40.2/IOO~
Research Centres, N=2388) at 18 months 56.9/IOO ~ 55.5/l00~
at 24 months 68.6/IOO~ 67.4/100~
No statistical differences Discontinuation rates due to:
Amenorrhoea
at 6 months 1.6/l00~ 1.8/IOO~
at 12 months 7.6/100~ 6.9/IOO~
at 18 months 13.2/l00~ 12.7/100~
at 24 months 23.8/IOO ~ 20.I1IOO ~
No statistical differences Heavy & prolonged bleeding
at6 months 3.5/l00~ 3.2/100~
at 12 months 7.5/l00~ 6.5/l00 ~
at 18 months ll.I/IOO~ 1O.6/100 ~
at 24 months 15.6/l00 ~ I3.5/IOO~
No statistical differences Irregular bleeding
at 6 months 2.5/l00~ 4.0/100 ~
at 12 months 7.8/l00~ 7.5/100 ~
at 18 months 10.6/100~ I 1.8/100~
at 24 months 12.1/100~ 16.4/100 2
* Given every 12 weeks or every 90 days




Study Notes Measure DMPA NET-EN 200mglt
(WHO=World Health Organization) 150mg* Regimen 1 Regimen 2 Regimen 3
6. Meade et at, 1984 Rates> WHO (1983, 49.7), but N=5792
(prospective clinical field study, similar to the Mexico City Total discontinuation rates:
rural Mexico, N=5792) participating centre of the at 12 months 57.0/l00 ~
WHO study (53.1 at 12 at 18 months 69.0/100 ~
months)
Discontinuation rates due to:
Amenorrhoea 12.6/100 ~
at 12 months 14.3/100~
at 18 months
Bleeding problems
at 12 months 8.0/100~
at 18 months 9.3/l00~
7. Rahman et al, 1985 Overall discontinuation rate N-913
(field study in 6 clinics NET-EN and reasons for discontin- Total cumulative discontin. rates:
only Bangladesh, N=913) uation varied markedly at 6 months 26.3/l00~
between clinics, in spite of at 12 months 37.3/100~
similar participant age, parity, at 18 months 42.9/100 ~
residence and history of
contraceptive use. Discontinuation due to:
Heayy and/or prolonged bleeding
at 6 months 4.3/l00 ~
at 12 months 6.3/100~
at 18 months 6.7/100~
Irregular bleeding or spotting
at 6 months 2.8/l00~
at 12 months 3.9/100~
at 18 months 5.2/l00~
Amenorrhoea
at 6 months 2.8/100~
at 12 months 5.1/100~
at 18 months 6,411002
* Given every 12 weeks or every 90 days




Study Notes Measure DMPA NET-EN 200mgll
150mg* Regimen 1 Regimen 2 Regimen 3
8. Salem et al, 1988 N=200 N=200
(randomized comparative study,
Egypt, N=400) DMPA users had better one- Continuation rates at one year 68.8/l00 s;? 57.l/100 s;?
year continuation rates
Cumulative discontin. rates due to:
More commonly experienced Amenorrhoea 10.6/100 s;? 13.0/l00 s;?
by DMPA users, but higher Bleeding problems 8.l/100 s;? 12.5/100 s;?
discontinuation with NET-EN
9. Beksinska et al, 2001a N=52 N=137
(prospective cohort study, South No difference in continuation Continuation rates:
Africa, urban clinic recruits, rates for DMPA and NET-EN at one year 42% 41%
n=189) at two years 21% 20%
* Given every 12 weeks or every 90 days
# Regimen 1: Given every 56/60 days; Regimen 2: Given every 60 days or 8 weeks for six months and then every 12 weeks; Regimen 3: Given every 12 weeks.
1.1.6 CURRENT SAFETY CONCERNS
A comprehensive description of the safety of progestogen-only injectable contraceptives
is beyond the scope of this thesis. However, for the sake of completeness, the most
important safety concerns are briefly described in this sub-section.
Progestogen-only injectables are considered to be relatively safe contraceptive methods
(Fraser, 1986a; Garza-Flores et al, 1992; Kaunitz, 1994; Kaunitz and Rosenfield, 1994;
Lande, 1995; Cayley, 1998). Little is published comparing the safety ofDMPA and NET-
EN. Current safety concerns about progestogen-only injectables use are the reduction of
bone mineral density, particularly in young and or long-term progestogen injectable users
(Cayley, 1998, Watts , 1998), and increased risk ofHIV acquisition (Stephenson, 1998;
Kiddugavu, 2003). A concern largely laid to rest , but about which has been the focus of
some South African researchers, is the relationship between IPC use and breast cancer
(Bailie et at, 1997; Shapiro et al , 2000).
1.1.6.1 Bone Mineral Density and IPCs
Considerable attention is currently focused on the possible suppression of oestrogen in
long term DMP A users and resultant concerns about the reduction ofbone mineral
density (Cundy et al1991; Weisberg, 1992; Cayley, 1998; Bigrigg et al, 1999; Weisberg,
1999) particularly in young users (American Health Consultants, 1998; Watts, 1998), and
long-term users (Watts, 1998). These concerns are particularly pertinent in South Africa
where the injectables are used for longer periods of time than anywhere else in the world
(Bailie , 1997, Shapiro, 2000) and where they are used widely by young women
(Department ofHealth et al, 2002) . Findings from many studies are inconclusive and have
been criticized for their small sample size and failure to control for confounding factors
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(Weisberg, 1992; Lande, 1995; Cayley et al, 1998; Bigrigg et al, 1999). Findings from
prospective studies in progress are awaited (Bigrigg et al, 1999; Weisberg, 1999). Some
of these studies , on DMPA and NET-EN , are being undertaken in South Africa (M
Beksinska, Director, Reproductive Health Research Unit, pers. comm., June 2003).
Attention has largely focused on DMPA. However, Cundy et al (1996), point out that
progestins possessing androgenic properties, like norethisterone, have beneficial effects
on bone density, in that they ameliorate the effects of oestrogen deficiency induced by
Gonadotrophin-releasing hormone analogs in young women. The WHO comments that
there are theoretical concerns regarding the hypo-oestrogenic effects of IPCs, particularly
ofDMPA, when used by women under 18 years of age and over 45 years (World Health
Organization, 2000) . Concern was also expressed about whether women over 45 years
regain bone mass after discontinuation ofDMPA. The WHO does not however advise
that NET-EN rather than DMPA should be used by women under 18 years or over 45
years and DMPA and NET-EN are assigned the same medical eligibility category (2),
where the advantages of using a method are considered to outweigh the theoretical risks
(World Health Organization, 2000).
Ofnote from the published data on DMPA and bone density are the following:
•
•
Cundy et al (1991) compared cross-sectional lumbar and femoral neck bone densities
in long-term DMPA users with pre- and post-menopausal women (n=30 in each
group). They found the bone density values for DMPA users between those of the
pre- and post-menopausal groups and concluded that DMPA may adversely affect
bone density.
Cundy et al (1994) undertook a comparative study (n=54) of long-term DMPA users
who discontinued use during the course of the study, and were followed-up for two
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years, women who were currently using DMPA, and women who had never used
DMPA. The authors suggest that, even after long-term use ofDMPA, bone loss may
be almost completely reversible.
• Cromer et at (1996), in study amongst 15 adolescents, suggested that DMPA may
decrease bone density, at least temporarily.
• Taneepanichskul et at (1997), in a study ofbone density in long-term use ofDMPA
by 50 Thai women, suggested that long-term use ofDMPA should not adversely
affect bone density, even if oestrogen levels are suppressed.
• Watts (1998) reported that DMPA is associated with a significant reduction in bone
density and that the risk for long-term users and users who have not reached peak
bone mass may be highest.
• Orr-Walker et at(1998) in a cross-sectional study ofbone density in 34 post-
menopausal former users of DMPA, concluded that fracture risk in post-menopausal
women who used DMPA are minimal as the residual effects ofDMPA on post-
menopausal bone density are small. These authors point out that fracture rates in pre-
menopausal women are low, thus current DMPA users are not at great risk of
fractures due to decrease in bone density.
• Tang et at (2000), who undertook a longitudinal cohort study on 59 Chinese women
using DMPA, concluded that DMPA could be used long-term without worrying about
linear bone loss leading to early osteoporosis.
• Wanichsetakul et at (2002) found that DMPA use results in decreased bone mineral
density only at the lumbar spine and that it was safe for long-term contraceptive use.
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Conclusion
Findings from prospective studies currently undertaken should provide conclusive
evidence about the effect of injectables on bone mineral density. Findings from the South
African studies amongst young users and long-term users will be of note. Existing
evidence is inconclusive, but suggests that effects on bone mineral density do occur at
some bone sites.
1.1.6.2 Risk of HIV Acquisition and IPCs
Ever since Marx et al (1996) found an increase in simian immunodeficiency virus
infection in SlV-exposed monkeys, there has been concern about the effect ofhormonal
contraceptives on HlV acquisition (Marx et al, 1996; Mostad et al, 1997; Stephenson,
1998; Kiddugavu, et al, 2003). Mechanisms by which HlV risk could, theoretically, be
increased include: Thinning of the vaginal epithelium, increasing cervical ectopy,
increasing HN shedding in the genital tract, increasing vaginal pH, direct influence on HN
virulence, changes in menstrual bleeding patterns and immunological changes (Stephenson,
1998; le Riche et al, 2002; Kiddugavu et al, 2003). Whether a relationship exists between
progestogens and HN transmission warrants further investigation (Family Health
International, 1996) as the evidence currently available is conflicting (Ntozi and Kirunga,
1998; Stephenson, 1998; Kiddugavu et al, 2003) .
A systematic review ofepidemiological evidence on hormonal contraception and risk of
HN transmission was undertaken by Stephenson in 1998. This comprehensive review
revealed the poor quality of studies undertaken and highlighted the considerable
methodological problems which need to be overcome in designing a study to adequately
answer this research question. These include the timing between contraceptive use and HlV
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infection, confounding of sexual behaviour on method choice, what an appropriate control
group might be and difficulties in precisely measuring the level of exposure to RN. She
concluded that the relationship between hormonal contraceptives and RIV transmission is
uncertain and recommended that hormonal contraceptives should continue to be provided.
The most recent data published on the association between hormonal contraception use
and RIV acquisition originated from a study undertaken in a rural community-based
cohort in the Rakai District ofUganda (n=5117). This is the first prospective study
undertaken to investigate if there is an association between hormonal contraceptives and
RIV acquisition. After adjustment for behavioural confounding, use of injectable
hormonal contraception was not associated with RIV acquisition with an adjusted IRR of
0.84 (95%Confidence Interval: 0.41-1 .72) (Kiddugavu et al, 2003). The authors of the
study do not indicate whether the injectable product used by respondents of this study was
DMPA or NET-EN or a mix ofthese. Results of other studies on IPC use and risk of RIV
are expected in 2003 (Best, 200 I).
Conclusion
While the association between IPCs and RN acquisition is questionable, we do know that
IPCs offer no protection against STI and RN infection. In cases where risk ofRN
infection is high, counselling on the need to use a method for dual protection against
infection and unwanted pregnancy is essential. This could take the form ofa barrier method
(male or female condom), or the use of two methods (dual method used) one ofwhich
should be a barrier method , the other could be a hormonal injectable method.
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1.1.6.3 Breast Cancer and IPCs
A possible relationship between IPCs and breast cancer has long been a cause of concern .
The main bases for this concern were the results of toxicology experiments which found
that DMPA caused benign and malignant mammary tumours in beagle dogs (Senanayake,
1991; Thomas, 1992). These findings were the reason for the delay in the licensing of
DMPA for contraceptive use in the United States (Duncan and Kirton , 1992; Kaunitz,
1996; Bailie et al, 1997; Shapiro et al, 2000). DMPA was only finally licensed for
contraceptive use in 1992 after studies undertaken by Paul et al (1989) and the World
Health Organization (1991) showed no increase in the risk ofbreast cancer among
women who had started DMPA use more than 5 years previously or those who had used
DMPA for a long time. A pooled analysis of the World Health Organization (1991) study
and the New Zealand (Paul et al, 1989) study confirmed these findings. However, Paul et
al (1989) reported increased relative risks in women under age 35 years, and in those who
had used DMPA for at least two years before age 25 years. The World Health
Organization (1991) study raised similar concerns about an increased risk within the first
4 years of exposure, particularly in women younger than 35 years (Skegg et al, 1995).
Little research appears to have been undertaken on the risk ofbreast cancer amongst
NET-EN users . Lande (1995) in an extensive review ofIPCs discusses the risk ofbreast
cancer in relation to DMPA use, but makes no reference to the risk of breast cancer for
NET-EN users. Fraser (1982, p.75) in his review oflong acting injectable hormonal
contraceptives suggested that there was no good clinical evidence to support the concern
about neoplasias and DMPA ..." or any ofthe other injectable contraceptives". Fraser
and Weisberg (1981) document that NET-EN was also part of the tumour controversy
related to IPCs, but report that the studies undertaken on rats were discounted as the rat,
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like the beagle, is an inappropriate test model. The Toxicology Review Panel of the
World Health Organization (1982) concluded, from a review of animal studies , that both
DMPA and NET-EN were safe for human use.
A recent study described by Bailie et al (1997) and Shapiro et al (2000) was undertaken
amongst users of both DMPA and NET-EN. The published findings from these latter
studies do not differentiate between DMPA and NET-EN users, but Shapiro et al (2000)
state: " . .. that IPCs, principally DMPA, do not increase the overall risk ofbreast cancer"
p. 400. It can be assumed therefore that these findings also apply to NET-EN users , but it
would be useful if the findings from this study were disaggregated by product. Ofnote
about this study also, is that it was undertaken amongst African and Coloured women in
Cape Town, South Africa, and is thus one of the few studies that provides local data about
IPC use. The study reports the relative risk ofbreast cancer with IPC use to be 0.9 (95%
confidence interval: 0.7, 1.2) and found that age category, recency ofuse and length of
use are not consistently associated with risk of breast cancer (Shapiro et al, 2000).
Conclusion
The review of the literature, especially the more recent studies (Bailie et al,1997; Shapiro
et al 2000) is reassuring and there seems little reason to be concerned about either DMPA
or NET-EN causing an increased risk ofbreast cancer.
1.1.7 OBJECTIVES
The objectives of Section 1 are to:
• Determine the prevalence of injectable contraceptive use amongst rural women in
KwaZulu-Natal, South Africa.
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• Investigate the contraceptive method mix among women in rural KwaZulu-Natal.
• Determine the side effects and discontinuation patterns among injectable
contraceptive users.
• Undertake a comparative analysis ofDMPA versus NET-EN focusing particularly on
utilization patterns, side effects, discontinuation patterns and costs.
• Make appropriate recommendations for rational use of injectable contraceptives.




This study was undertaken in the Hlabisa sub-district, a deep rural area and one of four
sub-districts of the Hlabisa magisterial district. This site was selected as it was fairly
easily accessible, yet preserved its rural nature because of the intervening game reserve;
was relatively safe from crime and political unrest; and had strong community support for
research activities. In addition, the establishment of an international research Centre in the
Mpukunyoni sub-district provided scientific and financial support to local research studies.
Hlabisa is situated in the northern part of the province of KwaZulu-Natal (KZN), about
300km north-east of Durban on the Indian Ocean coast of South Africa. A map showing
the location of the district in South Africa and the four sub-districts is provided in
Appendix 1.2.1. Hlabisa is approximately 50 x 70km in aerial extent and according to the
1996 Census had a population of 198179 (Curtis et al, 2002), who are largely Zulu-
speaking. A major national road, the N2 runs through the eastern half of the district,
linking the major port and commercial towns of Durban, Richards Bay and Empangeni to
Swaziland and Mozambique. There are large sugar farms and eucalyptus plantations
along the N2. The district is home to a relatively poor populace who rely largely on
income from subsistence fanning, migrant labour, pension remittances and casual labour.
Key reproductive health issues are HIV, sexually transmitted infections, poor pregnancy
outcome and high fertility. Just before the survey commenced, the incidence ofHIV in
women, aged 15 to 30 years, attending antenatal clinics in Hlabisa, was reported to be
12% in 1997 (Abdool Karim, 1997). The prevalence of HIV amongst women attending
antenatal clinics in the district was reported to have increased from 4% in 1992 to 22% in
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1997 and it was estimated that a quarter of women in Hlabisa in the age range 15 to 49
years, were infected with at least one STI on any given day (Wilkinson et al, 1999).
Wilkinson and Sach (1999) placed the infant mortality rate in the Hlabisa District at 53
per 1000 total births . Whist the fertility rate for the Hlabisa district was not known, the
fertility rate for KZN Province was reported to be 4.3 in 1991 (Erasmus, 1994) and 3.3 in
1998 (Department of Health et al, 2002). A teenage birth rate for KZN of 15.3 was
reported in 1994 (Erasmus, 1994) and 16.7%ofKZN teenagers interviewed in the 1998
SADHS had been pregnant (Department ofHealth et al, 2002).
The Hlabisa sub-district, where the survey was conducted, is separated from the rest of
the district and the main transport routes by the Hluhluwe and Umfolozi Game Reserves .
It lies to the north of the game reserves and is characterised by hilly undulating terrain
and savannah like vegetation. Giraffe, zebras, impala, buffalo, warthog, rhino and
elephant are commonly encountered on the way to Hlabisa sub-district. It has a sub-
tropical climate, with summer rainfall and average summer temperatures of28 to 30
degrees centigrade and winter temperatures between 16 and 25 degrees. Only 7% of
households had piped water in 1996 and 25% had access to public taps (Curtis et al,
2002). Most households obtained water from rivers and dams (Curtis et al, 2002). Only
3% of households had flush toilet systems with the majority (66%) having access to pit
latrines , and 29% having no sanitation system (Curtis et al, 2002). Typical rural
homesteads (kraals) are sparsely scattered across the sub-district. Some modem style
houses are also to be found, usually close to the Hlabisa village. The further one moves
from the village, the more scattered the homesteads become. Most homes are electrified,
on a card system basis , and most roads are gravel or dirt.
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The Hlabisa sub-district is governed by a traditional tribal authority system, typical of
rural areas ofKZN, and a chief, Inkosi M. Hlabisa was the local traditional leader. At the
time ofthe survey, it was estimated, from aerial photographs to be comprised of 2088
homesteads, with an estimated population of 20000 people. A detailed mapping exercise
undertaken subsequent to this study places the population at 2316 homesteads, a
population of 16124, and an average number of people per household of7 (F Tanser, GIS
Specialist, Africa Centre for Population Studies and Reproductive Health, pers. comm.,
September 1998). Figures from the 1996 Census released after the survey was conducted
placed the population of the sub-district at 21425 with an average household size for the
whole district of7.5 (Curtis et al, 2002). Most households comprise extended families.
The sub-district was further divided into 13 isigodi or wards, each of which was governed
by an induna (headman), responsible for the allocation of tribal land and the maintenance
of a local census of those living within the isigodi. The thirteen isigodi were: Qunwane,
Madondo, Khalokazi, Emajikeni, Mabundeni, Hlambanyathi, Matshamnyama, Macekeni,
Mabhokweni, Makopini , Empembeni, Amabhokisi, and Stezi. The boundaries of the
isigodi can rarely be delineated by the induna or people living within the isigodi. A
Council ofIzinduna is chaired by the Chief of Hlabisa, and he serves on the KZN Council
ofTraditional Leaders (Abdool Karim, 1996).
At the time of the study, the only health facility in the area was a 400-bed district
hospital, the Hlabisa Hospital , situated close to the Hlabisa village in the Lutheran
Mission area. Services provided by the hospital included medicine, basic surgery,
obstetrics and paediatrics (Abdool Karim, 1996). In addition, 3 primary care mobile
clinics serviced the area. Community health workers provide a health service to those
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who do not have access to the mobile clinics or the hospital. The location of the hospital
can be seen on the map provided in Appendix 1.2.1. There were eight primary schools
and four secondary schools.
1.2.2 STUDY DESIGN
Over the period September 1998 to April 1999, data were collected by means of a cross-
sectional community-based survey at household level and focus group interviews,
drawing upon both quantitative and qualitative techniques. The focus group interviews
(thematic guided discussions) were conducted to draw out contextual information and to
provide insight, depth and perspective to the quantitative cross-sectional data. Records of
contraceptive use at the local family planning clinic at the Hlabisa Hospital were also
analysed. Triangulation, also known as the "inter-technique" approach, is used to ensure
the validity of findings , by corroborating data with other data collected in a different way
from another source (lick, 1979; Bemard, 1994). In the Hlabisa study, this was done by
combining a quantitative technique, the cross-sectional community-based household




A large enough total sample size had to be determined in order to be able to make
statistical inferences about side effects experienced by the sub-sample ofwomen who
were current users of the injectable contraceptives. For example it was important to be
able to test for significant differences between users of the two injectables, Depo-
Provera'" and Nur-Isterate" . It was also considered necessary to have a large enough total
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sample size to be able to test for significant differences in the prevalence of injectable use
and/or experience of side effects between sub-samples of those surveyed. In consultation
with a statistician and using the formula cited by Fleiss (1981, pAS) which includes the
continuity correction, it was determined that 107 women should be selected in each
injectable product user group (i.e. DMPA users and NET-EN users) to show a significant
difference (at the 0.05 level) in respect to the main side effects documented in the
literature (assuming at least 20% difference between the two groups) with 80% power. In
this way it was predicted that approximately 200 injectable contraceptive users should be
interviewed. The remaining women interviewed would either have discontinued use or
never have used this method. The minimum sample size required, allowing for a 5%
sampling error and a 5% refusal rate, and using an estimated ratio of 3 non-users to one
user of the injectable contraceptive (Abdool Karim, 1997), was determined to be 835
women. Thus it was determined that 40% of the estimated 2088 households should be
visited . Further, in order to ensure an even spread ofhouseholds across the sub-district,
the sample was stratified by isigodi, selectively including a fixed sampling fraction in
each isigodi. A total of 848 women were interviewed.
Household Selection
A baseline mapping exercise of the Hlabisa sub-district had taken place prior to the
survey. A starting point for the household interviews was selected in each isigodi by blind
random placement of a pencil mark on the isigodi map. Commencing from this selected
point, the fieldworkers radiated out in different directions, each in a straight line. An
interview was conducted at every second household until 40% ofhouseholds in each
isigodi had been visited. If no one was home or if a woman refused to be interviewed the,
nearest neighbouring household was visited.
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Selection within a Household
Among women in the age range 15 to 49, one woman was randomly selected to be
interviewed from each household visited. Only one woman was interviewed from each
household to avoid within household correlation. The random selection was achieved by
ascertaining the number of women resident in the household between the ages of 15 and
49. The age of each woman was recorded and a ribbon of a different colour was assigned
to each woman of the household. One of these ribbons was then randomly selected and
the woman to whom that coloured ribbon was assigned was interviewed. When arriving at









Knock on the door.
Introduce yourself - show the letter of introduction.
Explain the study - give the person who answered the door the study information
sheet.
Ask how many women between the ages of 15 and 49 live in the household.
Record the number and ages of the women living in the household on the sheet
provided for this purpose. No names should be recorded.
If there is more than one woman, assign a different coloured ribbon to each woman,
by entering the colour next to the age of the woman on the sheet referred to above.
Select !m&.ofthese women in the following way:
if there is only one woman, she is the person who should be asked for her consent
to be interviewed
if there are two or more women, draw one of the ribbons out of the box. The
woman whose age corresponds with that ribbon colour should be interviewed
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if that woman is present, she is the person who should be asked for consent to be
interviewed
if that selected woman is not in, ask when she is likely to be home. Ask if it would
be in order to come back and talk to her at that time. Come back at the appointed
time, introduce yourself, explain the study and ask for consent to interview her
if she is not going to be back at any time in the next six days, re-select another
ribbon and go through the selection process again amongst the remaining women
of that household.
• If the person selected to be interviewed does not give consent, go to the house next
door and go through the selection process again.
1.2.3.2 Focus Group Interviews
Community groups active in the study area were identified by key informants living in the
area. At least one group of each type was selected for interview. Where two or more
groups of the same type had been identified, a group was selected by convenience
sampling, according to availability of the group and availability of a venue to hold a
discussion. Focus group interviews were held with fourteen groups in all. The size
and composition of each group and the characteristics of individuals within these groups
are provided in Chapter 1.5, Table 1.5.3.
1.2.3.3 Analysis of Family Planning Clinic Records
An analysis of the records of contraceptive methods supplied by the family planning
clinic of the Hlabisa Hospital was undertaken for the period July 1998 to July 1999.
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1.2.4 COMMUNITY ENTRY AND ETHICAL SAFEGAURDS
1.2.4.1 Community Entry and Community Consultation
Extensive consultation was undertaken prior to designing the research instruments and
collecting the data. The study was first introduced to community leaders in the Hlabisa
district as part of the research programme of the Africa Centre for Population Studies and
Reproductive Health. More specifically, the study was introduced to the Chief of the
Hlabisa district along with other studies , also being undertaken in this sub-district area.
The Medical Superintendent, Chief Matron, Community Matron, Medical Officer in
charge of training and other nursing staff of the Hlabisa Hospital were informed about the
study. Under the auspices of the Chief Matron, a workshop was conducted for Hlabisa
Hospital family planning nursing staff. The objectives of the workshop were to inform
family planning nursing staff about the study, and to seek assistance in designing the data
collection instruments.
Workshops and meetings were also held with the indunas of each isigodi, with
community health workers from the sub-district, with traditional healers and with other
researchers working in the study area. Across-the-board support and encouragement were
provided for the study. In addition, much helpful advice and information were proffered
about study design. This phase of the study took place over the period February 1998 to
September 1998. Feedback about the study has been provided to the Hlabisa community
in the form of scientific colloquia and imbizos through the Africa Centre for Population
Studies and Reproductive Health. A final community meeting to report on findings will
be held once results have been finalized.
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1.2.4.2 Informed Consent
Care was taken to obtain informed consent from individuals requested to participate in the
study. Interviewers were intensively trained in the ethics of informed consent and were
exhorted not to place pressure on anyone who was, or appeared to be, reluctant to
participate in the study. It was made clear to potential respondents that they did not have
to participate if they did not wish to, and that they could withdraw from the interview at
any time. A patient information sheet was designed to acquaint potential respondents of
the household survey with the institutional affiliations of the researchers, the objectives of
the study, the methodology to be employed and the potential benefits of the study. A
similar information form was developed for focus group participants. The information
sheets were made available in English and Zulu (Appendix 1.2.2) and were given to all
study participants. The information was also provided verbally. Each fieldworker also
carried a personal letter of introduction with her.
1.2.4.3 Confidentiality
Individual Household Interviews
Since women who use the injectable contraceptive may do so secretly, great care was
taken to ensure that confidentiality was maintained. Fieldworkers were intensively trained
about the right of study participants to confidentiality. Particular care had to be taken
since the fieldworkers were drawn from the study area. Since women were to be
interviewed regardless of whether or not they were injectable contraceptive users, the
mere fact that they were being interviewed did not identify them as users of the injectable
contraceptive method .
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Ofnote are these excerpts from the fieldworker training notes:
"Many respondents will not want other people to know ifthey are using the injectable
contraceptive. It is very important to ask the questions in a place where other people
can 't hear the answers. "
"The answers you are given must be kept strictly confidential. In other words, you must
not tell anyone else what the respondent has told you and you must not show the answers
to the questions to anyone else. "
Respondents were assured of the confidentiality of their responses in both the patient
information sheet and the interviewer letter of introduction.
Focus Group Interviews
Whilst confidentiality is less easy to control in the group discussions, members were
assured that care would be taken to maintain individual confidentiality. Group facilitators
also requested that members of a group should respect the right to confidentiality of other
members of the group. Since the discussion was to be captured by means of a tape
recorder, permission to record the interview was obtained prior to commencing the
discussion.
Family Planning Clinic Records
Names of women appearing on the records of the family planning clinic at the Hlabisa
Hospital were not recorded.
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1.2.4.4 Approval to Conduct the Study
The study was approved by the ethics committees of the University ofDurban-Westville
(Ethics approval Number 97296B) and the Nelson R Mandela School of Medicine of the
University of Natal (Ethics clearance number H150/00).
1.2.5 DATA COLLECTION
1.2.5.1 Data Collection Instruments and Procedures
Individual Household Interviews
An extensive structured interview schedule was designed in consultation with health
providers and other researchers and after a thorough literature review of instruments used
in studies with similar methodologies, including the 1998 South African Demographic
and Health Survey instrument (Department ofHealth et al, 2002). Many questions are
common to users, previous users and those who had never used the method, but some
questions were designed specifically for only one or two of these categories. For
simplicity of administering and analysing, the questions relevant to each sub-category
were assembled in separate interview schedules. The three schedules were colour coded
to allow easy recognition by the interviewers: the interview schedule for current users
was printed on yellow paper, blue was used for previous injectable users and white
interview schedules were printed for those who had never used the method. This gross
visual recognition technique was very successful and the schedules soon became known
as the "yellows", "blues" and "whites". Copies of the interview schedule, broken down
according to the type of injectable contraceptive user to whom it would be administered,
can be found in Appendix 1.2.3. As can be seen, the most extensive schedule was
developed for current users of the injectable contraceptive.
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Questions on demographic characteristics, contraceptive history, plans about future use,
knowledge, perceptions and opinions of injectable contraceptives, men's views and
friend's views were asked of all user categories. Extensive questions on brand of
injectable being used or previously used, side effects, length ofuse, reasons for choice of
method , secrecy of use and source ofmethod , were included for current and previous
users. Questions on medical history relevant to injectable contraceptive use, e.g.
breastfeeding status and concomitant use of enzyme inducing drugs, were included for
those currently using the injectable. Contraceptive methods currently used by those not
using the injectable were directed towards the non-user and previous user categories.
Questions exploring reasons for discontinuing use were included for previous users. The
interview schedule was comprised ofdichotomous questions, lists ofoptions to be ticked,
and open-ended questions.
The interview schedule was developed in English, but the interviews were to be
conducted in Zulu since almost all the respondents were expected to be Zulu speakers .
Considerable research and consultation were undertaken to determine the best method of
administering an interview schedule in a language other than that in which it was
developed. Current practice favoured the approach of partial translation ofkey phrases
rather than complete translation of the whole instrument. In using this approach, nuances
ofmeanings are less likely to be lost in the translation process and one is not forced to
find a translation for a word that doesn 't exist or that may be taboo (Katzenellenbogen et
al, 1997). The use of this type of approach to translation is supported by the views of
African participants (from Botswana, Kenya and Ghana) of the London School of Health
and Tropical Hygiene's 1998 Short Course on Reproductive Health Research. They
indicated that, if respondents understand English in addition to their home language,
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questions on sensitive issues such as sexual practice, are better asked in English, since
translating some questions may require the use of words which are taboo in the home
language (M L McFadyen, course participant, pers. comm., August, 1998).
Thus, a partial translation approach was adopted for this study. An extensive participative
workshop was held to identify key phrases for translation. Senior researchers, the
fieldwork manager and fieldworkers were involved in this process. Zulu was the first
language of the fieldworkers and they were also all fluent in English. Phrases identified
for translation were printed on the interview schedule in English and Zulu. For instance,
the English and Zulu translation of all side effects listed appeared one below the other in
all cases. The interviews were all conducted in Zulu. A description of the fieldworker
training process for translation is provided in the section on training below.
Various techniques were employed to ensure that the instrument was valid and reliable .
The face validity of the household interview schedule was checked to determine whether
or not, on the face of it, the questions make sense (Bemard, 1994, Katzenellenbogen et al,
1997), by conducting a validation process with a group ofpharmacology master's students
from the University ofDurban-Westville. The students were asked to read and critique
the interview schedule in the advanced stages of its development. A seminar with the
students was arranged for feedback and comment. A very useful discussion was held
which helped to identify ambiguous questions and issues omitted. For instance,
additional side effects associated with injectable use were identified and included.
A face validity check was also performed to ensure that the standardised translation
agreed on was valid. This involved one ofthe interviewers conducting the interview with
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a skilled English/Zulu translator and obtaining her view on the accuracy of the translation.
The translator (Z Gwamanda) who participated in this process was a first language Zulu
speaker from the Biostatistics Division of the Medical Research Council. She was of the
opinion that the translation was accurate.
In designing the interview schedule, the 1998 South African Demographic and Health
Survey (SADHS) instrument was consulted and some similar questions were included . In .
this way, criterion validity, which involves evaluating the results of this study's findings
against a "gold-standard" can be assessed (Bernard, 1994, Katzenellenborgen et aI, 1997) .
The instrument was also designed to incorporate reliability measures, i.e. whether or not
the same answer is provided when a question is repeated:
(a) Some questions were asked in different ways in different parts of the schedule. For
instance:
• the answer to the question about the type of injectable contraceptive being used
(question 16), should be consistent with the answer given to question 21, which asks
how often the respondent returns to the clinic.
• respondent's age (question 2) can be cross-checked by adding age of first pregnancy
(question 9) and age of first child (question 10).
(b) An important objective of this study was to obtain detailed information about the
experience of side effects while using the injectable contraceptive. A question exploring
side effects experienced by current users was asked first in open-ended form (question
25) followed by a closed question (question 26), where respondents had to indicate
whether or not they had experienced any of22 different pre-listed side effects . This was
done to elicit the side effects uppermost in respondent's mind without prompting, whilst
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ensuring that side effects were not forgotten, and also as a reliability check. Questions
41(d) and 41(e) (side effects experienced by past users) were handled in the same way.
Findings from the unprompted version of the question on side effects were found to be
consistent with the prompted responses, although, as expected, frequencies of reporting
were lower.
Interviews were conducted by three young women hired from the Hlabisa community.
These young women were of a similar age and all three had achieved their matriculation
certificates. Researchers participating in research projects under the umbrella of the
Africa Centre for Population Studies and Reproductive Health have made an undertaking
to hire local people wherever possible and this policy was applied in hiring fie1dworkers
for this study. The hiring of local people proved to be advantageous as these three young
women are familiar with the terrain and are well accepted by the community. Their advice
and insight into appropriate ways of approaching community leaders and respondents
were invaluable. A fourth, older and very experienced fieldworker, based in Durban also
assisted with interviews. She has been involved in interviews on reproductive health
issues for 10 years and is trained in anthropology and sociology. She was involved in the
early training stages and was part ofthe interview team for the first two weeks, and from
time to time thereafter. Her role was to conduct interviews (with older women where
appropriate), but also to guide the newly trained fieldworkers and monitor the quality of
their interviewing. After much discussion, it was decided that it would not be appropriate
to have males to interview women. The fieldworkers were supervised by a male fieldwork
manager who was continuously on site during the data collection phase of the study.
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The household interviews, 848 in total , were conducted in September, October,
November and December 1998. They were mainly held during the day from Monday to
Friday, but where a selected woman was not at home during the day, a revisit was made
in the evening or on Saturday. No one refused to participate in the study, although one
interview was terminated before completion as the respondent did not wish to continue.
No substitutions were made, as revisits were arranged where no one was in at the selected
household or where the selected woman was not home. The univariate statistics for
interview lengths are provided in Table 1.2.1 below:
Table 1.2.1 Interview length
Mean Median Mode Range
(minutes) (minutes) (minutes) (minutes)
Injectable users 41 40 45 30-85
Previous IPC users 37 35 35 15-60
2who had never used IPC 24 25 25 5-49
Focus Group Interviews
A semi-structured aide memoire was designed for the focus group interviews. Six themes,
identified in the consultative phase of the study and from responses to the individual
household interviews, were included for discussion. The themes included were: general
views and opinions on contraception; opinions ofthe injectable contraceptive; side effects
of the injectable contraceptive; the experience of vaginal wetness with injectable
contraceptive use; the use of the injectable contraceptive in the context of high HIV
prevalence and the views of community leaders and elders on the use of contraceptives. A
copy of the semi-structured focus group interview schedule can be found in Appendix
1.2.3. A short questionnaire was also administered to each person participating in the
group discussion to obtain demographic information so that the discussion group could be
described. This questionnaire can also be found in (Appendix 1.2.3).
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Each group was facilitated by two trained interviewers. The same four interviewers hired
to undertake the household survey were hired to conduct the group discussions. In
addition, the male fieldwork manager (see next section for a description ofhis role), was
also part of the team, and conducted the interviews with male groups. The focus groups
were comprised ofmen and/or women, therefore it was essential to include a male
interviewer in the team. Discussions were conducted in community halls, schools or at the
hospital. The interviews were conducted in Zulu and were recorded using an audio tape
recorder. One facilitator conducted the interview while the other took notes by hand and
ensured that the tape recorder was functioning throughout the interview. The second
facilitator was also responsible for ensuring that the discussion stayed on the topic, that
the discussion was not dominated by one individual and that reticent members of the
group were drawn into the discussion.
Fourteen focus group interviews were conducted from February to April 1999. By the
time these fourteen group interviews had been held, very little new information was
gained from successive group interviews. Only one type of group could not be assembled,
namely the indunas. There were never more than two ofthem available at anyone time as
they were very busy with the run-up to the country's national elections on the 2nd of June
1998. However, it was felt that sufficient information was obtained from the focus
groups which were conducted, so attempts to organise this group were halted.
Family Planning Clinic Records
A data collection form (see Appendix 1.2.3) was developed to record contraceptive units
issued per month at the family planning clinic of the Hlabisa Hospital. Data were
collected by a senior researcher for the period July 1998 to June 1999.
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1.2.5.2 Training and Fieldwork Management
Training
The training of fieldworkers was considered very important in obtainingquality data and
much time and effort was accorded to this aspect of the study. As mentioned above, an
initial workshop was held to identify key phrases for translation. This was the first in a
process of participative workshops with the fieldwork manager, fieldworkers and
researchers. The fieldworkers were provided with detailed information about the
objectives ofthe study and were trained in general survey research methods. Good ethical
practice and the rights of respondents regarding informed consent and confidentiality
were emphasised. Issues about appropriate conduct, for instance introduction of
themselves and the study were emphasised. Safety issues were also discussed and the
fieldworkers were advised to withdraw immediately from potentially unsafe situations.
The importance of accurate translation and the need to accurately convey the meaning of
each question was highlighted repeatedly. Intensive workshop sessions to standardise
translation and fine tune interpretation of the household survey instrument were held in
the first two weeks of September 1998. In this way a "gold standard" for translation and
interpretation (method described by Montgomery and Harrison, 1998) was agreed on by
the end of the workshops. This process was led by the fieldwork manager Sihle Ncgamu,
whose home language was Zulu. He is an experienced social scientist and academic with
considerable experience in education and survey research, and was completing his
master's degree in education at the time the fieldwork was being undertaken.
Once the translation had been standardised, the fieldworkers were required to "role play"
interviews, first with each other, then with friends or colleagues and finally with
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strangers. The role play included the whole interviewing process: knocking on the
potential respondent's door; introducing the study; selecting a respondent; asking for
permission to interview; conducting the interview in Zulu; thanking the respondent and
saying goodbye. These "role-play" sessions were monitored by the fieldwork manager.
For the first week of interviewing, the fieldworkers worked in pairs, swapping partners to
entrench consistency in interview technique and translation. Thereafter, interviews were
conducted individually. Once fieldwork had commenced, on-going training was provided
on a daily basis on site. Opportunities to train and clarify issues were provided at a
briefing session at the beginning of each day of interviewing, at mid-day and at the end of
the day.
Intensive training for conducting focus group discussions was provided in February 1999.
Fieldwork Management
In order to ensure quality of data a fieldwork manager, Sihle Ngcamu, was appointed.
Sihle was also responsible for other aspects of the project, namely community liaison,
translation tasks, fieldworker training, and organising and conducting focus group
discussions. He was familiar with the customs and traditions of the people of northern
KwaZulu-Natal, as he has lived, studied and worked in this area all his life. The study
area is very remote and it was no easy task to implement and monitor the fieldwork. A
local office was set up at the Hlabisa Hospital with the kind assistance of the Medical
Superintendent. This office served as the administrative and training centre during the
fieldwork phase. Sihle lived at the fieldsite and weekly visits were made to the fieldsite
by the principal investigator of the study (the author of this thesis) . Daily telephonic
contact was maintained between the principal investigator and the fieldstaff.
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The following quality control procedures were put in place:
• Interview schedules were numbered in advance and issued to fieldworkers on a daily
basis.
• At the end of the day, completed questionnaires were submitted to Sihle and were
checked overnight. Each checked questionnaire was signed off as checked.
• Interview schedules issued and returned were entered in a daily log sheet designed for
this purpose.
• A map of the isigodis and a chart of the number ofhouseholds to be visited in each
isigodi were displayed on the office wall. Each day, the number ofhouseholds visited
in the isigodi was entered on the chart.
• Fieldwork commenced in the Mabundeni isigodi which was close to our field-site
office, so that teething problems could be ironed out.
• Sihle informed the interviewers which households to visit according to the preplanned
sampling strategy. He transported the fieldworkers to the selected households and
ensured that the correct household was visited and that the interview was conducted.
• On-going training was provided at briefing sessions held at the administrative centre
each morning. At these sessions Sihle discussed problems he may have noted from the
previous day's interviews and clarified responses where necessary. The fieldworkers
were also given opportunities to raise problems they were experiencing or to seek
clarity about the interviewing process.
Longer briefing sessions were held when the weekly site visit was made by the
principal investigator. In the initial stages of interviewing, all completed
questionnaires were also checked by the principal investigator. Problems were
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addressed at these sessions. As the fieldwork progressed, spot checks of completed
interview schedules were made by the principal investigator.
• One of the roles of the fourth fieldworker was to provide additional quality checks
and to provide advice and support to the less experienced fieldworkers.
• The principal investigator provided support, in the form of training, advice and on-
going consultation with the field staff during the focus group discussion phase.
Measures to ensure safety of the fieldworkers were also put in place. The fieldworkers
always worked in the same general area and thus could easily access help from a
colleague. Sihle transported them directly to the households to be interviewed and
ensured that all was in order before he left. He knew at all times where the fieldworkers
were and fetched them again at lunchtime, so they were never left alone for extended
periods of time. They were also instructed to withdraw immediately from potentially
unsafe situations. Fortunately, no such incidents occurred.
The diligence and competency of the fieldwork team, working in very rugged terrain,
often having to walk up hill and down dale in inclement weather, are to be commended.
1.2.5.3 Validity and Reliability
As described above, various techniques were employed to ensure that the instruments
were valid and reliable . These included face validity checks, evaluation of this study's
findings with findings from the South African National Demographic and Health Survey
(Department of Health et al, 2002) for criterion-related validity, checks for predicted
validity, consistency checks between similar or related questions, asking the same
question first as an open-ended question followed by a closed-ended question,
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standardization of translation, hiring of interviewers with similar characteristics (age,
gender, education level) , intensive and continuous fieldworker training, close supervision
and monitoring of fieldworkers by the fieldwork manager and a more senior interviewer,
continuous quality control of completed interview schedules, intensive probing of
important issues during interviewing and the use of triangulation or inter-technique
approach .
1.2.6 PILOT STUDY
A pilot study to test the interview schedules for ambiguity, interpretation and
appropriateness was conducted in an adjacent sub-district ofHlabisa. Eleven interviews
were conducted. The pilot study occurred after the workshop processes set up to design
and translate the questions, and after the face validation of the instrument had been
undertaken. By the stage the pilot study was undertaken most problems had been solved.
Only one minor correction was made and an extra coding option 'None/No Problems'
was added to question 70.
1.2.7 DATAANALYSIS
1.2.7.1 Individual Household Interviews
The responses to questions were painstakingly postcoded by two of the fieldworkers who
conducted the interviews and by the fieldwork manager. Detailed uniform coding
instructions were developed for this purpose. The coding of each and every questionnaire
was checked by one of the coding team who had not coded that questionnaire. The coding
of all the questionnaires was rechecked by the principal investigator with particular
attention being paid to complicated questions or questions considered to be key to the
objectives of the study.
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A database was developed using Epi-Info Version 6.43 (Centers for Disease Control and
Prevention, Atlanta, Y2K compliant). Data were captured and double entered by skilled
data punchers of the Biostatistics Division of the Medical Research Council. Data were
cleaned and the analysed using Epi-Info Version 6, the Statistical Analysis System (SAS)
Version 6.12 (SAS Institute, CarryN.C.) and SPSS Version 9.0 (SPSS Corporation,
USA). Data analysis was undertaken with the expert advice and assistance ofKhangelani
Zuma, a biostatistician of the Medical Research Council. Statistical methods employed
were univariate statistics. Differences in quantitative variables were assessed using
Student's t test. Significance tests for categorical variables were based on the Chi-squared
test, Fisher's exact test or Cochran-Mantel-Haenszel statistics where appropriate.
Multiple logistic regression analyses and survival analyses were also undertaken where
appropriate. All p-values were based on a two-sided test. A p-value ofless than or equal
to 0.05 was considered to be statistically significant.
1.2.7.2 Focus Group Interviews
The focus group interviews were transcribed and translated from Zulu into English. The
translation/transcription process was undertaken by one member of the data coding team
and checked by another. Data from the focus group interviews were manually analysed in
terms of identified themes (thematic analysis) and standard content analysis approaches.
Where feasible and appropriate, descriptive statistics and frequency tables were
generated. Demographic data from individual members of groups were captured and
analysed using Epi-Info Version 6.43 (Centres for Disease Control and Prevention,
Atlanta, Y2K compliant).
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1.2.7.3 Family Planning Clinic Records
Annual consumption (units dispensed) was calculated for each method supplied. Couple-
Years of Protection (CYP) for each method was estimated using standard tables (Centers
for Disease Control and Prevention, 1998) and percentage contraceptive method mix was
determined.
1.2.8 LIMITATIONS
• Caution should be exercised in generalising these findings too broadly as this study
was conducted in a remote deep rural area. However, the area is not atypical of other
deep rural areas ofKwaZulu-Natal. Findings are not inconsistent with those of the
1998 South African Demographic and Health Survey as discussed in Chapter 1.6.
• Data obtained are self-reported by respondents and are therefore subjective.
• The instrument was conceptualised and designed in English and conducted in Zulu.
Responses were analysed and reported on in English. Under these circumstances, it is
difficult to ensure that intended meaning is not lost in translation. However, as
described above, great lengths were taken to ensure maximum accuracy in translation.
• Limitations inherent to survey research, and knowledge, attitude, behaviour and
practice (KABP) surveys apply (Katzenellenbogen et al, 1997). However, every
attempt was made to overcome these inherent limitations.
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CHAPTER 1.3 RESULTS (I). INJECTABLE CONTRACEPTIVE
PREVALENCE, USER CHARACTERISTICS AND
CONTRACEPTIVE METHOD MIX
In this chapter, an analysis of injectable contraceptive use , who uses the method and
reasons for use, is undertaken. Other contraceptive methods used and reasons for not
practising contraception are also explored. An in depth investigation of this kind has not
previously been undertaken. However, it is extremely important to understand why
injectable contraceptive use is so high, when the use ofbarrier methods, for dual
protection against HIV and pregnancy, should be a primary consideration in decision-
making regarding the choice of contraceptive method.
1.3.1 DESCRIPTION OF THE STUDY POPULATION
In total 848 African women, whose home language was Zulu , were interviewed. Selected
demographic characteristics of respondents are shown in Table 1.3.1. Their mean age was
26.3 years (SD 7.7) and almost two thirds had an education level of Grade 8 or higher.
Only 8.6% were employed (formally or informally) and 23.9% were students or scholars.
Most of the women (61.6%) were in a single-stable relationship, and few were married
(17.1 %). Many (58.8%) were first pregnant in their teens and 41.3 % ofthose under 20
years at the time of the survey were or had been pregnant at least once. Whilst nearly all
respondents (97.2 %) were resident in the area, many of their partners (67.6 %) were not,
and 74.1% of these migrant partners did not return home for a month or longer. A more
detailed description of the respondent's demographic characteristics, by injectable user
status , is provided later in this chapter.
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Mean (SD) 26.3 (7.7)






Average household income of ZARl 000 or less per month 92.1%
Marital status
Married (by civil , religious, traditional or customary ceremony) 17.1%
Single-stable relationship 61.6%
Single with casual relationships 7.8%
No relationship 13.6%
Number ofliving children: mean (SD) 2.3 (1.8)
Age at first pregnancy (years)
Mean (SD) 19.2 (3.1)
Proportion first pregnant < 16 years 8.0%
Proportion first pregnant < 20 years 58.8%
Proportion < 20 years who were or had been pregnant 41.3%
Proportion resident in district 97.2%
Proportion with migrant partners 67.6%
Proportion of migrant partners who did not return home for a month or longer 74.1%
1.3.2 INJECTABLE PROGESTOGEN CONTRACEPTIVE PREVALENCE AND
USER CHARACTERISTICS
A detailed analysis of the demographic patterns of injectable progestogen contraceptive
(Il'C) use is undertaken here, to provide some explanations for the popularity of this
method in South Africa. This understanding should inform contraceptive policy for
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service delivery which better suits the needs of South African women. Each of the three
injectable user categori es of the study are described, i.e. those women who were using the
injectable contraceptive at the time ofthe survey; those who were not using it but had
used it previously; and those who had never used it. These three sub-samples will be
referred to as IPC users (injectable users) , previous or discontinued users (those who had
used IPCs previously but were not current users) and a never-used group (those who had
never used IPCs).
1.3.2.1 IPC Prevalence
At the time of the survey, 187 (22.1%) of the 848 women interviewed were using an
injectable contraceptive method, either Depo-Provera'" or Nur-Isterate®(Table 1.3.2). Just
over half the women had used an IPC at some time.
Table 1.3.2 Prevalence of IPC use
IPC Use Status of Respondents N=848 %
Current IPC Users 187 22.1
Discontinued IPC Users 244 28.8
(currently not using IPC's)
Total Ever-Used IPCs 431 50.8
Never-Used IPCs 417 49.2
1.3.2.2 Demographic Characteristics of IPC Users
All the injectable contraceptive users interviewed in the Hlabisa sub-district were Zulu-
speaking African women. The predominant religions practiced were Zionist (31.5%),
Lutheran (19.6%) and Roman Catholic (17.9%). Similar proportions ofRoman Catholics
had ever used the injectable method (52% used DMPA; 51% used NET-EN). Key
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demographic characteristics ofIPC users are summarized in the second column ofTable
1.3.3 (see sub-section 1.3.3.1 later in this chapter), which also provides comparative
demographic data of discontinued users and the never-used group.
Only women in the age range 15 to 49 years were selected into the study. Injectable
users ' ages ranged from 17 to 49 years, with a mean age of 26.1 (median and mode = 25)
years. Over three quarters (76.4%) were under 30 years of age, with 13.9% under 20 years
(Figure 1.3.1). Ofall the under 20 year-olds interviewed, 14.6% were IPC users and
23.9% ofall respondents under 30 years were using an IPC. Injectables are thus widely
used by young women. A more detailed analysis of the age of injectable users in
comparison to discontinued users and the never-used group is provided later in this
chapter.









17-19 20-24 25-29 30-34 35-39
Age (years)
40-44 45-49
Most IPC users (77.5%) were in a single-stable relationship and only 13.4% were married
by civil, religious, traditional or customary ceremony (Figure 1.3.2). Two women had
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been divorced, and six had been widowed. Four women, who indicated that they were not
in any type of relationship, yet were using the injectable contraceptive method, had all
lost their partners within the few weeks preceding the interview. Two were recently
widowed and the partners of two had recently left the relationship.






The average household size of IPC users was 8.5 people, with a median of 8, a mode of 7
and a range of2 to 25 people. The average number ofwomen (agedl5 to 49 years) per
household was 1.7 (median 2, mode 1, range 1-5).
IPC users were fairly well educated with 75.3% having attained an education level of
Grade 8 (8 years of schooling) or higher. However, 70.6% were unemployed or
housewives and 19.8% were scholars or students. Of those employed, in both the formal
and informal sector, seven were professionals (teacher or nurse), five were working as
semi-skilled workers (clinic assistant, cook or dressmaker), three were involved in sales
work, and one was a domestic worker. Most IPC respondents (91.8%) had no personal
income and 91.6% reported a household income ofRlOOO per month or less.
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1.3.2.3 Reproductive and Contraceptive History ofIPC Users
Table 1.3.4 (see sub-section 1.3.3.2 later in this chapter) provides a summary of the
reproductive history and past contraceptive use of IPC users. Only six IPC users had
never been pregnant, with 96.8% having been pregnant. The mean age at first pregnancy
was reported to be 19.2 years. Of those ever pregnant, the youngest age at first pregnancy
was 12 and the oldest was 30, with 7.2% first pregnant when they were under 16 years
and 60.2% when they were under 20 years. Only 12 (including the six never pregnant)
had no children and the maximum number of living children was seven. Of those who had
children (n=175) the average number was 2 (median and mode =1). Nearly halfthe IPC
users (48.7%) had one child (Figure 1.3.3). Twenty-eight women reported miscarriages,
six of these had miscarried twice; only four women had had children who had died. Of
the IPC users under 20 years at the time ofthe survey all but one, a 19 year old, had been
pregnant.











The average age at first contraceptive use was 22.3 years with an age range of 16 to 42
years. In most cases IPCs were the first method used. NET-EN was the first method used
by 54.0% and DMPA by 36.4%. The oral contraceptive was the first method for 9.1% of
the respondents and only one woman first used the male condom.
1.3.2.4 Residential Status
Most ofthe injectable users (98.4%) were, for the purposes of this study, classified as
Hlabisa residents, since they slept at their home for at least 4 nights per week and for at
least 50% of the time. In contrast, most of their partners did not reside with them, with
88.2% of women married or in a stable relationship reporting that their partners resided
elsewhere (i.e. for four nights a week or more, and for more than 50% of the time), and
76.3% of the partners resided out of the Hlabisa sub-district. Hence, few couples were co-
habiting. Thirty-two percent ofmarried women's partners resided with them, compared
with 8.3% ofthe women in stable relationships. Most partners returned to their partners
once a month (31.5%) or 2 to 3 times a month (21.1%). Their locations when they were
away were mainly Johannesburg (20.3%), Richards Bay/Empangeni/NselenilUlundi
(16.2%) , DurbanlPietermaritzburg (10.8%), MtubatubalSt Lucia (10.1%) and
NongomalBuxedeni (7.4%), with 23.0% ofpartners residing elsewhere in the
H1abisalH1u1u1we area. Only one respondent's partner returned only once a year and he
lived in Johannesburg when he was away. Eight respondents could not predict when their
partners would return, and in all these cases the partners lived in the Hlabisa sub-district
(six) or close by (Mtubatuba or Richard's Bay area).
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1.3.3 COMPARISON OF INJECTABLE CONTRACEPTIVE USERS WITH
DISCONTINUED USERS AND THOSE WHO HAD NEVER USED THE
METHOD
1.3.3.1 Comparing Demographic Characteristics
The three user groups were similar in terms of age, average household income and
household size (Table 1.3.3). While few women in all three categories were employed ,
more of those never having used the injectable were students or scholars and, predictably,
more had never had a relationship. More IPe users were students or scholars than
previous users (p=0.025). IPe users were better educated than the other user groups
(p=0.002), with previous users the least well educated (p=0.012). Less than 20% of all
respondents were married (by civil, religious, traditional or customary ceremony) with
more in the discontinued user group being married. More IPe users were in a stable
relationship (77.5%), and more were married or in a stable relationship (90.9%) (Table
1.3.3).
More IPe users had migrant partners than previous users, but in the case of IPe users,
fewer partners were away for a month or more (Table 1.3.3).
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Table 1.3.3 Comparative demographic characteristics according to IPC user status
* by CIvl1, religious, traditional or customary ceremony
** partner recently died or left
***of those married or in a stable relationship




Mean (SD) 26.1 (5.9) 28.6 (7.2) 25.1 (8.4)
Range 17-49 17-48 15-48
Education level grade 8 or above (%) 75.3 58.7 64.5
Employment status (%)
Employed (formal or informal) 8.6 9.5 8.0
Housewife/pensioner 10.7 16.9 11.6
Students/scholars 19.7 11.9 32.9
Unemployed 61.0 61.7 47.4
Average household income of ZAR1 000 per month or < (%) 91.6 92.4 92.2
Average household size 8.5 8.3 7.9
Range ofhousehold size 2-25 2-18 2-25
Marital status (%)
Married* 13.4 19.7 17.3
Stable relationship 77.5 64.3 52.8
Single, casual relationships 7.0 6.6 8.9
No relationship 2.1** 9.4 8.4
Never had a relationship - - 12.7
Proportion with partners residing with respondent*** 11.8 20.0 9.8
Proportion with migrant partners (i.e. living outside the 76.3 59.0 69.2
district)***
Proportion of migrant partners who did not return home for a 61.1 81.0 79.9
month or longer
. . . . . .
A logistic regression analysis which explores associations between current use of IPCs
and demographic variables is described later in this chapter (sub-section 1.3.3.3).
1.3.3.2 Comparing Reproductive and Contraceptive History
Pregnancy History
Forty percent of those who had never used the injectable method had never been
pregnant. Ofthose who had never used IPCs and who had ever been sexually active,
31.3% had never been pregnant. By comparison, very few of the current IPC users and
previous users had never been pregnant (3.2% and 4.1% respectively) (Table 1.3.4).
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Table 1.3.4 Comparative reproductive history by IPC user status
* The rope IS a traditional contraceptive method obtained from a faith healer or a traditional healer .
According to a male traditional leader who participated in the group discussions, a few threads from a
mule's tail are used to make a rope. The woman ties this rope around her waist to prevent pregnancy.




% never pregnant 3.2 4.1 40.0
% never pregnant (of those ever sexually active) - - 31.3
Number pregnant at time of interview - 25 23
Number unsure ifpregnant at time of interview - 7 8
Age at first pregnancy (years)
Mean (SD) 19.2 (2.8) 18.8 (2.7) 19.6 (3.3)
Range 12-30 12-31 13-31
% < 20 years who were or had been pregnant 96.2 82.4 24.4
(p=0.000)
% first pregnant < 16 years (of those ever pregnant) 7.2 9.8 12.5
% first pregnant < 20 years (of those ever pregnant) 60.2 63.8 53.1
Parity
Mean number ofliving children (total sample) 1.9 2.2 1.4
Mean number of living children (of those ever 2.0 2.4 2.3
pregnant)
Maximum number ofliving children 7 10 10
% with one child (of total sample) 48.7 38.9 25.2
% with more than one child 44.9 54.1 29.7
Contraceptive history
Ever used a contraceptive method (%) 100 100 18.2
Ever used a contraceptive method (% of those ever 100 100 21.5
sexually active)
Age at first contraceptive use (years)
Mean (SD) 22.3 (4.9) 22.0 (5.2) 20.1 (3.3)
Range 16-42 14-41 15-34
First contraceptive method used n=187 n=244 n=74
IPC 90.4 94.3 -
OC 9.1 5.7 71.6
Male condom 0.5 0 2.7
Female condom 0 0 1.4
IUD 0 0 2.7
Tuballigation 0 0 1.4
Thigh sex 0 0 10.8
Withdrawal 0 0 2.7
Rope* 0 0 1.4
Quinine 0 0 2.7
Essence of life 0 0 1.4
Other - - 1.4. .
109
Most of those who were in the group that had never used IPCs and who had never been
pregnant were under 20 years (60.5%). By contrast, few who had been pregnant were
under 20 (13.6%) (Figure 1.3.4).
Figure 1.3.4 Pregnancy history of women who had never used IPCs
Never used IPCs
n=417
40% never pregnant (31.3% of sex active ~)
• 60.5% < 20 years
60% pregnant at some time
• 13.6% < 20 years
Just over two thirds (68.2%) ofthose who had never used an IPC and who had never been
pregnant, had had a relationship at some time. Those who had never been pregnant and
had never had a relationship (31.8%), were particularly young -- 84.9% were under 20
years and 58.5% were 15,16 or 17 years old (9 were 15 years, 12 were 16 years and 10
were 17 years old).
Figure 1.3.5 shows that many of the non-users who were under 20 had never been
pregnant (74.8%) in contrast to the very few under 20s in the IPC user group (3.8%) and
the discontinued user group (11.8%) who had never been pregnant.
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Many of the IPC users and discontinued users were first pregnant before they turned 20
(60.2% and 63.4% respectively), compared to only 53.1% ofthe ever sexually active non-
users (Table 1.3.4). Mean age at first pregnancy was similar for the 3 user categories
(Table 1.3.4).
Relatively few respondents reported that they had ever had difficulty in conceiving:
• 0.5% of current IPC users
• 0.8% ofprevious IPC users
• 3.9% ofthose who had never used the injectable.
Slightly more women were unsure about whether or not they had a fertility problem:
• 1.2% ofcurrent IPC users
• 0.8% ofprevious IPC users
• 7.3% ofthose who had never used the injectable.
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Parity
More IPC users had only one child than the other user categories (Table 1.3.4 and Figure
1.3.6), and many of those who had never used the injectable had no children.













Whilst many current and discontinued IPC users in the under 20 year age group had only
one child, fewer teenagers who had never used the injectable had one child (Figure 1.3.7).
Bearing in mind however that many non-users, particularly those under 20 years, had
never been pregnant (Figure 1.3.6).













Very few of those who had never used the injectable had ever used any method of
contraception (18.2%) (Table 1.3.4). Excluding those who had never been sexually active,
21.5% of those who had never used an IPC had ever used any contraceptive method --
most often the oral hormonal contraceptive method which was the first method used by
71.6%. The oral contraceptive was the first method for far fewer current IPC users and
discontinued IPC users (Table 1.3.4). A greater mix of first contraceptive methods is
evident for those never having used the injectable method, including a wide range of
traditional methods - thigh sex, withdrawal, rope (Table 1.3.4) and substances not
registered with the Medicines Control Council as contraceptives (quinine, essence of life).
Mean age at first contraceptive use was similar for the 3 user categories, and, particularly
for users and discontinued users, was higher than mean age at first pregnancy (Table
1.3.4).
1.3.3.3 Characteristics Independently Associated with IPC Use
A logistic regression analysis model was developed, using Nagelkerke R2, to explore
associations between current use of IPCs and demographic and reproductive variables. A
backward stepwise dropping approach was used. The dependent variable was "currently
using IPe or not". The independent variables included in the model were: "age",
"education", "employment status", "marital status", "ever pregnant" and "number of
children" (Table 1.3.5). Nagelkerke R2was found to be 0.186 with 77.7% correctly
classified .
The analysis showed that younger, more educated women in a married or stable
relationship were more likely to be using an IPC (Table 1.3.5). Having ever been
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pregnant was strongly associated with IPC use (OR=12, see Table 1.3.5). Whilst a non
significant association was found between IPC use and employment status, or IPC use
and number of children, removal of these variables from the model increased the variance
and they thus played some role in the association.
Table 1.3.5 Characteristics independently associated with IPC use
Odds Ratio Confidence P Value
Interval (95%)
Age (years) 0.0288
15-24 1.50 0.74; 3.03 0.2569
25-34 2.08 1.15; 3.77 0.0157
35-49 1
Education
No school or primary 0.50 0.33; 0.77 0.0017
Secondary or higher 1
Marital status
Married or stable relationship 2.10 1.20; 3.69 0.0099
Casual or no relationship 1
Ever pregnant
Yes 12.23 3.40; 43.97 0.0001
No 1
Employment status 0.3837
Employed 0.87 0.46; 1.65 0.6596
Student or scholar 1.39 0.83; 2.34 0.2162
Housewife 0.70 0.38; 1.29 0.2556
Unemployed 1
Number of children 0.9552
No children 0.90 0.32; 2.55 0.8450
One child 0.94 0.61; 1.45 0.7801
More than one child 1
1.3.4 CONTRACEPTIVE METHOD MIX
Contraceptive prevalence amongst survey respondents is described here and contraceptive
methods used by respondents as well as reasons for method choice are presented. Reasons
for not practising contraception are also explored. A manuscript describing the results of
this analysis has been published in the peer reviewed journal African Journal of
Reproductive Health ('Where is the condom? Contraceptive Practice in a Rural District in
South Africa', 2002, 6(2) , 71-78 . For a copy of this manuscript, see page xvii of the thesis
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in the section after the abstract). An analysis of the contraceptive method mix issued from
the Hlabisa Hospital family planning clinic is also undertaken.
1.3.4.1 Current Contraceptive Practice
Less than a third (29.7%) of all women (N=848) reported use of a contraceptive method
at the time ofthe survey. The most commonly used methods were the IPCs depot
medroxyprogesterone acetate and norethisterone oenanthate, used by 22.1% of all the
women. The oral contraceptive (OC) was used by 4.5% ofthe total sample and only 1.3%
of respondents reported the male condom as their current method. No-one used the female
condom. While 17.4 % of respondents under 20 years were using a contraceptive
method, over a third (37.8%) of the teen respondents who had ever been pregnant were
using a contraceptive method. Excluding the 211 respondents who were not sexually
active, or were pregnant, infertile or menopausal, 28.6% were using IPCs, 5.9% were
using the oral contraceptive and 1.7% were using the male condom.
Ofthose who reported using a method (n=252), 94.4% were using a modern method
(injectable or oral hormonal contraceptive, male condom, intrauterine contraceptive
device [IUD], tuballigation), 3.2% a traditional method and 2.4% substances not
registered with the Medicines Control Council for contraceptive use (Table 1.3.6).
Current use ofnatural family planning methods such as the calendar or rhythm method or
the basal body temperature method was not reported. In contrast to the wide spread use
of the injectable method (74.2% ofwomen practising contraception), the condom was
used by only 4.4% of current users.
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Table 1.3.6 Current contraceptive practice (n=252)
* Use of a snail's shell IS a traditional contraceptive practice which mvolves takmg the cloth or pad used
during menses, putting it in the shell of a snail , and digging a hole and burying it. Care has to be taken to
prevent it from getting washed away when it rains as it is believed that if it gets washed away the woman
following this practice won't be able to conceive (female parent, from focus group discussion)
Current method Number of users 0/0
Modern methods 238 94.4
Injectable contraceptive 187 74.2
Oral contraceptive 38 15.1
Male condom 11 4.4
IUD 1 0.4
Tuballigation 1 0.4
Traditional methods 8 3.2
Thigh sex (ukusoma) 3 1.2
Rope 2 0.8
Snail's shell* 2 0.8
Withdrawal 1 0.4
Other methods 6 2.4
Quinine 3 1.2
Essence oflife 2 0.8
Flagyl 1 0.4
. .
In the age range 15-19 years, 83.9% of those using a method were using the injectable,
whilst only one woman reported the male condom as her current contraceptive method
(Table 1.3.7). More women in the 20-24 year age group were using the oral contraceptive
compared to other age groups, but OC use was still much lower than IPC use in this age
group. In the group of women who were 40 years or older, injectable use was very high
(85.7%) and no OCs or condoms were used.
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Table 1.3.7 Current contraceptive method by age
AGE GROUP (YEARS)
CURRENT METHOD <20 20-24 25-29 30-34 35-39 40-49
n(%) n(%) n(%) n(%) n(%) n(%)
Injectable contraceptive 26 (84) 55 (69) 62 (73) 25 (86) 13 (65) 6 (86)
Oral contraceptive 3 (10) 17 (21) 13 (15) 3 (10) 2 (10) o (0)
Male condom 1 (3) 3 (4) 5 (6) 1 (4) 1 (5) o (0)
Other methods 1 (3) 5 (6) 5 (6) 0 (0) 4 (20) 1 (14)
Total number 31 (100) 80 (100) 85 (100) 29 (100) 20 (100) 7 (100)
All but three teen respondents who had ever been pregnant and were using a
contraceptive method were using the injectable method. The other methods used by
teenagers ever pregnant were : oral contraceptives (n=2) and flagyl Cl), which is not a
contraceptive and should not be used as such. Amongst students and scholars, 18.4%
were using the injectable and only 1.0% the male condom (Table 1.3.8).
Table 1.3.8 Contraceptive practice of scholars and students (n=201)
CURRENT METHOD SCHOLARS STUDENTS TOTAL
n = 180 (%) n=21 (%) n =201 (%)
No method* 139 (77.2) 13 (61.9) 152 (75.6)
Injectable contraceptive 30 (16.7) 7 (33.3) 37 (18.4)
Oral contraceptive 5 (2.8) 1 (4.8) 6 (3.0)
Male condom 2 (1.1) 0 (0) 2 (1.0)
Other methods 4 (2.2) 0 (0) 4 (2.0)
* Of these, 56 were not sexually active , and 8 were pregnant
Not surprisingly, given the low use of any method other than the injectable, contraceptive
practice was very low amongst the non IPC users and discontinued IPC users (Table
1.3.9). Condom use was low amongst women in these two user groups and some




Table 1.3.9 Current contraceptive use by IPC user status
Contraceptive use Current Users Previous Users Never Used Total
Current contraceptive use
n=187 n=244 n=417 n=848
% Currently using a contraceptive method 100 11.5 8.9 29.7
(all women)
n=187 n=178 n=272 n=637
% Currently using a contraceptive method 100 15.7 13.6 39.6
(excluding: sexually inactive, pregnant,
had hysterectomy, menopausal, infertile)
Current contraceptive method
n=187 n=28 n=37 n=252
IPC 187 - - 187
QC - 12 26 38
Male condom - 7 4 11
Female condom - - - -
100 - 1 - 1
Tuballigation - - 1 1
Thigh sex - 1 2 3
Withdrawal - - 1 1
Rope - 1 1 2
Quinine - 2 1 3
Essence oflife - 1 1 2
Snail 's shell - 2 - 2
Flazvl - 1 - 1
1.3.4.2 Reasons for Contraceptive Method Choice
In response to an open-ended question about reasons for choosing the injectable method,
the most common reason, given by 35.0% of respondents, was that it was convenient. The
method was considered to be convenient since it only has to be used every two or three
months, or because one does not have to remember to take it every day as with the oral
contraceptive. Nearly a quarter of the injectable users (23.0%) chose this method because
it is effective, often making statements such as "its always in my blood" or "it stays in the
blood a long time". The third most common reason given for using the injectable was that
it was recommended by the clinic health personnel, with 19.7% giving this response.
Some respondents (4.9%) simply stated that the method "suited them", others expressed a
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dislike of oral contraceptives because of side effects experienced (4.4%). A few (2.7%)
chose the method as it could be used without their partner's knowledge.
Similar responses were given when injectable users were prompted to respond to each of
a list of 10 possible reasons for choosing the injectable method. Almost all (96.3%) the
187 injectable users indicated that they chose this method for convenience, as they only
had to return to the clinic every two or three months. Other common responses were that:
it was effective (47.6%); it was recommended at the clinic (37.4%); few problems or side
effects were experienced (27.3%); it caused amenorrhoea (23.0%); it was recommended
by friends or relatives (21.5%); and it was a method that could be hidden from partners
(20.9%) . Although not reported in response to the open-ended question, 52.9% said that
they chose the method because they felt that it was a safe way to prevent pregnancy.
A quarter (25.8%) ofthe women who were practicing contraception were using a method
other than the injectable, and the most common reason for method choice, given by
43.3% in response to an open-ended question, was related to injectable side effects.
Although almost halfofthe women giving this response had used the injectable method
before, only 55.6% of these previous injectable users gave this as their reason for current
method choice. A few were using a method on the recommendation of their partner (n=4),
relatives or friends (n=I), or the health provider (n=2). Six of the women giving this
response were using the oral contraceptive and one was using the withdrawal method . Of
note is that 7 women were using the condom and 3 were using thigh sex, because these
methods were considered to provide protection against both pregnancy and sexually
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transmitted diseases. The remaining condom users indicated that they did not like the side
effects of oral contraceptives, or that their partner was often away and a regular method
was not needed.
1.3.4.3 Reasons for Not Using a Method
Of the 848 women interviewed 70.3% were not using a contraceptive method. Reasons
for not using a method are broadly grouped as follows: 5
1. Most women (66.8%) indicated that they did not need to practise contraception. These
women reported that they: had never been sexually active (11.1%); were not sexually
active (11.8%); had sex infrequently (11.1%); were pregnant (6.6%); were wanting to
conceive or waiting until after the birth of their first baby (11.0%); were breastfeeding
(9.1%); were menopausal, had had a hysterectomy, or their husbands were infertile
(6.1%). The 20.2% ofwomen who had sex infrequently and those who were
breastfeeding, believed that they did not need to practise contraception, yet they were
at risk of an unplanned pregnancy. Also potentially at risk of an unplanned pregnancy
were those who reported that they were menopausal or had infertile husbands, as they
may not have had these conditions clinically confirmed.
2. Disapproval of contraception was given as a reason for non-use by 13.3%.
Disapproval was based on partners' views, personal views or the views of others, or
on religious or cultural grounds.
5 More than one reason was given by some respondents.
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3. Reasons related to the method itself such as side effects, health concerns and
inconvenience were given by 14.6% ofthe respondents, with over three quarters of
reasons in this category related to side effects. Close to 90% of these women had used
a contraceptive method previously, most commonly the injectable method, suggesting
that many had given reasons based on experience.
4. Reasons related to the provision of contraceptive services were given by only 2.4%
and included: lack of knowledge about contraceptives; long distances from the health
facility; and that the respondent was too shy to go to the clinic.
5. Other reasons were given by 7.3% of the women. For instance some respondents were
awaiting parental permission to use contraception, while others said that they didn't
have a reason.
In all 61.2% ofthose not using a method were not sexually active, were pregnant or
wanting to get pregnant, or had had a hysterectomy. This suggests an unmet need,
amongst nearly 40% ofwomen not practising contraception, for more appropriate
contraceptive methods or services than those available.
1.3.4.4 Method Mix according to Hlabisa Hospital Clinic Records
The ratio oforal to injectable contraceptives issued by the family planning clinic of the
Hlabisa Hospital in the July 1998 to June 1999 period was similar to the ratio ofICP to
OC amongst respondents surveyed within the same timeframe. According to the clinic
records, there were 4.3 injectable users to 1 OC user (Table 1.3.10), compared with 4.9
injectable users to 1 OC user, according to the survey (Table 1.3.6).
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No intrauterine contraceptive devices were issued and no records were kept of the number
of condoms distributed. IPCs are clearly the most commonly used contraceptive method
in the sub-district.
Table 1.3.10 Contraceptive methods issued from Hlabisa Hospital: July 98-June 99
Contraceptive Method Units issued Time period covered cyp
by unit issued
Injectable contraceptives
DMPA 1401 3 months 350
NET-EN 2289 2 months 382
Total 732
Oral contraceptives
Ovra1 342 1 month 29
Nordette 615 1 month 51
Triphasil 963 1 month 80
Microval 141 1 month 12
TOTAL 2061 172
IUD 0 0
Condoms No records kept No records kept
1.3.5 MAIN FINDINGS
• Injectable contraceptives were much more widely used than other contraceptive
methods (IPCs are used by 74% ofwomen practicing contraception).
• Condom use was low (used by 4% ofwomen practicing contraception).
• A few women were practicing dual protection, the simultaneous prevention of
pregnancy and STIs.
• Amongst women under 20 years, 83.9% ofthose using a contraceptive method were
using IPCs. Only one respondent reported the male condom as her current method.
• Younger, more educated women in married or stable relationships were significantly
more likely to be using an IPC.
• Mean age at first contraceptive use was higher than the mean age at first pregnancy,
particularly amongst those who had previously used an IPC.
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• Having ever been pregnant was strongly associated with IPC use with almost all
(97%) the IPC users having been pregnant at least once.
• Many IPC users had only one child, suggesting that IPC use commences after the first
pregnancy.
• Health workers play an important role in women's decisions to use IPCs.
• There is an unmet need for more appropriate contraceptive methods and services
amongst many of the sexually active women not practising contraception.
• The survey findings on contraceptive method mix are consistent with methods issued
from the Hlabisa Hospital family planning clinic.
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CHAPTER 1.4 RESULTS (11): INJECTABLE CONTRACEPTIVE
PRODUCT MIX AND DISCONTINUATION PATTERNS
Findings on current users and discontinued users ofDMPA and NET-EN are the focus of
this chapter. The data presented here provide a comparative analysis of the usage of the
two IPCs. This includes a cost analysis of the provision ofDMPA or NET-EN based on
utilization patterns of these two products in the Hlabisa District, and on distribution
patterns from four pharmaceutical depots in South Africa. A manuscript based on this
comparative analysis has been published in the peer reviewed journal BMC Health
Services Research (2001, 1(4), http://www.biomedcentral.com/1472-6963/1/4). under the
title ' Counting the costs: Comparing depot medroxyprogesterone acetate and
norethisterone oenanthate utilisation patterns in South Africa ' . A copy of this paper can
be found on page xxv of this thesis immediately after the abstract. A comprehensive
analysis of this kind has not previously been undertaken. In the final sub-section of this
chapter the discontinuation patterns of the two IPCs are described.
1.4.1 DEMOGRAPHIC CHARACTERISTICS OF DMPA AND NET-EN USERS
1.4.1.1 Current DMPA and NET-EN Users
An analysis of the demographic profile of respondents using the injectable progestogen
contraceptive (IPC) at the time ofthe survey shows that NET-EN users were significantly
younger than DMPA users (p=O.OOOI). The mean age ofDMPA users was 29.6 years and
that ofNET-EN users was 23.3 years (Table 1.4.1). Figure 1.4.1 below further illustrates
the age discrepancy between users of the two injectable products. NET-EN users were
also more likely to be students or scholars , and to be more highly educated (Table 1.4.1).
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Table 1.4.1 Demographic characteristics of current DMPA and NET-EN users 6
Significant difference between DMPA and NET-EN users
* Significant difference between DMPA and NET-EN users based on sum of scholars & students
Characteristic DMPA Users NET-EN Users
Age (years) 0=86 0=101





Education (%) 0=85 0=101
No formal education 4.7 0.0
Up to Grade 3 11.8 1.0
Grade 4 - Grade 7 30.6 5.0
Grade 8 - Grade 10 27.6 47.5
Grade 11- Grade 12 22.4 40.6
Tertiary 3.5 5.9
% Grade 8 and above 52.9 94.1t
Chi-Square: p=O.OOl
Employment status (%) 0=86 0=101
Employed - formal sector 5.8 5.9
Employed - informal sector 4.7 1.0
Housewife/pensioner 19.8 3.0
Unemployed 64.0 58.4
Scholar (n=5;25) 5.8 24.8
Student (n=0;7) 0.0 6.9
Chi-Sauare: p=O.001*
Marital status (%) 0=86 0=101
Married 22.1 5.9
Stable relationship 69.8 84.2
Single - casual relationship 5.8 7.9
Single no relationship 2.3 2.0
Monthly personal income (%) 0=85 0=98






6 Note: where the sample size is less than expected, the missing values were where responses were not
recorded or were inappropriate, unless otherwise indicated.
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NET-EN userswere more likelyto havefewer childrenand to start using a contraceptive
method at a youngerage than DMPA users (Table 1.4.2). Manyof both DMPAandNET-
EN usershad onlyone child, withmore NET-EN (69.3%) usershaving onlyone child
than DMPA users (24.4%), p<O.OOI) (Figure 1.4.2).
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Table 1.4.2 Reproductive history of current DMPA and NET-EN users
Significant difference betweenDMPAandNET-ENusers
DMPA Users NET-EN Users
% ever pregnant 0=86 0=101
Chi-Square p =0.527 97.7 96.0
Number never pregnant 2 4
Agefirst pregnant (years) 0=84 0=97
Mean(SD) 19.3 (3.0) 19.1 (2.7)
TTest p=O. 7129
Median(years) 19 19
Mode (years) 18 20
Range (years) 13-30 12-27
Agefirst used any method (years) 0=86 0=101





Number ofchildren 0=84 0=97
(excluding women neverpregnant)






Figure 1.4.2 Proportion of number of children ofcurrent DMPA and NET-EN
users
Number of Living Children
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In order to determine the influence of multiple variables on product choice, a forward
stepwise logistic regression analysis was performed, The variables selected for the model
were age, education, employment status, age at which a contraceptive method was first
used, number of living children and number of side effects experienced with the
injectable product being used. Age and education were found to be independently
associated with which injectable product was used, with younger, more educated women
more likely to be using NET-EN? (Table 1.4.3).
Table 1.4.3 Factors independently associated with product choice
Variable Odds Ratio Wald Confidence Limits (95%) P value
Age 1.24 1.14; 1.35 0.0001
Education
Primary school or < 9.55 3.32; 26.95 0.0001
Secondary school or > 1
1.4.1.2 Previous DMPA and NET-EN Users
Despite the differing times since discontinuation of the injectable, similar trends to
current user characteristics are apparent, with considerably more previous NET-EN users
found to be students or scholars and more highly educated than DMP A users. A summary
of the main demographic characteristics of previous DMPA and NET-EN users is
provided in Table 1.4.4. At the time of the survey, previous NET-EN users were younger
and had fewer children than previous DMP A users. Tests of significance were not
7 The Hosmer-and-Lemeshow Goodness-of-Fit Statistic = 2.7667 with 7 degrees of freedom (p=O.9057).
This is not significant, indicating a good fit of the model to these data.
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performed because of the differing times since discontinuation of the injectable among
the respondents.
Table 1.4.4 Demographic characteristics of previous DMPA and NET-EN users
Characteristic Previous Previous NET- Used Both
(at the time of the survey) DMPA Users EN Users Previously
n=138 n=96 n=10
Age (years)
Mean 31.9 23.9 28.4
Range 17-48 17-39 24-37
% ever pregnant 97.1 87.5% 100%
Number never pregnant 4 12 0
Number ofliving children
Mean 3.0 1.5 2.0
Range 0-10 0-6 1-4
Education grade 8 & > (%) 43.8 76.8 90.0
Married/stable relationship (%) 87.6 80.2 80.0
No personal income (%) 88.3 87.4 100.0
% scholars or students 5.8 (6 scholars, 21.8 (20 scholars, 0
2 students) 1 student)
*Ten respondents had previously used DMPA and NET-EN
1.4.2 UTILISATION PATTERNS AND REASONS FOR CHOICE
1.4.2.1 Product Mix
The injectable contraceptive method was extensively used in the Hlabisa sub-district, with
50.8% (n=431) of the respondents ever having used it and 22.1% using it at the time of
the survey (Table 1.4.5). Both injectable contraceptive products were widely used with
more current users found to be using NET-EN and more previous users having used
DMPA (Table 1.4.5 and Figure 1.4.3).
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Table 1.4.5 Injectable contraceptive product mix
Ten respondents had previously used DMPA & NET EN
t Discontinued users were not using the injectable contraceptive method at the time of the survey
DMPA NET-EN DMPA& TOTAL
NET-E~
N % N % N % N %
Current Users 86 46.0 101 54.0 - - 187 22.1
Discontinued Userst 138 56.6 96 39.3 10 4.1 244 28.8
Total Ever-Used 224 26.4 197 23.2 10 1.2 431 50.8
Never-Used - - - - - - 417 49.2
1f -











Amongst the sub-sample of respondents not currently using the injectable, but who had
previously used this contraceptive method, 10 had previously used both products (Table
1.4.5). Twenty-one current users had previously used an IPC. Fourteen current DMPA
users had previously used NET-EN; one had previously used both products. Five NET-
EN users had previously used DMPA and one had used both before. In this study, these
21 women are regarded as current users and do not form part of the sub-sample of
previous users.
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As described in the literature, both products have been available in South Africa for some
time. Records indicate that both DMPA and NET-EN were available through the public
sector as far back as 1994. There are however no records indicating which products were
available prior to this (1 van den Berg, Deputy Director: Medical Stores and Systems,
National Department of Health , pers. comm., March 2001). A Gray remembers issuing
both products from the South African DefenceForce to state clinics in the late 1980s (A
Gray, Department of Experimental and Clinical Pharmacology, Nelson R Mandela School
of Medicine, pers. comm., March 2001) .
1.4.2.2 Duration of Injectable Use
The mean length ofuse for current users ofDMPA and NET-EN were very similar. For
previous injectable users, the mean length ofuse ofNET-EN was less than that ofDMPA
users, although the difference is not significant (Table 1.4.6).8 As far as can be
determined, both products could have been available at the Hlabisa Hospital for more
than a decade preceding the study. According to the sister in charge of family planning at
the hospital , both products were available at the hospital when she first started working
there in 1980 (D Masondo , Sister-in-Charge, Hlabisa Hospital, pers. comm., August
2001). For both current and previous users, the range oflength ofuse ofDMPA was
greater than for NET-EN. Table 1.4.6 shows that DMPA had been used for up to 11 years
by current users and for up to 10 years by previous users. By contrast , current NET-EN
users had only used the method for up to 6 years and all previous NET-EN users
(excluding those who had used both products) had discontinued by 7 years ofuse.
8 Note that , in the case ofcurrent users, the end of the use period had not yet been reached.
131
Previous DMPA users were more likely to continue the method beyond 5 years than were
NET-EN users (p=O.OOI).
Table 1.4.6 Duration of use of current and previous DMPA and NET-EN Users
Duration of Use DMPA NET-EN
Current Users* N=86 N=lOl
Mean (years) (SD) 2.3 (2.3) 2.2 (1.6)
TTest p=O.886
4#Mode (years) 2
Median (years) 1.4 2
Range (years) 0.1-11 0.1-6
% using for 1 year or less 45.3 37.6
% using for 2 years or less 69.8 60.4
% using for 5 years or more 14.0 6.9
Previous Users+ N=137 N=95
Mean (years) 2.1 1.7
TTestp=O.088
Standard deviation 2.0 1.3
Mode (years) 2 2
Median (years) 1.4 1.1
Range (years) 0.2-10 0.2-7
% using for 1 year or less 48.9 49.5
% using for 2 years or less 67.9 77.9
% using for 5 years or more 9.5 3.2
Chi-Square: p=O.OOJ
* Since these are current users, the end of their use period had not yet been reached
# 21 respondents had used NET-EN for 4 years and 18 for 2 years , almost a bimodal distribution
+ The 10 respondents who had used both products previously were excluded from the analysis
1.4.2.3 Reasons for Choosing the Injectable Method According to Product Used
Current Users - Responses to Open-Ended Question
In response to an open-ended question, the most common reason for choice of the
injectable method by current DMPA users was that it was effective. This reason was
given by 2.6 times more DMPA users than NET-EN users (Table 1.4.7). For current
NET-EN users, the most common reasons given were: because one doesn't forget to take
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it, as with the oral contraceptive (31%) and the method was recommended by the health
worker (27%). By comparison, only 10.8% of current DMPA users gave
"recommendation by the health worker" as a reason for selecting DMPA. A few NET-EN
users indicated that it was a good method for young women, while no DMPA users gave
this as a reason for choice.




Don 't forget like pill
Recommended by health worker
Convenient
Easy to hide method from partner











* Some respondents gave two reasons (# of reasons = 187, n=183)
Previous Users - Responses to Open-Ended Question
Women who had discontinued the injectable contraceptive method were asked why they
had decided to use the method previously (Table 1.4.8). Responses to this open-ended
question were unprompted. As with the current users, the most common reason for
method choice was that it was effective, but in this sub-sample many more women gave
this reason, particularly NET-EN users . Again forgetting to take the pill was a frequently
given reason.
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Table 1.4.8 Reasons for previous DMPA and NET-EN users choosing the injectable
method
Reasons tor Choice* #
Effective
























*Excludes the 10 respondents who had previouslyused both products
# Somerespondentsgave two reasons (# of reasons =233, n=226)
Figure1.4.4shows clearly the extentto which previous usersof bothDMPA andNET-
EN chose the injectable method because of its effectiveness - evidently a lasting memory.
Figure 1.4.4 Main reasons for choosing the injectable method: Current and

















Current Users - Responses to Pre-constructed List ofPossible Reasons
When asked to respond to a pre-constructed list" of possible reasons for choosing the
injectable method, findings for current users were consistent with responses to the
unprompted question, with respondents indicating that they chose the method because it
was considered safe, effective, convenient and often recommended by the health provider
(Table 1.4.9). Although more NET-EN users indicated that the health provider played a
role in the decision about method use , the difference was not significant. A third of both
product users also indicated that the privacy afforded by the injectable method was a
factor in choosing the method. It is interesting to note that 32.8% ofthe current users
reported that their partners did not know that they were using the injectable.
Table 1.4.9 Reasons given by current injectable users for choosing the injectable
method
Reasons for Choice* DMPA(%) NET-EN (%) Total % Chi-
n=86 n=lOl n=187 Square
P Value
NET-EN convenient 97.0 51.9
DMPA convenient 95.3 44.4
Safe 51.2 54.5 52.9 0.653
Effective 52.3 43.6 47.6 0.232
Recommended at the clinic 32.6 41.6 37.4 0.204
Suits her, few problems or side effects 25.6 28.7 27.3 0.632
Causes amenorrhoea 17.4 27.7 23.0 0.096
Recommended by friends or relatives 21.2 21.8 21.5 0.920
Want to hide method from partner 20.9 20.8 20.9 0.982
Want to hide from friends & relatives 12.8 12.9 12.8 0.987
*Respondents were asked to respond in the affirmative or negative to each option listed in this table
9 This list was administered to current users only.
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A fair proportion ofboth DMPA and NET-EN users (17.4%; 27.7% respectively- Table
1.4.9) regarded amenorrhoea as a positive effect of IPCs, with more NET-EN reporting
this, possibly because amenorrhoea is more favoured by younger (more modem) women.
An analysis of the ages ofthe respondents who chose the injectable method because it
causes amenorrhoea showed that younger women were more likely to give this reason
than older women (p=0.0405). Further analysis showed that, in the case ofNET-EN
users, younger women were significantly likely to choose the injectable method because
it caused amenorrhoea (p=0.0311), whilst amongst DMPA users, age did not influence
whether or not the injectable method was chosen because it caused amenorrhoea
(p=0.7349).
In response to a question on the source of advice about how the method was chosen 10,
health providers were most commonly reported to have recommended IPC use for users
ofboth products (Table 1.4.10).
Table 1.4.10 Who advised method use?
Source of advice DMPA(%) NET-EN (%)
(n=86) (n=100)






10~is question was asked in relation to current contraceptive use only and therefore did not apply to
previous IPe users.
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1.4.2.4 Reasons for Current Users' Choice of a Particular Injectable Product
Current users were asked, by means of an open-ended question, why they preferred the
injectable product (DMPA or NET-EN) they were using, and their reasons for choice are
provided in Table 104.11 . The following findings are of note:
• Many DMPA users (4204%) indicated that they preferred this product because it was
"stronger", on the other hand, NET-EN was favoured by 36.0% of those using it as it
was regarded as "weaker" or "lighter".
• Concern about delayed return to fertility with DMPA was expressed by 5.0% ofNET-
EN users and 14.0% indicated that they chose NET-EN because it did not delay return
to fertility.
• The idea that NET-EN is for younger women or teenagers and DMPA for older
women was expressed by 14.6% of the IPC users. This preference is clearly reflected
in the age distribution ofDMPA & NET-EN users depicted in Figure 1.4.1 earlier in
this chapter.
• Recommendation by health workers was given as one of the most common reasons
for product choice especially in the case of NET-EN users.
• Relatively few women (6.5%) mentioned that concern about side effects influenced
choice of either product. This minor influence of side effects on product choice was
reflected for both NET-EN and DMPA. Of interest is that a few women (n=7) were
particularly concerned that NET-EN caused more bleeding. This concern was not
expressly mentioned in relation to DMPA use.
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Table 1.4.11 Reasons for current users selecting a particular injectable product





DMPA more effective, "stronger" 42.4
NET-EN"weaker", "lighter"
Fertility
Easy to conceive after discontinuation 1.2
DMPA delays fertility/causes infertility
Age
NET-EN is for young people 3.5
DMPA used by older women
Advice
Recommended by nurse 16.5
Convenient 16.5
Side effects
NET-ENcauses less side effects
DMPA causes less side effects 2.4
NET-ENcauses more side effects
more bleeding 8.2
weight gain 1.2















Efficacy was also given as the characteristic current users "liked most" about both
products with this response given by 77.6% ofDMPA users and 76.2% ofNET-EN users.
Other reasons given were: one doesn't forget to take it - like the pill (DMPA users: 4.7%;
NET-EN users: 4.0%); it could be used secretly (DMPA users: 2.4%; NET-EN users :
4.0%); amenorrhoea (DMPA users: 3.5%; NET-EN users: 2.0%); convenience (DMPA
users: 3.5%; NET-EN users: 2.0%).
1.4.3 DISCONTINUATION PATTERNS OF PREVIOUS INJECTABLE USERS
1.4.3.1 Discontinuation Rates
Survival analysis was used to calculate life table discontinuation rates and the average
discontinuation rate was found to be 2.1 years for previous DMPA users and 1.7 years for
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previous NET-EN users (Table 1.4.12).1l As shown in the survival distribution curve
below (Figure 1.4.5), all NET-EN users had discontinued use by 7 years, whilst some
DMPA users continued to use the product for 10 years. Although DMPA was used for
longer periods than NET-EN, the difference in average discontinuation rates was not
significant. However, previous DMPA users were more likely to continue the method
beyond 5 years than were NET-EN users (p=O.OOl).
Table 1.4.12 Cumulative discontinuation rates and mean according to injectable
product (DMPA and NET-EN) used by previous users
Discontinuation Rates
Cumulative Discontinuation Rates






































* Excludes the 10 respondents who had previously used both products
11 Excluding the 10 respondents who had previously used both products
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Time (years) to discontinuation
In order to determine the influence of multiple variables on discontinuation rates an
analysis ofmaximum likelihood estimates was performed. The variables selected for the
model were injectable product (DMPA or NET-EN), age, education and side effects
(heavy bleeding, amenorrhoea, weight gain). The variables "heavy bleeding" and "age"
were found to be independently associated with method discontinuation, although age
was only marginally significant (Table 1.4.13). Those who experienced heavy bleeding
and the younger women were more likely to discontinue the injectable method.
Table 1.4.13 Factors independently associated with injectable discontinuation
Variable Risk Ratio P value
Heavy bleeding 1.55 0.0016
Older Age 0.98 0.0595
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1.4.3.2 Reasons for Discontinuation
Previous injectable users were asked to respond to a comprehensive list of possible
reasons for discontinuing the injectable method. Up to five reasons were given by
respondents. Side effects were most commonly cited as the reason for discontinuation,
accounting for 54.5% and 46.1% ofthe reasons reported by DMPA and NET-EN users
respectively (note that some respondents gave more than one reason). A significant
difference was found between DMPA and NET-EN users in terms of the proportion
reporting discontinuation due to side effects with more DMPA users giving this reason
than NET-EN users (p=O.006). The menstrual disturbances amenorrhoea and heavy
bleeding were the most frequent side effects leading to discontinuation. After these
menstrual irregularities, the next most common reasons leading to discontinuation were
"vaginal wetness" and weight gain, reported by similar numbers of respondents.
A common user related reason was "wanted to have a baby" , especially for previous
NET-EN users, with 21.1% of NET-EN discontinuers versus 14.5% ofDMPA
discontinuers giving this reason (Figure 1.4.6). No sexual partner and infrequent sex were
also frequent user related reasons for discontinuation (Figure 1.4.6).
Similar proportions ofDMPA and NET-EN users discontinued the method because of
partner or family opposition. Only two women, both previous DMPA users, discontinued
the method because they were concerned about a delay in return to fertility. Few reasons
for discontinuation were related to health service provision (n=5). One woman
discontinued DMPA because she believed that it caused HIV.
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A compliance related reason for discontinuation was that of a "non-use segment" where a
respondent discontinued the injectable to "giveher body a break". Thiswas a reason
givenby both DMPAandNET-ENusers (Figure 1.4.6).
One previous DMPA user and2 previous NET-ENusers indicated that theydiscontinued
the method as theybecame pregnant by mistake.
Figure 1.4.6 Main reasons for discontinuation ofDMPA and NET-EN by previous
injectable users










Heavy Amenorr Vaginal Wt gain Planned No partner jnfrequent sex Partner WBDtedbody
bleeding wetness pregnancy opposed to have a
break
Reason
Heavybleeding wassignificantly more likely to be givenas a reason for discontinuation
by previous users of bothinjectable products who discontinued in the first year of use
(Cochran-Armitage statistic: -2.861, p=O.004; -2.283; p=O.02, for DMPAandNET-EN
respectively). Younger DMPA users werealso morelikely to discontinue the method due
to heavybleeding than were olderDMPA users (Cochran-Armitage statistic: -2.336,
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p=0.019). Although this trend was also evident for NET-EN users, it was not statistically
significant.
It is important to note that respondents reported up to five reasons for method
discontinuation. The following proportions of respondents gave more than one reason for
d· . . 12iscontinuation:
• Up to two reasons: 30.4% (41/135) ofDMPA users; 18.7% (17/91) of NET-EN users
• Three or more reasons: 6.7% (9/135) ofDMPA users ; 3.3% (3/91) ofNET-EN users
• Total giving more than one reason: 37.1% ofDMPA users ; 22.0% ofNET-EN users
(p=0.016).
As described earlier in this Chapter, 21 current users had previously used an IPC. Their
reasons for discontinuation are similar to the reasons for discontinuation provided by
respondents who were no longer using any injectable product as described above. The
most common reason for discontinuation given by previous users of both products was
heavy menstrual bleeding (n= 10).
1.4.4 COST ANALYSIS OF DMPA AND NET-EN USE IN SOUTH AFRICA
The extensive use of the two IPCs in a rural area of South Africa is illustrated in the
previous chapter. A cost analysis of the provision ofIPCs is therefore essential if
appropriate policies for the rational use of IPCs are to be developed. This analysis is
undertaken here.
~ 2 Note: 3 .DMPA and 5 NET-EN respondents did not give a reason for discontinuation or gave an
mappropnate response.
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1.4.4.1 Procedures Used to Analyze Supply Patterns and Cost
IPC Supply Patterns and Costs from Pharmaceutical Depots
Consumption figures of IPC stock issued from provincial pharmaceutical depots were
requested from the Deputy Director, Procurement of the South African National
Department of Health. 13 Data for DMPA and NET-EN were requested and made
available for the KwaZulu-Natal (KZN), Gauteng and Free State Provincial
pharmaceutical depots and for the Port Elizabeth depot, which serves the western part of
the Eastern Cape Province. These four provinces (of nine South African provinces)
represent over 50% of the total South African population. Gauteng has a mostly urban
population and KZN and Eastern Cape are more rural. The following data were analysed
for financial years 1997/8, 1998/9, and for 1/04/99 to 7/12/99 of the 1999/2000 financial
year:
• Current and previous tender prices for DMPA and NET-EN.
• Position number on ABC (Pareto) analyses for DMPA and NET-EN. An ABC
analysis is a method which ranks drugs according to their annual usage (unit cost
times annual consumption). Class A items are the 10 to 20 % which account for 75 to
80% of the funds spent. Class B items have an intermediate contribution to total
expenditure, whereas Class C items (the majority of items) account for a small
percentage of funds spent. ABC analyses are used to identify priority cost drivers for
intervention (Quick JD, 1997).
• Percentage of total depot expenditure on IPCs per financial year for each depot.
• Number ofunits of each item issued in the same time period per depot.
13 J van den Berg (Deputy Director: Procurement, Nation al Department of Health) and Mr T Odendaal (System s
Manager, Co-ordinating Committee for Medical Procurement) provided access to the data from the pharmaceutical
depots and the initial Pareto analysis. A Gray (Senior Lecturer, Department of Experimental and Clinical
Pharma cology, Nelson R Mandel a School of Med icine) assisted with the analysis of these data. Their assistance is
gratefully acknowledged.
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• Total expenditure on DMPA and NET-EN for the time period 1 April 1999 to 7
December 1999.
Cost Analysis ofIPC Utilisation Patterns in Hlabisa: A Case Study
The cost of providing DMPA or NET-EN was calculated on the basis of the prevalence of
current use of these two products by respondents of the community-based survey
undertaken in Hlabisa in 1998. The following analyses were undertaken:
• The ratio ofNET-EN:DMPA use.
• The annual cost ofproviding DMPA or NET-EN to the 187 respondents who were
currently using IPCs.
• Savings or increased costs if all respondents had used only one or other product.
• Projected cost for women using IPCs in the Hlabisa Sub-District.
1.4.4.2 Analysis of Supply Patterns and Cost
IPC Supply Patterns and Costs from Four Pharmaceutical Depots
IPC product costs
DMPA products issued at primary health care outlets in the three financial years analysed
were Depo-Provera" and Petogen" , and NET-EN was available as Nur-Isterate'". Table
1.4.14 shows that the acquisition cost of a vial ofboth DMPA and NET-EN products
increased every year, and that the cost ofboth DMPA products rose particularly steeply.
In the 1999/00 financial year, the generic product Petogen® was almost the same price as
Depo-Provera'", the innovator product. A vial of Depo-Provera'" and Nur-Isterate'" cost
exactly the same in the 1999/00 fiscal year.
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Table 1.4.14 Acquisition costs of IPCs: 1997/8, 1998/9, 1999/2000
Product Cost per vial (South African Rands)
1997/8 1998/9 1999/2000
DMPA
Depo-Provera" (Pharmacia Upjohn) 2.17 4.56 4.78
Petogen®(Pharmacare) -- * 2.07 4.29
NET-EN
Nur-Isterate® (Schering) 4.10 4.28 4.78
* tender not awarded
Since DMPA is given less frequently than NET-EN, cost per couple year ofprotection
(CYP) provides a more accurate cost comparison ofDMPA and NET-EN. Based on the
1999/2000 state tender price for Depo-Provera'" and Nur-Isterate'", the cost per couple
year was 28.68 South African Rands (ZAR) for Nur-Isterate'" (six vials per year) and
ZAR19.12 for Depo-Provera'" (four vials per year). If the calculation was based on the
Petogen®price, use of DMPA would have been even cheaper (ZAR17.16 per CYP). It
should be noted that the cost of syringes, needles and swabs, personnel costs and client
transport and time were not included in the calculations. These costs can be considerable
and are obviously higher for NET-EN because it is administered more frequently.
Analysis of annual expenditure on DMPA and NET-EN
In all four depots, both IPCs consumed an important share of total drug expenditure
(Table 1.4.15). A Pareto analysis shows that both DMPA and NET-EN appeared in the
top ten in each year (based on actual volumes multiplied by constant 1999 prices), with
the exception ofNET-EN in KZN where it was19th in 1997/8, 1998/9 and 1999/2000. The
items each accounted for between 0.55 and 2.73% of total spend in each year (Table
1.4.15).
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Table 1.4.15 Pareto analysis ofIPCs: 1997/8,1998/9,1999/00
*based on actual volumes multiplied by constant 1999 Depo-Provera and Nur-Isterate pnces
Pharmaceutical Depot Rank* (% of Total Spend on Drugs)
1997/8 1998/9 1999/00
GAUTENG
DMPA 3 (1.77) 4 (1.44) 4 (1.79)
NET-EN 2 (1.86) 3 (1.64) 2 (2.26)
KWAZULU-NATAL
DMPA 4 (1.64) 6 (1.82) 4 (1.82)
NET-EN 19 (0.55) 19 (0.62) 19 (0.68)
FREE SATE
DMPA 2 (1.99) 3 (2.25) 5 (2.73)
NET-EN 50.31) 50.55) 60.73)
PORT ELIZABETH
DMPA 3 (2.23) 6 (1.93) 3 (1.63)
NET-EN 4 (2.23) 4 (2.16) 4 (1.46).. ,IBJ
Ratio ofNET-EN:DMPA issued
The ratios of NET-EN:DMPA issued fromthe 4 depots, basedon CYPratherthan on
numberof vialsissued, are shown in Figure1.4.7. DMPA was increasingly used in Port
Elizabeth where the ratio decreased from0.64 in 1997/8 to 0.57 in 1999/00. In Free State
the market sharewasmoreor less stable(0.42, 0.44, 0.40). A similar picture emerged in
KZN (0.22, 0.23, 0.25), withsomeincrease in NET-ENuse. However, in Gauteng, while
DMPAwasstill issuedmost, NET-EN use was clearly increasing (0.67,0.73,0.81).

















*Ratio based on CYF
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The ratio of NET-EN to DMPA based on volume ofproduct (number of vials) issued and
on CYPs is provided in Table 1.4.16. The NET-EN:DMPA ratio , based on volume issued,
clearly shows that more vials ofNET-EN were issued by the Gauteng Depot over the
period being analysed. However DMPA is still more commonly used, as only 4 vials of
DMP A are administered annually, compared to 6 vials for NET-EN.
Table 1.4.16 Ratio ofDMPA and NET-EN issued: 1997-1999
Pharmaceutical Ratio Issued Ratio Issued Ratio Issued
Depot NET-EN: DMPA NET-EN: DMPA NET-EN: DMPA
1997/1998 1998/1999 1/4 to 7/31/99
Volume* CYP# Volume CYP Volume CYP
Gauteng 1.01 0.67 1.10 0.73 1.21 0.81
KZN 0.33 0.22 0.34 0.23 0.37 0.25
Free Sate 0.63 0.42 0.66 0.44 0.61 0.40
Port Elizabeth 0.95 0.64 1.07 0.72 0.86 0.57
*Ratio based on number of vials Issued; # Ratio based on couple years of'protection (CYP)
Counting the Cost of !PC product choice
If all NET-EN clients in the 1999/2000 (annualised) had been given DMPA instead, the
four depots together might have saved ZAR4.95 million. Conversely, ifNET-EN had
been issued to all DMPA clients, then the estimated additional cost in the same year for
the four depots would have been R9.35 million. Savings and additional costs would be
increased ifother costs (surgical supplies, personnel costs , client transport etc.) were
included. The savings are calculated on the annualised total CYP for Depo- Provera® and
Nur-Isterate'", If the price of the cheaper generic preparation (Petogen'") had been used in
the calculation, the savings would have been greater.
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For the 1999/2000 financial year, possible savings on expected IPC drug expenditure
were calculated assuming that all NET-EN users had been supplied with DMPA instead.
The estimated percentage saved for this financial year, for each depot, is provided in
Table 1.4.17. Likewise, the additional costs for a scenario where all DMPA users had
been provided with NET-EN were calculated (Table 1.4.17). In KZN for example, a
9.0% saving (on product cost alone) could be effected by supplying DMPA only. On the
other hand, if only NET-EN were available , the additional load on the expected annual
IPC drug bill would have been 36.5% (ZAR2.9 million for the 1999/2000 annualised).
Table 1.4.17 Expected savings (by supplying only DMPA) or additional costs (by
supplying only NET-EN) on expected expenditure on Il'Cs in the 1999/2000 fiscal
year
Pharmaceutical Depot % Savings % Additional expenditure
Gauteng 18.3 22.6
KZN 9.0 36.5
Free Sate 12.6 31.1
Port Elizabeth 15.4 26.9
Cost Analysis of[PC Utilisation Patterns in Hlabisa: A Case Study
Of the 848 women interviewed, 187 (22.1%) were using an injectable contraceptive
method, either DMPA or NET-EN. Forty-six per cent (86) of the IPC users were using
DMPA and 54% (101) were using NET-EN. The ratio ofNET-EN:DMPA users was thus
1.2 to 1. The Hlabisa Hospital provides health services including family planning services
to the Hlabisa sub-district. It is the only health facility in the sub-district and other health
facilities are far away across a game reserve. Thus almost all women living in the area
attend the Hlabisa Hospital or its mobile clinics for their health care needs, including
contraception, where this is required . An analysis of the Hlabisa Hospital family planning
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clinic records from July 1998 to the end of June 1999 reveals that the ratio ofNET-
EN:DMPA (based on CYP) issued to women during that period was 1.1 to 1. This is
consistent with the survey findings.
The annual cost of DMPA for the 86 survey respondents who were using it, based on the
1999/00 tender price of Depo-Provera" , would be ZAR1644 and the cost of an annual
supply ofNET-EN for the 101 survey users would be ZAR2897. The total annual cost for
supplying IPCs to the 187 women would be ZAR4541. It is estimated that there are 3910
women of reproductive age living in the sub-district of Hlabisa. With an IPC user
prevalence of22.1 %,864 women were likely to be using an IPC. Of these, 467 would be
using NET-EN and 397 would be using DMPA, which would cost the state ZAR20985
annually.
If IPC users in the district were only supplied with DMPA, the annual cost would be
ZAR16520. If only NET-EN was provided, the annual cost would be ZAR24780. By
supplying only DMPA, a saving of21.3% could be achieved, but by providing only NET-
EN, the cost would increase by 18.1%.
1.4.4.3 Rising Price of Generic DMPA Product and Net-En
The price of the generic DMPA product (Petogen'") increased markedly- from R2.07 in
the 1998/9 financial year to R4.29 in the 1999/00 year. This represents a 107.2% increase
in cost over a one-year period. In the 2000101 financial year, Depo-Provera" was cheaper
than Petogen" (Figure 104.8).
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97/8 98/9 99/00 2000/01 2001/02
Financial year
The priceof a Nur-Isterate" also continued to rise in the 2000/01 and2001/02 fiscal years
outstripping the cost of Depo-Provera" and Petogen" (Figure 1.4.8).
1.4.5 MAIN FINDINGS
Utilsation Patterns
Both injectable products were extensively used withoverhalf the respondents having
everusedoneor otherproduct. Morecurrent users of IPCs wereusingNET-EN than
DMPA(ratio ofNET-EN:DMPA use = 1.2:1).
User Characteristics
Age and education wereindependently associated withthe injectable product used.
Younger moreeducated women weremorelikely to be usingNET-EN.
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Reasons for Choosing the Injectable Method
• Health providers play an important role in contraceptive method choice. Health
worker recommendation was one of the most frequent reasons given for choosing an
IPC for current NET-EN users. For current and previous DMPA users and previous
NET-EN users, the main reason was that IPCs were effective.
• IPCs are regarded as a convenient method by users ofboth products.
• A few current NET-EN users indicated that it was a good method for young women-
a reason never put forward by DMP A users.
• Some DMPA (17.4%) and NET-EN (27.7%) users regarded amenorrhoea as a
positive effect of Il'Cs, giving this as the reason for contraceptive method choice.
Younger NET-EN users were significantly more likely to choose the method because
it caused amenorrhoea.
• About a third of both product users chose the method because it was a private method
that could be used without the knowledge ofpartners or others.
Reasons for Product Choice and Perceived Product Preference
• DMPA is regarded as the "stronger", more effective product and NET-EN as the
"weaker" or "lighter" product.
• NET-EN is regarded as the product of choice for younger, nulliparous and/or
unmarried women.
• NET-EN is regarded as less likely to delay return to fertility.
• Concern about side effects had little influence on product choice.
• Health worker recommendation was given as one of the most common reasons for
product choice, particularly by NET-EN users.
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Duration ofUse
Some women used IPCs for long periods of time, with DMP A users more likely than
NET-EN users to continue use beyond 5 years.
Reasons for Discontinuation
• Side effects, mainly amenorrhoea and heavy bleeding, were most commonly cited as
the reason for discontinuation.
• Heavy bleeding was significantly more likely to lead to discontinuation in the first
year of use.
• Younger DMPA users were more likely to discontinue use due to heavy bleeding.
This trend was also seen for NET-EN users, but it was not statistically significant.
• Wanting to conceive and no sexual partner were also common reasons for
discontinuation.
• Having a break (non-use segment) was sometimes given as a reason for
discontinuation.
• Discontinuation was often a result of a number of reasons.
Cost Analysis
• IPCs accounted for a substantial share of the total state expenditure on drugs.
• Of the two IPCs available on the EDL, DMPA was a cheaper option than NET-EN at
the time that the Pareto analysis was undertaken. Since then, the price ofNur-Isteratef
has continued to escalate with the per vial price ofNur-Isterate" exceeding that of
Depo-Proveraf and Petogen'" in the 200012001 and 200112002 financial years
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• DMPA was supplied to more women from the four depots than NET-EN.
• In Gauteng, while DMPA was still used by more women, NET -EN use was clearly
increasing. To a lesser extent, this is also true ofKZN. Gauteng and KZN are the two
most populous provinces, representing 18% and 21% of the population respectively
(Statistics South Africa, 1998). A shift to the more expensive product therefore has
important cost implications.
• Substantial savings could have been effected if more DMP A had been supplied. If
only DMPA was made available, the savings for the 4 depots over the three-year
analysis period was calculated to be 17%. In the H1abisa sub-district, savings as high
.
as 21% could have accrued.
• The price of the generic DMPA product was found to increase to the extent that there
was little difference between the costs of generic and innovator products.
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CHAPTER 1.5: RESULTS (Ill): EXPERIENCE OF SIDE EFFECTS
WITH INJECTABLE CONTRACEPTIVE USE AND PERCEPTIONS
OF EFFICACY AND REVERSIBILITY
1.5.1 EXPERIENCE OF SIDE EFFECTS
In this chapter self reported side effects of IPC users and discontinued users are
described. As can be seen from the literature review, little is known about side effects
experienced by African women and few studies have compared the two injectable
products. Many published reviews describe IPCs as a broad group, not differentiating
between the two products available. The results presented here are based on a cross-
sectional survey, not a randomized controlled trial. Nevertheless, some useful insights are
obtained as these findings provide a direct comparison between side effects experienced
by DMPA and NET-EN users at the time of use. IPC user and non-user perceptions of
IPC efficacy and reversib ility are also presented.
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1.5.1.1 Side Effects Reported by Current Users
Current injectable users were asked to indicate what side effects, if any, they were
experiencing with the injectable contraceptive method. They were first asked to respond
to an open-ended question about their experience of side effects. The most frequently
reported side effects were amenorrhoea, vaginal wetness, heavy bleeding and irregular
bleeding (Figure 1.5.1) and no statistical differences were found between side effects
reported by DMPA and NET-EN users .
Figure 1.5.1 Side effects most frequently reported by current DMPA and NET-EN

















Respondents were subsequently prompted to respond to a list of22 possible side effects.
In responding to this list, the majority of women (88.4%) reported that they experienced
at least one side effect and 7% reported 5 or more side effects. The side effects most
commonly reported were amenorrhoea (62.5%), vaginal wetness (18.4%), weight gain
(11.2%) and spotting (11.2%) (Table 1.5.1).
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The side effect profile for DMPA and NET-EN users was similar (Table 1.5.1) and no
significant differences were found between users of the two products in terms of their
experience of side effects. The side effects most commonly reported by both product
users were amenorrhoea, vaginal wetness and weight gain (Table 1.5.1 and Figure 1.5.2).
The side effect profile for DMPA and NET-EN users was similar with no significant
differences found in terms of their experience of side effects.
Table 1.5.1 Side effects reported by current NET-EN and DMPA users
Other SIdeeffects, reported by 5 or less respondents, were: half falls out (2.8), depression (1.1),
t breast tenderness (1. I) , swe~ting (?6), bloating of abdomen (0.6), bloating of breasts (0.6).
00 P.values were determined usmg Chi-square (1 degree offreedom, significance tested at the 5% level).
EIght respondents had very recently started injectable use « 3 months) and reported no side
effects . They were therefore excluded from this analysis.
# Includes thirty breastfeeding women. Although amenorrhoea was reported as a side effect of IPC use it
could have been lactational amenorrhoea. '
Side Effect* DMPA(%) NET-EN (%) P Value t Total %
(0=84) (0=95) (0=179) 00
Menstrual Irregularities
Amenorrhoea # 67.5 58.9 0.240 62.5
Spotting 9.5 12.6 0.510 11.2
Heavy periods 8.3 7.4 0.792 7.8
Irregular periods 3.6 10.5 0.074 7.3
Longer periods 2.4 4.2 0.497 3.4
Dysmenorrhoea 1.2 1.1 0.930 1.1
Vaginal Wetness 22.6 14.7 0.175 18.4
Weight Gain 14.3 8.4 0.214 11.2
Loss of Libido 10.7 8.4 0.601 9.5
Dizziness 10.7 6.3 0.289 8.4
Headache 10.7 4.2 0.094 7.3
Nausea 9.5 3.2 0.077 6.1
Vaginal Discharge 8.3 3.2 0.132 5.6
Vaginal Discharge with odour 7.1 3.2 0.223 5.0
Delayed return to fertility 0.0 1.1 0.346 0.6
Vaginal dryness 0.0 0.0 - 0.0
*
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Figure 1.5.2 Side effects commouly reported by current DMPA and NET-EN users
in response to the administration of a set list of possible side effects









Many ofthe users of both DMPA (73.2%) and NET-EN (80.4%) who reported
amenorrhoea as a side effect had been using the injectable for a year or more. By contrast,
all (n=7) DMPA users and 1 of the 7 NET-EN users who reported experiencing heavy
periods had been using the injectable for less than a year. A Cochran-Armitage Trend
Test was used to analyse the experience ofthe most frequently reported side effects
(amenorrhoea, heavy periods, vaginal moistness, and weight gain) over time for both
products. Heavy bleeding was significantly more likely to occur amongst DMPA users in
the first year ofuse (Cochran-Armitage statistic =-3.319; p=O.OOl). It is important to note
however that the number reporting heavy bleeding was small. Although not significant,
vaginal moistness was also decreasingly experienced over time by both DMPA and NET-
EN users (DMPA: Cochran-Armitage statistic =-1.567; p=0.117 ; NET-EN: Cochran-
Armitage statistic =-1.656; p=0.098). When combining the DMPA and NET-EN users so
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that the sample size was larger (33), the Cochran-Armitage Trend test for decreased
experience of vaginal moistness over time was significant (Cochran-Armitage statistic =-
2.394; p=0.017).
Findings from the prompted list of possible side effects were consistent with the
unprompted responses, but frequencies of reporting were higher especially for
amenorrhoea and vaginal wetness (Figure 1.5.2). In response to an unprompted question,
none of the women using contraceptive methods other than the injectable method reported
any of the side effects most frequently experienced by injectable users.
The side effect vaginal wetness was frequently reported by respondents. As the literature
review shows, this side effect is not clearly understood nor is it well documented. A
detailed analysis of both survey and focus group respondents' experiences and
perceptions ofvaginal wetness was thus undertaken. This analysis was published in the
journal Social Science and Medicine (2002, 55, 1511-1522) under the title 'Vaginal
wetness: an underestimated problem experienced by progestogen injectable contraceptive
users in South Africa'. A copy of the manuscript can be found on page xxxiv of this
thesis, just after the abstract.
1.5.1.2 Side Effects Reported by Previous Users
In response to a list of20 possible side effects, those most commonly reported by the
previous users of both products were heavy periods, amenorrhoea, vaginal wetness and
weight gain (Table 1.5.2 and Figure 1.5.3). The side effect profile for DMPA and NET-
EN users was similar in most respects , but significant differences were found between
DMPA and NET-EN in the reporting ofloss oflibido and longer periods . These two side
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effects were not however the most common ones reported. DMPA users were more likely
to report these two side effects than NET-EN users (Table 1.5.2). Not surprisingly,
respondents who had used both methods previously almost always reported more side
effects than those who had used either DMPA or NET-EN previously.
Table 1.5.2 Side effects most frequently reported by previous NET-EN and DMPA
users in response to the administration of a set list of possible side effects
Side Effect* DMPA NET-EN Both Total
(%) (%) 0/0 %
(n=138) (n=94) (n=10) (n=242)
Menstrual Irregularities
Heavy periods 39.9 34.0 60.0 38.4
Amenorrhoea 36.2 37.2 50.0 37.2
Longer periodst 13.8 4.3 10.0 9.9
Irregular periods 10.9 7.4 0.0 9.1
Dysmenorrhoea 7.2 2.1 10.0 5.4
Spotting 4.3 5.3 10.0 5.0
Vaginal Wetness 30.4 24.5 50.0 28.9
Weight Gain 21.0 12.8 30.0 18.2
Loss ofLibidJt 13.8 6.4 40.0 12.0
Dizziness 9.4 6.4 10.0 8.3
Headache 5.8 5.3 20.0 6.2
Nausea 8.0 2.1 10.0 5.8
Bloating of Abdomen 5.8 3.2 20.0 5.4
Delayed return to fertility 2.9 1.1 10.0 2.5
Vaginal dryness 2.9 1.1 0.0 2.1
* Other side effects were: hair falls out (2.1) , depression (1.7), sweating (1.7%) , breast tenderness (0.4),
bloating of breasts (0.4 %) (% based on DMPA + NET-EN users)
t Significant difference, p=0.017 (ldf), comparing side effects reported by those who had previously only
used DMPA or NET-EN
tt Significant difference, p=O.005 (2df), comparing side effects reported by those who had previously used
DMP A or NET-EN or both.
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Figure 1.5.3 Side effects commonly reported by previous DMPA and NET-EN users
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Up to 9 side effects were reported by both DMPA and NET-EN previous users. The mean
number of side effects for previous DMPA users was 1.9 and for previous NET-EN users
was 1.6. Although not significant, previous DMPA users experienced more side effects
than previous NET-EN users (OR=1.08; 95%CI: 0.87,1.34).
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As with current IPC users, respondents were first asked to respond to an open-ended
question about their experience of side effects. Once again findings from this unprompted
version of the question were consistent with the prompted responses for most side effects ,
but with lower frequencies of reporting (Figure 1.5.4 below). However, heavy bleeding
was reported almost as frequently as in the prompted version of the question. No
statistical differences were found between side effects reported by DMPA and NET-EN
users.
Figure 1.5.4 Side effects most frequently reported by previous DMPA and NET-EN
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1.5.1.3 Comparison of Side Effects Reported by Current and Previous Users
In analysing responses to the set list of side effects, similar side effects were reported by
current and previous users of both IPC products. However, whilst amenorrhoea was by
far the most frequently reported side effect for current users ofboth DMPA and NET-EN,
heavy bleeding was reported at very similar frequencies as amenorrhoea amongst
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previous IPC users (Figure 1.5.5). Greater differences were thus reported by previous
users compared to current users, than by users ofthe different products.
Figure 1.5.5 Comparison of side effects reported by current and previous DMPA
and NET-EN users
80 ,------ ------ - - --------- - - - - - - --
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Note regarding legend: (C) = Current users
(P) = Previous users
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1.5.1.4 Side Effects Reported in Focus Group Discussions
The composition of the focus group interviews is provided in Table 1.5.3 below.
Table 1.5.3 Composition of focus groups
Type of Group Number of Women Number of Men
(age range in years) (age range in years)
Sewing group 6 (34-59) -
Gardening group 5 (26-35) -
Community health workers 5 (34-47) -
Nurses attached to the district hospital 8 (25-55) -
Traditional healers 6 (35-60) 4 (48-74)
Church ministers 2 (47-48) 4(37-75)
Taxi drivers - 8 (24-48)
High school teachers 5 (23-37) 3 (26-28)
Primary school teachers 4 (23-33) 3 (26-33)
Parents 7 (30-60) -
Members of a school governing board 3 (44-59) 3 (29-57)
Grade 12 secondary school girls 8 (17-24) -
Grade 11 & 12 secondary school boys - 8 (18-23)
Grade 11 & 12 secondary school girls & boys 4 (17-18) 4 (21-24)
Number of women of reproductive age 50 -
(15-49 years)
TOTAL 63 37
During focus group interviews, the most commonly mentioned side effects of injectable
contraceptives were: vaginal wetness (14 groups), delayed return to fertility (13 groups),
heavy bleeding (12 groups), weight gain (12 groups) and amenorrhoea (10 groups). The
side effects regarded as the worst were vaginal wetness (9 groups), heavy bleeding (7
groups) and amenorrhoea (1 group).
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The problem ofvaginal wetness with injectable contraceptive use was raised repeatedly in
every focus group interview, and was raised spontaneously in the first instance. It came
up repeatedly in the discussions with the group of high school teachers (women and men),
with the group ofhigh school girls, with the traditional healers (women and men), with
the gardening group (women) and with the members of the school governing board
(women and men). Some comments about the experience ofvaginal wetness follow.
Focus group participants, men and women, made frequent reference to the problems of
"wetness" "coldness" and "tastelessness" with injectable contraceptive use. Coldness was
used in the context of the female partner being perceived to be sexually unresponsive or
losing her sexual appetite, and tastelessness as the female partner being sexually
unappetizing or undesirable. Examples of comments made are l4:
"People using the injection used to complain about vaginal wetness. They say their
partners do not enjoy sex with them and state that it all becomes a big dam. This vaginal
wetness is associated with coldness and you eventually lose sex appetite" (woman from
sewing group).
"They say a lot of things like the injection makes one to be always wet and sometimes
that their male partners complain that women who are using injection do not taste
good.. ..." (nurse). The group of nurses all agreed that women report experiencing vaginal
wetness with injectable contraceptive use.
" truly speaking our children are finished by this injection, they are big in sizes, they
are wet. There is another problem from the male side, I once overhead them talking saying
14 All quote s have been translated from Zulu .
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that it is much better to have sex with an old lady because she is not wet, teenagers are just
swimming pools" (woman traditional healer).
" injection makes them gain weight, not that they are fat, the body is just full of water,
and when having sex with such a person she is just a pool of water, you do not feel
anything" (male church minister).
"They [men] also say we become cold, wet and the vagina opens, as it opens you are
tasteless" (high school girl in the girls only group).
" a lot of men know that once she is wet she is using the pill or injection, so these
days secret is out. Men can sense that the woman is using contraceptive method"
(traditional leaders).
"The injection causes women to be wet and you as a man do not enjoy sex with such a
woman to the extent that if it is your girlfriend and not a wife, you can be sure that she is
from another man, she has been with someone else" (male member of the school
governing board).
" ..... .it [the injection] gets them into trouble; once she is wet the man would say she is
having an affair" (female member of the school governing board).
A more detailed description of side effects discussed in focus groups is documented in the
publication mentioned earlier in this chapter (entitled 'Vaginal wetness: An
underestimated problem experienced by progestogen injectable contraceptive users in
South Africa ').
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1.5.1.5 What Respondents Liked Least about DMPA and NET-EN
Both current and previous users ofDMPA and NET-EN reported similar dislikes about
the injectable method , most commonly reporting amenorrhoea, heavy bleeding, vaginal
wetness and weight gain as aspects they liked least. Amenorrhoea was the effect most
disliked by current users and heavy bleeding was most disliked by previous users. Again,
greater differences were reported by previous users compared to current users, than by
users of the two different pro~ucts.
The aspects liked least were consistent with the respondents' experience of side effects
described earlier in this chapter (Figure 1.5.5). However, whilst heavy bleeding was much
less commonly reported as a side effect by current users, many reported that this was
what they liked least about the injectable (Figures 1.5.5 and 1.5.6). Current users reported
that they disliked heavy bleeding almost as often as they reported a dislike for
amenorrhoea.
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Figure 1.5.6 Aspects liked least by current and previous DMPA and NET-EN users
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Effect
Heavy period Nothing
Note regarding legend: (C) = Current users
(P) =Previous users
1.5.2 PERCEPTIONS OF EFFICACY AND REVERSmILITY
This sub-section explores perceptions about the efficacy and reversibility ofDMPA and
NET-EN. The views ofall survey respondents: current injectable users, previous users,
those who have never used the injectable and of focus group participants are reported
here.
1.5.2.1 Survey Findings
Survey respondents clearly regarded both injectable products to be effective as shown by
the following findings:
• Efficacy was given as the characteristic current users and previous users liked most
about both products , with this response given by 77.6% ofcurrent DMPA users,
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76.2% of current NET-EN users, 75.2% of previous DMPA users and 77.5% of
previous NET-EN users.
• When directly asked, 97.8% of current users believed that it was an effective method,
with 2.2% not knowing whether or not it was effective.
Three previous IPC users discontinued use because they became pregnant by mistake -
one was using DMP A and 2 were using NET-EN.
Perceptions of efficacy and reversibility were also illustrated when survey respondents
were asked to state whether they thought women (in general) prefer DMPA or NET-EN,
and why they thought this to be the case (Table 1.5.4). Most respondents (51.1 %) thought
that DMPA was the preferred product and the main reason given was its perceived
effectiveness. DMPA was clearly regarded as "stronger" than NET-EN and NET-EN as
"weaker' than DMP A. It should be noted however that many respondents, especially
those who had never used an injectable contraceptive method, indicated that they did not
know which was the preferred injectable product (Table 1.5.4).
NET-EN was perceived to be the preferred product for younger, nulliparous and/or
unmarried women. This product was also considered not to delay return to fertility - a
view held particularly by previous injectable users (34.0% - Table 1.5.4). That NET-EN
is seen to be the preferred product for younger women is probably linked to the belief that
it is the "weaker" of the two products and less likely to result in a delay in return to
fertility. These findings are consistent with reasons given by current users for product
choice which are reported in the previous chapter (Chapter 1.4, Table 1.4.11) and are
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borne out by the age distribution of current DMPA & NET-EN users depicted in Figure
1.4.1 of Chapter 1.4.
Table 1.5.4 Reasons for injectable product preference
Current Users Previous Users Never Used (%)
(%) (n=180) (%) (n=242) (n=407)
~ Prefer DMPA (51.1 %) 56.7 66.5 39.6
Main reasons for preference
Effective 51.0 48.4 76.8
"Stronger" than NET-EN 11.8 10.1 6.5
Convenient 32.4 35.8 7.1
Good for married ~ 2.0
~ Prefer NET-EN (20.0%) 31.7 20.2 14.7
Main reasons for preference
Effective 12.7 7.5 11.9
"Lighter" than DMPA 44.4 41.5 47.5
Convenient 1.6 9.4 3.4
No delay if want to conceive 14.3 34.0 6.8
Less side effects than DMP A 12.7
Safe 7.9
Right for those still wanting 4.8 9.4 11.9
children; young ~ ; unmarried ~
Don't know which product is 11.7 13.2 45.7
preferred (28.7%)
1.5.2.2 Findings from Focus Group Interviews
Participants of the focus group discussions corroborated the survey respondents ' views
about NET-EN being "weaker" or "lighter" than DMPA and the perceptions that NET-
EN is intended for younger nulliparous women. Participants often alluded to their beliefs
that NET-EN won't, or is less likely, to delay fertility or cause infertility than DMPA .
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Which Contraceptive Method(s) were considered best for young women and which for
older women?
Focus group participants were asked what contraceptive method(s) were considered
"best" for younger or older women. Responses to this question were unprompted and
discussants were free to mention any methods , including traditional or modem methods.
Group participants had the following to say about DMPA and NET-EN:
"Even with injection there is one for the young people, the one for 2 months" .. .." (female
community health worker).
"Nur!Sis better for young people because it is weaker than Depo" which is too strong... "
(female high school teacher).
"Girls say, Nur is suitable for young people and the Depo for the older people" (high
school girl from group of girls and boys).
"Injectables (Nur) [for younger women]" (high school boy in the boys only group).
"Depo is good [for older women] because it stays a long time in the blood" (high school
teacher) .
"Injection (Depo) [for older women] " (high school boy in the boys only group) .
15 The one for 2 months or "Nur" were terms often used in referring to NET-EN
16 "Depo" was a term used in referring to DMP A.
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"There is an injection for older people which they call it Depo, they say it is good for
older people and to those who already have children because if you don 't have one it
makes you infertile" (high school girl in the girls only group).
The above comments show that DMPA was regarded as the more effective, stronger
product, more suitable for older women. The view that DMPA is more likely to cause
infertility was also expressed here. Also ofnote is that IPCs were often volunteered as the
appropriate method ahead of other methods such as the condom or the traditional
ukusoma (thigh sex) although this was not always the case.
Was DMPA or NET-EN regarded as the better product?
In response to a question about which was regarded as the better product, DMPA or NET-
EN, the following comments were made:
"I think Depo is better because it stays a long time in the blood, whereas with Nur, ifyou
did not take it when you were su~posed to then you get pregnant" (female community
health worker).
"Depo is better for older people" (female high school teacher).
"I think the two monthly Nur is right for the youth because I used to hear from girls
saying that, it is weaker than Depo. That weakness is what makes it lighter than Depo
making it have few dangers in one's body" (high school girl from group of girls and
boys).
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"What many people are saying is that , Depo is good for older people because it is strong,
so for those who have many children or the ideal number of children, Depo is good.
Because to them, getting a baby or not getting a baby is just the same" (high school boy
from group of girls and boys).
"I heard that Nur is right for the youth and Depo is for adults" (female parent).
"To me, it is Nur, which is better, the two monthly because I used to hear that it was
designed for young women and the Depo is for elder women and if you use it for a long
time, you end up having no children" (female primary school teacher).
"Nur is better for young people" (female member of sewing group).
"Nur is lighter and you get children at anytime after stopping using it and Depo is bad
because it make people to be infertile especially adults" (female member of sewing
group).
"Depo is strong and they say it takes a long time in the blood system and I also heard that
it is right for adults" (high school boy in the boys only group).
"Nur is right for the youth because of its weakness" (high school boy in the boys only
group).
"I heard that Depo causes infertility" (high school girl in the girls only group) .
"Depo is for older people whereas Nur is for young people" (high school girl in the girls
only group) .
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"Depo is strong whereas Nur is weak" (high school girl in the girls only group).
Again, DMPA was regarded as more effective than NET-EN, more suitable for older
women and more likely to cause infertility. On the other hand, NET-EN was seen to be
the better product for younger women, still wanting to have children. The high school girl
(comment 3 above) also believed that the "weakness" or "lightness" ofNET-EN made it
less harmful.
However, not all participants believed that one product is better than another as illustrated
by the following comments. Note however that the nurse (third comment hereunder) does
provide a restriction to the use ofDMPA for those not having at least three children.
"What I can say about the injectables is that they are the same but the difference is in
people's blood" (female high school teacher) .
"There is no injection we can say is better; we think it depends on the blood of an
individual. One can use Depo and encounter many problems and the other person can use
the same injection and do not encounter problems" (female member of sewing group).
"Depo has been made to suit all ages, it can be someone with a child or without. It is good
to everybody, the only difference comes in when people say, it has got side effects that is
one, delays return of fertility . That is not right, we tell people that it is nine to twelve
months one has to wait for the return of fertility before she can fall pregnant after
stopping using Depo . However on the other hand, Nur takes three to six months, so we
give everybody, young and old because, even those young girls, sometimes they are not
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prepared to come to the family planning clinic every two months for Nur, that is why we
give them Depo as well so that they can save transport money because some might be
coming from afar, as long as the person is para 3, being a young girl or a married women,
you get Depo" (female nurse).
Which injectable product was considered better for young women?
In response to a question which specifically explored whether DMPA or NET-EN was
considered the better product for young women, or those without children the following
comments were made:
"Nur is better because it is weak" (female high school teacher).
"Nur is better because Depo can cause sterility while with Nur you still can get pregnant
after use" (all participants ofthe sewing group - all women - shared this view).
"Young people must take Nur and even at the clinics they used to be given Nur and even
those who do not have babies must take Nur" (female community heath worker).
"Two monthly injection is better for those who do not have children because they can
easily get pregnant when they want to" (female community health worker).
"They [women without children] must use Nur" (female parent) .
"Nur [but] for those who do not have children yet. It is because the Nur is mild and the
Depo is strong. It makes the return of fertility quicker and easily, whilst Depo delays
fertility as it takes nine to twelve months" (female nurse) .
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"Nur is good and it is made for younger people" (female member of sewing group) .
"It is Nur because it does not make people to be infertile" (female member of sewing
group) .
"People without children must also use Nur because it is weak and is right for those who
are still looking to get children" (high school boy in the boys only group).
"Depo is good because young people used to go to the clinic once and they stay a long
time without going to the clinic" (high school boy in the boys only group).
"I know two kinds of injection, the first one is Depo Provera, that one is given to a female
who already have a child. The second one is Nur-Isterate which is given to school girls
with no children" (unprompted comment was made by a member of the group of taxi
drivers - all males) .
All but one of these comments indicate that NET-EN was regarded as the better product
for younger women or those without children. A member of the sewing group suggested
that NET-EN was "made" for younger people. Once again, a frequent conclusion drawn
was that NET-EN is weaker than DMPA and is therefore more appropriate for those
(often young women) still wanting to have children. However, one ofthe high school
boys regarded DMPA as the more convenient product for young women due to the longer
interval between clinic visits.
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Perceptions about reversibility
In addition to the references to the perceived effect of injectable products on fertility
made above, opinions about the reversibility ofDMPA and NET-EN were expressed as
follows :
"Pills are better because they prevent pregnancy and at the same time make you more
fertile unlike Depo which can sterilise you" (female high school teacher).
"Nur is best for teenagers because it does not disturb the cycle while Depo causes one not
to menstruate and as a result one becomes infertile. But all the same I would say it
depends with the blood of that person" (female high school teacher) .
"It depends on the period one has used an injection. If you have used an injection for
longer period you definitely have to wait a long time come to get a child after you have
stopped using it" (female high school teacher) .
"Even at the clinics they tell you that as you are taking Depo you will have some
problems of getting a child by the time you want it" (female high school teacher).
"Depo is good for the elder women. It is because, let us say you do not like to get babies
anymore, then if you use the Depo, fertility returns after a long time or not to get it at all"
(female nurse) .
"Other females end up not getting the child after using Depo" (female nurse).
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"With Nur, one definitely gets the baby after using it and even sooner than expected if she
has defaulted. Like one did not turn up on the specified date, she falls pregnant because
the return offertility is high and quick" (another female nurse) .
" . .. there are a lot of people I can mention, who used the Depo when it was still new in
the market , the people who were using it timeously, they never got children when they
wanted them , they became sterile" (another female nurse).
" ... with Depo it is very difficult to get babies after stopping using it. I once heard that if
you using it maybe for six months and when you stop it let say you want a baby, maybe
you have just got married, like you are twenty one years and your husband need a baby,
you will go from doctor to doctor without getting the baby until you get sacked by the
husband. And he will marry one who will get babies for him" (female primary school
teacher) .
"I heard that if you are a teenager and you want to start using a method you mustn 't start
using a Depo because it will make you infertile because it is very strong" (high school girl
in the girls only group).
"It is not good to take a Depo for quite a long time you must give yourself a break so that
it won't cause a problem of infertility" (high school girl in the girls only group) .
"When it comes to sterility I would say it differs with people because I know ofmany
people who used Depo and still got pregnant after stopping using it" (female high school
teacher).
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"I personally would like to differ [with those who say that Depo causes fertility problems]
and stress the point that it differs with people, some get pregnant immediately they stop
using injection and some wait for a long period" (female high school teacher).
With only two exceptions (see last two comments), all the comments made above reveal
the perception that DMPA delays return to fertility or even results in infertility, whereas
this is not the case with NET-EN.
In summary, in 11 of the 14 focus group discussions'", the perception that NET-EN was a
more appropriate injectable product for younger and/or nulliparous women was clearly
enunciated. Further, DMPA was frequently referred to as the "stronger" product of the
two and more likely to result in a delayed return to fertility. Within the groups, comments
about the efficacy and reversibility of the two products were more often made by female
members of the groups.
1.5.3 MAIN FINDINGS
Side effects
• Multiple side effects were experienced by users ofboth products.
• Similar side effects were most commonly reported, in similar frequencies, by users of
both products.
• Amenorrhoea was the side effect most commonly reported by current users and heavy
bleeding the most common amongst previous users.
17 The three groups who did not make any comments about the differences between the two products were
t~e chur~h ~inisters, the traditional healers and the school governing board. These groups were unable to
give their VIews on the two products as they were not familiar with them.
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• Greater differences in the experience of side effects were found between current and
previous users of IPCs than between users of the different products.
• Vaginal moistness was frequently reported as a side effect and appears to decrease as
duration of use increases.
• Aspects liked least by both DMPA and NET-EN users were amenorrhoea, heavy
bleeding, vaginal wetness and weight gain.
• Respondents regarded both products as highly effective, but DMPA is perceived to be
"stronger" and more likely to delay return to fertility. As a consequence, NET-EN is
regarded as the preferred method for younger, nulliparous and/or unmarried women.
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CHAPTER 1.6: DISCUSSION AND CONCLUSIONS
1.6.1 INJECTABLE CONTRACEPTIVE PREVALENCE AND USE
Contraceptive prevalence in the rural area ofKZN surveyed was only 30% compared to a
national prevalence of 62% reported by the South African Demographic and Health
Survey" (SADHS) which was conducted in the same year (Department ofHealth et al,
2002). Injectable progestogen-only contraceptives (IPCs) were widely used with over half
the respondents in the survey having used the method at some time, and nearly three
quarters , who were practicing contraception at the time of the survey, having used the
injectable method. Use of injectables among those practising contraception was thus
higher than that found in the SADHS for women living in non-urban areas and for
residents of KwaZulu-Natal (KZN) as a whole. This suggests that injectable use among
those practising contraception in deep rural areas may be higher than in urban and peri-
urban areas of South Africa.
Consistent with the SADHS, the injectable method was most widely used by young
women, with the highest prevalence amongst women in their teens and twenties. By
contrast, a recent study conducted in Nigeria amongst secondary schoolgirls (aged 14-21
years) found that the most popular contraceptive was the rhythm method, followed by the
oral contraceptive and withdrawal, used by 47%, 21% and 10% of sexually active
respondents respectively (Okpani and Okpani , 2000). The injectable method was used by
only 3% of these young women. In the Hlabisa study younger, more educated women in
married or stable relationships were significantly more likely to be using the injectable
method.
18 Contraceptive prevalence: percentage of sexually active women currently using a contraceptive method.
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Mean age at first contraceptive use was higher than mean age at first pregnancy. All but
six of the IPC users had been pregnant at some stage, and their mean age of first
contraceptive use was 3 years higher than the mean age of first pregnancy. Many women
who had ever used the injectable method had only one child. On the other hand many
who had never used the injectable method had no children. Having been pregnant was
found to be strongly correlated with injectable contraceptive use (Odds Ratio=12). This
suggests that contraceptive use commences some time after the first pregnancy, and, once
respondents had at least one child, those seeking a contraceptive method were likely to
opt for a very effective contraceptive method, the injectable.
Possible reasons put forward for young South African women initiating contraception
only after the first pregnancy are:
• Demonstration of fertility will enhance marriageability as documented by Preston-
Whyte (1990).
• Young women only receive adequate education about the need for contraception once
they attend for ante-natal care or delivery services (Garenne et a/2000).
A recent study of age-specific fertility rates in the Agincourt sub-district, a rural area of
South Africa, reports an atypical bi-modal pattern of fertility with underlying modes of
premarital fertility among women aged 18-20 years, and marital fertility among women
aged 28-30years (Garenne et a/2000). Pre-marital fertility accounted for 47% ofbirths
among women aged 12-26 years , but accounted for 21% of all births. A low incidence of
contraceptive use before the first birth, particularly among adolescents, and high
contraceptive uptake thereafter, are reasons the authors give for the high rate of pre-
marital fertility. In the Hlabisa study a similar trend was observed with regard to initiation
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of contraceptive use in relation to first birth. However, few women of any age were
married, and this was especially true for injectable users (Table 1.3.3), with only three
mothers under 25 years who were using the injectable being married. These low levels of
marriage have important social and economic implications for women, as many have to
fend for themselves or rely on extended families for support. The tendency for teenagers
to conceive because they have unprotected sex is further illustrated in a study undertaken
in Cape Town by Vundule et al (2001) where teenage pregnancy was found to be strongly
associated with having sex without reliable contraceptive protection (Risk Ratio:24.35).
Likewise Buga et al (1996) found that poor knowledge of contraceptives was a risk factor
for unprotected sexual activity among Transkei (now Eastern Cape Province) school girls.
In the Hlabisa study, the main contraceptive method used by women who were under 20
years was the injectable method. A higher proportion of younger women were using the
injectable contraceptive (84%) compared to the proportion of all the women surveyed
who were using the injectable (74%). The Cape Town study on teenage pregnancy also
found high rates of injectable contraceptive use amongst teenagers who had ever used
contraception (Vundule et al, 2001). While Garenne et al (2000) note a pattern of low
contraceptive use before adolescents delivered, followed by high use after delivery, these
authors did not report which contraceptive methods were used.
Conclusions and Recommendations
The pattern of contraceptive usage in South Africa is unlike that found in most other
countries in the world. This is important for policy makers , health planners, programme
mangers and trainers to note, as, while contraceptive prevalence in South Africa is
relatively high, there is great reliance on a single method (the injectable) , which offers no
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protection against HIV and other STls . Attention should focus particularly on the method
mix in deep rural areas, where injectable use may be even higher.
The contraceptive needs of young women should be addressed before their first
pregnancy, as many sexually active young women are unprotected not only against
unwanted pregnancy but also against sexually transmitted infections. The high rates of
premarital fertility are cause for concern and should be further examined as they
contribute to the social and economic vulnerability of women and children. Even after
initiating contraceptive use, the injectable method, adopted by most young women, offers
no protection against HIV/STls, bearing in mind that women under 30 years of age are
the hardest hit by HIV. Effective sexuality education programmes, which include
information about contraceptive options, are urgently required for young women since
they are particularly vulnerable to unplanned pregnancies and HIV/STIs.
1.6.2 METHOD MIX AND REASONS FOR CONTRACEPTIVE PRACTICE
The survey findings provide an extensive analysis of contraceptive use amongst rural
KZN women. The pattern oflow condom use and high injectable contraceptive use
reported in this study is consistent with findings from the SADHS (Department ofHealth
et aI, 2002) which was conducted at the same time as the Hlabisa survey. Given the high
prevalence ofHIV in rural areas of KwaZulu-Natal, the low use of condoms for
contraception requires attention. Only 11 women reported the male condom as their
current method, and none were using the female condom. The practice of thigh sex,
which may offer some degree of protection against HIV/STIs and pregnancy, was also
low, with only 3 women reporting that they use this method. Since the teenage pregnancy
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rate was also high, the need for effective, but appropriate, contraceptive methods is
clearly evident.
Developing an understanding of why women choose a particular contraceptive method
and recognising that many women do not need or wish to use a contraceptive method, and
understanding their reasons why, are essential to the provision of effective advice about
reproductive health, family planning and HIV/STI preventive measures. Findings from
the Hlabisa survey provide this insight and are discussed below.
Understanding Method Choice
While studies undertaken in South Africa have examined contraceptive prevalence,
contraceptive method mix, and reasons for method switching or discontinuation (Smit and
Venter, 1993; Reproductive Health Task Force et al, 1994; Chimere-Dan, 1996; Bailie et
al, 1997; Westaway et al,1997; Beksinska et al, 1998; Beksinska et al, 2001a; Smit et al,
2001; Department ofHealth et al, 2002), an extensive literature search revealed no
published studies which describe reasons for method choice amongst South African users.
This lack ofdata is addressed by the Hlabisa study. Health workers played an important
role in women's decisions to use injectable contraceptives, with many injectable users
indicating that they chose this method because it was recommended at the clinic. Only
two women using other contraceptive methods gave this as a reason for method choice.
While counselling and decision-making about appropriate contraceptive methods should
take into account and address the dual risk ofpregnancy and acquisition ofHIV/STls (Ott
et al, 2002; Mantell et al, 2003) , findings from the Hlabisa study suggest that there are
many missed opportunities for counselling about barrier methods to minimize the dual
risk of pregnancy and HIV acquisition. The need for South African family planning
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providers to assist in HIV/STI prevention was documented early in the 1990s (Abdool
Karim et al, 1992). However a recent survey in 89 South African public primary care
clinics found that only 12% of women were protected from STI and pregnancy at last
intercourse (Morroni et al, 2003) indicating that little progress has been made some ten
years later.
Other reasons ofnote for choice of the injectable method were that it was a convenient
and effective method that could be used secretly. The low use of condoms may be
explained by their failure to meet these criteria to the extent that the injectable does. The
need by some for secrecy particularly precludes the use of the condom which requires the
co-operation of the partner. Since over 90% of injectable users reported no personal
income, they are not in a strong position to negotiate condom use. For women who want
to prevent pregnancy without their partners' knowledge, the injectable remains a rational
choice. Where contraceptive efficacy is the criterion for method choice, women at risk of
HIV acquisition could be counselled to use condoms in addition to their hormonal
method. This "dual method" use approach is increasingly being advocated where
appropriate and practiced (Stanton et al, 1996; Mantell et al, 2003; Morroni et al, 2003).
An important observation from this study is that at least 10 respondents had embraced the
concept of dual protection against pregnancy and HIV/STls, indicating that they were
using the male condom or thigh sex because it provided protection against pregnancy and
STls.
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This finding is encouraging as it may indicate that educational messages aimed at
19 Since this study did not explicitly explore whether condoms were used concurrently with other methods
of contraception for STI/HIV prevention, it is possible that the number of women practicing dual
protection could have been higher. Exploration of dual protection practice was not an objective of this
study and is beyond the scope of this thesis.
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dual protection against unwanted pregnancy and HIV/STIs are reaching even remote rural
areas ofthe country, or that women are recognising the need for dual protection.
Amenorrhoea is frequently reported as a side effect that women do not like, and often
leads to method discontinuation (see Chapter 1.1). Yet, in the Hlabisa survey, while
amenorrhoea was a reason for discontinuation for some women, nearly a quarter of
injectable users, particularly the young NET-EN users, regarded amenorrhoea as a
positive effect and chose the method for this reason. This may be an indication that
younger women, who are often more educated, have a greater understanding of
reproductive biology and do not regard the lack ofmenstruation associated with injectable
use as a sign ofpathology. It may also reflect a modernization of younger women who
may be less concerned about the notion of womanhood embodied by menstruation. It is
possible also that health providers give good counselling with regard to injectable side
effects. It is clearly more convenient, especially for poor rural women with limited access
to water, not to menstruate.
A recent study undertaken amongst family planning clinic clients and providers in China,
South Africa, Nigeria and Scotland showed that the majority ofBlack African women,
particularly those from Nigeria, liked menstruating (Glasier et al, 2003). These authors
felt however that providers overestimate the importance of regular menstruation. In the
Hlabisa study, whilst many women did not like amenorrhoea associated with IPC use,
some women, particularly NET -EN users regarded amenorrhoea as a positive effect of the
method. Providers should take this into account as it may affect their counselling
approach.
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Understanding Why Women are not Currently Practising Contraception
Few studies have explored reasons for non-use of contraception. The 1998 SADHS
(Department of Health et al (2002) sought this information, but only amongst married
women not using a method and not intending to use contraception in the future. The main
reasons given by these women for non-use were: desire for more children, health
concerns, and opposition to family planning on the part of the respondent or partner. For
the older women, being menopausal, having had a tuballigation and sub-fertility were
also frequently given reasons. One other study on this topic, a qualitative study amongst
40 adolescents in the Northern Province of South Africa, was found (Wood et al, 1997).
In this study, the main barriers to contraceptive use among the adolescents were the
experience or fear of side effects, and harassment by clinic nurses, who regarded them to
be too young to be sexually active (Wood et al, 1997). Vundule et al (2001) examined
risk factors for teenage pregnancy, but regretted that they did not sufficiently explore
reasons for not using contraceptives in this study. Developing an understanding ofwhy
women choose a particular contraceptive method and recognising that many women do
not need or wish to use a contraceptive method, and why, are essential to the provision of
effective advice about contraception and HN preventive measures. The Hlabisa study
explored reasons for non-use of contraception and findings assist in the development of
pragmatic guidelines for counselling women about appropriate contraceptive options as
suggested below.
Over two thirds of the Hlabisa women interviewed were not using a contraceptive
method. Many had never been sexually active or were sexually inactive at the time, and
these women were not at risk ofunwanted pregnancy or infection. However nearly 40%
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of the non-users were estimated to be at risk of an unplanned pregnancy and even more,
including those who were pregnant or wanting to conceive, were at risk of acquiring HIV.
Common reasons given for not practicing contraception were similar to the SADHS
results with 'not needing a method' followed by being opposed to contraception and
method related reasons e.g. side effects and health concerns. Unlike the study by Wood et
al (1997) few women attributed non-use to service provision factors.
Many of the women had migrant partners who were absent for long periods of time and a
reason put forward for not practising contraception was infrequent sexual intercourse.
These women 's contraceptive needs are intermittent and often unpredictable and they
may be reluctant to use the injectable, with its poor side effect profile, continuously. For
these women, provider counselling, which promotes injectable use, is inappropriate.
Provided the partner was willing, the condom (male or female) may be a more
appropriate contraceptive option for them, particularly as a dual protection method, since
several studies have shown that migrants are at greater risk ofbeing infected with HIV
and other STls (Lurie, 2000).
The "use a condom" message, which generally refers to male condoms, is also
inappropriate for women whose partners refuse to use male condoms. The female condom
was not widely available in South Africa at the time of the Hlabisa survey. However, the
national female condom introductory strategy launched just prior to the survey, is being
expanded to more public sector health facilities (Mqhayi et al, 2003). Preliminary
evaluation of this introductory programme suggests that some women may be able to
negotiate use of the female condom more easily than the male condom (Mqhayi et al,
2003). This will make this female controlled method more widely available. However, it
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should be noted that two female condom acceptability studies undertaken in South Africa
have reported a mixed reaction to the acceptability ofthe female condom (Sapire, 1995;
Beksinska et al, 200lc). The cost of the female condom compared to the male condom
is a barrier to widespread distribution of this method (J Wilson , Logistics Advisor:
Chief Directorate HIV/AIDS and STls, pers . comm., March 2003). Nevertheless, the
female condom should be offered to those women who cannot negotiate use of the male
condom.
Conclusions and Recommendations
The importance of individualized contraceptive counselling tailored to women's specific
circumstances, including their risk of HIVISTI acquisition, is clear from this and other
studies (Mantell et al, 2003). Health workers play an important role in decision-making
about contraception, and are highly influential in the choice of the injectable method in
South Africa. They may be happier to promote condom use over the injectable method, if
they are reassured about barrier method efficacy. Promotion of the use of emergency
contraceptive pills, as a back-up to condom use, may also result in increased likelihood of
the promotion of condoms instead of injectables.
The choice of contraceptive methods available in public sector clinics is limited. The need
for greater access to female controlled methods like the female condom, which also
protect against HIV/STls, should be addressed. A high priority for education intervention
strategies are programmes which enhance women's ability to negotiate male condom use.
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1.6.3 INJECTABLE CONTRACEPTIVE PRODUCT MIX
Although not extensively documented, it is claimed that there has been a shift away from
the predominant use ofDMPA in South Africa, to NET-EN, especially amongst younger,
nulliparous women (Beksinska et al, 1998; Wood et al, 1997; Beksinska et al, 200la).
Prior to the Hlabisa study, no study in South Africa (and perhaps the world) has
specifically examined the injectable product mix. The WHO's Medical Eligibility Criteria
for Contraceptive Use classifies DMPA and NET-EN together (World Health
Organization, 2000). The Primary Health Care Essential Drugs List for South Africa
provides no guidelines with respect to the circumstances under which DMPA rather than
NET-EN should be prescribed, or vice versa(National Department ofHealth, 1998).
In the Hlabisa survey, both injectable products were extensively used, with more
respondents using NET-EN than DMPA. The main predictor for NET-EN use was
younger age. This trend seemed largely to be based on the perception that NET-EN was
the "weaker" of the two products and would be less likely to result in delayed fertility for
those still wanting to have children. DMPA was clearly regarded as the more effective
("stronger") product. This perception was inextricably linked to perceptions about method
reversibility and was shared by many of the household survey respondents and by
participants of the focus group discussions which included community health workers,
nurses and teachers. Further, health workers appeared to play an important role in
decision-making about which IPC product was provided. These findings are consistent
with results from a study undertaken in the Northern Province of South Africa where
providers were found to recommend NET-EN for younger women based on their
perception that DMPA use may result in permanent infertility, whilst NET-EN was
considered ".... less strong and 'usually reversible' 11 p. 13 (Wood et al, 1997).
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As illustrated in the literature review (Chapter 1.1), both IPC products are demonstrably
highly effective and there is no reason to provide one product over another on the basis of
efficacy. Further, there is no evidence that one product has a better safety profile than the
other. Although menstrual irregularities are reported in the literature to occur more often
with DMPA than with NET-EN, in the Hlabisa study side effects appeared to have had
little influence on whether DMPA or NET-EN was used. While return to fertility is
reported by some reviewers to be more rapid with NET-EN (Fraser and Weisberg, 1982;
Howard et al, 1985), others (Bigrigg et al, 1999) have suggested that there is no delay in
return to fertility with DMPA use if one considers the methodological bias of early
studies, which did not take into account the date ofthe last DMPA injection.
Age as a criterion for prescribing one or other IPC product on the basis ofreversibility is
also not supported by the literature. Some policy documents and publications specifically
debunk the notion that IPCs should be restricted according to age. For instance, Lande
(1995, p.?) recommends that: "Providers may need to reassure clients and the public that
injectables do not cause infertility but to note that women should expect a wait of some
months after stopping injectables to become pregnant. Service policies based on a fear of
infertility - in particular, age and parity restrictions - can be dropped". In the first edition
of the WHO Medical Eligibility Criteria for Contraceptive Use (World Health
Organization, 1996) the only restriction made in relation to age and IPC use, was that
'For women under 16 years of age, there are theoretical concerns regarding hypo-
oestrogenic effects due to POC use" p.54 (POC refers to Progestogen-only
contraceptives). This restriction was applied to IPCs in general, not to one or other
product. In the second edition of the WHO Medical Eligibility Criteria for Contraceptive
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use (World Health Organization, 2000) this restriction has been revised as follows: "For
women under 18 years of age, there are theoretical concerns regarding hypo-oestrogenic
effects particularly due to DMPA use." and, "For women greater than age 45, there are
theoretical concerns regarding hypo-oestrogenic effects particularly due to DMPA use,
and whether these women will regain bone mass after discontinuation of DMPA."
(Progestogen-only contraceptives - p.1). The WHO does not however advise that NET-
EN rather than DMPA should be used by women under 18 years or over 45 years.
Further, for these younger and older women, DMPA and NET-EN are assigned the same
medical eligibility category (2), where the advantages ofusing a method are considered to
outweigh the theoretical risks (2000). The WHO applies no restriction to the use of
progestogen-only contraceptive methods by nulliparous women. The South African
Department of Health's National Contraception Policy Guidelines (2001, p.25)
specifically states that: "Young clients should not be prevented from using either DMPA
or NET-EN because of their age."
A cost analysis ofthe supply patterns ofIPCs from four pharmaceutical depots showed
that they accounted for a substantial share of the total state expenditure on drugs in South
Africa. Of the two IPCs available on the South African Essential Drugs List (National
Department of Health, 1998), DMPA is a cheaper option than NET-EN, even if only
considering acquisition costs . The analysis showed that if all NET-EN clients had been
given DMPA, between 9% and 18% of the expected annual drug bill for IPCs could have
been saved per depot.
In highlighting key issues in financing family planning services in Sub-Saharan Africa,
Janowitz et al (1999, p.64) make the following statement "Given limited resources, the
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universal provision ofmethods based on demand and without regard to cost will restrict
the number of individuals whose need for family planning services can be met". The
balancing of needs and resources becomes even more challenging when attempting to
meet reproductive health needs more broadly. For instance, in developing countries like
South Africa many drugs such as antiretrovirals for HIV treatment are not available
through the public sector since they are not affordable. Despite the growing demand for
access to the female condom, distribution by the Department ofHealth is currently
limited to 214 of approximately 5,000 public sector clinics across the country (M
Beksinska, Director, Reproductive Health Research Unit , pers. comm., May 2003)
because of the high cost of the female condom compared to the male condom. The price
of the female condom is about 55 US cents while the cost of the male condom is 2-3 US
cents. Careful analysis of current expenditure on drugs is thus required so that resources
can be allocated to meet changing therapeutic needs.
Rational use of drugs cannot be based on financial criteria alone and clinical criteria, such
as efficacy, reversibility, acceptability of side effects, discontinuation patterns and safety
must also be considered. The World Health Organization's general criteria - safety,
affordability, necessity and efficacy (SANE) - for inclusion on the Model List of Essential
Drugs (EDL) (Kanji , 1992) provide a useful basis upon which to make decisions about
drug selection and rational use. Ifone were to embrace the WHO promoted Essential
Drugs concept (Kanji , 1992) the decision about which IPC to supply should be made on
cost since DMPA and NET-EN have comparable efficacy and safety profiles. Based on the
cost analysis presented in this paper, DMPA should be the product selected. However,
reducing contraceptive options, flies in the face ofprogressive reproductive health policies
which promote expansion of contraceptive choice. For instance, the WHO "is giving
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priority to improving access to high-quality care in family planning through a variety of
strategies" (World Health Organization, 2000, p.2), and lists one ofthese strategies as
"promoting the widest availability ofdifferent contraceptive methods so that people may
select what is most appropriate to their needs and circumstances", p2. The Programme of
Action adopted at the International Conference on Population and Development held in
Cairo in 1994 recommended that family planning programmes should "Recognize that
appropriate methods for couples and individuals vary according to their age, parity, family-
size preference and other factors, and ensure that women and men have information and
access to the widest possible range of safe and effective family-planning methods in order
to enable them to exercise free and informed choice" (United Nations Population
Information Network, 1994, p.39/132). The Population Council's approach to contraceptive
introduction in developing countries involves an assessment of the context of contraceptive
use in that country, on the basis ofwhich "recommendations for upgrading contraceptive
services - which could include introducing new methods, improving the utilisation of
existing ones, and/or removing one or more from the method mix" (Population Council,
1996, p.1).
The injectable contraceptive method is an important option in South Africa, since some
women choose this method because its use does not require partner knowledge or consent
(Kaufinan, 1997). In cases where side effects such as amenorrhoea are particularly
problematic with DMPA, NET-EN may be a good alternative. By providing NET-EN
explicitly as a second-line option, the range ofcontraceptive products would be restricted,
but not reduced. Such a policy should not be considered to overly restrict choice since, even
in the western world only one product (usually DMPA) is available.
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Arising out ofthese findings, a Cochrane systematic review ofDMPA and NET-EN is
underway. The Fertility Regulation Group of the Cochrane Collaboration has accepted a
proposal from the author of this thesis for a review to be undertaken. The registered title
is: A comparison between the progestogen-only injectable contraceptives depot
medroxyprogesterone acetate and norethisterone oenanthate for contraceptive use. The
protocol is currently being developed and the review will be submitted as a master's
dissertation by Dr B Draper, under the supervision ofMargaret Hoffman, in the
Department of Public Health of the University of Cape Town.
Also of importance in regard to health care costs is that, while use of generic drugs is
promoted in the South African National Drug Policy (Department of Health, 1996) as a
cost-containing mechanism, the price differential between the generic and innovator
DMPA products, appeared to be almost negligible. The rising cost of generic medicines
is documented in an editorial in the British Medical Journal which states, in relation to the
United Kingdom National Health System: " ... these price rises threaten to undermine the
development ofprimary care groups and suggest that the market for generic drugs can no
longer remain unregulated." (Walley and Burrill, 2000, p.l Jl ).
Conclusions and Recommendations
There is no reason to provide one injectable product over another on the basis of efficacy,
reversibility, discontinuation or safety. In the Hlabisa study side effects appeared to have
had little influence on whether DMPA or NET-EN was used. Providing IPCs on the basis
ofage is not appropriate or cost effective. Training ofhealth workers and counselling of
clients to correct this misconception is clearly required. Where clients require immediate
return to fertility upon discontinuing contraception, neither IPC preparation is ideal. Since
196
DMPA is a cheaper option than NET-EN, health worker training about the rational use of
injectable contraceptives should include consideration of the cost implications of
prescribing one product over another. DMPA should be considered as the first option, but
where DMPA is not well tolerated, NET-EN should be available as a second option. The
price of the generic DMPA product in relation to the innovator product should be further
investigated. Consideration should be given to encouraging the registration of the combined
injectable contraceptive in South Africa, which has a better side effect profile than the IPCs
(Kaunitz et al, 1999). This would be an expensive option thus combined injectable
contraceptives should only be provided where side effects with the IPCs are intolerable. A
better contraceptive option, especially for young people, might however be the male or
female condom with back up of emergency contraceptive pills to provide dual protection
against unwanted pregnancy and HN and other sexually transmitted infections.
1.6.4 DISCONTINUATION RATES AND REASONS
Most discontinuation rates are derived from clinical trials, women attending health
facilities and clinic record reviews, thus data from women lost to follow-up are seldom
included in the analysis. In the Hlabisa study women were randomly selected at
household level and discontinuation rates were calculated on all discontinuers in the
selected sample. Cultural, religious and personal attitudes influence perceptions about
injectable use and especially menstrual side effects. Generalization of findings from
international discontinuation studies to South African users may not be appropriate. Since
unwanted pregnancy and teenage pregnancy rates in South Africa are high (Smit et al,
2001; Department of Health et al, 2002), it is important to have data on local
discontinuation rates and to develop an understanding about reasons for discontinuation
of the most commonly used contraceptive method.
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The discontinuation rates for injectable contraceptive use were high among the rural
Hlabisa women who had previously used the method. Notably, more women respondents
had discontinued IPCs than were current users, and few previous users were found to be
using another contraceptive method with hardly any (n=28; 16%) protected against
pregnancy. One reason for the low contraceptive prevalence in discontinued injectable
users may be the limited choice ofmethods available in public clinics.
Cumulative discontinuation rates ofDMPA and NET-EN at two years (68% and 78%
respectively) were higher than the discontinuation rate (41%) reported in a study on urban
injectable users in Soweto Johannesburg (Beksinska et ai, 2001a). However the Soweto
figure did not include those lost to follow-up. There are no published discontinuation
rates for injectable users among rural South African women. The Hlabisa discontinuation
rates were similar to those reported in the WHO two year multinational comparative
randomized trial which compared the two injectable products in 13 centres (n=3172)
(Table 1.1.4, World Health Organization, 1983). However, in the WHO study, the rates
varied widely between regions with discontinuation rates in the two sub-Saharan African
countries reported to be 62% (Nigeria) and 92% (Zambia) after two years of use.
Despite the high discontinuation rates after two years, some Hlabisa women had used
IPCs for long periods of time. As in the Soweto study, no difference was found in
continuation rates for DMPA and NET-EN amongst Hlabisa IPC users. However DMPA
users were more likely to continue using the method for longer periods (beyond five
years). Since the NET-EN users were younger, one could speculate that more stopped
using the method, after shorter periods of use, to have a baby. Women who experienced
heavy bleeding and those who were younger were more likely to discontinue the method.
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Reasons for discontinuation amongst previous IPe users were similar to those reported in
the literature with side effects , particularly amenorrhoea and heavy bleeding most
commonly cited. As in other studies, heavy bleeding was commonly the cause for
discontinuation in the first year of use and amongst younger users. One reason for
discontinuation rarely reported in the literature, but fairly commonly reported in the
Hlabisa study was the experience of "vaginal wetness". Only one other study, also a
South African study has ever documented a 'watery discharge' as a reason for
discontinuation (Beksinska et al, 2001b). This was reported as a reason for
discontinuation less frequently than vaginal wetness reported by rural Hlabisa injectable
users (4 % versus 8%). Weight gain and vaginal wetness were the third and fourth most
common reasons for discontinuation. The experience ofvaginal wetness is explored more
fully in the next sub-section.
"Taking a break,,2o was reported as a reason for IPe discontinuation in the Hlabisa
survey. Temporary discontinuation has been documented in studies undertaken in
Johannesburg, South Africa (Beksinska et a11998; Beksinska et al, 2001a) . It has also
been reported in IPe studies undertaken in Kenya and the USA (Sekadde-Kigondu et al,
1996; Potter et al, 1997; Polaneczky and Liblanc, 1998; Potter, 1999) and for oral
contraceptive use (Forest and Silvennan, 1989, Sekadde-Kigondu et al, 1996). It has been
suggested that temporary discontinuation be regarded as an adherence problem, which
could lead to an unwanted pregnancy. It may occur because some women want to see
menses (Beksinska et a11998; Department of Health et al, 2002) and may be encouraged
by an incorrect belief that the method provides protection as long as women are
amenorrhoeic (Beksinska et al, 2001a). It may also occur where women are advised that it
20 Sometimes referred to in the literature as a non-use segment (Beksinska et al, 1998).
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could take up to year to conceive after discontinuing the injectable and thus mistakenly
believe that they are protected against pregnancy for a year after injection (Potter, 1999).
Three respondents in the Hlabisa study reported that they stopped using the injectable as
they became pregnant. Reasons for these cases of method failure were not explored, but
could indicate an adherence problem, with defaulters returning late for the next scheduled
injection appointment. Other studies amongst South African injectable users have found
that women do return late for their next scheduled dose (Dickson-Tetteh et al, ' Profile of
women accessing termination of pregnancy services under the new legislation'
unpublished observations, cited in Beksinska et al, 2001a, p.12), and may be under the
impression that the method is protecting them as long as they are amenorrhoeic. A delay
in returning for the next injection would be more likely to affect the efficacy of NET-EN
than ofDMPA.
Injectables were often discontinued for more than one reason with respondents reporting
up to five reasons and significantly more DMPA users giving more than one reason. It is
simplistic therefore to assume that discontinuation is based on only one reason.
Conclusions and Recommendations
Discontinuation rates for injectable contraceptive use among rural women were high.
Even though contraceptive prevalence in South Africa is high, so are the rates of teenage
and unwanted pregnancies. Counselling to improve rates of continuation and adherence to
dosing regimens could impact positively on unwanted pregnancy rates. More data on
discontinuation patterns among South African users is needed as so few studies have been
undertaken. Further studies should take care to define discontinuation criteria clearly,
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differentiating between poor adherence and discontinuation. The experience ofvaginal
wetness as a reason for discontinuation also needs to be explored further. The multiplicity
of reasons for discontinuation is seldom commented on in the literature, but is important
to take into account when counselling injectable users. Discontinuation rates with DMPA
and NET-EN are not different and should not form the basis for advising use of one rather
than other.
1.6.5 SIDE EFFECTS WITH INJECTABLE CONTRACEPTIVE USE
The Hlabisa study provides the first comprehensive account of the experience of side
effects amongst South African IPe users. Uniquely, it documents the experience of
current and discontinued users ofboth DMPA and NET-EN users. It is evident from the
previous section that side effects are instrumental in decisions to discontinue the method
and a good understanding of the undesirability of side effects experienced by South
African users is crucial for effective method counselling.
In general, the side effect profile experienced by the Hlabisa injectable users was similar
to those reported in other studies. Users experienced many side effects with the method,
but despite this, it continues to be the most popular method. Amenorrhoea was the most
commonly experienced side effect among current users and heavy bleeding most
common amongst previous injectable users . Heavy bleeding was also a more frequently
mentioned side effect than amenorrhoea in focus group discussions. This suggests that
injectable users are more likely to discontinue use because ofheavy bleeding rather than
because of amenorrhoea. Side effects reported by DMPA and NET-EN users were
similar. In fact, greater differences were reported between previous and current users than
by users of the different products.
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Unlike other studies , a side effect translated from the vernacular as "vaginal wetness",
was a frequently reported side effect by both current and previous IPC users in the
Hlabisa study. It was also found to be what many of the women liked least about using
the method. Consistent with findings from the study by Beksinska et al (2001b) it seemed
to be experienced more often in the first few months of use. It was also a recurrent theme
in focus group discussions and was identified as the worst side effect in the majority of
focus group discussions. Vaginal wetness is a side effect that is not well accepted in the
study area, and may result in method discontinuation. Many comments made in focus
group interviews convey the negative way in which vaginal wetness is regarded and the
negative impact it may have on the enjoyment of sexual intercourse and on relationships.
It is noteworthy that some survey respondents who did not report it as a side effect (41%)
were clearly concerned about the possibility of experiencing it, as they listed this as a
reason for least liking the injection.
This side effect is discussed in some detail here as there is little reference to it in the
literature. More detail is also provided in a paper on these findings published in Social
Science and Medicin e (copy included in the section after the abstract on page xxxiv of this
thesis). Vaginal wetness was reported separately from vaginal discharge, and vaginal
discharge with an unpleasant odour, the latter two being reported less often. Whilst the
nature of the difference in the experience of vaginal wetness and vaginal discharge was
not explicitly explored in the survey, different Zulu phrases were used in referring to
vaginal wetness and vaginal discharge. The distinction was identified in the development
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and translation of the interview schedule prior to commencing the survey and has been
corroborated with Zulu/English translators subsequently (ZGwamanda, Medical Research
Council, MKubeka, R Ngcamu, Africa Centre for Population Studies and Reproductive
Health , pers. comm., September 1998; W Dlamini, D Msweli , Medical Research Council ,
pers. comm., October, 2000). The approximate English translations ofZulu concepts or
commonly used phrases (in brackets) were:
• Increased vaginal moisture or wetness (Ukubamanzz)
• Vaginal discharge (Ukuphuma kokeJsheziebulilinibawesimame)
• Vaginal discharge with unpleasant odour/smell (UkuphumakokeJsheziolwzephungaeliht).
Respondents in the survey were not asked to describe vaginal wetness, however
reproductive health workers suggested that it is of a watery consistency (N Ntuli ,
Research Nurse, Medical Research Council, pers.comm., September 1999) and
discussants in the focus groups also described it as a watery substance which occurs in
excessive quantities. Vaginal discharge reported by injectable users is also described as
watery by Beksinska et al (2001b). Female participants in a study described by Brown et
al (1993a) distinguish between three types ofvaginal secretions - (i) secretions which
occur in small amounts at certain stages of the menstrual cycle and during sexual arousal;
(ii) excessive secretions described as ' too much water ', resulting in a 'wet vagina'; and
(iii) unusual discharges resulting from infections. The second type of secretion described
by Brown et al (1993a) is consistent with the description of vaginal moistness which the
KZN focus group respondents associate with injectable contraceptive use. As described in
the literature review (Chapterl .1) early studies, the Petogen'" product brochure and the
more recent study in Soweto, South Africa (Beksinska et aI, 2001b) describe vaginal
discharge as a side effect, whereas respondents in the Hlabisa survey differentiate
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between vaginal wetness and vaginal discharge, both ofwhich are reported as side effects.
It is not clear whether the early reports of vaginal discharge, and the vaginal wetness
reported in the present study, are analogous. Whether either of these effects is in reality a
consequence of injectable contraceptive use is also unclear, and if so the mechanisms by
which they occur are not understood.
According to almost half the respondents in the Hlabisa survey, men regard women who
use the injectable contraceptive as "wet", "cold" and/or "tasteless. Women also stated that
the reason men dislike the injectable was because they believe that women who use it
misbehave. Injectable users are clearly concerned about the response of their male
partners to vaginal wetness thought to be produced by injectable use. Likewise, in focus
group discussions, women using the injectable method were frequently described as wet,
cold and/or tasteless and were sometimes perceived as being unfaithful or promiscuous.
This notion can only serve to deepen the disempowerment experienced by many South
African rural women. Beksinska et al (2001b) also reported that men disliked the increased
vaginal discharge which they linked to injectable use. Since some South African men may
prefer dry sex the perception that the injectable contraceptive increases vaginal wetness
may be problematic for women who use it.
Previous studies have shown that women in many parts of Central and Southern Africa
have a preference for "dry sex,,21 ,22 (Brown et al, 1993a; Brown et al, 1993b; Civic and
Wilson, 1996; Morar and Abdool Karim, 1998; Beksinska et al, 1999; Brown et al,
21 The ~ractice ofdry sex is defined as the drying, tightening, and sometimes warming of the vagina for
~~xual intercourse (Brown.et aI, 1993a; Dallabetta et aI, 1995; Beksinska et aI, 1999) .
Only so~e ofthes~ studies were conducted exclusively amongst commercial sex workers and the practice
of dry sex IS not restncted to commercial sex workers.
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2000). For instance, in a study undertaken in Zaire (now the Democratic Republic of
Congo), Brown et al (1993b) found that "Both men and women expressed a definite
preference for dryness and tightness, saying that when a woman 's vagina is moist or
large, neither she nor her partner experience full sexual pleasure" p.97. Further,
Beksinska et al (1999) found that 60% of men and 46% of women surveyed in Orange
Farm, South Africa expressed a preference for dry sex. One of the main reasons for
practising dry sex given by both men and women respondents was that it shows that the
woman is not promiscuous. Another reason given, but only by women, was "for partner
satisfaction" (Beksinska et al, 1999). Where dry sex practices are preferred women resort
to potentially harmful measures to dry, tighten and warm their vaginas (Ba1eta, 1998;
Beksinska et al, 1999). Injectable contraceptive users who perceive that use of the
injectable results in increased wetness may well resort to these practices.
Increased vaginal wetness linked with the most popular contraceptive method used in
South Africa, is clearly a problem which must be regarded seriously. At this stage there is
no explanation for this side effect widely reported by women in the H1abisa study as well
as by family planning service providers. It is possible that, even ifwomen from western
countries have experienced vaginal wetness with injectable use, it may not have been
reported or documented, since in these countries, increased vaginal moistness may not be
regarded as a problem. One would in fact expect the anti-oestrogenic properties of
progestogen to result in vaginal dryness, which is a documented, though rarely reported
side effect (Guillebaud, 1993; Nelson, 1996). One possible explanation for the reported
wetness is that the women who report this problem have sexually transmitted infections
(STI's). However, the nature of the wetness does not, for the most part, appear to fit the
description of an infection. Another possible explanation is that vaginal wetness,
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attributed to progestogen injectable contraceptive use, is a perception that has grown and
spread over time, possibly fueled by men's concerns about loss of control of their
partner's fidelity and fertility if she uses the injectable contraceptive.
Conclusions and Recommendations
Consistent with findings from other studies, many side effects, particularly menstrual
disturbances were experienced by users of both injectable products. Unlike other studies
however, this study has found that vaginal wetness is a commonly reported side effect of
progestogen-only injectable contraceptive. This side effect appears to be particularly
disturbing in terms of the way in which men view women who use it. Yet, despite this
undesirable effect, women continue to use the injectable method, mainly because they
find it a convenient and effective method which can be hidden from their partners. Whilst
vaginal wetness can only be classified as a subjective side effect at this stage, further
investigations are needed. It is also an issue that must be addressed by health workers
responsible for counseling women who use this method of contraceptive. Wright (2003)
recently reviewed the published findings on vaginal wetness from the Hlabisa study and
recommended that health workers should be aware that the perception that injectables
cause vaginal wetness can affect acceptability and lead to discontinuation.
A study is being developed to explore the nature and possible etiology ofvaginal wetness,
how it may differ from the vaginal discharge reported by respondents, and whether it is a
consequence of a vaginal infection or a relatively transient problem that resolves for most
women on continued use.
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Africa Centre
fo r" Population Studies and Reproductive Health
INFORMATION TO HOUSEHOLDERS ABOUT 'nns RESEARCH STUDY ON THE
USE OF THE CONTRACEPTIVE INJECTION
WHO IS DOING THE STUDY?
This study is being undertaken by researchers from the Departments of Pharmacy and
.. --Pharmacology of the University ofDurban-Westville and the Africa Centre for Population
Studies and Reproductive Health
WHAT IS THE STUDY ALL ABOUT?
We know that many women have worrisome problems when they use the injection. We
hope that by doing this research we will be able to lessen these problems and in this way
help women who wish to use the injection.
HOW WILL THE STUDY BE DONE?
We need to ask you questions about family planning methods you may have used. We
especially want to know what you think about the use of the contraceptive injection. We
would like to ask you some questions even if you have never used the injection or other
ways of delaying pregnancy, so that you can tell us what you think about these methods.
We would also like to find out how much you weigh so that we can find out about
whether people who are using the injection gain weight, compared to those who do not
use the injection.
WHY IS THE STUDY IMPORTANT?
What we find from this study could improve the life of many women who use the
injection. We believe that this is a very important study and without your help it can't be
done.
RESEARCHERS' PROMISE :
The people doing this study promise that no-one will be told anything about you. Nobody
will be told what your particular answers to the questions are, as your name will not be
used. We will not even ask you what your name is.
THANK YOU VERY MUCH FOR YOUR HELP
Jenni Smit
(Senior Lecturer, Pharmacy Department , University of Durban-Westville)
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INCAZELO KUBASEBENZISI MJOVO MAYELANA NOCWANINGO
NGOKUSEBENZA KOMJOVO WOHLELOMNDENI
UBANIOZOQHUBA LOLUCWANINGO ?
Lomsebenzi wokucwaninga uzoqhutshwa ngabacwaningi bomnyango wezokuthakwa
nokukhishwa kwemithi yokwelapha eNyuvesi yase- Durban-Westville.
LUZOSlZA NGANI LOLUCWANINGO ?
Siyazi ukuthi abesifazane abaningi bahlanga- bezana nezinkinga eziningi ezibakhathazayo uma
besebenzisa umjovo. Sinethemba lokuthi ngokwenza lolucwaningo sizokwazi ukunciphisa
lezizinkinga, ngalendlela kusizakale labo besifazane abafuna ukusebenzi- sa umjovo .
LUZOKWENZWA KANJANI LOLUCWANINGO?
Sifisa ukuthatha igazi lokusampulisa iziqubu ezintathu kuwena ukuze sazi ukuthi kwenzekani
emzimbeni wakho uma ukade ujova. Kuzomele sithole isampula Legazi Kuwena namhlanje
ngaphambi kokuba ujove bese siphinda sicele ukuba ubuye esikhathini esiyinyanga sithathe elinye
isampula legazi. Kuyodingeka ubuye ezinyangeni ezimbili ukunikeza isampula legazi lokugcina.
Siyazi ukuthi sikunikeza umthwalo odulele Kodwa uyobe usisize Kakhulu uma uvuma ukuba
yingxenye yaloluhlelo. Ukukubonga ngokusisiza, siyokunika isipho esincane mhlazane ufika
okokugcina. Sikholwa ukuthi lolucwaningo lungolubaluleke kakhlulu Kanti lungeka lwaba
yimpumelolo ngaphandle Kosizo lwakho.
KUNGANI LOLUCWANINGO LUBALULEKILE?
Sikholwa ukuthi konke esiyokuthola ocwaningweni kungasiza ukwenza ngcono izimpilo
zabesifazane abaningi abasebenzisa umjovo ukuhlela.
ISETHEMBISO SABACWANINGI:
Abantu abazobe benza loluwaningo bayakuthembisa ukuthi akukho muntu oyotshelwa utho
ngawe noma badlulisele phambili loko obatshele khona Igama lakho ngeke lisetshenziswe
nangengozi, akekho futhi oyotshelwa ukuthi uyeza kulomtholampilo noma uyajova.
OKUFANELE UKWENZE?
Uma uzimisele ukuba ingxenye yalolucwaningo, sicela :
• Usayinda imvume kulelipheshana elihambisana nalencwadi
• Uphendule imibuzo ozoyibuzwa ngumhlengikazi eMtholampilo
• Uvumele umhlengikazi athathe isampula legazi
• Uphinde uze kulomtholampilo wohlelomndeni ngalezi zinsuku ezilandelayo :
......... .................. , ./ ./98
..........................., ./ ./98
SlYALUBONGA USIZO LWAKHO
Jenni Smit Lynn Me Fadyen
(Senior Lecturer, Pharmacy Dept.) (Ass. Professor, Pharmacology Dept.)
University of Durban-Westville
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INFORMATION TO FOCUS GROUP PARTICIPANTS ABOUT rms RESEARCH
STUDY ON THE USE OF THE CONTRACEPTIVE INJECTION
WHO /S DOING THE STUDY?
This study is being undertaken by researchers from the Departments of Pharmacy and
Pharmacology of the University of Durban-Westville and the Africa Centre for Population
Studies and Reproductive Health
WHAT IS THE STUDY ALL ABOUT?
We know that many women have worrisome problems when they use the injection. We
also know that some men have worries about women using it. We hope that by doing
this research we will be able to lessen these problems and in this way help women who
wish to use the injection.
HOW WILL THE STUDY BE DONE?
We want to have a discussion about family planning methods you or your relatives and
friends may have used. We especially want to know what you think about the use of the
contraceptive injection. We would like to ask you to tell us your views even if you have
never used the injection or other ways of delaying pregnancy. We especially want to
know about problems or worries people have about using the injectable contraceptive.
WHY IS THE STUDY IMPORTANT?
What we find from this study could improve the life of many women who use the
injection. We believe that this is a very important study and without your help it can't be
done.
RESEARCHERS' PROM/SE:
The people doing this study promise that we will not tell anyone anything about you
personally. Nobody will be told what your particular answers to the questions are, as
your name will not be used.






INCAZELO KUBASEBENZISI MJOVO MAYELANA NOCWANINGO
NGOKUSETSHENZISWA KOMJOVO WOHLELOMNDENI
Ubani ozogbuba lolucwaningo ?
Lomsebenzi wokucwaninga uzoqhutshwa ngabacwaningi bomnyango wezokuthakwa
nokukhishwa kwemithi yokwelapha eNyuvesi yase-Durban-Westville ibambisene ne-Africa
Centre for Population Studies and Reproductive Health ezinze eMtubatuba.
Luzosiza ngani lolucwaningo ?
Siyazi ukuthi abesifazane abaningi bahlangabezana nezinkinga eziningi ezibakhathazayo uma
besebenzisa umjovo. Sinethemba lokuthi ngokwenza lolucwaningo sizokwazi ukunciphisa
lezizinkinga, ngaleyondlela kusizakale labo besifazane abafuna ukusebenzisa umjovo.
Luzokwenziwa kanjani lolucwaningo ?
Sifisa ukukubuza imibuzo ngezindlela zokuhlela umndeni osuwake wazisebenzisa. Sifisa ukuzwa
ikakhulukazi uvo lwakho ngokusetshenziswa komjovo njengendlela yokuhlela. Sizocela
ukukubuza imibuzo noma ngabe awukaze uwusebenzise umjovo noma yiyiphi-ke indlela
yokuvikela ukukhulelwa yikhona sizozwa olwakho uvo ngalezizindlela. Sifisa futhi ukuthola
isisindo sakho yikhona sizokwazi ukubona ulcuthi ngabe abantu abasebenzisa umjovo
bayakhuluphala yini uma beqhathaniswa nalabo abangawusebenzisi.
Lubaluleke ngani lolucwaningo ?
Sikholwa ukuthi konke esiyokuthola kulolucwaningo kungasiza ukwenza ngcono izimpilo
zabesifazane abasebenzisa umjovo. Sikholwa ukuthi lolucwaningo lubaluleke kakhulu ekanti
ngaphandle kosizo lwakho lungeze lwenzeka.
Isetbembiso sabacwaningi
Abantu abazobe benza lolucwaningo bayakuthembisa ukuthi akukho muntu oyotshelwa utho
ngawe noma badlulisele phambili lokho obatshele khona. Igama lakho ngeke lisetshenziswe
nangengozi.
SlYALUBONGA USIZO LWAKHO





• Community-based survey composite interview schedule
• Focus group interview schedule
• Individual interview schedule for focus group participants
• Record of focus groups
• Family planning clinic record of contraceptive units
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Injectable Contraceptive Usage: A Community-Based Study
COMPOSITE INTERVIEW SCHEDULE
(Font reduced and spacing removed to reduce document size)
BLACK QUESTION NUMBERS =Questions common to all subsamples
YELLOW QUESTION NUMBERS =Questions for current users only
BLUE QUESTION MUMBERS =Questions for previous users only
GREY QUESTION NUMBERS =Questions only for ~ who had never used IC
--------------------------------------------------------------------------------------------------------------
1. Respondent Number:
2. How old are you? (state in years or give date ofbirth):
3. Residential Status:
(a) Do you sleep in this house for four nights a week or more?
Yes 0
No 0




Marital Status ./ Length of relationship
(as perceived bv the respondent)
Married - by civil, religious or
traditional/customary ceremony ... ... ...... ....... ...............
Single: in stable relationship currentlv .... .......................... .. ..
Single: casual relationships currently
Single: no relationship now, but has had
previous relationships
Single: never had a relationship
Other (explain) . .. .. . . .. . . . .. . . .. . .. .. .
4. Are you married or single?
(a) Current Marital Status
(b) Are you or have you ever been divorced?
Yes 0
No 0
(c) Are you or have you ever been widowed?
Yes 0
No 0
(d) If you are in a relationship, does your husband or partner sleep in this house for four
nights a week or more?
Yes 0
No 0
IF NO, How often does your husband or partner return to Hlabisa?
.. .. ... ..... ..... ..... ... ... .. ...... ... .... ...... .. ... ..... ..... ........ .. .. ..... ... ... ...... ....
IF NO, Where does your husband or partner stay (sleep) when he is away?
.................................................................................................
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(e) If you are in a relationship, does your husband or partner stay (sleep) in this house for at
least 50% of the time
Yes 0
No 0
IF NO, How often does your husband or partner return to Hlabisa?
......... .. .... ... ... .. ... .. ... ..... ....... ...... .... ... .... ... .... .... ... ........... .. ... ... ....
IF NO, Where does your husband or partner stay (sleep) when he is away?
.... .. .. .... .... ...... .... ...... ..... .. ...... .. ... .... ... .... ... .... ..... ..... .... ... .... .... ....
5. What is your religion? (be as specific as possible)
... ... ....... .. ... ... ...... ... ... .......... ..... .................... ..... ...... .... .. ... .. .... .... ...
6. What is your level of education?
No Formal Schooling
Schooled up to Standard I (Grade 3)
Standard 2 (Grade 4) to Standard 5 (Grade 7)
Standard 6 (Grade 8) to Standard 8 (Grade 10)








7. Household size: How many people live in this house who share or contribute to
household resources? (only include those who sleep in the house for at least 7
nights in a year; also include children) .., .
Employed (formal sector)







8. What is your occupation?
(a)
IF EMPLOYED,
(b) What is your job? (actual job/job title)







How old were you when you were first pregnant? (years)
How many times have you been pregnant? .
How many live births have you had? ..
10. How many living children do you have?
What is their sr=e~x-=a:::n::::d-=a:.tlgfe?~.__---. ,--__-r-r- _
I~~~ IAge rge IAge IAge IAge I-AgeIAge IAge IAge I
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11. Are you pregnant now?
Yes 0
No 0
Don 't know 0
IfYES, how many months pregnant are you?
12. Have you ever had difficulty in getting pregnant
Yes 0
No 0
Don 't know 0





(a) How old were you when you first used a contraceptive method? (years)
(b) What method did vou FIRST use? (Don't read list but orobe if necessarv)
METHOD For how long used
(years & months)
Pill! Oral Contraceptive (state brand name ifpossible)
.... .. ........ .... ... ...... .. ....... ...... .... .. ........ .... ....
Iniection: 2 monthly, Nur-Isterate
Injection: 3 monthly, Depo Provera; Petogen (state brand name if possible)
..... ... ... ... ... .. ...... ....... .. ..... ... .. .......... ... ........ ..












Herbs! remedy (state which) ... ...... ........ .. ..... ....... .................
Abstinence (state which) .... .............. ...... .. ..... . ..... . ... ...........
Female sterilisation/tubal Iization(state how long ago)
Male sterilisation/vasectomv
Other (state which) .... .. ..... ... . ......... .. ........ .. .... .. ..................
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14. Are you currently (now) using a way or a method to avoid or prevent getting pregnant?
Yes 0
No 0
IfYES, answer Questions 15-29
eked)
Never been sexually active
Sexually inactive/ no partner
Infrequent sex
Pregnant





Respondent is opposed to contraceptive use
Husband/partner is opposed to contraceptive use
Relatives/friends are opposed to contraceptive use
Religious reasons
Respondent knows no contraceptive method
Respondent does not know where to go to get contraceptives
Too far to go to the health facility
Health reasons or concerns (explain) .. . ........ ..... .......... .... ......... ..
Fear of side effects (explain) ... .......... .... .. .. ... ..... ... . ... ... ... .... ... .. .....
Inconvenient to use (explain)
Interferes with body's natural processes
Costs too much
Other (explain) ... ... .......... .. ... ...... ... ...... ........... . ... ... ... ..... ..... .. ... ...
IfNO, what are the main reasons for not using a method? (After answering this
question, go on to question 38). (Don't read out. More than one reason may be
ti
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QUESTIONS 15 to 29 below FOR CURRENT CONTRACEPTIVE USERS ONLY (i.e. for those who
answered YES to uestion 14 above)
15. What method are you currently using and for how long have you used it?
METHOD For how long used
(years & months)
Current method is the same as the first method used
Pill! Oral Contraceptive (state brand name ifpossible)
... ... .... .... .... .... ........ .... ..................... .. .. ... ..
Injection: 2 monthly, Nur-Isterate
Injection: 3 monthly, Depo Provera; Petogen (state brand name if possible)
.. ... ............. ............ .. ... ....... .... ........ .............
Intrauterine contraceptive device : IUCD/IUD/coil!loop











Herbs/ remedy (state which) .... ... .. ... ... . .. .. ... .... . ..... ... ... . .. . .. . .. .
Abstinence (explain) ... .................... ..... ... .... ......... . ....... ,.....
Female sterilisationltuballigation (state how long a~o)
Male sterilisationlvasectomy
Other (state which) ......................... ... ................................
If the respondent is using the injectable contraceptive, go to question 16 on page 4 of the yellow
questionnaire
16. What injectable contraceptive method are you currently using and for how long have you
used it?
METHOD For how Ionz used (years & months)
2 monthly, Nur-Isterate
3 monthly, don't know which brand
3 monthly, Depo Provera (Depo)
3 monthly, Petogen
Other (state which) ... ... ... ... ... ... ... ... ... .....
17. (a) Why did you decide to use the injectable contraceptive rather than another method of
contraception?
... ... ... ........................ .... .... ............. ....... .... ............. .... .........
17. (b) Why did you decide to use this contraceptive method?
... .... ... ..... ...... ......... .. ....... ..... ... .... ... .... ......... ..... ..... ... ..... ......
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e reason ifnecessary)
You only have to have Depo Provera (Depo) every 3 months or 12 weeks
Yingoba udinga ukujova emva kwezinyanga ezintathu kuphela
You only have to have Nur-Isterate every 2 months or 8 weeks
Yinzoba udinga ukuiova emva kwezinyanga ezimbili kuphela
You don't want your partner to know you use contraception
Awufuni ukuthi umngani wakho azi ukuthi uyahlela
You don't want your friends or relatives to find out that you use contraception
Awufuni ukuthi abangani nezihlobo zakho zazi ukuthi uyahlela
Your friend or relative recommended it
Yiyona ndlela eyanconywa abangani nezihlobo
It was recommended for you at the clinic
Yivona ndlela eyanconyelwa wena emtholamnilo
Its an effective way to prevent pregnancy (it works)
Yiyona ndlela esebenzayo yokuvikela ukukhulelwa
Its a very safe way to prevent pregnancy (it doesn't cause harm)
Yiyona ndlela ephephile yokuvikela ukukhulelwa
You don't have a period when you're using it
Awuyi esikhathini uma usebenzisa lendlela
It suits you as there are few problems or side effects
Iyangichaza ngoba izinkinga zincane enaihlanzabezana nazo
18. Did you choose this method for any of the following reasons? (Read the list and tick more than
on





........ ....... .............. .. ........... ..... .............................. ..... .. ........







Other (state who) ..... . '" .... .. .... .. ...... .... ..... ... ... ...
20. Wh d' d
21. How often do you go to the clinic or hospital to get the injectable contraceptive?
Every two months
Every three months
Other (state how often)
22. Explain why you prefer the injectable you use (i.e. the two monthly rather than
the three monthly injectable contraceptive; or the three monthly rather than the
two monthly injection) .
..... .... ... .......... ...... ......... ............ ... ......... ......... ..... ........ ... .... .... ....... ..
23. Approximately when (approximate date) did you last go to the clinic to get the injectable
contraceptive: ..... .1......./......
24. When did you start using the injectable contraceptive? (years and months)
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25. What side effects or problems have you experienced with the injectable
contraceptive?
...... .... ... ........ .... .......... .... ...... ..... ..... .. ........ .... .. .. .... ........... .............
ore than one option ifnecessarys
SIDE EFFECT NOW BEFORE






Ukuya esikhathini izinsuku ezingaphezulu
kwezijwayelekile
Spotting
Ukopha kancane phakathi nenyanga
Irregular periods
Ukuya esikhathini ngezikhathi ezingafani
Painful periods

















Increased vaginal moisture or wetness
Ukubamanzi
Vaginal discharge
Ukuphuma koketshezi ebulilini bowesimame
Vaginal discharge with unpleasant odour (smell)
Ukuphuma koketshezi olunephunga elibi
Vaginal dryness
Ukoma
Hard to get pregnant after stopping the injection
Ubunzima bokukhulelwa emva kokuyeka umiovo
Loss of libido/don't feel like sex
Ukuzizwa ungathandi ukuya ocansini




26. Have you experienced any of the following side effects? (Read the list and tick
m
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d IIivdid von have a break? (Recor a reasons eiven
REASON ./
Became pregnant (by mistake, unplanned)
Wanted to get pregnant! wanted more children
Sexually inactive/no partner
Infrequent sex (explain} ... ... ... ... ... ... ... ...... ..... . ... ... ... ... ·.. ·.. ·.. ·.. ..· ..· .... ..
Wanted to menstruate
Wanted body to have a rest from contraceotion
Health Reasons (explain) . . . ... . . . . . . .. . .. . . .. ... . ... . . . .. .. . .. . .. . . ... .. .. . .. . .. . ..
Other (explain) .. , ....... ...... , ..... ..... ........... . ......... ............ .. .......
IfYES:
(a)Wh
(b) For approximately how long did you have a break in using it?
.. ....... ... ... ... . (years and months)
28. Over the last 2 years have you had a break in using the injectable contraceptive. In other





(a) Why did you have a break? (Record all reasons given; don't read list butprobe if
necessary)
REASON ./
Became pregnant (by mistake, unplanned)
Wanted to get pregnant! wanted more children
Sexuallv inactive/no partner
Infreauent sex (explain} .... ....... ... . ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ......
Wanted to menstruate
Wanted body to have a rest from contraceotion
Health Reasons (explain) .... .... ........ .... .. ... ... .. ... ... .......... .. ..........
Other (exvlain) ...... .............. ................................. .................
(b) For approximately how long did you stop using it?
more t an one option can e tic e
NAME OR PLACE OF HEALTH FACILITY
State Hospital
General Clinic (not mobile)







29. Where do you go to get the injectable contraceptive? (Write the name or place of the health
facility; h . b k d)




IF NO, why not?
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• ?ho made the decision to use the injectable contraceptive.
Yourself
Your partner
Joint decision between myself and nartner
Clinic sister or doctor




Other relative (state which) ...... ... ... ..........
31. W
32. Will you continue to use the injectable contraceptive?
Yes 0
No 0
Why not? (Do not read list, but nrobe ifnecessarv)
REASON.:. Want to get pregnant .:.
Partner is leaving/will not be sexually active
Partner will not be around very much so I will infrequentlv have sex
Want to menstruate
Gained a lot of weight
Want body to have a rest from contraception
Interferes with body's natural processes
Don't like the side effects I exnerience (exolain) ...............................
Health Reasons (explain) .........................................................
Worried that it may delay return to fertility
Want to change to another method
Going to have a hysterectomy/tubal ligation
Menopausal
Partner not happy with the method (explain) .......................... .......
Use not recommended by familv or friends
Change of method recommended bv health worker
Religious reasons




•:. Ifpregnancy is the reason, ask respondent If she would be willing to allow follow-up to see how
long it takes for her to get pregnant?
Yes, willing to allow follow-up 0
No 0
IF YES: Name ofrespondent .
Address of respondent ..
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What method will yOU use instead?
None/no method
Pill! Oral Contraceptive
Another type/brand ofInjection (state which one) .... , . . . , . . . . .. .. .. . ..
.. ... ... ... ........ .. .. .... ... .... .. .. ......... ...... ..... ... .. ........ .. ... ..... .
Intrauterine contraceotive device : IUCD/IUD/coil!loop






Natural method (e.g. Withdrawal, coitus interruptus, rhythm, calendar






Other (state which) .... .... . . .. . . .. . .. .. .. .. . . .. . .. . . . .. . . .....
IF NO
(b
33. What do you like most about using the injectable contraceptive?
..... .. .......... ....... ........... .... ... ..... ...... ..... .......... ... ... ... .... ...... ... ....... ....
34. What do you like least about using the injectable contraceptive?
...... .. ...... ... .... .. ........ .. ...... ... .. .. ..... ... ....... .. ... .. .. .. .. ... ........ .... ... ....... .
35. (a) What contraceotive method did you use last. i.e. before you started uslnz the iniection?
METHOD For how long used
(vears & months)
None/have only ever used the injectable
Pill! Oral Contraceptive
A different type ofInjection (state which) . .... .... . . . . . . ... . .. .. .. .. . . . ..
.......... .... .............................................. .......................
Intrauterine contraceotive device: IUCD/IUD/coil!loop











Herbs/ remedy (state which) .... ..... .... .... .. .. .. ... ......... .. .... .. .....
Abstinence (state whiciJ .. . . .. .. .. . .. ... .. . .. . .. . . .. ... . . . . .. ... . . .. .. . .. .. ..
Female steril isation/tubal liaation (state how lone ago)
Male sterilisation/vasectomy




















(b) Why did you change from this method to the injectable contraceptive method?
........ .... .... ... .............. .. ... ........ ... .... .. .. ........... .... .... ... ....... .... .
Possible reasons could include (don't read out this list):
i) Stopped the method to get pregnant and then started the injectable after the birth
ofthe baby
Got pregnant by mistake (method failure) and started the injectable after the birth
ofthe baby
Wanted body to have a breakfrom contraceptive use
Interferes with body's naturalprocesses
Side effects - find out what these were
Health reasons or concerns e.g. harmful or dangerous to use
Change ofmethod recommended by health worker
Religious reasons
Partner not happy with method - find out why
Use not recommended by family or friends
Method no longer available!couldn't get method/out ofstock
To far to go to get the methodllack ofaccess
Difficult or inconvenient to use
Unpleasant or painful to use
Messy to use
Puts one offsex
Difficult to remember to take
Have to use each time one has intercourse
Other
36. What other contraceptive methods have you nsed previously? (More than one can be ticked)
METHOD YEARS &
./ MONTHS USED
None/ have onlv only ever used the injection
Pill/ Oral Contraceptive
Injection; 2 monthly, Nur-Isterate
Injection: 3 monthly, Depo Provera; Petogen
Intrauterine contraceptive device: IUCD/IUD/coil/loop











Herbs/remedv(state which) ......... .............. ... .. .. '" ... '" ... ....
Abstinence (explain) ... ... ... ... ... .., ... ... ... .... .. ... ... ... ... ... .......
....... .. ... ....... ... ... .. .. .... .... ... .. .. ..................... . .............. ... .. ....
Female sterilisationltuballigation (state how long ago) .. .... ...
Male sterilisationlvasectomy
Can't remember
Other (state which) .. .. .. .. . . .. . . . . .. .. . ... .. . .. . .. . ... ... .. . .. . . .....
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37. For each method listed in question 36 above. explain whv you stopped using the method.
METHOD REASONS STOPPED USING

























Became pregnant (by mistake or unplanned)






Wanted body to have a breakfrom contraceptive use
Interferes with body's naturalprocesses
Side effects - find out what these were
Health reasons or concerns e.g. harmful or dangerous to use
Change ofmethod recommended by health worker
Religious reasons
Partner not happy with method - find out why
Use not recommended by family or friends
Method no longer available!couldn't get method/out ofstock
To far to go to get the methodllack ofaccess
Difficult or inconvenient to use
Unpleasant or painful to use
Messy to use
Puts one offsex
Difficult to remember to take
Have to use each time one has intercourse
Other
38. What methods have you used oreviouslv? (More than one can be ticked)
METHOD YEARS &
,f MONTHS USED
NonelNever used a contraceptive method
Only ever used one method which is the first metohd
PilV Oral Contraceptive
Iniection: 2 monthly, Nur-Isterate
Iniection: 3 monthly, Depc Provera; Petoaen
Intrauterine contraceptive device: IUCDIIUD/coiVlooD











Herbs/remedy (state which) ...... ... ... ......... ....... ..... '" '" ... ...
Abstinence (explain) ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ....
.. ... ..... .................................................................... ....... ....
Female sterilisation/tubal Iization (state how IOnJ! ago)
Male sterilisation/vasectomy
Other (state which) ............... ..... ............. ...... .. .. .. ... ..
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39. For each method listed in question 38 above, explain why you stopped using the
method.
METHOD REASONS STOPPED USING
Injectable (provide a detailed
explanationfor this method)
Possible reasons could include:
xx) Became pregnant (by mistake, unplanned)
xxi) Wanted to get pregnant/wanted to have more children
xxii) Sexually inactive!no partner
xxiii) Infrequent sex
xxiv) Menopausal
xxv) Had a hysterectomyltuballigation
xxvi) Wanted to menstruate
xxvii) Wanted body to have a breakfrom contraceptive use
xxviii) Interferes with body's naturalprocesses
xxix) Side effects <find out what these were
xxx) Health reasons or concerns e.g. harmful or dangerous to use
xxxi) Change ofmethod recommended by health worker
xxxii) Religious reasons
xxxiii) Partner not happy with method - find out why
xxxiv) Use not recommended by family orfriends
xxxv) Method no longer available!couldn't get method/out ofstock
xxxvi) Tofar to go to get the methodllack ofaccess
xxxvii) Difficult or inconvenient to use
xxxviii) Unpleasant or painful to use
xxxix) Messy to use
xl) Puts one offsex
xli) Difficult to remember to take
xlii) Have to use each time one has intercourse
xliii) Other
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ead the list and tick more than one reason ifnecessary)
I became pregnant by mistake
Ngakhulelwa nzenhutha
I wanted to get pregnant
Naanzifuna ukukhulelwa
I no longer had a sexual partner and did not need contraception
Angisenaye enzanzikade nzithandana nave futhi ngingasadingi kuhlela
My partner was not around very much/infrequent sex (explain)
Engithandana naye wayengekho eduze / angiyi njalo ocansini (chaza)
............ .................. .............................. ... ......................... ... ..................... ..........
I wanted to menstruate
Ngangifuna ukuya esikhathini
I gained weight! Ngangikhuluphala
I wanted to give my body a break from using the injection
Naanzifuna ukuphumuza umzimba wami ekusebenziseni umjovo
It interfered with my body's natural processes
Kwakuphazamisa ukusebenza ngokwemvelo komzimba wami
I did not like the side effects I experienced (explain)
Angizithandanga izinkinga engahlangabezana nazo (chaza) ........ .... ... .... .. ... ... ..... .... ....
I thought it was unhealthy (explain)
Ngangicabanga ukuthi akunayo impilo (chaza) ............ ... ..... . ... ... ..... . ...... ......... .... .....
I thought it would make me infertile
Ngangicabanga ukuthi kuzongiqeda inzalo
I wanted to change to another method (state which method)
Ngangifuna ukushintshela kwenye indlela ... ... ... .... .. ... .... ... ... ... ....... .. ... ... ... ... ..... . ... .
The health worker recommended that I change to another method (state which method)
Isisebenzi sezempilo sangincomela ukuthi ngishintshele kwenye indlela(shono ukuthi iyiphi)
.......................................
I had a tubal Iiaation/ Nzaboshwa amashubhu
I had a hysterectomy/ Ngakhishwa isibeletho
I was menopausal! Ngangingasayi esikhathini
My partner did not want me to go on using it (explain)
Engithandana naye wayengasafuni ukuthi ngiqhubeke nokusebenzisa umjovo(chaza)
........................ ........................................................................... ... ..................
Use was not recommended by family or friends
Ukuwusebenzisa kwakunganconviwe umndeni noma abangani
Religious reasons/ Izizathu zenkolo
The health facility was too far to go to get the injection regularly
Umtholampilo wawukude kakhulu ukuba ngiye kothola umiovo nzesikhathi enginqunyelwe sona
40. Did you decide to give up using the injectable contraceptive for any of the following reasons?
(R
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41. (a) When did you stop using the injectable contraceptive? .. , .
(b) For how long did you use the injectable contraceptive method? .
(c) Why did you choose the injectable contraceptive method at the time?
(d) What side effects or problems did you experience with the injectable
contraceptive when you were using it?
(e) Did you experience any of the following side effects? (Read the list and tick







ukuya esikhathini izinsuku ezingaphezulu
kweziiwavelekile
Spotting
Ukopha kancane phakathi nenyanga
Irregular periods
ukuya esikhathini ngezikhathi ezingafani
Painful periods





















Hard to get pregnant after stopping the injection
ubunzima bokukhulelwa emva kokuyeka umiovo
Loss of libido/don't feel like sex
ukuzizwa unzathandi ukuya ocansini









IfYES, what method did you change to? (Don't read list but probe if necessary
Pill! Oral Contraceptive (state brand name ifpossible) ... .. . . .. .. . . . ..
... ............ ................ ..... ... .. ............. .. ........ .. ... ... ...... ....
Another typefbrand of Injection (state which one) . .. ... . .. .. . . ... . . . . .
.................................... ... ... ................. ........................
Intrauterine contraceptive device: IUCDIIUD/coil!loop






Natural method (e.g. withdrawal, coitus interruptus, rhythm, calendar





Other (state which) ........................ ....................
IF YES, why did you choose to use this method?












........... ......... ..... ..................... ......................... ....................
45. What did you like most about using the injectable contraceptive?
... ...... .... .... .... ...... ....... .......................... .. .. .................... ....... ...... ...
46. What did you like least about using the injectable contraceptive?
........ .......... ........ ... .... ... ............................ .. ...... ...... .. ... ............... ..
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NOW I AM GOING TO ASK YOU SOME QUESTIONS ABOUT OTHER PEOPLE'S USE
AND OPINIONS OF THE INJECTABLE CONTRACEPTIVE
47. (a) What do you thiuk is the most popular method of contraceptive used?
(b) Why do you think this method is popular?
48. Do you think the injectable contraceptive is used by
IVery many women I Many women IA fair number of women I Few women IVery few women I





50. Why do you think women choose to use the injectable contraceptive?
51. Why do you think women choose NOT to use the injectable contraceptive?
52. Do women refer the two monthl or the three monthl iniection?
Two month! ur-Isterate)
Three month! e o-Provera, Peto en
Don't know
Explain your answer
........ ..... ... ... .... ........... .............. ..... .... ..... ............. ...... .... ......




IF YES OR NO, explain your answer
....... ...... ............. ......... .. ................... ........ ......... ...... ........... .




IF YES OR NO, explain your answer
........ ..... .. ........ .. ....... ... ......... ......... ... ..... ......... ...... ... .. ....... .. .





IF YES OR NO, explain your answer
.............. .. ..... .... ... .. .. .... ...... .... .. .. ....... ..... ... ...... ...... .......... ... .
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IF YES OR NO, explain your answer
.. .... ....... ..... ..... ...... .... ..... .... ...... ...... ... ...... ... .. .......... ...... .......




IF YES OR NO, explain your answer
.......... ..... ............. ............................. ... ......... ..... .... .. ... ..... ...




IF YES OR NO, explain your answer
.. .............. ............. ..... ...... .... .... .... ... .. ......... .......... ......... .......




IF NO, why not? .







ukuva esikhathini ngezikhathi ezingafani






Bloating of abdomen and breasts
Ukukhukhumala kwesisu nababele
Increased vaginal moisture or wetness
Ukubamanzi
Vaginal discharge
Ukunhuma koketshezi ebulilini bowesimame
Vaginal discharge with unpleasant odour (smell)
Ukunhuma koketshezi olunephunga elibi
Vaginal dryness
Ukoma
Hard to get pregnant after stopping the injection
Ubunzima bokukhulelwa emva kokuyeka umiovo
Loss of libido/don't feel like sex
Ukuzizwa ungathandi ukuya ocansini
Depressed mood/feel sad & unhappy
Ukukhathazeka emoyeni
NausealUkucanuzela kwenhliziyo
60. Do you know of or have you heard of any side effects or problems experienced by people
using the
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NOW I AM GOING TO ASK YOU SOME QUESTIONS ABOUT YOUR HEALTH
61. Do you smoke? Yes 0 No 0





63. What medicines do you use regularly? (Write the name ofthe medicine and what it is usedfor)
....... .................................................................................................................. ....... ................................

































66. How much did you weigh when you first started using the injectable contraceptive
............ ......... kilograms.
IF RESPONDENT CAN'T GIVE A FIGURE, ASKHER IF HER WEIGHT
WHEN SHE FIRST STARTED USING THE INJECTION WAS (Tick only one):
Much less than now
Less than now
The same as now
More than now
Much more than now
Can't remember
ow much do you yourself earn per month woss)?
No income
R 1 - R 500 per month
R 501 - R1000 per month
R1001-R2000permonth
R2001 - R3000 per month
R3001 - R4000 per month
Over R4001 per month
Don't want to answer
67. Income Level:
(a) H
l(lh Id'hat IS your ouse 0 Income eve rouei IV, •
No income
R 1 - R 500 per month
R 501 - R1000 per month
RI 00 1 - R2000 per month
R2001- R3000 per month
R3001 - R4000 per month
Over R4001 per month
Don't want to answer
Don't know
(b) Wh .
(c) What are the sources of your household income?
.. .. .. ... .. .. .. ... ....... ... .. ..... ................ ....... ...... ... ..... ..... ... .. ..... ....
68. MEASURE RESPONDENT'S WEIGHT (in Kilograms) .
69. MEASURE RESPONDENT'S HEIGHT (in Centimeters)






ukuya esikhathini nzezikhathi ezingafani
Other problems with periods or menstruation
Izinkinza ngokuya esikhathini
Other (explain) ...•....... ......•......•................ .
None/No Problems
70. Do you have any of the foUowing menstrual/bleeding problems? (Read list,
mo




Length of Interview (how long did it take?) .
Home Language of Respondent .
Interview Conducted in:
Race of Respondent if not African
Zulu
English 0
Combination of English & Zulu 0
o
••••••••••••••••
Checked by: . On (date): ..
••••••••••••••••
GENERAL INTERVIEWER COMMENTS ABOUT THE INTERVIEW
(INTERVIEWER TO WRITE AS MUCH AS SHE WANTS)
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FOCUS GROUP INTERVIEW SCHEDULE
Themes for Focus Group Discussions: Injectable Contraceptive
THEME!
What are your views and opinions about contraception and contraceptive methods
• Do you approve or disapprove?
• What methods are most used?
Which is most popular?
Which is least popular?
What traditional methods are used?
What unusual methods are used?
• What methods are best?
For young people
For older people
• How would you like to improve existing methods?
THEME 2
What do you think about the injectable contraceptives
• Which is better, Depo or Nur?
• Which is best for young people?
• Which is best for people without children?
• What don't you like about the injectable?
• What do you like about the injectable?
• How popular is the injectable contraceptive?
• What do men think about women using it?
• Why do many women use it?
• Do women tell their partners that they use it?
THEME 3
What problems or side effects do people who use the injectable contraceptive have?
Prob efor:
• Menstrual problems like no p eriod, heavy bleeding etc.
• Vaginal wetness
• Delayed return to f ertility
• Weight gain
• Which problem in the worst, no p eriod, heavy period or wetness?
THEME 4
Some women say that they experience wetness or moistness in the vagina from the injectable. Do these
women use anything to reduce the wetness or dry out the vagina?
• What do women do or use to "dry" the vagina?
• How do they use these substances?
THEMES
Is the injection is a good contraceptive method to use when many people have AIDS?
THEME 6
What are the views of the community leaders and elders about the use of contraceptives
• Especially by young women
• What do you think young people should do?
What are the views of the church about the use of contraceptives
• Especially by young women
• What do you think young people should do?
GENERAL
Is there anything else you can tell us about the use of the injectable contraceptive?
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INDIVIDUAL INFORMATION: FOCUS GROUP
PARTICIPANTS






4. Current Marital Status
Married - by civil , religious or
traditional/customary ceremony
Single: in stable relationship currently
Single: casual relationships currently
Single: no relationship now, but has
had previous relationships
Single: never had a relationship
cupa Ion
Employed (formal sector) 1








6. Level of Education
No formal schooling 1
Schooled up to Standard 1 (Grade 3) 2
Standard 2 (Grade 4) to Standard 5 (Grade 7) 3
Standard 6 (Grade 8) to Standard 8 (Grade 10) 4
Standard 9 (Grade 11) to Standard 10 (Grade 12) 5
Tertiary (University/Technikon/College) 6
7. Number of living children
8. Are you or your partners currently using a contraceptive method?
Yes Y No Y
IfYes, what method are you using --------
(see list below)
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Other Pill (named) 06
Other Pill (unspecified) 07
Iniection: 2 monthly, Nur-Isterate 08
Injection: 3 monthly (brand not specified) 09
Depo Provera 10
Petogen 11
Intrauterine contraceptive device: IUCD/IUD/coil/loon 12






Withdrawal, coitus interruptus 19
Ukusoma, thigh sex 20
Rhythm/Calendar method 21




Female sterilisation/tubal ligation 26
Male sterilisation/vasectomy 27
Other: Brewer's Yeast 28
Other: Rope 29
Other: Flagyl 30
Other: Shell/Snail's Shell 31




RECORD OF FOCUS GROUPS
TYPE OF GROUP DATE NO. OF NAME OF NAME OF VENUE TIME TIME







Family Planning Clinic Record of Contraceptive Units Issued
Number of Units dispensed each month for each method issued
Product Number of Units dispensed each month: July 1998 to June 1999
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CHAPTER 2.1 LITERATURE REVIEW AND OBJECTIVES
2.1.1 PHARMACOLOGY OF DEPOT MEDROXYPROGESTERONE ACETATE
Pharmacokinetics is defined as the study of the time course ofdrug absorption, distribution,
metabolism and excretion (Benet et al, 1996). Mathematical models are used to describe
these processes in order to condense the data by estimation ofdrug pharmacokinetic
parameters such as clearance (CL) , volume ofdistribution (V), half-life (t!!,), and rate of
absorption. In addition, mathematical modelling may allow exploration ofmechanisms and
be used to make predictions (Bourne, 1995). It is widely recognised that a high priority
should be placed on understanding the pharmacokinetic variability ofdrugs (Whiting et al,
1986), and the assessment ofphannacokinetic parameters of contraceptives is regarded by
Sang (1994, p..219) to be "of critical importance in assessing contraceptive efficacy of
depot medroxyprogesterone acetate (DMPA), side-effects and menstrual bleeding patterns".
However, Fotherby (1990) draws attention to the lack of attention paid to the
pharmacokinetics of contraceptive steroids in most textbooks and monographs. He
attributes this to the difficulty in deriving and interpreting phannacokinetic parameters for
gestogens.
Whilst some phannacokinetic studies ofDMPA have been published, studies for long-
acting injectable agents used by South African women, are entirely lacking. The previous
section ofthis thesis highlighted the efficacy ofDMPA and the poor side effect profile
experienced by users ofDMPA. Given its extensive use in South Africa, the lack of
phannacokinetic data for South African women is a glaring omission since international
studies suggest that regional and population differences exist in the pharmacokinetics of
steroidal contraceptives (Fotherby et al, 1980b; Sang, 1994; Garza-Flores et al, 1994). Over
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20 years ago Fotherby et al (1980b) recommended that studies investigating these
differences be conducted in countries where injectables are widely used , yet no such studies
have been undertaken in South Africa.
The pharmacokinetics ofDMPA are reviewed below. This review is a prelude to the
presentation ofdata from a population pharmacokinetic study undertaken amongst DMPA
users in Durban, South Africa. Whilst use ofnorethisterone oenanthate (NET-EN) is
increasing, especially amongst younger women (Beksinska et al, 2001a), DMPA is still
the most commonly used injectable (see copy of paper by Smit et al (2001) in Section 1
of this thesis , page xxv). Due to high drug assay costs , data collection was confined to
DMPA users. Hence this review is restricted to DMPA studies. Reference is only made to
NET-EN pharmacokinetic studies where these studies have relevance to DMPA
pharmacokinetics.
2.1.1.1 Chemistry
Medroxyprogesterone acetate (MPA) is a chemical derivative of 17a-
hydroxyprogesterone (6a-methyl-4-pregnen-3,20-dione-17a-yl-acetate) (Figure 2.1.1)
(Benagiano and Primerio, 1983a; Garza-Flores et al, 1992). MPA and progesterone have
similar structures, but MPA has an additional methyl group at C-6 and an acetoxy group
(OCOCH3) at C-17 (Kaunitz and Rosenfield, 1994), resulting in greater potency and a
longer half-life (Theron and Grobler, 1998). Babcock et al (1958, p.2905) first
synthesized it and described it as a "progestational agent of exceptional potency". MPA
(C24H3404) has a molecular weight of386.5 (Benagiano and Primerio, 1983a;
Martindale, 2002; USP DJ, 2002) and solubility in water ofless than l rng/ml (Benagiano
and Primerio, 1983a).
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2.1.1.2 Mechanism of Action of DMPA
r~.. I .&= 0 .
..r; y rei•.. ..
. - ' .- .. , '..-.-.: .- -..
Medroxyprogesterone Acetate (MPA)
DMPA inhibits ovulation by suppressing the release ofpituitary gonadotrophins, resulting
in the abolition of the mid-cycle surge oflutenizing hormone (LH) and follicle
stimulating hormone (FSH) (Mishell et al, 1968; Mishell et ai, 1972; Kirton and Comette,
1974; Schwallie, 1974; Jeppsson and Johansson, 1976; Garza-Flores et al, 1992; Mishell ,
1996; Clark et ai, 2001). Basal LH and FSH levels are reported to remain around luteal
phase levels (Goldzieher et al, 1970; Mishell et al, 1972; Jeppsson et al, 1977; Ortiz et al,
1977).
Although published studies of the effect ofDMPA on circulating hormones are sparse,
some studies have investigated the plasma concentrations ofhormones achieved with
DMPA, and have related these to the effect on follicular and luteal activity and on
ovulatory function. This information is summarized in Table 2.1.1. At a dose of 150mg
administered intramuscularly every 3 months , DMPA has been shown to be effective as a
contraceptive for at least 90 days (Ortiz et ai, 1977; Koetsawang et al, 1979; Fotherby et
al, 1980a; Bassol et al, 1984; Lan et al, 1984; Jeppsson and Johansson, 1976; Mishell ,
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1996) and ovulation is reported to resume when MPA blood concentrations decline to less
than O.lng/ml (Ortiz et al, 1977). MPA exerts secondary contraceptive effects at
endometrial and cervical levels (Garza-Flores et al, 1992; Mishell, 1996; Clark et al,
2001).
Table 2.1.1 Effect ofDMPA on ovulatory function
Reference
• MPA levels >O.l ng/m1: Ovulation inhibited Ortiz et al, 1977
• MPA levels ofO.1-0.2ng/ml: Threshold MPA concentrations Rahimy et al 1999b
expected to exert a contraceptive effect
• MPA levels <O.lng/m1: Resumption of ovulation Ortiz et al, 1977
• Progesterone level >3ng/m1: Resumption of normal ovulatory Ortiz et al, 1977
pattern Fotherby et ai, 1980b
• Progesterone levels of at least 4.0ng/ml: Evidence of ovulation Siriwongse et ai, 1982
• Progesterone levels :2:4.7ng/m1: Confirmation of ovulation Rahimy et al1999b
• Progesterone levels :2:3ng/ml; Oestradiol levels :2:150pg/ml: Fotherby et a11980a
Indicative of luteal and follicular activity respectively Rahimy et al1999b
• Significant correlation between the concentration ofMPA in Fotherby et al1980a
blood and the return of follicular and luteal function
• For inhibition of ovulation in initial injection cycle: DMPA Siriwongse et al, 1982
should be administered within 5 - 7 days of onset of menses Kaunitz 1994
2.1.1.3 Absorption and Serum Medroxyprogesterone Acetate Concentrations after
Injection ofDMPA
The recommended dose ofDMPA for contraception is 150mg every 12-13 weeks by the
intramuscular route (Pharmacia and Upjohn, 1993 ; Martindale, 2002; USP DI, 2002).
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When administered as an aqueous microcrystalline suspension into the deep gluteal or
deltoid muscle, MPA is slowly absorbed from the intramuscular site. The prolongation of
hormonal activity is a result of this formulation as described by Babcock et al (1958).
MPA blood concentrations are determined by the rate of absorption from the surface of
the microcrystals at the absorption site, the degree of protein binding in the bloodstream,
the rate of hepatic metabolism and enterohepatic circulation, and the rate of urinary
excretion of water-soluble metabolites (Fraser and Weisberg, 1981; Fotherby and
Koetsawang, 1982b; Theron and Grobler, 1998). Drug formulation and crystal size may
influence effectiveness (Garza-Flores et al, 1992) and it has been suggested that massage
of the site ofthe injection can enhance absorption (Theron and Grobler, 1998). Following
intramuscular injection of DMPA there is an initial high release ofprogestogen into the
bloodstream, followed by a fall in MPA concentrations according to first-order release
rates (Kirton and Comette, 1974). Prolonged circulating levels of active progestogen are a
result of delayed absorption from the injection site due to the low solubility of the
microcrystals. This is reported to extend protection beyond the 3 month dosing interval
(Kaunitz, 1994).
Early published studies have determined serum or plasma concentrations of MPA after
intramuscular injection of 150mg of depot medroxyprogesterone acetate (DMP A) (Kirton
and Comette, 1974; Jeppsson and Johansson, 1976; Jeppsson et al, 1977; Ortiz et al,
1977; Shrimanker et al, 1978; Koetsawang et al, 1979; Fotherby et ai, 1980a; Fotherby et
a11980b; Bassol et al, 1984; Lan et al, 1984). However, these studies used a variety of
different assay techniques and, in all but three (Jeppsson et al, 1977; Koetsawang et al.
1979; Jeppsson and Johansson, 1976), MPA levels were reported after only one dose. In
addition, the sample sizes were small and none of the populations studied were African.
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MPA can be detected in the systemic circulation within 30 minutes of injection and levels
rise steadily to contraceptive levels within 24hours (Ortiz et al, 1977; Mishell , 1996;
Kaunitz, 2000). Following injection ofDMPA, blood concentrations ofMPA are reported
to peak within 3 weeks (Ortiz et al, 1977; Fotherby et al, 1980b; Jeppsson and Johansson,
1976; USP DI, 2002). A summary of peak levels reported is provided in Table 2.1.2.
Cornette et al (1971) reported that intramuscular injection ofMPA resulted in fluctuating
blood levels that were maximal at 2-15 days post injection and Jeppsson and Johansson
(1976) measured peak levels during the first week after injection. Fotherby et al (1980b)
reported peak concentrations, between 1 and 7ng/ml, within three weeks ofDMPA
injection in a study undertaken amongst 4 Indian and 4 Swedish women. In an earlier
study with 3 subjects, maximal MPA concentrations of 10-25ng/ml were achieved
between 5 and 20 days following intramuscular injection of 150mg ofDMPA (Kirton and
Cornett, 1974). It has been suggested that the higher serum levels reported in this study
could be because the assay (RIA) used measured additional substances as well (Ortiz et
al, 1997; Mishell , 1996). Higher peak serum concentrations were also reported by
Fotherby et al (1980a). Mishell (1996) suggested that the lack of an initial plateau and
relatively rapid decline in MPA levels in Fotherby's study could have been due to
manipulation of the injection site. This could also explain why higher peak levels of MPA
were recorded (Fraser and Weisberg, 1981; Mishell, 1996).
Kirton and Cornette (1974) found that MPA concentrations decreased to 5-10ng/ml by 30
days after DMPA administration. MPA concentrations are reported to remain fairly
constant in the range of 1.0-1.5ng/ml for the 2 to 3 months post injection (Ortiz et al,
1977) and MPA is reportedly absorbed at a relat ively constant rate over a 2 to 3 month
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period. Levels then decrease gradually to O.2nglmlby the sixth month and eventually to
undetectable levels ofless than O.02nglml by up to nine months (Ortiz et al, 1977; Lan et
al, 1984; Mishell , 1996).
Reported findings on MPA levels after injection ofDMPA are summarized in Table 2.1.2
and discussed in subsequent sub-sections. While these studies often reported peak,
plateau and/or trough MPA levels and/or the time after injection at which MPA
concentrations were still detectable, none reported pharmacokinetic parameter values of
MPA. Nevertheless many of these studies were referred to as pharmacokinetic studies.
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Table 2.1.2 Summary of relevant findings on MPA serum levels from key DMPA studies
Study Peak MPA Cone. Plateau or Trough MPA Min detectable MPA Effect ofMPA on
Cone. Cone. endogenous progesterone
levels
Cornette et al, 1971 Fluctuating blood levels Not reported Not reported Ovulatory status not returned
n=3 maximal at 2-15 days post beyond the 4th month post
Determination of the cone. of MPA inj. treatment as indicated by
(Provera) after i/m administration serum progestin levels
Kirton and Cornette, 1974 1O-25ng/ml 5-20 days post 5-lOng/ml by 30 days post 0.5ng/ml Progesterone levels ~
n=3 inj. inj. thereafter gradual ,J.. for levels >0.5ng/ml found in
Examined relationship between peripheral rest of study (260 days) a113 subjects up to 185 MPA cone. when
cones. ofMPA & progesterone after a days post inj. progesterone rise first
single i/m inj. of 150mg ofDMPA. detected: 5.1,0.8, <0.5ng/ml
Blood sampled prior to inj & post inj on @ 203, 238 & 245 days post
Mon, Wed, Fri for 9 specimens, then inj.
weeklyuntil return ofovulation
Jeppsson and Johansson, 1976 Maximum levels within Not applicable - all had <0.5ng/ml during treatment
n=2 first week after inj. detectable cone.
Measured MPA blood levels after i/m inj of
150mgDMPA Peak levels: Trough levels (at end of 12
week dosing period):
Subject 1: ±4ng/ml (after Subject 1: 0.5ng/ml at end
1st ever dose ofDMPA) of 12 week dosing period
Subject 2:_±3ng/ml (after Subject 2: 1ng/ml at end of
20th ini. ofDMPA) 12 week dosing period
Jeppsson et al, 1977 One week after inj. 0.6±0.lng/ml at end of i2 Not applicable - all had <0.6ng/m1 one week after inj.
n=l1 3.57±0.51ng/ml- the week dosing period detectable cones. and at end of dosing period
Women on long term treatment (6-18 doses) article doesn't indicate if
with DMPA 150mg i/m every 12th week. this is the peak level
Blood samples taken 6·15 days after inj. &
12 weeks after ini,
tv
Vl-





Study Peak MPA Cone. Plateau or Trough MPA Min detectable MPA Effect of MPA on
Cone. Cone. endogenous progesterone
levels
Ortiz et ai, 1977 1-3ng/ml within 24h o 1-1.5ng/m! for 2-3 mths Undetectable @ Rise in progesterone (luteal
n=3 o 0.5ng/ml in 4th_5 th mth. <0.02ng/ml ± 7.5 - 9 mths activity) only occurred when
Measured serum MPA & ovarian function o 0.2ng/ml in 6th mth. after inj. MPA <D.1ng/ml , 7-9 mths
after 150mg ofDMpA i/m. after inj.
MPA levels measured daily x2 weeks, then
3x a week for 3mths, then weekly until
undetectable
Shrimanker et al, 1978 7 days post inj.: 75 days post inj.: Not reported Not reported
N=10 (Thai) Range: 1.75-9.0ng/ml Range: 0.680-2.600ng/ml
Measured serum MPA 7 & 75 days after Mean (SD): 3.56ng/ml Mean (SD): 1.25ng/ml
l50mg DMPA given i/m (2.46) (0.62)
Koetsawang et iLL, 1979 Not measured Levels 90 days post in], 2 had levels <0.lng/mI90 Not measured
N=21 (Thai) After 1st ever dose: days post inj.
Serum MPA levels measured 90 days after Range: <0.10-1.28ng/ml,
i/mDMPA Mean: 0.61ng/ml.
10 received only one inj. 90 days prior to
blood sampling; After 8 consecutive doses:
11 had received 8 consecutive doses Range: 0.12-2.56ng/ml,
Mean: 0.90ng/ml
Fotberby et al, 1980a For 150mg dose: No initial plateau, & Days MP A detectable with Progesterone levels did not
n=20 (Thai) Mean (SD): 8.3ng/ml relatively rapid decline. lS0mg dose: rise until MPA <100pg/ml,
Measured MPA levels after different (3.16) Mean (SD): 92ng/ml initial rise of progesterone 3.5
DMPA doses (25,50, lOO lSOmg) on days (44.2) mths. after inj. of 150mg of
4-6 of cycle. DMPA
Blood sampled 2x weekly for 1 cycle prior





Study Peak MPA Cone. Plateau or Trough MPA Min detectable MPA Effect of MPA on
Cone. Cone. endogenous progesterone. levels
Fotherby et aI, 1980b Highest concentrations in Not specifically reported Undetectable <1OOpglml at Not specifically reported
[Only MPA findings summarized] 1st 3 weeks : 120-200 days post inj.
n=8 (4 Indian & 4 Swedish) 1-7ng/ml except in 2 slow absorbers
Comparative pilot study on PK & PO
properties ofOMPA & NET-EN.
DMPA given on day 1-5 of cycle
Blood sampled weekly 1 cycle prior to &
after inj. until resumption ofovulation or
6mths post ini.
Bassol et at (1984) Not specifically reported Not reported MPA remained detectable Not specifically reported
n=20 (Mexican) after 140 days with 150mg
Subjects randomly assigned to 4 groups & Graphically presented data dose
different DMPA doses given to each group indicate levels ± Ing/ml
(25,50, 100 150mg) with dose of 150mg
DMPA given on day 4-6 ofcycle. Blood
sampled 2 weekly for 6mths
Lan et at (1984) Not measured MPA levels @ 14th week MPA was undetectable Progesterone profiles
n=8 (Swedish) post inj. ranged from 0.9- between 17 & 24 weeks in suggested that ovulation
Single dose (l50mg) ofDMPA given 2.24 nmol/L* 4 cases, and after week 33 occurred between 20 and 49
MPA levels measured 3 times a week in 4 cases. (lower level of weeks.
during pre-treament (control) cycle, then detection = 250pmol/L*) Based on progesterone
daily during post inj. weeks 14-17,22-25, profiles, ovulation was judged
and 30-33. to have occurred in 7 ofthe
women when MPA levels
were undetectable; in one
woman MPA levels were very
low, but still detectable
Conc.=concentration; inj .=injection; ilm= intramuscular; mth=month; PK=pharmacokinetic; PO=pharmacodynamlc
*1 nmollL=0.3865nglml
2.1.1.4 Distribution and Metabolism
MPA circulates in the blood bound by protein, especially serum albumin (Akpoviroro et
a11981; Perez-Palacios et al, 1981; Garza-Flores et al, 1992; Martindale, 2002). It has a
low affinity for sex hormone-binding globulin (SHBG) (Garza-Flores et al, 1992; Gibbon
and Swanepoel, 1995) and is also not bound to corticosteroid-binding globulin
(Akpoviroro et ai, 1981,. Perez-Palacios et al, 1981; Garza-Flores et al, 1992). These
authors point out that the way in which MPA is transported in the blood is unusual and
differs from that of natural progesterone. It is however unclear why MPA differs from
progesterone in this way.
Unchanged MPA is the active molecule, and is responsible for the contraceptive effect of
DMPA (Akpoviroro et a1198l; Garza-Flores et al, 1992). MPA is metabolized in the
liver and excreted mainly as glucuronide conjugates in the urine and faeces (Martindale,
2002; USP DI, 2002).
Ohtsu T et al (1998) conducted a study comparing the pharmacokinetics of high oral
doses ofMPA (120Omg), administered daily to women being treated for cancer, versus
lower doses (600mg). Intersubject variability in the pharmacokinetic parameters (area
under the concentration versus time curve, peak plasma concentration, me~n minimum
steady-state concentration) was found. The authors speculated that MPA is metabolised
in a similar way to progesterone by the cytochrome P450 system. They point out that
marked interindividual variability in P450 of the small bowel and liver has been reported,
and endogenous and exogenous factors (such as age, blood pH, concomitant diseases and
drug therapy, meal preparation procedure, nutritional habits and smoking) are thought to
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contribute to P450 system heterogeneity. If MPA is metabolized by the cytochrome P450
system it might explain the interindividual variability in the pharmacokinetics ofMPA.
Population differences in the metabolism of contraceptive steroids have also been
suggested (Fraser and Weisberg, 1981). However, in an extensive review ofDMPA
which was published in 1981, these authors pointed out that, given that DMPA had been
available for a considerable length of time, surprisingly little is known about its
metabolism and excretion. Over two decades later, there is still very little published on
the metabolism of DMPA.
The efficacy ofDMPA may be impaired by the concomitant administration of enzyme-
inducing agents such as rifampicin, phenytoin, meprobamate and alcohol. In cases where
these drugs are used with DMPA it is recommended that DMPA be administered every 8
weeks instead of every 12 weeks (Gibbon, 2000; National Department of Health, 1998).
2.1.1.5 Elimination
MPA is rapidly cleared from the bloodstream and its prolonged presence in the blood is
said to be due to slow release from the injection site (Ortiz et al, 1977). Gupta et ai,
(1979) reported a high metabolic clearance rate of 1668liters per 24 hours after 50 IlCi
eH]medroxyprogesterone acetate was administered intravenously. This is lower than for
progesterone but still shows rapid metabolism (Fraser and Weisberg, 1981). In the studies
summarizedin Table 2.1.2 the half-life (t y,) ofDMPA is not provided. However, Garza-
Flores et al (1994) described a highly variable DMPA half-life in reviewing unpublished
data from some ofthese studies, with ty, varying from 24.1days to 112.2 days (Table
2.1.3). The ty, was reported to vary between population groups , with a shorter ty, for Thai
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women than for the Mexican women (Table 2.1.3). Likewise the area under the curve
(AUC) was also highly variable between studies and populations (Table 2.1.3).
Table 2.1.3 Mean pharmacokinetic parameters ofDMPA (150mg) in 3 studies
undertaken among Thai and Mexican women
Study (n) Tmax(days) Cmaxnmol/L tYz (days) ADC T, (days)
(~ng/ml)* nmol.day/L
Thai (10 thin) 7.0±3.2 16.5±6.1 27.4±22 .8 606±307 160±73
(6.4)
Thai (10 obese) 8.6±4.9 18.2±15.7 30.2 ±18.1 582±326 145±42
(7.0)
Mexican (5thin) 22.4±14.5 2.3±0.9 56.4±42.8 96±22 171±95
(0.9)
Mexican (5coese 8.8±3.0 2.4±0.8 112.2±117.8 93±25 305± 274
(0.9)
Thai (5) - 21.5±8.3 24.1±23.6 558±79 92±44
(8.3)
Mexican (4) - 3.4±5.2 62.5±23.7 259±152 187± 85
(1.3)
Thai (14) 8.0±3.7 25.9±16.3 24.3±18.1 606±352 143±78
10.0
Adapted from Garza-Flores et al (1994). Primary data from these studies appear to be unpubltshed
*1 nmollL=0.3865ng/ml
Cmax=maximum serum concentration; ty,=half-life; AUC=steady-state area under the serum concentration-
time curve ; Tc=time to reach serum concentration below limit ofdetection «0.259)
According to the USP DJ (2002) and the US approved physician prescribing information
published on the manufacturer's website (Pharmacia and Upjohn, 1999), the apparent t\l,
forthe 150mg intramuscular dose is approximately 50 days. The t\l, after oral
administration is reported to be 30days (USP DJ 2002).
Trough levels ofMPA and time taken for MPA levels to become undetectable, as
reported in the published literature, are summarised in columns three and four of
Table 2.1.2. Most of these studies clearly illustrate that MPA concentrations above the
level required for contraceptive efficacy (O.1ng/ml) were attained up to and beyond the
DMPA dosing interval of 12-13 weeks. Circulating levels of MPA could be detected up
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to 9 months following injection of DMPA (Table 2.1.2). For instance, Kirton and
Cornette (1974) found that, at the time that a rise in progesterone serum concentrations
was first detected, MPA concentrations in the study 's 3 subjects were 5.1, 0.8, and
<0.5ng/ml and occurred at 203,238 and 245 days after injection of MPA. Levels above
the minimal detectable concentration of 0.5ng/ml were found in all 3 subjects up to 185
days post injection. Ortiz et al (1977) reported that MPA became undetectable
«0.02ng/ml) seven and a half to nine months post injection. Kirton and Cornette (1974)
concluded that a single intramuscular dose of 150mg of DMPA inhibited formation of a
functional corpus luteum for ~200 days. Similarly, Lan et al (1984) deduced that DMPA
suppressed ovulation for at least four to five months.
However in one study (Fotherby et aI1980a), MPA was detectable for more than 100
days in only 1 of 5 women who received 150mg of DMPA, it was detectable for about 90
days in 2 subjects and was undetectable by days 55 and 64 in 2 subjects. The authors of
this study pointed out that their findings were not consistent with other studies which had
shown detectable levels ofMPA for 200 days or more. Nevertheless, luteal function was
inhibited in all five subjects for longer than the 90 day dosing interval. Mishell (1996)
commented on the different pattern ofMPA clearance found in the Fotherby et al study
(1980a) and speculated that the differences could be attributed to manipulation of the
injection site, causing more rapid dispersion of MPA.
Four studies have reported specifically on serum or plasma MPA levels at the end of the
DMPA dosing interval. In the first study of two women , the MPA levels 12 weeks after
injection were reported to be approximately 0.5ng/ml in a woman who had had one
previous injection, and 1.0ng/ml in a woman who had received her 20th injection
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(Jeppsson and Johansson, 1976). The second study of 11 women who had received
between 6 and 18 injections, found a mean (SD) MPA level of 0.6 (±0.1)ng/ml 84 days
after the last injection (Jeppsson et al,1977). In the third study, amongst Thai women who
had received only one injection (n=10) 90 days earlier, plasma MPA levels ranged
between <O.lOng/ml and 1.28ng/ml, with a mean ofO.61ng/ml. In those who had received
8 consecutive doses (n=ll) the range was 0.12ng/ml to 2.56ng/ml, with a mean of
0.90ng/ml. The difference between the groupreceiving multiple injections and the group
receiving only one injection was not statistically significant (Koetsawang et ai, 1979).
The fourth study by Lan et al (1984) MPA levels of8 Swedish women ranged between
0.9 and 2.24 nmol/L (:::::0.35-0.87ng/ml)14 weeks after injection.
2.1.1.6 Variability
Large intraindividual, interindividual and interpopulation differences in pharmacokinetic
parameters of contraceptive steroids have been reported (Aedo et al, 1985; Garza-Flores
et al, 1994; Sang, 1994). The variability has been attributed to factors such as body
weight or size, ethnic differences in fat distribution and storage of steroid in fat cells,
levels of protein such as sex hormone binding globulin, genetic factors, dietary factors
and drug interaction or disease.
Interindividual Variability
Koetsawang et al (1979) describes the interindividual variability in 21 Thai women,
whose MPA levels were found to vary from 100 to 2560 pg/ml , (mean = 897 pg/ml) 90
days after DMPA injection. Fotherby et al (1980b) found that DMPA became
undetectable by between 120 and 200 days after injection in all but 2 of 8 women studied.
Levels in these 2 women were still detectable beyond 200 days after injection and it was
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postulated that these 2 women, an Indian and a Swede, absorbed DMPA very slowly.
Several review articles also comment on the interindividual variability of MPA levels in
DMPA users (Sang, 1994; Kaunitz, 2000) . Sang (1994) cites personal communication
with Dr Odlind ofUppsala University, Sweden, who found a significant negative
correlation between peak value and body weight (p<0.05), and area under the curve
(AUC) and body weight (p<0.02), in a pharmacokinetic study of women using two
DMPA preparations (Gestapuran depot and Depo-Provera). Lan et at (1984) also
comment on the interindividual variation in return of ovulation, metabolism and
elimination ofMPA amongst the 8 Swedish women they studied. However, in this study
no correlation was found between the obesity index ofthe subjects and the time taken for
MPA levels to become undetectable.
Rahimy et at (1999b) studied the pharmacokinetics of the combined injectable containing
25mg ofMPA and 5mg of estradiol cyprionate (Lunelle'") administered every 28 days.
They found that trough levels at the end of the dosing interval were consistently above the
threshold MPA concentrations of 0.10-0.20nglml necessary to suppress ovulation.
However the authors of this paper did not recommend lowering the dose ofMPA because
of substantial interindividual variability in levels of MPA, especially at the end ofthe
dosing interval (range of individual concentrations at day 28 after the third monthly
injection: 0.24-0.71nglml). Rahimy et al (1999a) found that while MPA tended to be
absorbed more quickly by thin women, the average trough MPA levels were higher in
thin than in obese women ruling out the possibility of reduced efficacy in thinner women.
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Interpopulation Variability
Evidence of differences in interpopulation MPA metabolic clearance rates and disposition
has been shown (Garza-Flores et al, 1992; Garza-Flores et al, 1994; Sang, 1994). A
study amongst 20 Thai women (Fotherby et al, 1980a) showed a significant difference in
the length ofDMPA induced ovarian suppression at all four dosing regimens used,
compared with a similar study undertaken amongst 20 Mexican women by Bassol et al
(1984). A longer delay in resumption of ovulation was observed in the Mexican women.
The radioimmunoassay method described by Shrimanker et al (1978) was used in both
studies (Fotherby et al, 1980a; Bassol et al, 1984).
Ovulation was inhibited in all Mexican women for at least 3 months, even at the 25mg
dose. The authors point out that this was in keeping with the longer disappearance of
MPA from the serum in this population (Bassol et al, 1984). Garza-Flores (1994) and
Sang (1994) reviewed MPA data on Thai and Mexican women and conclude that, for
Thai women, the serum MPA peak was significantly higher and reached earlier, serum
concentrations of MPA decreased more quickly and ovulation returned sooner. Sang
(1994) comments further that these differences could not be explained by body weight
differences only.
In the study amongst four Swedish and four Indian women, progesterone levels amongst
the Indian women suggested an early return of some luteal function within 73 days with
MPA levels> 600pg/ml (Fotherby et a11980b). The Swedish women did not ovulate until
more than 156 days after injection when MPA levels were undetectable. However the
Indian women ovulated within 73 days of injection when MPA levels were still over
0.6ng/ml. No significant differences were found between the two groups for time taken
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for plasma MPA to be undetectable, however differences in return to luteal function were
significant (Fotherby et aI1980b). Few other studies comparing interpopulation
variability have been published and the Fotherby et al (1980a) and Bassol et al (1984)
studies are cited repeatedly in reviews of the pharmacokinetics ofDMPA (Garza-Flores et
al, 1992; Garza-Flores et al, 1994; Sang, 1994).
Findings from a large randomized multicentred comparative trial on the use-effectiveness
of200mg ofNET-EN and 150mg DMPA, with both preparations given every 12 weeks,
showed that the body weight ofNET-EN users who became pregnant was significantly
lower than those who did not conceive (World Health Organization, 1977). In this study, 24
NET-EN users (n=832) and 4 DMPA users (n=846) became pregnant. As a result of these
findings, the NET-EN dosing interval was reduced to every 2 months and studies on the
influence ofweight on the pharmacokinetics ofDMPA and NET-EN were undertaken. In a
review ofthe studies amongst DMPA users ofdifferent populations, no significant
differences were observed between fat and thin women, but a tendency for the thin women
to absorb the hormone more rapidly was found (Garza-Flores et al, 1994). However peak
values ofMPA were found to be "almost an order ofmagnitude greater in Thai women than
in Mexican women, and the area under the curve was some six-fold greater" p.72 (Garza-
Flores et al, 1994). The reviewers ofthese studies (Garza-Flores et al, 1994) postulated that
differences in fat distribution and adipocytic metabolism are a major influence on the
pharmacokinetics of the long-acting hormonal contraceptives and explain the
pharmacokinetic differences between Thai and Mexican women. A WHO study on the
combined injectable containing 25mg ofMPA and 5mg of estradiol cyprionate (HRP112)
also found differences in the pharmacokinetics of MPA between Mexican and Thai
women. The implications for South African women are important, given their morphology.
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Since no significant differences were found in serum levels of MPA when DMPA was
given in doses of 100 or 150mg, the possibility of reducing the dosage of DMP A from
150mg to 100mg, especially for Mexican women, was considered (Garza-Flores et al,
1994). This led to a multi-centred study comparing the efficacy and side effects ofdoses
of 100 and 150mg of DMPA (World Health Organization, 1988). Little difference was
found between the 2 groups. However, because of the occurrence of2 pregnancies in the
100mg group (n=609), there was a reluctance to reduce the dose. Garza-Flores et al (1994)
in reviewing these findings suggested that improved formulation of DMPA may, in the
future, result in dose reduction. The 2 women, 1 from Jamaica and 1 from the Philippines,
who conceived whilst taking 100rng ofDMPA had a Quetelet's Index23 of 16.7 and 21.3
respectively. These values suggest that these 2 women were thin as they are consistent with
the Quetelet's indices found in women classified as thin in Fotherby and Koetsawang's
(1982b) study of the metabolism ofDMPA amongst thin and obese women. It is ofnote
however that Fotherby and Koetsawang (1982b), in comparing the thin (n=lO) and obese
(n=10) women, found no difference in serum levels ofDMPA, nor in the rate ofreturn of
ovarian, follicular and luteal function.
Garza-Flores et al concluded that, despite the small sample sizes and wide interindividual
variability, Thai women irrefutably absorb DMPA more rapidly, resulting in higher peak
serum concentration levels and more rapid elimination than Mexican women. They suggest
that these differences appear to be due to "ethnic difference in fat distribution and the
behaviour of fat cells in steroid storage" (Garza-Flores et al, 1994, p. 81).
23 Quetelet's Index: weight divided by the square of height (W/H2)(Fotherby and Koetsawang, 1982b , RM61)
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Differences were also observed between Thai and Mexican women in regard to the
pharmacokinetic parameters ofMPA when given in combination with estrogen. Thai
women exhibited higher peak serum concentrations, which also occurred earlier (WHO
1987). In reviewing these findings, Garza-Florez (1994) calls for further study ofpopulation
differences in MPA pharmacokinetics.
2.1.1.7 Combination Progestogen/Oestrogen Injectables
In reviewing the pharmacokinetics of DMPA it is appropriate to note that there are
published studies on the pharmacokinetics of combined progestogen/oestrogen
injectables, including a number of studies undertaken in the 1980s. They comprise a
combination of synthetic progestogens and short or medium acting oestrogen, and are
administered on a monthly basis. Amongst these were studies published by Fotherby et at
(1982a), Aedo et at (1985) and the World Health Organization (1987). Some
pharmacokinetic parameters for MPA were reported in these two studies (see Table 2.1.4).
Table 2.1.4 Comparison of mean pharmacokinetic parameters of MPA reported in
studies of combined progestogen/oestrogen injectables
e ". Values converte.d from nmol/L (I nmol/L 0.3865ng/ml) , ty, reported ill Rahimy et ai, 1999b
Tmax= time to reach maximum concentration; Cmax=maximum serum concentration; AUC=steady-state
area under the serum concentration-time curve; Cday 2&= trough ; ty,=half-life
Pharmacokinctic Aedo et al1985 WHO 1987 Zhou et al1998 Rahimyetal
Parameters 8 Swedish ~ 7 Thai ~ 9 Chinese ~ 1999b
8 Mexican 2 14 US 2
Cyc1oprovera HRP112 Cyclofem" Lunelle™
Dose 25mgMPA& 25mgMPA& 25mgMPA& 25mgMPA&
5mg estradiol 5mg estradiol 5mg estradiol 5mg estradiol
cyprionate cyprionate cyprionate per cyprionate per
0.5rnl (post 6th 0.5rnl (post 3rd
injection) injection)
Tmax(days) not reported 2.3 (Thai) 4.3 3.5
7.8 (Mexican)
Cmax(ng/rnl) 1.12* 3.6 (Thai) 2.14* 1.25
1.5 (Mexican)
Cday28 /trough 0.28* not reported 0.93* 0.47
(ng/ml)
t y, (days) 14# 12.1115.4 12# 14.7
Not S' * -
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Relevant findings on MPA pharmacokinetics from 2 recent studies of the combined
injectable contraceptives, Cyclofem'" and Lunelle™ are summarized in Table 2.1.5 and
Table 2.1.6.
It should be noted that the recommended contraceptive dose ofMPA for the combined
injectable agents is much lower (25mg) than for the MPA-only injectables (150mg), and
that they are given in combination with oestrogen (Zhou et al, 1998; Rahimy et al, 1999b)
on a monthly basis. Despite the lower dose ofMPA in combined injectables, similar peak
MPA concentrations to the DMPA-only products were found (Tables 2.1.2, 2.1.4, 2.1.5
and 2.1.6). Studies on combined injectables ( MPA/estradiol cyprionate) give a half-life





Table 2.1.5 Summary of mean pharmacokinetic parameters of MPA after the 6th injection of Cyclofem'"
Study Tmax C max AUC~28 MRT C day28 [trough]
(day) (nmol/L)* (nmol-day/L)" (days) (nmol/mL)
Zhou et al1998 4.3 ±2.2 5.54 ± 1.79 95.45 ± 26.56 12.77 ± 0.47 2.43 ± 0.70
n=9 (Chinese) {::::: 2.14 ng/ml) (::::: 0.93nglml)
Cyclofem" given i /m every month for up to a year
Dose: 25mg MPA & 5mg estradiol cyprionate/O.5ml Wide inter- Wide inter-
Blood sampled immediately prior to injection & on days individual variation individual variation
1,3,5,7,14, 21,28 during 1st, 6th, 12th treatment cycle
Tmax= time to reach maximum cone.; Cmax=maximum serum cone. ; AUC=steady-state area under the serum concentration-time curve; MRT=mean residence time,
indicating the duration necessary for 63.5% ofa given dosage to leave the body from time of administration: MRT=AUMC/AUC; AUMC=area under the moment curve;
Cday2s=day 28 serum cone
Table 2.1.6 Summary of steady-state pharmacokinetic parameters of MPA after the 3rd monthly injection of Lunellef
Study Tmax C max AUC O_28 ty, Cday28
(day) (ng/ml) (ng-day/ml (ng/ml)
Rahimy et ai, 1999b Mean : 3.5 Mean: 1.25 Mean: 21.51 Mean: 14.7 Mean: 0.47
n=16 (US); 14 completed SD:2.9 SD:.33 SD: 3.98 SD: 7.8 SD: 0.14
study; 13 white, 1 black Range:l-l0 Range: 0.94-2 .17 Range: 14.44-27 Range: 6.2-36.0 Range:0.24-0.71
Lunelle™ given i/m 'every 28 days x 3 months.
Dose: 25mg MPA & 5mg estradiol cyprionate/O.5ml
Took 63-84 days to
drop below 0.1-
Blood sampled on days 3-7 ,12,14, 0.2ng/ml (Le. to fall
18,21,28 prior to inj. Then days 1,29,57 after first inj. below the lower
Then days 58,60,62,64,67,69,71,75,78,85 and weekly limit of
until day 141. quantitation)
Tmax= time to reach maximum concentration; Cmax=maximum serum concentration; AUC=steady-state area under the serum concentration-time curve; ty,=half-life,
Cday28 = trough (post Ist dose); SD= Standard Deviation
2.1.2 DETERMINATION OF PHARMACOKINETIC PARAMETERS
A number of methods can be used to estimate pharmacokinetic parameters including
compartmental modelling and noncompartmental methods. With compartmental modelling
methods there are two broad approaches: the traditional methods using rich experimental
data, and the alternative population approaches which use sparse routine patient data (Sheiner
and Beal, 1980a).
2.1.2.1 The Traditional Approach
Traditionally, pharmacokinetic studies involve a small number of subjects with a relatively
large number ofplasma concentration values (Whiting and Kelman, 1985). A limitation of
this approach is that the numbers of representative patients may be insufficient and results
may be imprecise with a biased estimate of variability (Whiting and Kelman, 1985).
Traditional pharmacokinetic studies are also known as the standard two-stage (STS)
approach (Sheiner and Beal , 1980b) when attempting to relate parameter values to other
patient factors such as weight. The pharmacokinetic parameters of an individual are
calculated by analysing data collected from that individual using weighted or un-weighted
non-linear regression with the least-squares criterion. Least-squares regression is used to
calculate the relationship between the pharmacokinetic parameters and physiological factors
(Sheiner and Beal, 1980a; Sheiner and Beal, 1980b).
2.1.2.2 The Population Approach
The alternative approach, a population approach, can be successfully used to estimate
population pharmacokinetic data from sparse clinical data, obtained from a large number of
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individuals, during routine care (Sheiner et aI1977, Sheiner and Beal , 1980a, Sheiner and
Grasela, 1991; Whiting and Kelman, 1985). Typically one or two concentration values are
obtained for each subject. This approach provides results which are highly representative of
the subjects being studied with the population being the unit of analysis rather than the
individual (Whiting and Kelman, 1985).
• "The principle aim of population pharmacokinetic analysis is to account for the inherent
kinetic variability within a population ofpatients in terms of readily identifiable factors
which may be physiological, pathological, environmental or genetic." (Whiting et al, 1986,
p.398). Population pharmacokinetics describes this variability in terms of fixed effects
(true pharmacokinetic variability) and random effects (inter- and intra-individual
variability) (Whiting et al, 1986) in the form of nonlinear mixed effect modelling.
Data required for population pharmacokinetic analysis include:
• Kinetic data: dose, route of administration, dosage interval, whether steady-state has been
achieved, details ofdosage history, concentration measurements and time(s) since previous
dose (Whiting et al, 1986).
• Demographic data: age, sex, weight, height, race, patho-physiologic status, nutritional
status, smoking habits, alcohol consumption, eo-medication, biochemical and
haematological indices (Whiting et al, 1986).
The population approach to estimating the pharmacokinetic parameters of DMP A allows for
the use of data collected from women routinely using the injectable contraceptive, thus
generating pharmacokinetic parameters more likely to be representative of injectable users.
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Further, as the subjects are comprised of women from the general population, the possibility
of a chance discovery of a previously unknown influence exists . The population approach is
also a more ethical approach as the women recruited into the study are likely to have chosen
to use the method prior to recruitment and few blood samples are required per subject
(Whiting et al, 1986; Wahlby, 2002).
The main limitations of the population approach are:
• A sophisticated statistical approach is required to analyse the data
• Bias may be introduced due to the effects of unknown concomitant variables (e.g. an
undisclosed drug interaction) that are correlated with included variables
• Model misspecification may lead to erroneous results (Sheiner et aII977; Sheiner and
Beal, 1980a).
Sang (1994) has highlighted the need for population pharmacokinetic studies of steroidal
contraceptives in order to assess regional or population differences. He questioned the
clinical significance of comparisons made between regions or populations where a
population approach has not been adopted and stresses the importance of collecting data in
the population actually using the contraceptives. An extensive literature search has revealed
no published population pharmacokinetic studies of injectable hormonal contraceptives. In
South Africa, studies of this kind are ofparticular importance since injectable methods are
extensively used, particularly by African women. In addition, and unlike most other places in
the world, injectables are widely advocated for use in young women.
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Population pharmacokinetics describe the pharmacokinetic variability of drugs in tenus of
mixed effects, that is, a combination of fixed and random effects (Whiting et al1986):
• Fixed effect parameters consist of mean values of pharmacokinetic parameters such as
drug clearance (CL), volume of distribution (Vd), absorption rate constant (KA) and
bioavai1abi1ity (F), as well as the relationship to patient factors such as weight, age and
creatinine clearance.
• Random effect parameters quantify the interindividua1 error and the residual error.
Pharmacokinetic analyses have advanced due to the development of appropriate computer
software capable of analysing population pharmacokinetic data (Whiting et al, 1986). One
such programme, NONMEM (Nonlinear Mixed Effects Model) (Beal and Sheiner, 1980;
Bea1 and Sheiner, 1992) is discussed here, as this programme was used to test models
describing MPA pharmacokinetic behaviour in the present study. The statistical model used in
the NONMEM programme is based on the premise that individual pharmacokinetic parameters
of a patient population arise from a distribution which can be described by the population mean
and the interindividual variance (Whiting and Kelman, 1985).
Non-linear mixed effects models consist of three sub-models (Wahlby, 2002):
• The structural or pharmacokinetic sub-model describing the main tendency in the data.
• The statistical sub-model which includes the models for interindividual and residual
variability.
• The covariate sub-model describing relationships between covariates and model
parameters by means of fixed effects parameters.
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Each sub-model is selected separately and the model building process usually proceeds in a
step-wise fashion (Beal and Sheiner, 1992; Ette and Ludden, 1995).
NONMEM can also be used to investigate the possibility of inter-occasion variability (IOY)
which occurs when a parameter (e.g. clearance) varies within subjects between study
occasions (Karlsson and Sheiner, 1993). Failure to identify IOV may result in model
misspecification, biased parameter estimates and false co-variate relationships (Karlsson and
Sheiner, 1993).
2.1.3 OBJECTIVES
As discussed in the above review few studies have been undertaken on the pharmacokinetics
of DMPA. Sample sizes are small and assays have been inconsistent or not specific,
sometimes measuring other substances in addition to DMPA. Despite the widespread use of
DMPA in South Africa there are no published pharmacokinetic parameters for DMPA
amongst South African DMPA users or amongst African DMPA users. Several international
studies highlight the interindividual variability in the pharmacokinetics of DMPA.
Interpopulation variability has been suggested by some researchers and has been attributed to
differences in fat distribution and fat cell storage of MPA amongst different ethnic groups,
with women with heavier builds showing a tendency to have more prolonged MPA levels
and longer delays in resumption of ovulation than women of a lighter build. These population
differences are less important when considering the efficacy ofDMPA in the standard dosing
regimen, but may be important considerations for those women who experience intolerable
side effects with DMPA, like menstrual disturbances and/or a long delay in return to fertility.
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Since South African DMPA users tend to be of a heavy build, it is possible that at the
recommended dose, DMPA may remain in the body for longer periods of time than expected.
While there have been no population pharmacokinetic studies of MPA, this approach may be
particularly useful in estimating pharmacokinetic parameters for this substance. Accordingly
the objectives of this study were to:
• Measure MPA levels in South African DMPA users
• Use the population approach to:
determine the pharmacokinetic parameters, clearance and volume ofdistribution
investigate the possible influence of covariates such as weight, BMI and ethnicity on
the pharmacokinetic parameters of MPA.
27 1
CHAPTER 2.2 METHODS
This study was undertaken at family planning clinics in Durban, South Africa amongst
women routinely attending for family planning services.
2.2.1 ETHICAL APPROVAL AND CONSENT
The study was approved by the ethics committees of the University ofDurban-Westville
(Ethics approval Number 960l4B) and the Nelson R Mandela School of Medicine ofthe
University ofNatal (Ethics clearance number HI 50/00) . Permission to conduct the study
at Durban local health authority family planning clinics was obtained from the Durban
City Medical Officer ofHealth, the Deputy Medical Officer ofHealth, and the Chief
Nursing Sister of the Durban City Health Department.
Prior to commencing the study, workshops were held with all nursing staff of the three
clinics involved to develop the interview schedule. They received comprehensive training
about the study objectives, protocol and procedures. Women who were requested to
participate in the study were provided with verbal and written information about the study
(in English and/or Zulu) . They were assured that participation was voluntary and that all
information would be confidential. Each study participant signed a consent form provided
by the Durban City Health Department in accordance with the local health authority
protocol for research being conducted at their facilities. They were assured that they could
terminate participation in the study at any stage without their subsequent management being
compromised. Client information sheets and instructions to family planning nursing staff
involved in the study are shown in Appendix 2.2.1. All information collected has been
stored and used in a manner which ensures the protection ofparticipants' rights to
confidentiality, anonymity and privacy.
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2.2.2 STUDY POPULATION
Study participants were recruited at three municipal family planning clinics in Durban.
Quota sampling (Bernard, 1994) was used to select the three clinics , Lancer 's Road,
Chatsworth and Bluff, in order to ensure a spread of ethnic groups (African, Indian,
Coloured and White). After consultation with internationally recognised
pharmacokineticists, and taking into account practical considerations such as the need for
minimal disruption of the clinic and the high cost of the blood assays, a sample size of
120 was decided on (40 women per clinic). Only women who were already acceptors
(new or current users) of the depot medroxyprogesterone acetate (DMPA) product Depo
Provera®(Pharmacia & Upjohn) were eligible for recruitment. Starting in October 1996,
all acceptors attending the clinics were invited to participate in the study. Clients were
recruited until the target of 40 women per clinic was reached and by the end ofNovember
1996, 122 Depo Provera®users had been recruited.
2.2.3 DRUG ADMINISTRATION
The dosage regimen for DMPA at the clinics is 150mg every 12 weeks given by
intramuscular injection into the gluteal or deltoid muscle.
2.2.4 DATA COLLECTION
The study involved the collection of:
• Demographic data including: age, weight, height, race, pathophysiologic status,
nutritional status, smoking habits, eo-medication, blood pressure measurements,
biochemical and haematological indices, and side effects experienced with DMPA use.
• Drug information including: dose, dosage interval, time since previous dose, duration
ofuse.
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• Blood samples to assay for MPA.
The client interviews were conducted and blood samples drawn by the clinic nurses. The
interview schedule can be found in Appendix 2.2.2. Data collection was completed in
March 1997. Blood samples were drawn from each woman every four weeks over a period
of4 months. For repeat users ofDMPA, the first sample was drawn on the day of return to
the clinic for their next dose, that is approximately 12 weeks after their last dose.
Thereafter, they were requested to return to have further samples taken four and eight
weeks later. For new users, blood samples were drawn on the day ofrecruitment and four
and eight weeks after receiving their first injection. In the case of early study recruits, a
fourth blood sample was drawn 12 weeks after recruitment. Even if a women returned early
or late for her scheduled appointments, a blood sample was taken. A detailed interview was
conducted with each woman at each visit (Appendix 2.2.2). Where necessary, the study
clinic staff followed-up telephonically to remind clients to return to have blood samples
taken. Participants were given a ZAR20grocery voucher at each blood sampling appointment
to cover transport costs. Cash reimbursement could not be provided for security reasons.
On the day of sampling blood samples were stored in the clinic refrigerator. They were then
collected from the family planning clinics on a daily basis by research staff, and transported
to the university laboratory in cooler boxes. After centrifuging at 3700 revolutions per
minute for 10 minutes, the resultant serum was stored at -70°C, until couriered in dry ice
by DHL Worldwide Express to Irnrnunometrics Ltd., London, United Kingdom for
analysis. The samples were packed in dry ice with the assistance of FARMOVS Research
Centre at the University of the Free State.
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2.2.4.1 Exclusions
The following subjects were excluded:
one woman from whom the clinic sister was unable to draw a blood sample
three first-time users who did not return for further appointments thus no serum samples
were obtained
insufficient samples were available for four women (Immunometrics,1999: MPA
laboratory assay results , Final Report)
the interview schedule for one woman was lost by the clinic staff
Thus nine women were excluded, leaving 113 women in the study.
2.2.5 MPA ANALYSIS
MPA was measured using a Tritium-labelled radioimmunoassay (RIA) with charcoal
separation developed for the World Health Organization Special Programme ofResearch
in Human Reproduction.i" as described by Ashan et al (1998). The analytical work was
performed by Immunometrics Ltd., London, United Kingdom in 1999, and detailed in a
report from which relevant extracts on the quality control and assay procedures employed
are provided below:
2.2.5.1 Summary of RIA
Calibration: Steroid-free human serum with preservative containing
medroxyprogesterone acetate solution (concentration of MPA solution added to serum
24 Recognising the difficulty in interpreting results from different studies, the World Health Organization's
Task Force on the Long Acting Systemic Agents for Fertility Regulation has produced standardised
protocols and matched reagents for radioimmunoassay of synthetic progestagens [Ashan et al, 1998].
275
confirmed by UV Absorbance).
Analytical sensitivity: 96 pmol/L. Defined as 3 x SD of measurement of zero dose, i.e.
lowest dose analytically distinguishable from zero .
Detection limit: 102 pmol/L (0.04ng/mL). This is the lowest level for which
Immunometrics Ltd consider the assay provides a reliable quantitative result, and is the
lowest point on the standard curve.
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The full assay protocol and reagent batches used in this study are documented in the Final
Report Appendices (Immunometrics, 1999).
2.2.5.2 Quality Control Materials
In all assay batches, medroxyprogesterone acetate was measured in 3 different Quality
Control (QC) Pools which cover the range of the standard curve. QC pools were prepared
by addition of medroxyprogesterone acetate solution to steroid-free human serum.
2.2.5.3 Quality Control and Acceptance Criteria
Data processing programme
Beta-counts measured were entered into the Data Processing Programme - the
programme used was the WHO Immunoassay Program, written by PR Edwards
(Department ofMolecular Endocrinology, University College London Medical School ,
London). Results were calculated in pmollL.
All data entry stages were checked for all data points, and any errors corrected.
Standard curve fitting
Each point of the standard curve was measured in duplicate in every assay. The standard
curve was fitted from the data using a single-binding site model. All points of the
standard curve were used in curve fitting, and none were dropped in order to improve the
curve fit.
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Subject samples and QC pools
Samples were stored at -20°C until analysis. Samples were identified by study number
and date ofvisit. All subject samples and QC pools were assayed in duplicate. Any
duplicate results identified by the data processing programme as poor replicates (defined
as observed SD more than three times the SD predicted at that dose) were re-assayed until
results met this limit. Of all samples in the study, 7 were identified as poor replicates and
re-assayed.
Dose estimates above the highest standard are not reported. 15 study samples gave results
above the highest standard dose. These samples were re-assayed after dilution in zero
standard (steroid-free human serum).
Three samples with high results within the standard range (near the highest standard dose)
were assayed at several dilutions (i.e., 1:2, 1:4, 1:8 sample:zero standard by volume) to
establish linearity of results on dilution.
The dilution of the high samples was selected so that the diluted result fell within the
most precise dose range of the precision profile, i.e., approximately 800 to 2500 pmol/L.
This was the 1:5 dilution. Reported results were corrected for dilution.
All samples from a subject (except poor replicates or high dose samples as specified in
the previous paragraphs) were assayed in the same assay batch to minimise the effects of
between batch bias .
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QC pools were assayed in duplicate at the beginning and end of each assay. Three pools
were used in this study. Target values and acceptance criteria are listed in Table 2.2.1.
QC pools were prepared by adding a solution ofmedroxyprogesterone acetate to steroid-
free human serum. The MPA concentration of the solution added was confirmed by DV
Absorbance. The target values were set according to the concentration of MPA added.
The acceptance criteria were set as a percentage of the target value.













2.2.5.4 Assay Acceptance Criteria
Assays were accepted if (1) the mean values of the four replicates per QC pool in an
assay were within the acceptance limits or (2) at least five out of six QC results were
within acceptance limits.
Within-batch drift was also calculated for the three QC pools by the Data Processing
Programme. This monitors whether there is a significant change in the QC pools results at
the beginning and end of the assay. Within-batch drift was not flagged as significant by




MPA serum concentrations and demographic data were captured using Microsoft®Excel.
Where values were missing, the median was used . Data were checked for outliers and
encoding errors using Xpose (version 3.007). Two subjects were excluded from analysis
on the basis of this checkout. One had been using another injectable product
norethisterone oenanthate (NET-EN) and was excluded as it was thought that this might
have affected her MPA serum level. The second exclusion was made as it appeared that
the woman had returned within 14 days of receiving her last dose, possibly as she wished
to be recruited into the study.
Data were analysed in two ways:
• First the serum concentrations were analysed, focusing particularly on measurements
taken at the end ofthe dosing interval (the trough levels).
• Second a population pharmacokinetic analysis was undertaken in order to estimate
pharmacokinetic parameters for DMPA and to investigate the influence of covariates
on the pharmacokinetic parameters.
2.2.6.1 Serum MPA Level Analysis Focusing on Trough Levels
Serum levels were analysed and are briefly described in the results chapter (2.3) . Most
levels were measured at the end of the dosing period when women returned for their next
dose. Hence, trough serum levels, which provide information related to product efficacy,
were analysed in detail. MPA serum concentrations and demographic data were analysed
using Microsoft®Excel 2002. In all, trough serum MPA levels were measured in 97
DMPA users. A manuscript describing the results of this analysis has been accepted by
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the Journal Contraception for publication. A copy of this paper can be found on page xlvi
of this thesis after the abstract.
2.2.6.2 Population Pharmacokinetic Analysis
The Non-linear Mixed Effects Modelling computer programme (NONMEM) Version 5,
level 1, described in the previous chapter was employed (Sheiner and Beal, 1994) in
conjunction with a Compaq Visual Fortran Optimizing Compiler, Version 6.6 (Compaq,
copyright 2001).
To identify a pharmacokinetic model which best describes the pharmacokinetic
parameters ofMPA, structural models were selected from the NONMEM PREDPp25
library. Interindividual variation in clearance (CL) and volume of distribution (V), as well
as residual variability and inter-occasion random effects were modelled with exponential
error models (statistical model). Estimates were obtained for the following:
• the population mean of the pharmacokinetic parameters, CL and V
• variance ofthe interindividual random effects (etas) of CL (l1CL) and volume of
distribution (rn
• variance of the residual error (EPS, e) (e.g. drug assay errors, model misspecification)
• standard errors of the parameter estimates
• inter-occasion random effects (n) , and
• the objective function value (OFV) which is equal to minus twice the log-likelihood
of the data.
25 P~DPP stands for "Pred for Population Pharmacokinetics. It is a PRED ("prediction") subroutine for
use with NONMEM and is specialized to the kinds ofpredications which arise in pharmacokinetic data
analysis (Boeckmann et aI, 1994 , pA).
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A NONMEM data file was constructed in Microsoft®Excel 2002 using a comma
delimited (.csv) file format, The data file parameters and the first 15 client records of the
data file are shown in Appendices 2.2.3 and 2.2.4 respectively.
Xpose (version 3.007) was used for model building and diagnostics. Xpose is an S-PLUS
based model building aid for population analysis using NONMEM (Jonsson and
Karlsson, 1998a, (http://www.biof.uu.se/Xpose accessed 8/29/02). It facilitates data set
checkout, exploration and visualization, model diagnostics, candidate covariate
identification and model comparison.
Graphics were used in exploratory data analysis to examine distribution and correlation
between covariates.
Estimation Method
Initially, the default first order method (FO) in NONMEM was used to estimate the
typical values of the population parameters. The FO method makes expansions around the
population average predicted value by using first-term Taylor series expansion in the
approximation (Beal and Sheiner, 1992). Thereafter, the First Order Conditional
Estimation (FOCE) method was used as it was considered to be more accurate since
random interindividual variability was large. It has been recently reported that use of
appropriate conditional estimation methods give a better agreement between nominal and
true p values when using the likelihood ratio test for assessing nested models (Wahlby et
a/2001; Gobburu and Lawrence, 2002; Wahlby et aI2002).
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The Structural (Pharmacokinetic) Model
Two models from the NONMEM PREDPP library were selected to take into account the
slow absorption of MPA from the intramuscular site of administration:
Model one: A one compartment linear model parameterized in terms of clearance (CL)
and volume of distribution (V), using the programme subroutines ADVANI TRANS2.
DMPA is administered by the intramuscular route and is slowly absorbed from
intramuscular sites after administration, thus MPA blood concentrations are controlled by
the rate of absorption from the surface of the microcrystals at the absorption site. It is
possible for NONMEM-PREDPP to estimate the input rate of a constant-rate drug
delivery system (e.g. sustained release tablet, implant). Accordingly, the RATE data item
was assigned the value -2 (Boeckmann et al, 1994) and an additional pharmacokinetic
parameter, duration of input (D1), was included in the model. Based on time to reach
peak MPA levels after intramuscular injection ofDMPA documented in the literature (see
Table 2.1.2 , previous chapter), a sensitivity analysis was carried out to determine a
suitable value for Dl. Various fixed values ofDl were tested and attempts were also
made to estimate its value.
Model two: A one compartment linear model with first order absorption parameterized in
terms of absorption, volume, and clearance, using the programme subroutines ADVAN2
TRANS2. This subroutine was selected because, in addition to the central compartment, it
specifies a depot compartment where the dose goes and from which the drug enters the
central compartment by a first order process (Boeckmann et alI994).
283
In both models a scale parameter S=V/1000 was entered so that the units of the predicted
responses match the data.
Since the drug is absorbed from a depot compartment, the estimated clearance and
volume are apparent, CL/F and V/F respectively, where F=bioavailability.
The Statistical Model
Inter-individual differences (deviations ofthe drug 's apparent clearance [CL/F] and
apparent volume [V/F] of each individual from the population mean values) were
estimated using the exponential, error model. This model was selected as it is appropriate
for pharmacokinetic parameters which generally show a log normal distribution.
The residual error, which accounts for the difference between the observed concentrations
and those predicted by the regression model, was estimated using exponential, additive
and combined error models (Boeckmann et aI1994). The possibility of inter-occasion
variability was also investigated.
Correlation between CL/F and V/Fwas tested with the BLOCK(2) option in the
$OMEGA record as described by Boeckmann et al, (1994) and, alternately, by including
a bioavailability term fixed to one, but with interindividual variability included.
Statistical model selection was based on goodness of fit, graphical analysis , the size of the




Covariate modelling is an iterative process with the basic model (structural and statistical)
forming the basis for identifying potential covariates (Wahlby, 2002). Potential covariates
can be tested within NONMEM, but this is very time-consuming. Thus methods which
lessen the number of covariates to be tested in NONMEM are often employed.
Covariates identified by these methods can be included in the model by stepwise forward
inclusion, or all identified variables are combined as the full model and covariates are
then tested using stepwise backward deletion (Wahlby, 2002). An automated procedure
where the covariate model is built within NONMEM in a stepwise fashion can also be
used to identify potential covariates (Wahlby, 2002).
In line with the covariate screening procedures described above, covariate modelling was
undertaken in two ways in this study:
(i) Covariate selection with generalized additive modelling (GAM).
Starting with the basic model, covariate influences were explored using the GAM method
(Mandema et aI, 1992) as implemented in Xpose (Jonsson and Karlsson, 1998a). Linear
and nonlinear models are tested on the parameters from a basic model run without
covariates. Using GAM, model discrimination was made by undertaking a univariate
analysis of covariate effect on CLIP and V/F. Plausible covariates identified by GAM
were tested in NONMEM. This was done in a stepwise fashion, singly and in
combination, on CLIP and VIP respectively.
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The covariates tested in this way were:
• The continuous covariates age, weight, height, duration of use ofDMPA, creatinine,
alkaline phosphatase, gamma GT, aspartate transaminase, alanine aminotransferase,
total bilirubin, conjugated bilirubin
• The categorical covariates race and smoking
(ii) Covariate selections using a step-wise automated procedure within NONMEM.
Identification of covariates was also carried out using an automated procedure in
NONMEM (Jonsson and Karlsson, 1998b) which allows for covariate testing within
NONMEM runs. This process involves a stepwise testing of linear and non-linear
relationships in a forward inclusion (~OFV of3.84,p=O.05) and backward exclusion
(~OFV of 1O.83 ,p=O.OOl) procedure. For each covariate and pharmacokinetic
parameter, a hierarchical set of possible models was defined. For categorical covariates
this set was either no relation or a shift in the intercept, and for continuous covariates it
was no relation (first level), a linear relation (second level) or a non-linear relation (third
level). The latter was modelled as a continuous piecewise linear relation with two
different slopes, one for each side of the median value of the covariate.
The stepwise search for a covariate relation started at the naive model, that is the model
without covariates. A series ofnon-linear mixed effect models were fitted to the data. In
the first step, each parameter-covariate relation at the second level in the hierarchical set
ofmodels was added to the start model , one at a time, and its statistical significance was
assessed. The parameter-covariate relation, for which the lowest p value was obtained,
was retained in the model. In the second step each parameter-covariate relation, as given
by the next possible level in the hierarchical set of models , was tried in the new model
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and its statistical significance was assessed. This continued until no more statistically
significant parameter-covariate relations were found. After the forward inclusion of
parameter-covariate relations, a backward elimination followed. This was essentially the
reverse of the forward inclusion. In each step, the next lower model in the hierarchical set
ofmodels replaced each parameter-covariate relation in the model. The least important
relationship (giving the lowest change in OFV), given that it was not statistically
significant, was dropped in favour of the simpler model. This continued until no more
terms could be dropped.
The covariates tested in this way were:
• The continuous covariates age, weight, height, duration of use ofDMPA, creatinine,
alkaline phosphatase, gamma GT, aspartate transaminase, alanine aminotransferase,
total bilirubin, conjugated bilirubin.
• The categorical covariates race and smoking. Since there were relatively few Indian,
White and Coloured women (n=38), these women were grouped together and tested
versus Africans as the reference group (n=73).
The advantage of this method is that all selected covariates are tested singly and in
combination within NONMEM runs. Further, the covariate model is built for all
parameters at the same time, it can handle covariates that vary over time and is not
dependent on the quality of the posterior Bayes estimates of the individual parameter




NONMEM was used to identify which fixed effects had the most significant influence on
MPA apparent CUF and apparent VIF, and which regression model best described the
data. The value ofthe OFV, a goodness-of-fit statistic, was used to compare the validity
of successive models. Minimizing the objective function is equivalent to maximizing the
probability (likelihood) of the data. The ~OFV between two nested models is
approximately Chi-square distributed, and the improvement in goodness of fit of the
model, due to introduction or elimination of parameters, can be assigned significance




Degrees of freedom (df) in each of the above = 1, where the number ofdf is equal
to the number of differing parameters
According to Boeckmann et al (1994) a fall in OFV of4 shows that the new model
(where a single new parameter is introduced and where no existing ones are eliminated)
has substantially improved the overall goodness of fit. It is usual to apply significance
levels of 0.05 (~OFV=3 .83 or more) for forward inclusion ofparameters and 0.001
(~OFV=10.83 or more) on backward elimination.
Successive models were also evaluated by means of the relative standard errors of the
estimates and on the basis ofgraphical analysis which provides an important mechanism
for judging goodness-of-fit (Wahlby et al, 2001).
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The goodness of fit of the final model was assessed by means of the following graphical
analysis:
• Distribution of weighted residuals (WRES): If the model chosen is appropriate, the
data will be randomly distributed.
• Population predictions (PRED) versus observed values (DV): Gives an impression of
how well the model can predict data (Karlsson, 1998). Substantial and systematic
deviations from the line of identity suggest that there are problems with the fit
(Boeckmann et ai, 1994).
• Individual predictions (IPRE) versus DV: A general diagnostic tool which is better for
rich than sparse data and better for the assessment of the structural than the statistical
model (Karlsson, 1998).
• Individual plots ofobserved concentrations, individual concentration predictions and
final model concentration predictions.
• Individual weighted residuals (IWRES) versus individual predictions (IPRE): A
statistical model diagnostic which should show no trend in the magnitude of IWRES
(Karlsson, 1998).
• Weighted residuals (WRES) in relation to time after dose: A structural model
diagnostic. For a good model fit, the residuals should be scattered evenly around the
zero line (Karlsson, 1998).
• Plots which examined relationships between observed values and predicted values, in
relation to time after dose.
289
2.2.7 STUDY LIMITATIONS
Although this study included many more subjects than previous studies on MPA
concentrations and/or pharmacokinetic parameters, the following limitations should be
noted:
• The dataset contained few peak MPA measurements, so little light was shed on the
time taken to reach peak values, or the MPA value at peak level.
• There were relatively few Indian (n=28) and White (n=9) women and only one
Coloured woman, making it difficult to draw conclusions about these three races.
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CHAPTER 2.3 RESULTS
2.3.1 CHARACTERISTICS OF DMPA USERS
In all, data from 111 DMPA users were analysed. The characteristics of these DMPA
users are provided in Table 2.3.1 and their clinical chemistry is reported in Table 2.3.2.
They were 28 years old on average, with a mean weight of 62 kg. Most were African and
only a few, mainly white women were smokers. While some had used DMPA for many
years, the mean duration ofuse was three years. Five women had elected to use DMPA
on the day of recruitment into the study and 11 had been using it for only one dosing
cycle (i.e. 12 weeks).
Table 2.3.1 Characteristics of DMPA users
The heights of 16 women were not recorded at the clinic. The mean and median heights were calculated in
2 ways. ~irs~ by excluding the subjects,with missing values (n=95) and second by using the median height
for the missmg values . In both calculations, the mean and median obtained was the same as that reflected in
the table above .
"13~dy mass index was calculated as weight (kilograms), divided by height (meters) squared. This median
height was used for the missing height values in the BMI calculation
#The duration of use ofone woman was not recorded
tMixed race
Characteristic
Mean (SD) Median Range
Age (years) 28 (5.8) 27 17-42
Weight at recruitment (kg) 62 (11.8) 61 37-105
Height (meters)* 1.6 (8) 1.6 1.4-1.8
Body mass index (BMltbased on weight at recruitment 25.2 (4.8) 24.5 15.4-39.0











Table 2.3.2 Serum clinical chemistry of DMPA users
Test Mean (SD) Median Range Laboratory
Reference Range
Creatinine (umol/L) 81 (8) 80 58-115 63-115
Alkaline phosphatase (U/L) 143 (41) 139 14-290 68-212
Gamma GT (U/L) 13 (8) 11 3-48 8-37
Aspartate transaminase (UIL) 15 (10) 13 5-100 0-25
Alanine aminotransferase (UIL) 16 (15) 12 6-134 0-29
Total bilirubin (umol/L) 8.2 (3.9) 7.6 1.8-23.2 2-17 .0
Conjugated bilirubin (umollL) 1.8 (1.1) 1.7 0.1-5.4 0.1-8.5
Few women were taking concomitant medication:
• one woman was taking an oral anticonvulsant, carbamazepine, for epilepsy at a dose of
300mg daily
• three women were taking antihypertensive medication
• one woman was taking an oral hypoglycaemic drug and one was using insulin.
• one woman had used Ovral'" for heavy bleeding with DMPA use, and
• one woman had used Premarin" for 7 days.
2.3.2 SERUM SAMPLES AND SAMPLING TIMEFRAME
A total of291 serum concentrations were analysed from the 111 DMPA users . Sixteen of
these women had been using the injectable for one or less dosing cycles . In these cases
the levels were assumed not to be at steady state.
The median number of samples taken per woman was three with a range of one to four
(Figure 2.3.1).
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Concentrations were measured between 4 and 168 days post injection, with most
measurements (25.4%) occurring just before the next dose was due, that is 84 days after
injection. The frequency distribution of concentration measurements according to the
length of time after the last dose is shown in Figure 2.3.2.
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2.3.3 SERUM MPA LEVELS FOCUSING ON TROUGH LEVELS
Only 3 measurements were taken during the time period after injection when peak levels
were likely to occur. These measurements were obtained at days 4, 7 and 20 and were
3.51ng/ml (race: Indian; BMI: 15.6), 4.15ng/ml (race: African; BMI:22.77) and
4.27ng/ml (race: African; BMI: 23.88) respectively. The mean MPA concentration of
measures taken between 29 and 56 days post injection was 1.42ng/ml (median:
1.38ng/ml; range:0.49 to 3.50ng/ml). Most levels were measured at the end ofthe dosing
interval and these levels are described below in detail.
2.3.2.1 Trough Levels
Trough serum MPA levels were measured in 97 ofthe 111 DMPA users. Ninety-five of
the women returned between 11 and 14 weeks of receiving their last dose. The remaining
three returned more than 14 weeks after their last injection and were classified as
"defaulters" in keeping with clinic policy.
Demographic data and serum MPA levels of the 94 African, Indian and White women
returning between 11 and 14 weeks after their last dose are presented in Table 2.3.3. On
recruitment into the study, 12% of these had had one dose ofDMPA, 7% two doses, 5%
three doses and the remainder had been using DMPA for a year or more. Sixty-four were
Africans, 24 were of Indian descent, and six were White. The mean and median MPA
levels were 0.88ng/ml (Table 2.3.3). The MPA level of one woman was below the
minimum level ofdetection (0.04ng/ml).26
26 Where this value was included in determining a mean value, the level was set at O.02nglml that is half
the limit of quantitation. '
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Table 2.3.3 Demographic data and trough MPA levels
Age Weight BMI* MPA level
(years) (kg) (ng/ml)
n=94 n=94 n=80+ n=94
Mean 28 62 25.4 0.88
Median 27 61 24.3 0.88
Range 17-42 38-106 15.4-39.4 <0.04-1.77
*Body mass index was calculated as weight (kilograms), divided by height (meters) squared.
+The heights of 14 women were not recorded
Serum MPA levels in relation to the time after the last injection are presented in Figure
2.3.3. Levels of those who returned up to a week early, or up to two weeks late, were
similar to those returning exactly 84 days after their previous dose. The large
interindividual variability is well illustrated by the wide range oflevels, particularly in the
large group who returned at 84 days. MPA levels in these 55 women ranged between
<0.04ng/ml and 1.53ng/ml (median: 0.90ng/ml; mean [SD]: 0.86[0.31]ng/ml). The MPA
levels of the three defaulters who returned 109, 112 and 168 days after their last dose
were 0.77ng/ml, 0.74ng/ml and 0.29ng/ml respectively.
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Figure 2.3.3 also shows that the trough MPA levels ofAfricans and Caucasians were
similar. In the group returning at 84 days, the median (range) MPA levels were 0.90
(O.lO-I .40)ng/ml and 0.90 «0.04-1.53)ng/ml for Africans (n=4l) and Caucasians (n=14)
respectively. Although widely varied within each ethnic group, BMIs were similar
between groups with a median (range) BMI of25.8 (17.4-39.4) for African women
(n=51) and 23.6 (15.4-33.8) for Caucasians (n=29). The MPA levels of subjects with a
BMI less than 25 were similar to those with a BMI of25 or more (Table 2.3.4).
Table 2.3.4 Trough MPA levels ofwomen with different BMIs
MPA level (nz/ml)
n Mean Median Range
BMI < 25 43 0.85 0.85 <0.04-1.58
BMI ::?:25 37 0.88 0.88 0.31-1.45
Desirable BMI range IS 19-24 [17]
There was a slight trend (pearson' s Product Moment=O.13) towards higher MPA levels at
the end ofthe dosing interval with longer duration of use (Figure 2.3.4). However, wide
interindividual variability was evident irrespective of length of use.
Figure 2.3.4 Trough MPA levels in relation to duration of use (n=93)
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2.3.4 POPULATION PHARMACOKINETIC ANALYSIS
2.3.4.1 The Pharmacokinetic Data File
The pharmacokinetic data file was constructed as described in Chapter 2.2. All errors
identified in the data run checkout were corrected. The first 15 client records of this data
file are shown in Appendix 2.2.4 . Because there were so few women taking concomitant
medication in each group , the influence of concomitant drugs was not tested in the
population analysis.
2.3.4.2 Estimation Method
Initially, the default first order method (FO) in NONMEM was used (run 2, Run Record
in Appendix 2.3 .1) to estimate the typical values of the population parameters. Thereafter,
the First Order Conditional Estimation (FOCE) method was used (run 3, Run Record in
Appendix 2.3.1). Although the parameter estimates are not dissimilar (run 2 and 3),
FOCE gives smaller standard error of estimates. FOCE was thus used for all subsequent
runs .
2.3.4.3 Model Building
A summary of the main runs constructed during the model building process is provided in
Appendix 2.3.1.
The Structural (Pharmacokinetic) Model
Since the drug is absorbed from a depot compartment, the estimated clearance and
volume are apparent, that is CLIP and VIP, where F=bioavailability. Two one
compartment structural models were tested, both parameterized in terms of apparent
volume and apparent clearance. The first model assumed a zero order infusion with first
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order elimination while the second assumed first order absorption and first order
elimination. The models produced similar objective function values (OFV) (Table 2.3.5)
and similar values for CLIF and V/F (Appendix 2.3.1). The first model was chosen for






Table 2.3.5 Summary of key decisions taken in model building
Question OFV dOFV Conclusion Reference
Should the FO or FOCE estimation method be
used?
FO -216.262 No Run 2
FOCE -227.481 Yes Run 3
• Recent literature onp value (see previous chapter: 2.2.6.2)
• Variability parameters appear to be more precisely estimated
Structural Model
Which NONMEM Subroutine?
• ADVANl TRANS2 (CLIP; VIP; DI) -233.462 Yes- Covariate Matrix Run 8
• ADVAN2 TRANS2 (CLIP; VlF; Ka) -233.161 No Run 11
What value should be assigned to duration of -233.462 ,J,5.981 01=4 Run 8
input (Dl)? • Sensitivity test indicates that Dl=4 gives best OFV
• Literature indicates that MPA values likely to
peak within a week ofadministration -233.345 Dl estimated as 4.2 Run 4
Statistical Model
• Should the combined (additive and ·241.970 ,J,8.508 Yes Run 12 vs run 8
proportional) residual error model be used?
Is inter-occasion variability on CLlF and VIP -247.931 ,J,5.961 No Run 16 vs run 12
significant? • Small improvement in OFV
• Little change in parameters (CLIP & V/F)
• Large standard errors on IOV for CLIP (190%) & VIP (54%)
Is there correlation between CLIP and VIP? Yes
• Block (2) included -241.970 101% correlati on Run 12
• Block (2) removed -193.794 t48.l76 Run 13 vs run 12
• Bioavailability term=1 with IIV included -209.067 t32.903 IIV on VIP very small; estimates of IIV on CLIP not precise Run 14 vs run 12
OFV=objective function value; dOFV=difference in objective function value; NONMEM=Non-linear Mixed Effects Modelling; FO=the first-order estimation
method in NONMEM; FOCE=the first-order conditional estimation method in NONMEM; CLIP= apparent clearance; CLN=apparent volume; F=bioavailability;
DI=duration of input; Ka=first order absorption rate function; IOV=inter-occasion variability; IIV=interindividual variability.
Based on the time to reach peak MPA documented in the literature (see Table 2.1.2 in Chapter
2.1), Dl was initially set at 7 days. A sensitivity analysis was carried out to determine a suitable
value for fixing Dl (the duration of input as described in Chapter 2.2). Attempts were made to
estimate the value ofDl and various fixed values ofDl were also tested. Table 2.3.6 provides a
summary of the NONMEM runs carried out for the sensitivity analysis. Where Dl was
estimated, it was found to be 4.2 days and the best OFV was obtained for run 8 where D1 was
fixed at 4 days. The pharmacokinetic parameters (CLIF and VIF) and variability parameters
obtained were similar in the runs indicating that the value of D1 did not have much influence.
Accordingly, this fixed value, Dl=4, was selected for subsequent modelling.
Table 2.3.6 Sensitivity analysis: Duration ofinput (Dl)
Run # Dl (days) OFV CLIF (Uday) VIF(L)
3 7 -227.481 1110 90000
4 Estimated (4.12) -233.345 1090 90200
5 10 -200.348 1130 91500
6 5 -232.612 1100 89600
7 3 -233.334 1080 89100
8 4 -233.462 1090 89600
The Statistical Model
The exponential error model was selected to estimate the interindividual differences as this
model is appropriate for pharmacokinetic parameters which generally show a log normal
distribution.
300
The residual errors were estimated by means of proportional and combined (additive and
proportional) models. Based on an improvement in the OFVof 8.508 (run 12 versus run 8:
Table 2.3.5 and Run Record Appendix 2.3 .1), the residual errors were estimated by the
combination model as depicted by the following equation:
y= F (1+~>1) + 1> 2. 'J, I) ,
Where Y is the observed concentration and F is the corresponding model predicted value. E (or
eps) are the residual error terms for the ith individual and thejth concentration.
The possibility of inter-occasion variability (IOV) was also investigated (run 16, Table 2.3.5 and
Run Record, Appendix 2.3.1). The IOV on CLlF was found to be 6.4% and on V/F was 18%.
However, a relatively small improvement in the OFV (5.961), very little change in the
parameters (CLlF and VIF), and large standard errors on IOV for CLlF (190%) and V/F (54%)
were obtained (Table 2.3 .5). It was thus concluded that inclusion of inter-occasion random
effects did not offer much improvement in the model fit. Also, for most women in the data set,
information for only one dose interval was available.
As described in the Methods Chapter (2.2), correlation between CLIF and VIF was taken into
consideration by utilizing the Block (2) option, resulting in a 101% correlation between CLIF
and V/F. When the correlation was removed, the OFV increased by 48.176, indicating a worse fit
(run 13 versus run 12: Table 2.3.5 and Run Record in Appendix 2.3.1). An alternate strategy to
using the Block (2) involved the inclusion of a bioavailability term fixed to one, but with
interindividual variability added. This strategy produced an OFV that increased by 32.903
compared with the Block (2) option (run 14 versus run 12: Table 2.3.5 and Run Record in
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Appendix 2.3.1), again indicating a worse fit. In addition, the interindividual variability on VIP
became very small and interindividual variability on CLIF was not precisely estimated (run 14
versus run 12: Run Record in Appendix 2.3.1). The model including the correlation in the form
of a Block (2) option was thus considered to be the most suitable model for covariate model
building.
Covariate Modelling
(i) Covariate selection with generalized additive modelling (GAM).
The GAM on both CLIP and VIF indicated that weight and smoking may be significant
covariates. However neither proved significant when tested in NONMEM (run 19-22 of Run
Record in Appendix 2.3.1).
(ii) Covariate selections using a step-wise automated procedure within NONMEM.
Two covariate batches were created for the step-wise automated procedure as the number of
covariates to be tested exceeded the number of data items NONMEM can accommodate:
• The first batch included the covariates: race, smoking, age, weight, duration of use, alkaline
phosphatase, gamma GT and total bilirubin.
• The second batch included the covariates: race, height, creatinine, aspartate transaminase,
alanine aminotransferase, and conjugated bilirubin.
As race on VIF was found to be a marginally significant covariate in the first batch, it was also
included in the second batch.
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In the first batch of the automated covariate testing procedure only race was identified as a
significant covariate for VIF (~OFV of -4.9) in the forward inclusion procedure. However it was
rejected on backward elimination (~OFV of 4.9) as shown in Table 2.3.7.
Table 2.3.7 Identification of significant covariates in the automated covariate testing
a For the forward inclusion the z, OFV IS the OFV of the statistically most significant model ID each step mmns the OFV of the statistically most
significant model in the former step. b Difference in OFV between this model and the best model in round 1.
• See Appendix 2.2.3 for covariate abbreviations as entered in the data file
ROUND IMODEL IOFV I AOFV' I COMMENT
Base (RunI2) INo covariate relations I -241.970 I- IBasic model
Batch 1
Forward inclusion (AOFV of 3.84 for nominal p=0.05)
1 I RACE on V/F I -246.871 I -4.901 I Retain
2 I AGE on V/F I -250.655 I -3.784 I Do Not Retain
Backward elimination (AOFV of 10.83 for nominal p=O.OOI)
3 I Minus RACE on V/F I -241.970 I 4.901 b I Do Not Retain
Batch 2
Forward inclusion (AOFV of 3.84 for nominal p=0.05)
1 I RACE on V/F I -246.871 I -4.901 I Retain
2 I CREA on CL/F I -250.343 I -3.472 I Do Not Retain
Backward elimination (AOFV of 10.83 for nominal p=O.OOI)
3 I Minus RACE on V/F I -241.970 I 4.901 b I Do Not Retain
. . . .
The race covariate indicated that VIF was 22% larger for women who were not African. This
parameter was estimated at 0.22 with a standard error of 0.58 (run 24, Run Record, Appendix
2.3.1).
Serum creatinine on its own was a significant covariate for CLIF (~OFV of -4.8) in the first
forward round of the second batch. In the second round, when included with race, it was no
longer significant (~OFV of -3.5) and was therefore not retained.
The results ofunivariate analyses from Round 1 for both batches are shown in Table 2.3.8.
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Table 2.3.8 also shows that the covariates weight and smoking were not significant, .although
they were identified by generalized additive modelling (see (i) above) as covariates which might
be relevant. (See Appendix 2.2.3 for covariate abbreviations as entered in the data file)
Table 2.3.8 Univariate analysis of covariate effect on apparent clearance and apparent
volume
Hypothesis OFV AOFV p value Conclusion Reference
Basic model -241.97 Run 12
Did CREA influence CL/F? -246.757 -4.787 <0.05 Yes vs 12
Did height influence CLlF? -244.721 -2.751 >0.05 no vs 12
Did race influence CLlF? -244.711 -2.741 >0.05 no vs 12
Did weight influence CL/F? -244.495 -2.525 >0.05 no 21 vs 12
Did AST influence CLlF? -244.398 -2.428 >0.05 no vs 12
Did ALT influence CLlF? -243.142 -1.172 >0.05 no vs 12
Did CBIL influence CLlF? -242.815 -0.845 >0.05 no vs 12
Did ALKP influence CL/F? -242.414 -0.444 >0.05 no vs 12
Did GAMA influence CLlF? -242.392 -0.422 >0.05 no vs 12
Did BMI influence CLlF? -242.391 -0.421 >0.05 no 17 vs 12
Did age influence CLlF? -242.322 -0.352 >0.05 no vs 12
Did TBIL influence CLlF? -242.298 -0.328 >0.05 no vs 12
Did smoking influence CLlF? -242.107 -0.137 >0.05 no 19 vs 12
Did duration of use influence CLlF? -242.014 -0.044 >0.05 no vs 12
Did race influence V/F? -246.871 -4.901 <0.05 Yes 24 vs 12
Did CREA influence V /F? -244.295 -2.325 >0.05 no vs 12
Did ALKP influence V/F? -244.006 -2.036 >0.05 no vs 12
Did AST influence V/F? -243.433 -1.463 >0.05 no vs 12
Did smoking influence V /F? -243.366 -1.396 >0.05 no 20 vs 12
Did CBIL influence V/F? -243.256 -1.286 >0.05 no vs 12
Did age influence V/F? -243.063 -1.093 >0.05 no vs 12
Did height influence V /F? -242.96 -0.99 >0.05 no vs 12
Did ALT influence V/F? -242.693 -0.723 >0.05 no vs 12
Did BMI influence V/F? -242.29 -0.32 >0.05 no 18 vs 12
Did weight influence VIF? -242.157 -0.187 >0.05 no 22 vs 12
Did TBIL influence V/F? -242.143 -0.173 >0.05 no vs 12
Did GAMA influence VIF? -242.013 -0.043 >0.05 no vs 12
Did duration of use influence V/F? -242.006 -0.036 >0.05 no vs 12
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Although the covariate BM! was not included in the stepwise automated procedure, the influence
of race and BMIon VIF was tested in NONMEM (run23, RunRecord, Appendix 2.3.1)
resulting in a AOFV of -1.52 (run 23 vs run 24, Run record Appendix 2.3.1)whichwas not
significant.
FinalPopulation Pharmacokinetic Model
The final population pharmacokinetic model had no covariates on CLIF or VIF as nonewere
found to be significant at ap value of 0.001 on backwards deletion.
The goodness offit of the final modelwas assessed by means of graphical analysis as shownin
Figures2.3.5,2.3.6,2.3.7 and 2.3.8.
The frequency distribution of weighted residuals associated with the final modelwas randomly
distributed as shown in Figure 2.3.5.











The relationship between the measured concentrations and those predicted for the final model are
shownin Figure 2.3.6 (a) and (b). Concentrations measured earlyin the dosingcycleare less
accurately predicted thanconcentrations measured later. Figure 2.3.6 (c) shows the individual
weighted residuals (IWRES) versus the individual predictions indicating a reasonable statistical
modelas there does not appearto be a trend in the magnitude ofIWRES. Figure2.3.6 (d) shows
the weighted residuals (WRES) versus time after dose indicating that concentrations measured
within the first monthof administration of the dose are less accurately predicted than
concentrations measured later in the dosingcycle.
Figure 2.3.6 Scatterplots:
(a) Predicted (PRED) versus observed concentrations (ng/ml)
(b) Individual predictions (IPRE) versus observed concentrations (ng/ml)
(c) Individual weighted residuals (lWRES) versus individual predictions (lPRE)
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The relationship between the measured concentrations and individual predictions and those
predicted for the final model, in relation to time are shown in Figure2.3.7. While concentrations
measured within the first month afteradministration of the dose are not well predicted by the
model, concentrations measured later in the dosing cycleare more accurately predicted. Thisis
further illustrated by the individual plotsof measured concentrations, individual concentration
predictions and final model concentration predictions in relation to time afterdose (see for
instance ID:6 and ID:15 in Appendix 2.3.2).
Figure 2.3.7:
(a) Measured concentration (DV) (ng/ml) versus time after dose (TAD) (days)
(b) Individual predictions (IPRE) (ng/ml) versus time after dose (days)
(c) Model predictions (PRED) (ng/ml) versus time after dose (days)
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In sum, although higher concentrations measured within the first month of administration of the
dose are less accurately predicted than concentrations measured later in the dosing cycle, the
structural and error models are reasonable. There is however insufficient information about
concentrations early in the dosing cycle to explain the weak prediction of these observed
concentrations in some women.
The final model estimates for CLIP and V/F were 1080 (95% Cl: 994, 1166) Llday and 86200L
(95 %Cl: 68246, 104154) respectively. The parameter estimates obtained for the final population
pharmacokinetic model are summarized in Table 2.3.9. The mean predicted population half-life
(t'i1=0.693xV/CL) was calculated to be 55.31days.
Table 2.3.9 Final population pharmacokinetic model and its parameter estimates
Parameter Value RSE%
CL/F 1080 (Llday) 4.1
V/F (L) 86200 L 11
DV
V/F 71 % 19
CL/F 33 % 23
Correlation 101% 22
Residual Error
Additive 0.202 ng/ml 20




An extensive search of the literature indicates that this is the first study on the
pharmacokinetics of depot medroxyprogesterone acetate (DMPA) amongst African
women using DMPA, and the first ever population pharmacokinetic analysis ofDMPA.
The study has described serum concentrations ofmedroxyprogesterone acetate (MPA)
amongst 111 South African women (African, Indian, Coloured and White) using Depo-
Provera®. MPA serum levels are discussed first in this chapter, focusing particularly on
levels at the end of the dosing period (trough levels) , since most measurements were
taken when women returned to the clinic for their next dose. Secondly, findings from the
population pharmacokinetic analysis ofMPA are discussed.
2.4.1 SERUM MPA LEVELS
MPA levels were found to be similar to those reported in previous studies. The mean
trough level of O.88ng/ml, measured for 94 women, was comparable to mean trough
levels reported by Jeppsson and Johansson, (1976), Jeppsson et al (1977) , and
Koetsawang et al (1979) where means ranged from O.6ng/ml to O.9ng/ml.
Most studies have found MPA levels at the end of the three month dosing period to be
above the level at which ovulation is reported to resume (O.lng/ml) (Kirton and Cornette,
1974; Jeppsson et aI, 1977; Ortiz et aI, 1977; Koetsawang et a11979; Fotherby et al
1980b). In this South African study, with the exception of one undetectable level
«O.04ng/ml), all MPA levels between 11 and 14 weeks after the dose were above this
level. Even the MPA levels of three defaulters, two who returned 4 weeks late and one 12
weeks late, were still above O.lng/ml. In four of five women studied, Fotherby et al
(1980a) reported undetectable levels by days 55, 64, 87 and 87 post injection respectively
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(minimum detectable level >0.Ing/ml) and, in a study by Koetsawang et al (1979) , two of
21 women had levels of less than O.Ing/ml at the end of the dosing period . It should be
noted, however, that the assay used in these two earlier studies was less sensitive
(0.Ing/ml) than that ofthis South African study where the lower limit of quantitation was
0.04ng/ml. In addition, assays used in early studies varied . More recently, recognising the
difficulty in interpreting results from different studies, the World Health Organization's
Task Force on the Long Acting Systemic Agents for Fertility Regulation has produced
standardised protocols and matched reagents for radioimmunoassay of synthetic
progestogens (Ashan et al, 1998). These procedures were used in this South African study
and should be used in future studies to improve standardization and between-centre
comparability of assay results.
Wide interindividual variability in serum MPA levels has been noted in previous studies
(Fotherby et al, 1980a; Fraser and Weisberg, 1981; Sang 1994). Findings from this South
African study, based on a much larger sample size than those of previous studies, also
show wide interindividual variability with trough MPA levels ranging from <0.04 to
I.77ng/ml and levels measured between 29 and 56 days post injection ranging from 0.49
to 3.5ng/ml.
The possibility ofMPA levels increasing with successive injections has also been
investigated, by a few researchers. For instance, the study undertaken in Thailand by
Koetsawang et al (1979) reported a higher mean plasma level at the end of the dosing
period for those receiving multiple injections than that ofthose receiving a single dose,
although the difference was not significant. Fraser and Weisberg (1981) in reviewing
these findings, suggested that no significant difference was found because of the wide
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interindividual variation within each group and recommended further investigation. In an
early review of Depo-Provera'" studies, Schwallie (1974) presented data (Depo-Provera
Protoco19A) which showed no accumulation of MPA when comparing median serum
levels after the first and fifth injection period. This South African study demonstrated a
slight tendency towards increased MPA levels at the end of the dosing interval with
longer duration ofuse. However the wide interindividual variability precluded the
possibility of determining whether or not this was a real trend. In addition, this study, like
that ofKoetsawang et al (1979) was cross-sectional. A prospective study, which follows
DMPA use in the same women over time would be required to determine if accumulation
actually occurs.
The possible influence of weight , BMI and ethnicity on MPA levels has been studied
(Fotherby et al, 1980b; Fotherby and Koetsawang, 1982; Bassol et al, 1984; Garza-Flores
et al, 1994; Sang, 1994). In one ofthese studies which compared the rate ofuptake and
metabolism ofDMPA in obese and thin women, no difference in MPA serum levels was
found between the two groups (Fotherby and Koetsawang, 1982). However another study
reported a tendency for DMPA to be absorbed more rapidly in thin than in obese women
(Garza-Flores et al, 1994). Bassol et al (1984) reported a longer delay in resumption of
ovulation in Mexican than in Thai women, which they considered to be in keeping with
the longer time for disappearance ofMPA from the serum of the Mexican women. In
another study undertaken amongst Indian and Swedish women (Fotherby et al, 1980b),
luteal activity was found to return later in the Swedish women, but no difference was
found between the two populations in time taken for plasma MPA to become
undetectable. In this study of African, Indian, and White South Africans, serum MPA
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levels at the end of the dosing interval were not found to vary according to weight , BM!
or ethnicity.
Although few concentrations (n=3) were measured in this South African study in the time
period after injection when peak levels were likely to occur, these measurements
(3.51ng/ml at day 4 post injection; 4.15ng/ml at day 7 post injection; 4.27ng/ml at day 20
post injection) were consistent with peak concentrations reported in most of the literature
(see Table 2.1.2) .
More recent studies on the pharmacokinetics of the combination progestogen/oestrogen
injectables suggest differences in the pharmacokinetics of MPA based on weight and
ethnicity (WHO, 1987; Rahimy et aI, 1999a). Rahimy et al (1999a) found that MPA
tended to be absorbed more quickly by thin women, and that trough levels were higher in
thin than in obese women. Similarly, the WHO study (1987) found higher peak MPA
levels were attained in Thai than in Mexican women. It is possible that pharmacokinetic
differences, based on weight and ethnicity, may occur in the absorption phase of MPA
and may manifest at peak levels. Conclusions cannot be drawn from this South African
study as few peak levels were measured.
Further studies examining peak levels are needed to investigate weight and ethnic
variability with MPA, as this could explain why some women demonstrate a poorer side
effect profile with DMPA use. Based on this analysis oftrough levels and on literature
findings , it seems unlikely that weight or population differences in pharmacokinetics
affect efficacy ofDMPA.
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2.4.2 POPULATION PHARMACOKINETIC ANALYSIS
As already discussed, a few studies have described serum MPA levels, including
maximum (peak) and minimum (trough) concentrations, half-life (tt) and the steady-state
area under the serum-concentration time curve (AVC), after intramuscular injection of
150mg ofDMPA. However, as noted, these studies are limited; the sample sizes were
small, a variety of different assay techniques were used, MPA levels were often
investigated after only one dose and none studied levels in African women. Further, an
extensive search has yielded no published studies, using either compartmental or
noncompartmental methods, which describe the pharmacokinetic parameters clearance
(CL) and volume of distribution (V) for MPA after injection of 150mg ofDMPA. Since
values for CL and V are not described, relationships between these parameters and
subject characteristics are also not documented.
This is the first time that a pharmacokinetic model has been developed to describe the
population pharmacokinetics ofMPA.
A one compartment model , parameterized in terms of apparent clearance and apparent
volume, adequately described MPA concentrations in the later part of the dose interval.
However, higher concentrations measured within the first month, were not well described,
with observed measurements being higher than those predicted by the model. Wade et al,
(1994) explain that simple (parsimonious) pharmacokinetic models may appropriately be
used for a variety of reasons such as where data obtained at steady state are insufficient to
characterize a distribution phase. Since, in this South African study, too few
measurements were made early in the dosing cycle there is a weak prediction ofhigh
concentrations in some women, and it is appropriate that the most parsimonious model be
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used. A more complex model for the input function may provide a better definition of the
absorption phase, and it is possible that a two compartmental model may better describe
concentrations early in the dosing cycle. In order to better define the absorption phase, a
study which measures serum MPA levels at least every week for the first four weeks after
injection would have to be carried out.
When the nature of the data prevents characterization of the whole model, parts of the
model , often input, can be fixed according to the best a priori information (Wade et al,
1993). The MPA model developed here included an input rate parameter (Dl), which was
fixed at 4 days, based on the literature and after performing a sensitivity analysis to
determine the most suitable value as suggested by Wade et al (1993).
DMPA is administered by the intramuscular route and is slowly absorbed from the
intramuscular site. As the elimination is not true MPA elimination, but is rate limited by
absorption, the model is a 'flip-flop' model with the absorption rate from the depot site
being determined and not the true elimination (Gibaldi and Perrier, 1975).
As discussed previously, the possible influence ofweight, BMI, ethnicity and duration of
use on MPA levels has been studied (Fotherby et al, 1980b; Fotherby and Koetsawang,
1982; Bassol et al, 1984; WHO, 1987; Garza-Flores et al, 1994; Sang, 1994; Rahimyet
al, 1999b). While these covariates were found to affect MPA levels in some studies no,
differences were found in others . Moreover, the sample sizes of the studies were often too
small for findings to be conclusive.
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In this South African study trough MPA levels of DMPA users were not found to vary
according to weight, BMI or ethnicity. The possible influence of covariates including
weight, BMI and duration of use, were further tested in the population analysis. No
significant relationships were found between the covariates tested and phannacokinetic
parameters. In testing the influence of ethnicity on CLIP or VIF, and CLIP and VIP, the
race covariate was found to have a marginally significant influence on VIF. However a
study with a larger sample size would be needed to determine if race is a statistically
significant variable. Studies on the pharmacokinetics ofthe combination
oestrogen/progestogen injectables seem to suggest that differences in the
pharmacokinetics ofMPA based on weight and ethnicity may occur in the absorption
phase of MPA and may manifest at peak levels rather than at trough levels (World Health
Organization, 1987; Rahimy et aI, 1999b). A study examining peak levels would be
required to investigate weight and ethnic variability with MPA and to define whether or
not these covariates may explain why some women demonstrate a poorer side effect
profile with DMPA use.
Interindividual variability (IIV) in both CLIP (33%) and VIP (71%) was found. The IN
for CLIP and VIP was not explained by any of the covariates. While wide IIV in the
pharmacokinetics of contraceptive steroids, including MPA, has been emphasized (Gupta
et aI,1979; Koetsawang et aI, 1979; Fotherby et aI, 1980b; Fotherby, 1983; Fotherby,
1990; Shenfield and Griffin, 1991; Sang 1994; Rahimy et aI, 1999b; Kaunitz, 2000), no
population phannacokinetic analyses of contraceptive steroids have previously been
published to allow for comparison. However the IIV ofMPA on CLIP and VIP found in
this study was not dissimilar to those of other drugs reported in the phannacokinetic
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literature (Lalonde et al, 1996; Bruno et al, 1997; Mould et al, 2002 ; Staatz et al, 2002;
Csajka et al, 2003).
This study was not designed to collect data for the assessment of inter-occasion
variability (lOV) as for most women, information for only one dose interval was
collected. Nevertheless, the possibility ofIOV was investigated, but the inclusion of inter-
occasion random effects did not offer much improvement to the model. Karlsson and
Sheiner (1993, p.735) warn that ifIOV is ignored, "predictable biases occur in parameter
estimates and previously nonexistent period effects are found". It is recommended
therefore that the future study, proposed earlier, be designed as a longitudinal study which
includes a number of dosing intervals and measures both peak and trough MPA levels.
Pharmacokinetic parameters
This is the first study which has yielded values for apparent clearance and apparent
volume of distribution for MPA after intramuscular injection of 150mg of DMPA. The
values derived are 1080Lld and 86200L respectively. Since this is the first contribution to
the literature on CL and V values of MPA it is difficult to determine the validity of these
values. Only one published study which records a value for the CL of MPA was found in
the literature (Gupta et al, 1979). This study determined the mean metabolic clearance
rate (MCR) ofMPA from the steroid disappearance curve after a single intravenous
injection ofeH]MPA (50 ,uCi) and found it to be 1668 ± 146 (SEM) litres per day.
Studies undertaken on the combined progestogen/oestrogen injectable products which are
given once a month report 0-28 day AUC values. If one calculates the clearance values
(CL=dose/AUC) one can obtain a value for clearance: The average AUCO-28 for MPA
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after the third monthly injection of 25mg MPN5mg estradiol cyprionate was determined
by Rahimy et al (1999b), using noncompartrnental methods, to be 21.51ng/day/ml giving
a mean value for CL of 1162L/day. Zhou et al (1998) , on a model-independent basis ,
estimated the average AUC O-28 for MPA after the l st dose (25mg MPN5mg estradiol
cyprionate) to be 21.58ng/day/ml and after the 6th dose to be 36.89ng/day/ml
(;:::95.45nrnoloday/L). The mean values for CL calculated from the AUCO-28 values are
1158 and 678L/day respectively. These values for CL, especially the CL value reported
by Rahimy et al (1999b) are similar to the CL/F determined in this present study.
The average V/F for MPA estimated in this present study seems large and there are no
published values for MPA volume ofdistribution with which to compare it. In the study
by Gupta et al (1979) described above, it was reported that Vo could not be accurately
estimated due to the variable finite time required to take the early samples and thus they
were unable to estimate the volume ofdistribution. A possible explanation for the large
VIF is that, since MPA is slowly absorbed from the intramuscular site, absorption and
elimination are taking place concurrently earlier in the dosing interval. The study
proposed earlier, with more measurements taken in the absorption phase, may estimate
VIF better.
The apparent half-life of MPA determined in the present study (ty,/F=55.3 days) was
similar to the half-life of MPA for Mexican women in two of three studies cited by Garza
Florez et al (1994): ty,=56.4days (n=5) and ty,=62.5days (n=4). The half-life values cited
by these authors across the three studies (including Thai and Mexican women) were
highly variable ranging from 24 to 112 days (see Table 2.1.3 in Chapter 2.1). The USP DJ
(2002) and the US approved physician prescribing information published on the
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manufacturer's website (Pharmacia and Upjohn, 1999) report an apparent t y, for the
150mg intramuscular dose of approximately 50 days -- very similar to the South Africa
study finding .
In summary, this is the first study which estimates the pharmacokinetic parameters
apparent clearance (CLIF) and apparent volume of distribution (VIF) for MPA after
injection of l50mg ofDMPA. The population pharmacokinetic model, developed using
Non-linear Mixed Effects Modelling (NONMEM), is simple. The development ofmore
complicated models would require more data for each individual, particularly in the
absorption phase. The CL/F estimated was in accordance with the little published
information available. The influence of covariates on CL/F and VIF ofMPA were also
investigated, but no significant covariates were identified and findings from some
previous studies suggesting that weight, BMI or ethnicity influence the pharmacokinetics
of MPA were not confirmed. Based on this analysis oflargely trough levels and on
literature findings, it seems unlikely that weight or population differences in
pharmacokinetics affect efficacy of DMPA. Further investigation of the effect of
covariates on peak levels is needed. It is recommended that a longitudinal study be
undertaken with serum MPA levels measured at least every week for the first four weeks
after injection. Since norethisterone oenanthate is also widely used in South Africa and
elsewhere, a similar pharmacokinetic study of norethisterone oenanthate should be carried
out.
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INSTRUCTIONS TO FAMILY PLANNING CLINIC NURSING STAFF
RESEARCH STUDY ON DEPO-MEDROXYPROGESTERONE ACETATE
AIMS AND OBJECTIVES OF THE STUDY
Aim : To undertake a preliminary investigation of the population pharmacokinetics of
Depo-medroxyprogesterone acetate.
Objectives : (i) To assess the variation in the pharmacokinetics ofDMPA.
(ii) To establish relationships between physiological, pathological,
environmental or genetic factors and kinetic parameters ofDMPA.
DURATION OF STUDY: October to December 1996/January 1997
SELECTING CLIENTS
Number to be selected: At least 40 clients who use the injectablecontraceptive tobeseleded
These 40 women to be selected in the first month of the study (Oct. 96), on days and at
times when it is convenient for staff.
Follow up visits to be arranged for 4 weeks time and 8 weeks time.
Select those most likely to be able to return - e.g. those who live nearby.
Anyone can be selected, irrespective of whether or not they have had the injection before.
Women of any age, race, weight etc. can be selected.
If someone not initially selected comes back to the clinic before her next dose of the
injection is due (for example because of some problem being experienced) , it would be
very useful to include her in the study and take a blood sample. She should also be asked
to return for two more samples if this is possible.
INFORMATION/EXPLANATIONS FOR CLIENTS
1. Give an information pamphlet to the client
2. Fill in return dates on the information pamphlet
3. Ask the patient to sign the consent form (the consent form should be retained at the
clinic)
Points to be highlighted include:
• That a blood sample will have to be taken
• That the client should return in 4 weeks time and in 8 weeks time (fill in dates on
information pamphlet given to clients).
• That they will have to answer some questions .
• That the information they give will be regarded as strictly confidential.
• That they will receive a small "gift" for participating in the study.
• That we are most grateful for their help.
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INTERVIEWING CLIENTS AND FILLING IN THE QUESTIONNAIRE
A short questionnaire has been provided for interviewing each client selected. The
questions should be self explanatory, but if you experience any problems please let us
know.
• Only one questionnaire has been designed to include the first time a blood sample is
taken (pages 1 - 4) and the second visit (page 5) and the third visit (page 6). The
questionnaires should therefore be retained and accessible for the duration of the
study.
RECORDING INFORMATION ON CLIENT CLINIC RECORD
• Coloured stickers are provided to stick on the client clinic card to identify them as
subjects in this study




• Blood samples should be collected in 2 x 7ml plain tubes to be provided by
the City Health Department (CHD).
• 21 gauge needles should be used (to be provided by University of Durban
Westville [UDW])
Labeling blood tubes:
The following information should be recorded on the label of each blood sample
taken:
1. Client name
2. Client Clinic No.
3. Clinic name - Le. Township, Bluff or Lancer's Road.
4. Date of collection
5. Time of collection
Storing blood samples in the clinic:
Blood samples should be stored in the clinic fridge (not freezer) until transportion
to the next destination.
Transporting blood samples:
• The blood samples must be transported in cooler boxes to be provided by the
CHD.
• Samples from Chatsworth and Bluff Clinics must be transported to Lancer's
Rd Clinic within 24 hours of being collected. CHD will arrange (Audrey Clarke
or Louise Bamaschone) for the bloods to be taken to Lancer's Rd, Clinic.
• UDW staff will collect blood samples from all three clinics from Lancer's Rd
Clinic on a daily basis.
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CONTACT PHONE NUMBERS
Jenni Soot : Dept of Pharmacy, VOW, PB X54001, Durban 4000




Lynn McFadyen: Dept. of Pharmacology, VOW, PB X54001, Durban 4000
Phone: 8202720 (office), 815733 (home)
FEEDBACK ON RESULTS
On completion of this study, a seminar on the findings will be held for participating CHD
Staff. Copies of the research report and any publications will be made available the City
Health Department.
We would like to take this opportunity to thank City Health Department staff very
much for all their assistance in this study. It is very much appreciated.
Jenni Smit
(Senior Lecturer, Pharmacy Dept.)
Lynn McFadyen
(Ass. Professor, Pharmacology Dept.)
323
INFORMATION TO CLIENTS ABOUT THIS RESEARCH STUDY ON THE USE
OF THE CONTRACEPTIVE INJECTION
WHO IS DOING THE STUDY?
This study is being undertaken by researchers from the Departments of Pharmacology
and Pharmacy of the University of Durban-Westville.
WHAT IS THE STUDY ALL ABOUT?
We know that many women have worrisome problems when they use the injection. We
hope that by doing this research we will be able to lessen these problems and in this way
help women who wish to use the injection.
HOW WILL THE STUDY BE DONE?
We would like to take three blood samples from you which will tell us what happens in
your body when you get an injection . We will have to take a blood sample from you to-
day just before you get your injection , and then we would like to ask you if you would
please come back in one month so we can take another blood sample . It will be
necessary for you to come back again in two months' time for the last measurement.
We know that this is more trouble for you. But you would really be helping us a lot if you
would agree to do it. To say thank you to you for helping us, we will give you a small gift
on your last visit to us. We believe that this is a very important study and without your
help it can't be done.
WHY IS THE STUDY IMPORTANT?
What we find from this study could improve the life of many women who use the
injection.
RESEARCHERS' PROMISE:
The people doing this study promise that no-one will be told anything about you or about
anything you tell us. Your name will not be used at all and no-one will be told that
you come to this clinic or that you use the injection.
WHAT YOU HAVE TO DO ?
If you are willing to participate in this study, will you please:
• sign the consent form attached to this letter
• answer some questions that the clinic sister will ask you
• allow the clinic sister to take a blood sample
• return to this family planning clinic on the following dates :
...........................day, ./ ./96
...........................day, ./ ./96
THANK YOU FOR YOUR HELP
Jenni Smit
(Senior Lecturer, Pharmacy Dept.)
Lynn Mc Fadyen
(Ass. Prof, Pharmacology Dept.)
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ZULU TRANSLATION OF CLIENT INFORMATION
INCAZELO KUBASEBENZISI MJOVO MAYELANA NOCWANINGO
NGOKUSEBENZA KOMJOVO WOHLELOMNDENI
UBANIOZOOHUBA LOLUCWANINGO ?
Lomsebenzi wokucwaninga uzoqhutshwa ngabacwaningi bomnyango wezokuthakwa
nokukhishwa kwemithi yokwelapha eNyuvesi yase- Durban-Westville.
LUZOSIZA NGANI LOLUCWANINGO ?
Siyazi ukuthi abesifazane abaningi bahlanga- bezana nezinkinga eziningi
ezibakhathazayo uma besebenzisa umjovo. Sinethemba lokuthi ngokwenza lolucwaningo
sizokwazi ukunciphisa lezizinkinga, ngalendlela kusizakale labo besifazane abafuna
ukusebenzi- sa umjovo.
LUZOKWENZWA KANJANI LOLUCWANINGO?
Sifisa ukuthatha igazi lokusampulisa iziqubu ezintathu kuwena ukuze sazi ukuthi
kwenzekani emzimbeni wakho uma ukade ujova. Kuzomele sithole isampula Legazi
Kuwena namhlanje ngaphambi kokuba ujove bese siphinda sicele ukuba ubuye
esikhathini esiyinyanga sithathe elinye isampula legazi. Kuyodingeka ubuye ezinyangeni
ezimbili ukunikeza isampula legazi lokugcina.
Siyazi ukuthi sikunikeza umthwalo odulele Kodwa uyobe usisize Kakhulu uma uvuma
ukuba yingxenye yaloluhlelo. Ukukubonga ngokusisiza, siyokunika isipho esincane
mhlazane ufika okokugcina. Sikholwa ukuthi lolucwaningo lungolubaluleke kakhlulu
Kanti lungeka lwaba yimpumelolo ngaphandle Kosizo lwakho.
KUNGANI LOLUCWANINGO LUBALULEKILE?
Sikholwa ukuthi konke esiyokuthola ocwaningweni kungasiza ukwenza ngcono izimpilo
zabesifazane abaningi abasebenzisa umjovo ukuhlela.
ISETHEMBISO SABACWANINGI:
Abantu abazobe benza loluwaningo bayakuthembisa ukuthi akukho muntu oyotshelwa
utho ngawe noma badlulisele phambili loko obatshele khona. Igama lakho ngeke
lisetshenziswe nangengozi, akekho futhi oyotshelwa ukuthi uyeza kulomtholampilo noma
uyajova.
OKUFANELE UKWENZE?
Uma uzimisele ukuba ingxenye yalolucwaningo, sicela :
• Usayinda imvume kulelipheshana elihambisana nalencwadi
• Uphendule imibuzo ozoyibuzwa ngumhlengikazi eMtholampilo
• Uvumele umhlengikazi athathe isampula legazi
• Uphinde uze kulomtholampilo wohlelomndeni ngalezi zinsuku ezilandelayo :
........................... , ./ ./96




(Senior Lecturer, Pharmacy Dept.)
-----------------------------------
Lynn Mc Fadyen
(Ass . Prof, Pharmacology Dept.)
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APPENDIX 2.2.2
INTERVIEW SCHEDULE FORDMPA USERS ATTENDING
FAMILY PLANNING CLINICS
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POPULATION PHARMACOKINETICS OF DEPO·
MEDROXYPROGESTERONEACETATE
INTERVIEW SCHEDULE FOR DMPA USERS
PART I : FIRST BLOOD SAMPLE
Client to return on : day, ./ ./96.
...................day, ./ ./96.
SECTION 1 : CLASSIFICATION
1. Client No: ..
2. Date: ......../......../96
3. Clinic: Township Centre 0
SECTION 2 : PERSONAL DETAILS
Time: .
Lancers Rd 0 Bluff 0
4. Name: .
5. Phone (for follow-up) ..
6. Address:
......... ......... .......... ........ ..... ...... .. .... .. ... .... ... ...... ..... ...... ......... .... ................ ..
.............. .. ... ... ............. .. ..... .......... ....... ............... .. ...... .... ...... .... ............... .... ... .... ...
(if unable to get an exact address, indicate general area of residence e.g.
Bayview, Brighton Beach, Fynnlands, C/airwood, Merebank, Durban Central,
Umlazi, Inanda, KwaMashu, Berea, etc.)
7. Date of birth : .. (or age in years if date of birth is unknown)
8. Race : African 0 Indian 0 Coloured 0 White 0
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9. Individual Income :
R 0 - R 500 per month
R 501 - R1000 per month
R1001 - R2000 per month
Over R2000 per month
SECTION 3 : QUESTIONS RELEVANT TO THE USE OF THE
CONTRACEPTIVE INJECTION
10. How many children do you have? .
11. Do you smoke? Yes 0 No 0
12. Why have you decided to use the injectable contraceptive method?
(don't prompt client)
" .
.... .... .... .... ... ... ......... ... ... .. ..... ..... ...... .. ...... .. ... ... .... ... ... ..... .... ... ... .. ........ .. .. .. .. .. ......... .... .
... .. .... ..... .. .... ..... ..... .... .. ... .... ....... ... .... ... ... .... ..... .... .... .. ..... ... ..... .. ... .. .... .... .... ...... .. .. ..... ..
....... .... ......... .......... ... ........... ........... ......... .... .... ...... .. .... ... ... ... ... ..... .. ... ..... ........ ... ... .....
...... ... ...... ... ..... ........... ..... .... .... ... .......... ....... ................ .... .. .. ..... .... ...... .. .......... .. ........ ..
13. Which of the following are the reasons you are using the injection?
(more than one box can be ticked)
I onlv have to have it every 3 months
Mv partner does not know I use contraception
My friends/relatives don't not know I use contraception
My friend/relative recommended it
It was recommended for me at the clinic
Its a very safe way to prevent pregnancy
I don't have a period when I'm using it
It suits me (few problems/side effects)
other (state which)
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14. What problems or side effects have you had since your last injection/visit .
(don't prompt client) ,
..... .. .. ....... ... .... ...... ...... ... .... .... ...... .. ...... ... .. ...... ...... ... ... .......... ... ... ..... ..... ........ ... .... ... ....
.. .. ..... ........ .. ... ... .... ...... ..... ......... .. ... .. ... .......... ......... ...... ... ... .... ... ..... ... ....... .. .. .... .... ... .. .
.... .... .... ....... ... ......... ..... .. ... .... .... .. ...... ....... ... .... ...... ... ..... ........ .. ... ............... ... .... .. ... .....
......... ...... .... ...... .... ......... ... .... ........ ..... .. .. .... .... .... ... .. ...... ...... ...... .. ... ....... ........ .. ...... ... ..
.... .......... .... ..... ...... ...... ....... ... .. ....... .... ... .. ..... .... ... ... ..... ... .... ........ .... .. ..... .... ...... ..... .. .. ..
... .... .. ... ..... ...... ..... .... ... ........ ......... ... ... ..... .. ........ ..... ......... .... .... ... ....... ........ .... .. ..... .. ....
'ect ion?(more than one box can be ticked)
no period/menstruation









bloating of abdomen and breasts
vaqinal moisture increased
vaginal dryness
hard to qet pregnant after I stop the injection
loss of libido/don't feel like sex
depressed mood/feel sad & unhappy
My hair falls out
I worry that it may cause cancer
other (give details)
15. Which of the following side effects or problems have you had when taking
the inJ
16. What other medicines are you using now?
(list all medications mentioned as specifically as possible)
...... .... ...... ......... .... ....... ............ ... ..... ........ .. ............. ... ... ......... .......... ..... ...... ... .... .
....... .. ...................... ....... ... ............................ ..... ........ ....... .................. .. ... ..... ..... .. ....
.. ... .... ...... .. ..... .. .... .. .. .... ... ... ..... ..... .... .... ... .. ...... ..... ...... ... .... .. .... .... .... .... .... ... .... ... .......
........ .... ... ............... ..... ..... .. ...... ............ ... ... ..... .... .......... .. .. .... ... ............ ...... .. ... .... .. ...
329
SECTION 4 : RELEVANT MEDICAL HISTORY
17. Weight at commencement of injection use kg








SECTION 5 : USE OF CONTRACEPTIVE INJECTION
19. Brand of contraceptive injection given to-day:
20. Date when injectable last used: ....../......./......











22. Date when injectable first used: Specify date of commencement .
QI
Duration of treatment.. years, months
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SECTION 6 : MEASUREMENTS TO BE TAKEN
23. Weight to-day: kg
24. Height: ems
25. Blood Pressure .
26. OTHER COMMENTS: ..
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PART 11 : SECOND BLOOD SAMPLE
27. Date: ....../....../96
28. Name : .
Time: .
29. Phone (if changed since first blood sample was taken) :
30. Address (if changed since first blood sample was taken):
31. What side effects or problems have you had since your last injection/visit?
(don't prompt client)
32. What other medicines are you using now? (list all medications mentioned as
specifically as possible)
USE OF CONTRACEPTIVE INJECTION
33. Brand of contraceptive injection given to-day:
(if given at all)
34. Date when injectable last used: ....../......./......
MEASUREMENTS TO BE TAKEN
35. Weight to-day: kg





37. OTHER COMMENTS : .
........ .................... ..... ... ..... .... .. ........... ............ .. ... ..... ........ ... .. .. .. .. .................. ... .. .........
........ ...... .. .. .. ...... ........... ..... ................ ......... ......... .. .. ..... ... .. ....... .... .. ..... ..... ..... ..... .....
..................... ............ ..... ... .. .. ... ............. ........ ......... .. ... ... .... .. ....... .... .... .......... .... ...... .
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PART Ill: THIRD BLOOD SAMPLE
38. Date : ....../....../96 Time: .
39. Name : .
40. Phone (if changed) : .
41. Address (if changed ):
42. What side effects or problems have you had since your last injection/visit?
(don't prompt client)
43. What other medicines are you using now? (list all medications mentioned as
specifically as possible)
USE OF CONTRACEPTIVE INJECTION
44. Brand of contraceptive injection given to-day:
(ifgiven at all)
45. Date when injectable last used : ./ ./ .
MEASUREMENTS TO BE TAKEN
46. Weight to-day: kg





48. OTHER COMMENTS: .
.. .... .. .. .... ... .... .. ...... ... ....... .. .... .... ........ ...... ..... ..... ....... .... .. ..... ..... ... ...... .... .............. ....
............... ...... .. ....... .... ....... ..... ........ .... .... ... ............... ........ ... ..... ................ ... ......... ...
..... ... ......... ...... ........ .. ......... .. .. ......... ........ .. ..... .. ..... ... ..... ... ... ....... ......... ....... .. .... .. .. .. .. .
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BLOOD SAMPLE ON RETURN DATE FOR
INJECTION
1. Date: ....../....../96 Time: .
2. Name : ..
3. Phone (if changed): .
4. Address (if changed):
5. What side effects or problems have you had since your last injection/visit?
(don't prompt client)
6. What other medicines are you using now? (list all medications mentioned as
specifically as possible)
USE OF CONTRACEPTIVE INJECTION
7. Brand of contraceptive injection given to-day:
(ifgiven at all)
8. Date when injectable last used: ....../......./......
MEASUREMENTS TO BE TAKEN
9. Weight to-day: kg





11. OTHER COMMENTS: .
........ .... .................................. ............ ........ ........ ... ......... ..... .................................. ...
..... ......... ............. ....... .. .... ............. ...... ................. .... .... ... .. .... ............... ........ ........ ....
....... ................ ..... ..... .. .. .... .... .... ........ ..... ..... ... .. ... .... ..... ..... ... .. ... ........ ..... ..... ...... ...... .
THANK YOU VERY MUCH!
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APPENDIX 2.2.3
PHARMACOKINETIC DATA FILE PARAMETERS
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PHARMACOKINETIC DATA FILE PARAMETERS
A NONMEM data file was constructed with the following parameters (abbreviation in
parenthesis): The first 15 client records of this data file are shown in Appendix 3.2.5
Patient number (ID)
Days since dose based on the number of days a dose was given before recruitment
into the study (TIME). [In many cases, the woman would already have been on
DMPA and the first blood level, taken on recruitment into the study, would reflect
the concentration relating to her previous injection about 84 days ago. In some
cases, the woman was a first time user, and hence on recruitment her level would
be zero]
Serum MPA concentration in ng/ml (DV)
Event identification (EVID): O=observation event, 1=dose event
Steady-state (SS): 1=steady-state, O=not yet at steady-state
Interdose interval (ll)
Dose ofDMPA in mg/ml (AMT)
Dose rate (RATE). [-2=IV infusion of unknown rate or duration. The unknown
rate or duration is modelled in the NONMEM analysis]
Age in years (AGE)
Weight in kg (WT)
Race (RACE). 1=African, 2=Indian, 3=Coloured, 4=White
Smoking (SMOK). O=nonsmoking, 1=smoker
Serum creatinine levels in umol/L (CREA)
Serum alkaline phosphatase levels in U/L (ALKP)
Serum gamma GT levels in U/L (GAMA)
Serum aspartate transaminase levels in U/L (AST)
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Serum alanine aminotransferase levels in U/L (ALT)
Serum total bilirubin levels in umol/L (TBIL)
Serum conjugated bilirubin levels in umol/L (CBIL)
Whether taking anticonvulsant drugs (EPID)
Whether taking antihypertensive drugs (BPD)
Whether taking drugs for diabetes (DIAD)
Whether taking Ovral® (OV)
Whether taking Premarin®(PREM)
Height in centimeters (HT)
Duration ofuse ofDMPA in years (DUR)
Body mass index (BMI)
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APPENDIX 2.2.4
PHARMACOKINETIC DATA FILE RECORDS





SUMMARY OF MAIN RUNS CONSTRUCTED DURING THE
MODEL BUILDING PROCESS
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INDIVIDUAL PLOTS OF MEASURED CONCENTRATIONS,
INDIVIDUAL CONCENTRATION PREDICTIONS
AND FINAL MODEL CONCENTRATION PREDICTIONS
IN RELATION TO TIME AFTER DOSE
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o
Individual plots for run 12, AMT=NULL
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RECOMMENDATIONS FOR RATIONAL PROVISION OF
INJECTABLE CONTRACEPTIVES
Contraceptive Method Mix
• Attention should be directed at the disproportionate reliance on a single contraceptive
method (the progestogen-only injectable), which offers no protection against HIV and
other STls. Attention should focus particularly on the method mix for young people and
for people living in rural areas, where injectable use is especially high.
• The choice of contraceptive methods available in public sector clinics is limited. The
need for greater access to female controlled methods like the female condom, which also
protect against HIV/STIs , should be addressed.
• The findings documented in this thesis provide a comprehensive account of injectable
contraceptive use at a time wheri new health policies, specifically the National
Contraception Policy Guidelines (Department of Health, 2001) were being developed and
implemented. In this time period, the full impact of the HIV/AIDS pandemic was only
just being realised. This thesis provides important baseline data on contraceptive use and
should be used to measure whether recommended changes in the method mix occur.
Injectable Contraceptive Product Mix
• Age as a criterion for providing one injectable product over another on the basis of
reversibility is not appropriate or cost effective. Training of health workers and
counselling of clients to correct the misconception that NET-EN is the better product for
young women, on the basis of reversibility, is required. This recommendation has been
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published in BMC Health Services Research (copy included after the abstract on page
xxv of this thesis) and is already been implemented by contraception trainers and
programme managers (M. Moss , Changing Attitudes to Contraception: Contraception
update 2003 - Satellite Symposium, 11 July, 2003).
• Since DMPA is a cheaper option than NET-EN, provider training about the rational use of
injectable contraceptives should include consideration of the cost implications of
prescribing one or other product. DMPA should be considered as the first option, but where
DMPA is not well tolerated, NET-EN should be available as a second option.
Counselling
• Counselling about contraceptive options should be tailored to women's specific
circumstances, including their risk ofHIV/STI acquisition. Health workers play an
important role in decision-making about contraception, and are highly influential in the
decision to use the injectable method. They should be encouraged and supported to
promote barrier methods where these are more appropriate. For instance, training about
of the use of emergency contraceptive pills , as a back-up to condom use, may increase
likelihood of the promotion of condoms instead of injectables where providers have
concerns about shifting women from the more effective injectable method. Promotion of
dual method use (e.g. male or female condom plus hormonal method) is another strategy
which could be encouraged.
• The perception that injectables cause vaginal wetness can affect acceptability and lead to
discontinuation. Health workers should be aware of this and should counsel women
appropriately.
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• Counselling to improve rates of continuation and adherence to dosing regimens could
impact positively on unwanted pregnancy rates. Clients should be told about the
likelihood of amenorrhoea, especially with longer duration of use and advised against
"taking a break" or returning late for their next dose. They should also be informed that
they may experience heavy bleeding in the first few injection cycles, but should be told
that this side effect is likely to diminish with longer duration of use.
• Although amenorrhoea is a problem for some women, others see it as an advantage of the
injectable method. Counselling about this side effect should take this into account.
• The multiplicity of reasons for discontinuation is seldom commented on the literature, but
is important to take into account when counselling injectable users.
Focus on young women
• Many sexually active young women do not practice contraception until after their first
pregnancy. The contraceptive needs of young women should be addressed before their
first pregnancy, also taking into account their need for protection against RN and other
STIs
Pharmacokinetics ofDMPA
• Although some previous studies suggest that weight, body mass index or ethnicity
influence the pharmacokinetics ofmedroxyprogesterone acetate, this was not found in the
pharmacokinetic analysis of the influence of covariates on apparent clearance and
apparent volume of distribution for medroxyprogesterone acetate. This information
should be communicated to the research community and to health providers.
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Further research
• More data on discontinuation patterns among South African users are needed. Further
studies should take care to define discontinuation criteria clearly, differentiating between
poor adherence and discontinuation.
• Whilst vaginal wetness can only be classified as a subjective side effect at this stage,
further investigations are needed. A study is being developed to discover more
information about the nature and possible etiology of vaginal wetness, how it may differ
from the vaginal discharge reported by respondents, and whether it is a consequence of a
vaginal infection or a relatively transient problem that resolves for most women on
continued use.
• Future Demographic and Health Surveys should collect information on which injectable
product is being used (i.e. DMPA or NET-EN). The next SADHS is scheduled to take
place in the latter part of 2003 and, on the basis of the recommendation of the author of
this thesis , this disaggregated information will be collected. A study is also proposed in
Western Cape Province family planning clinics to investigate the injectable product mix.
This study will adopt a similar methodology as that used in this thesis and the author of
this thesis as been invited to be a collaborator.
• A systematic Cochrane review comparing DMPA and NET-EN in regard to side effects,
efficacy, discontinuation, reversibility and safety is underway. This review will focus
particularly on the effects of the two injectables on bone mineral density.
• Forthcoming findings from prospective studies of the effect ofDMPA and NET-EN on
bone mineral density should be carefully considered. Depending on the outcome,
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appropriate recommendations for South African users, particularly younger women
(under 18 years) and older women (over 45 years) should be made.
• A clinic-based study which investigates the influence of providers on contraceptive
method choice is needed.
• A comprehensive cost effective analysis ofDMPA versus NET-EN should be
undertaken. This should include, in addition to product costs , a costing ofpersonnel time
in providing each of the two products; an analysis of the content and quality of provider
counseling; time taken for counseling; time taken and cost incurred for clients to get to
the clinic ; and cost of materials such as needles , syringes and swabs .
• A pharmacokinetic/pharmacodynamic study should be undertaken to investigate
medroxyprogesterone acetate levels in relation to ovulation and side effects.
• Since norethisterone oenanthate is also widely used in South Africa and elsewhere, a
pharmacokinetic study of norethisterone oenanthate should be carried out.
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